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Lipid oxidation has long been linked to the generation of toxic products seen to trigger many 
different anti-inflammatory responses. Products such as 4-hydroxynonenal (HNE) and 
acrolein can react with nucleophilic groups in proteins to form lipoxidation adducts, that 
have been detected in diseases like diabetes, cancer and cardiovascular diseases and, 
hence, are considered powerful biomarkers of oxidative stress in vivo. In this work, the 
reactivity of HNE towards human serum albumin (HSA), the major protein of human serum, 
was studied and the lipoxidised protein was used as an immunogen to derive anti-HSA-
HNE antibodies (Ab) for subsequent characterisation and as a basis for development of a 
rapid diagnostic test. Mass spectrometry (MS) analysis confirmed the formation of HNE 
adducts on 15 HSA peptides, and one of the HSA-HNE immunised sheep sera was shown 
to contain specific antibodies to these adducts. Peptide arrays covering the HSA sequence 
and treated post peptide synthesis with HNE were used in a novel approach to characterise 
the binding patterns of the in-house anti-HNE Ab, and the results were in agreement with 
those obtained by MS. Nevertheless, the antibody showed cross-reactivity to HSA, which 
suggested some of the epitopes included not only the HNE moiety of the adducts, but also 
regions of HSA. Despite the cross-reactivity of this generated Ab, its potential for diagnostic 
applications was assessed by its deployment in a lateral flow assay together with a 
commercial anti-HNE Ab. The assay was able to distinguish HNE-modified proteins from 
non-modified ones, although further optimization is required. Finally, RNA from B 
lymphocytes of the HSA-HNE immunized sheep was extracted for construction of 
recombinant Fab and scFv phage display libraries, for the selection of monoclonal 
antibodies, but biopanning of anti-HSA-HNE clones was shown to be challenging due to the 
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to a light chain by a disulphide bond (B). The structure in panel B was taken from 
https://bxcell.com/antibody-structure/. ............................................................................. 55 
Figure I.9. Somatic DNA recombination of the V-region genes. Light-chain V region 
genes are constructed from the variable (V) and joining (J) gene segments of the genomic 
DNA to form a complete light-chain V-region exon. The light-chain constant region (C) is 
encoded in a separate exon and is joined to the V-region exon by splicing of the light-chain 
RNA to remove the V-to-J and the J-to-C introns. Heavy-chain V regions are first 
constructed from the diversity (D) and the J gene segments, and then the V gene segment 
joins to the combined DJ sequence, forming a complete VH exon. A heavy-chain C region 
gene is encoded by several exons, that together with the leader sequence, are spliced to 
the V-domain sequence during processing of the heavy-chain RNA transcript. The leader 
sequence is later removed after translation, and the disulphide bonds that link the 
polypeptide chains are formed. The hinge region is shown in purple. From Murphy, K., 
Travers, P., Walport, M., & Janeway, C. (2008). Janeway's immunobiology. New York: 
Garland Science. ............................................................................................................. 57 
Figure I.10. Principle of phage display technology. The genetic information of the 
desired antibody is inserted into the phage DNA and ends up being expressed as part of 
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the capsule protein on the surface of the phage, where it is displayed. Adapted from 
https://www.nobelprize.org/prizes/chemistry/2018/popular-information/........................... 61 
Figure I.11. Schematic representation of the phage display process. Once the antibody 
library is generated, phages expressing the different clones are incubated with the target 
antigen for positive selection, in a process called biopanning. After elution from the antigen, 
the phages are recovered, used to infect new bacteria for amplified and the generation of a 
more enriched library. This process is usually performed 2-4 times to allow a sufficient 
enrichment of the specific phages. .................................................................................. 62 
Figure II.1. Location of Cys34 (red), His146 (light blue) and Lys199 (purple) residues 
in the 3D molecular structure of human serum albumin (PBD FILE: 1AO6) (A) and in 
the amino acid sequence (B). Peptides 31LQQCPFE37, 141EIARRHPYFYAPEL154, 
198LKCASLQK205 containing these three key amino acids were selected for chemical 
synthesis and HNE treatment. ......................................................................................... 78 
Figure II.2. HPLC chromatogram (A) and MS spectra (B) obtained for purified 
31LQQCPFE37 HSA peptide (monoisotopic mass: 862.40). The crude peptide was initially 
dissolved in 5% v/v acetonitrile, 95% v/v water, plus 0.1% TFA, to a concentration of 1 
mg/mL, all eluted peaks were collected for MS analysis and once the peak corresponding 
to the HSA peptide was identified further HPLC runs were set up for purification of that 
single product. In the end all the fractions were combined, the peptide was freeze dried, 
and analytical runs by HPLC (A) and ESI-MS (B) were performed for confirmation of purity.
 ........................................................................................................................................ 79 
Figure II.3. HPLC chromatogram (A) and MS spectra (B) obtained for purified 
141EIARRHPYFYAPEL154 HSA peptide (monoisotopic mass:1801.93). The crude peptide 
was initially dissolved in 5% v/v acetonitrile, 95% v/v water, plus 0.1% TFA, to a 
concentration of 1 mg/mL, all eluted peaks were collected for MS analysis and once the 
peak corresponding to the HSA peptide was identified further HPLC runs were set up for 
purification of that single product. In the end all the fractions were combined, the peptide 
was freeze dried, and analytical runs by HPLC (A) and ESI-MS (B) were performed for 
confirmation of purity. ...................................................................................................... 80 
Figure II.4. HPLC chromatogram (A) and MS spectra (B) obtained for purified 
198LKCASLQK205 HSA peptide (monoisotopic mass: 930.53). The crude peptide was 
initially dissolved in 5% v/v acetonitrile, 95% v/v water, plus 0.1% TFA, to a concentration 
of 1 mg/mL, all eluted peaks were collected for MS analysis and once the peak 
corresponding to the HSA peptide was identified further HPLC runs were set up for 
purification of that single product. In the end all the fractions were combined, the peptide 
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was freeze dried, and analytical runs by HPLC (A) and ESI-MS (B) were performed for 
confirmation of purity. ...................................................................................................... 81 
Figure II.5. Identification of the products formed by reacting peptide 31LQQCPFE37 
with HNE at a peptide-HNE molar ratio of 1:10; and their respective difference in the 
retention time. The TIC chromatogram of the total reaction products (A) show a main peak 
at Rt 35 min corresponding to the prediction of the non-modified peptide (m/z 863) (B) and 
one HNE Michael adduct (m/z 1019), and a few other peaks with longer RT corresponding 
to a two HNE Michael adduct (m/z 1175). The experiment was performed in triplicate (n=3).
 ........................................................................................................................................ 82 
Figure II.6. Identification of HNE Michael adducts on peptide 31LQQCPFE37 by MS, 
following a 2 h reaction with HNE at a peptide-HNE molar ratio of 1:10. The formation 
of a single MA-HNE-peptide adduct was confirmed by the ion peak at m/z 1019.5 ( 
[M+HNE+H]+ ), and by the ion peak at m/z 501.24 ([M+HNE+2H]2+) (A). The ions peaks at 
m/z 1175.6 and m/z 579 correspond to the protonated molecular ion [M+2HNE+H]+) and to 
the double charged molecular ion [M+2HNE+2H]2+, respectively, confirming the formation 
of a double MA-HNE-peptide adduct (B). The experiment was performed in triplicate (n=3).
 ........................................................................................................................................ 83 
Figure II.7. Identification by LC-MS of a Schiff’s base (A) and a double MA (B) adducts 
formed on peptide 31LQQCPFE37, followed reaction with HNE at peptide-HNE molar 
ratio of 1:10. The MS spectrum of the peak with an RT of 43.817 shows the ion peaks with 
m/z 1001.5 and m/z 501.2, which correspond to the single ([M+HNE-18+H]+) and double 
([M+HNE-18+2H]2+) protonated ions relative to the predicted mass of a Schiff’s base 
adduct, and the MS spectrum of the peak with a RT of 44.240 depicts the molecular ion m/z 
579.3102 relative to the predicted mass of both a Michael and Schiff’s base adducts 
[M+2HNE-18+2H]2+. The ion peaks with m/z 1175.6560, 1001.5235 and 863.4132 suggest 
the co-elution of this adduct with other products, namely the non-modified peptide, the MA-
HNE and SB-HNE peptide adducts. The experiment was performed in triplicate (n=3). .. 84 
Figure II.8. Identification by LC-MS of the products formed by reacting peptide 
141EIARRHPYFYAPEL154 with HNE at a peptide-HNE molar ratio of 1:10; and their 
respective difference in the retention time. Panel A shows the total ion chromatogram 
of the total reaction products and panels B and C show the TICs relative to the prediction 
mass of the non-modified peptide and MA-HNE-peptide adduct, respectively. The 
experiment was performed in triplicate (n=3). .................................................................. 85 
Figure II.9. Identification by LC-MS of a Michael adduct formed on the peptide 
141EIARRHPYFYAPEL154 followed reaction with HNE at a peptide-HNE molar ratio of 
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1:10. MS spectrum relative to the peak with an RT of 37.740 min reveals the ions peaks at 
m/z 980.5313 and 653.6792, which correspond to the double ([M+HNE+2H]2+) and triple 
([M+HNE+3H]3+) charged ions regarding the predicted mass of the an MA-HNE-peptide 
adduct (m/z = 980.53). The experiment was performed in triplicate (n=3). ...................... 86 
Figure II.10. Identification by LC-MS of the products formed by reacting peptide 
198LKCASLQK205 with HNE at a peptide-HNE molar ratio of 1:10; and their respective 
difference in the retention time. TIC in panel A represents the total elution profile of all 
the reaction products formed and the XICs regarding peaks at RT 25 min (B), 30 min (C), 
33 min (D) and 36 min (E) correspond to the prediction of the non-modified peptide (m/z 
930.534), the single MA-HNE-peptide adduct (m/z 1008.595), the double MA-HNE-peptide 
adduct (m/z 1086.660) and the triple MA-HNE-peptide adduct (m/z 1164.724), respectively. 
The experiment was performed in triplicate (n=3). ........................................................... 87 
Figure II.11. Identification by LC-MS of Michael adducts formed on peptide 
198LKCASLQK205 followed reaction with HNE at peptide-HNE molar ratio of 1:10. Panel 
A shows the MS spectrum relative to the peak with an R.T. of 29.944 showing the ion peak 
relative to the predicted single Michael adduct (m/z = 1087.1615); Panel B shows the MS 
spectrum relative to the peak with an R.T. of 33.707 showing the ion peak relative to the 
predicted double Michael adduct (m/z = 1165.2288); Panel C shows the MS spectrum 
relative to the peak with an R.T. of 36.848 showing the ion peak relative to the predicted 
triple Michael adduct (m/z = 1165.2288). The experiment was performed in triplicate (n=3).
 ........................................................................................................................................ 88 
Figure II.12. Direct infusion ESI-MS analysis of native HSA (A) and HNE-modified HSA 
(D). Both spectra were smoothed (Panels B and E, respectively for native HSA and HNE-
modified HSA) and the peaks were centred (Panels C and F, respective for native HSA and 
HNE-modified HSA). ESI-MS spectrum of the native HSA shows multiply charged peaks 
ranging from m/z 1075-1858 and the spectrum of the modified HSA shows multiply charged 
peaks ranging from m/z 1164 to m/z 1877. ...................................................................... 92 
Figure II.13. MALDI-TOF-MS spectra of HSA treated with HNE at a protein:HNE molar 
ratio of 1:10 (A) and native HSA (B). The difference in mass between the peak 
representing the modified protein and the peak representing the native form correspond to 
the addition of ∼3 molecules of HNE per HSA. ................................................................ 93 
Figure II.14. Identification of HNE adducts on A1AT, HSA and OVA by direct ELISA 
using the commercial anti-HNE polyclonal antibody from Abcam. Each protein was 
individually incubated with HNE at three different protein-HNE molar ratios (1:1, 1:5 and 
1:10) for 2h at 37°C, and different concentrations from these batches, ranging from 0 to 1 
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g/mL, were adsorbed onto an ELISA plate (A). The data obtained when using 1 g/mL of 
each modified and non-modified antigen was isolated and represented in a graph bar for 
ease of understanding (B). The assay was performed in duplicate (n=2), with SEM of 
technical triplicates; * p<0.0125. ...................................................................................... 94 
Figure II.15. SDS-PAGE (A and B) and western blotting analysis (C) of non-modified 
and HNE modified HSA, OVA and A1AT. Non-modified proteins are represented in panel 
A whereas HNE modified HSA, OVA and A1AT at three different molar ratios (1:1, 1:5 and 
1:10) are depicted in panel B. The HNE modifications on the three proteins were also 
confirmed by western blotting analysis using the Abcam anti-HNE (C). The experiment was 
only performed once (n=1). ............................................................................................. 95 
Figure II.16. MS analysis of synthetic biotinylated 31LQQCPFE37 peptide (A) and 
corresponding structure (B). Ion peaks at m/z 1292.6338 and 646.8129 correspond to 
the single and double charged ions ([M+H]+) and ([M+2H]+2), respectively, of the peptide. 
The experiment was performed in triplicate (n=3). ........................................................... 96 
Figure II.17. Identification by LC-MS of HNE adducts formed on biotinylated 
31LQQCPFE37 peptide followed reaction with HNE at peptide-HNE molar ratio of 
1:10. An HNE-MA-peptide adduct was confirmed by the presence of the ion peaks m/z 
1448.7535 and 724.8722, that correspond to the single and double ion species, respectively 
(A), and a Schiff’s base adduct was confirmed by the ion peaks m/z 1430.7405 and 
715.8655, which correspond as well the single and double ion species, respectively (B). 
The experiment was performed in triplicate (n=3). ........................................................... 97 
Figure II.18. Kinetic and affinity analysis of Abcam anti-HNE pAb to immobilized HNE-
biotinylated-31LQQCPFE37 peptide. Kinetic constants were calculated testing eight 
different antibody concentrations (64, 32, 16, 8, 4, 2 and 1 nM) and the the binding curves 
(red lines) were fit using a global fit algorithm for 1:1 binding interaction in the Octet Data 
Analysis software v. 7.0. The assay was performed only once (n=1). .............................. 97 
Figure III.1. Illustration of the direct ELISA assay performed for the detection of anti-
HNE antibodies generated by animal immunization. The HNE-modified antigen was 
coated on a 96 well plate, to which the sera was added (after blocking). The detection was 
performed using an alkaline phosphatase labeled antibody anti-species. ...................... 107 
Figure III.2. Illustration of the sandwich ELISA assay developed for the detection of 
HNE adducts on proteins. The in-house sheep SA369 pAb was used as capture antibody 
and the Abcam anti-HNE pAb as detection antibody. .................................................... 109 
Figure III.3. Schematic representation of a peptide array. The membrane is firstly 
incubated with HNE and subsequently with the primary and the HRP-labelled secondary 
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antibody. After incubation with the substrate, the peptide spots to which the antibody is 
bound develop a blue colour. ........................................................................................ 111 
Figure III.4. Screening of anti-HSA-HNE polyclonal sera collected from sheep SA350, 
SA369, SA351 and SA352, by ELISA against HSA-HNE (A) and OVA-HNE (B). Sheep 
SA350, SA369 were immunized non-reduced HSA-HNE adducts and sheep SA351 and 
SA352 were immunized with NaBH4-reduced HSA-HNE adducts. All the three post-
immunization bleeds were screened against their respective pre-immunization collected 
bleed, as a control. The assays were only performed once (n=1), as the aim of this assay 
was to only assess the presence of target antibodies, in order to proceed to their purification.
 ...................................................................................................................................... 113 
Figure III.5. Screening of the antibodies present in the pre-immune bleed and in three 
post-immunization bleeds collected from rabbit RA511 and RA512 and sheep SA414 
and 415 immunized with KLH-31LQQCPFE37-HNE. The binding to Biotinylated-
31LQQCPFE37-HNE modified HSA was accessed by ELISA assay. The assays were only 
performed once (n=1), as the aim of this assay was to only assess the presence of target 
antibodies, in order to proceed to their purification. ....................................................... 114 
Figure III.6. Affinity purification chromatograms for purification of SA369 anti-HSA-
HNE pAb using an HSA-HNE-coupled resin to recover the mixture of anti-HNE and 
anti-HSA-HNE antibodies (A) and an HSA-coupled resin for depletion of anti-HSA 
antibodies (B). The bound pooled fraction of the antibodies obtained in (A) was loaded into 
the second column, where the enriched pooled fraction of anti-HSA-HNE was collected from 
the unbound fraction. Binding assessment of the enriched pAbs to HSA, HSA-HNE, OVA 
and OVA-HNE was performed by direct ELISA (C) by immobilizing the antigens at 1.25 
g/mL and testing with the antibody concentrations indicated on the graph. This assay was 
performed in duplicate (n=1), showing average of 3 technical replicates  SD. ............. 116 
Figure III.7. Purification of anti-HNE/HSA-HNE antibodies from SA369 crude serum. 
IgGs were first were enriched by affinity chromatography using a Protein G resin (A) and 
later a KLH-HNE-coupled resin was used for capture of anti-HNE pAbs (B). The IgG eluted 
fraction obtained in (A) was loaded into the second column, where the enriched pooled 
fraction of anti-HNE pAbs was collected (eluted peak) (B). Binding assessment of the both 
pAb populations (unbound (C) and bound (D) from KLH-HNE resin) were tested against 
HSA, HSA-HNE, OVA and OVA-HNE by direct ELISA by immobilizing the antigens at 1.25 
g/mL and testing with the antibody concentrations indicated on the graph. This assay was 
performed in duplicate (n=1), showing average of 3 technical replicates  SD. ............. 118 
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Figure III.8. SDS-PAGE gel analysis of the purified anti-HNE/HSA-HNE SA369 pAbs 
using a KLH-HNE covalently bound a sepharose resin. The collected pooled fractions 
contain still a trace of serum albumin as observed by a band corresponding to the weight 
of 65 kDa and some other immunoglobulins of higher molecular weight, possibly IgM. 
Samples in lanes 1, 2 and 3 were run under non-reducing conditions, while samples in lanes 
4, 5 and 6 were run under reducing conditions. In lanes 5 and 6 bands corresponding to the 
weight of the heavy (50 kDa) and light chains (25 kDa) of the pAbs are seen. Proteins were 
separated by SDS- PAGE and stained with Coomassie blue. ....................................... 118 
Figure III.9. Western blotting analysis of the SA369 anti-HNE enriched pAb. Human 
serum albumin (HSA), ovalbumin (OVA) and alpha 1-antitrypsin (A1AT) were treated with 
HNE at protein:HNE molar ratios of 1:1, 1:5 and 1:10, and their detection by the SA369 anti-
HNE enriched pAb (A) and by the Abcam anti-HNE (B) was determined by western blotting. 
Both membranes were visualized under identical conditions, so the binding strength would 
be comparable, and densitometry analysis of both the aggregates formed post-modification 
and the protein were generated for the blots detected with SA369 anti-HNE pAb (C) and 
Abcam anti-HNE pAb (D). The experiment was only performed once (n=1). ................. 119 
Figure III.10. Epitope mapping analysis for the SA369 enriched pAb using HNE-
treated and untreated peptide arrays. A and B are arrays of HSA peptides (15-mer) 
treated with HNE; C and D are the equivalent arrays without HNE treatment; E and F are 
arrays of ovalbumin (OVA) peptides (15-mers) treated with HNE. Binding of the commercial 
Abcam anti-HNE pAb is shown in the left-hand column (panels A, C, E) and binding of the 
SA369 enriched pAb is shown in the righthand column (panels B, D, F). Peptides 
recognized by both polyclonal antibodies are boxed in red and cross-reactivity to HSA 
peptides recognized by the SA369 enriched pAb are boxed in yellow. The single purple 
peptide represents an OVA peptide recognized by the in-house pAb but not by the 
commercial pAb. All experiments were carried in duplicate and representative blots are 
shown. The list of all peptide sequences can be found in Appendix 5 and Appendix 6, 
respectively for the HSA and OVA arrays. The arrays were synthesised in duplicate (n=2) 
and the immunoblot analysis performed in triplicate (n=3). ............................................ 121 
Figure III.11. HPLC chromatogram (A) and MS spectra (B) of the synthetic purified 
HSA peptide 365DPHECYAKVFDEFKPLV381 (theoretical monoisotopic mass: 2034.99) 
identified by epitope mapping experiments as the strongest epitope for the enriched 
SA369 anti-HSA-HNE pAb. The crude peptide was initially dissolved in 5% v/v acetonitrile, 
95% v/v water, plus 0.1% TFA, to a concentration of 1 mg/mL, all eluted peaks were 
collected for MS analysis and once the peak corresponding to the 
365DPHECYAKVFDEFKPLV381 peptide was identified further HPLC runs were set up for 
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purification of that single product. In the end all the fractions were combined, the peptide 
was freeze dried, and analytical runs by HPLC (A) and ESI-MS (B) were performed for 
confirmation of purity. .................................................................................................... 122 
Figure III.12. Identification of HNE Michael adducts on peptide 
365DPHECYAKVFDEFKPLV381 (m/z 2034.99) by MS, following a 2 h reaction with HNE 
at a peptide-HNE molar ratio of 1:10. The formation of a single MA-HNE-peptide adduct 
was confirmed by the ion peak at m/z 1096.3, that corresponds to the double charged 
molecular ion [M+HNE+2H]2+ (A). The ions peak at m/z 1173.3 that corresponds to the 
protonated molecular ion [M+2HNE+H]+) confirms the formation of a double MA-HNE-
peptide adduct (B). This MS analysis was performed in triplicate (n=3). ........................ 123 
Figure III.13. Characterisation of SA369 anti-HNE/HSA-HNE antibodies after affinity 
purification using an agarose resin conjugated to the HNE-modified 
365DPHECYAKVFDEFKPLV381 peptide. Proteins detected in the chromatogram (follow-
through and both the eluted fractions after washes with 1M NaCl and 0.1M Glycine-HCl) 
were collected and analysed by ELISA against HSA, KLH, HSA-HNE and KLH-HNE (B) 
and the purification pattern was assessed by SDS-Page gel (C). The experiment was done 
in duplicate (n=2), showing average of 3 technical replicates. ....................................... 124 
Figure III.14. Sandwich ELISA combining the enriched SA369 pAb as the capture Ab 
with HRP-linked Abcam anti-KLH-HNE at the detection Ab for analysis of HNE 
adducts. (A) Analysis of HNE-treated KLH, HSA and OVA by direct ELISA using the 
enriched SA369 pAb. Proteins were incubated individually with HNE at a 1:10 protein-HNE 
molar ratio, and non-HNE-treated protein tested as negative control. (B) Anti-HNE ELISA 
using a fixed concentration of the capture antibody (2 µg/mL) and a fixed concentration of 
the detection pAb (0.5 µg/mL). The antigen was added in a range of concentrations from 0 
to 20 µg/mL. The assays were performed in triplicate (n=3) and data is presented as mean 
 SEM, * p<0.01. ........................................................................................................... 126 
Figure III.15. 3D structure of HSA (PDB:1AO6) depicting HNE-modified peptides 
identified using the Sequest database search (A), and HNE-modified peptides 
detected by the commercial anti-HNE pAb (blue) and the in-house SA369 enriched 
pAb (red) on the HNE-treated HSA peptide arrays (B). The peptides recognized are 
indicated by backbone structure unless the nucleophilic residue likely to be responsible 
within the peptide could be identified. The residue numbering does not include the signal 
peptide (1-18) and pro-peptide (19-24) of HSA, in contrast to the arrays which did include 
these peptides. .............................................................................................................. 130 
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Figure IV.1. Schematic representation of a lateral flow immunoassay test strip. LFA 
devices are usually composed of a sample pad, conjugate release pad, membrane with 
immobilized antibodies and an adsorbent pad. The components of the strip may be fixed to 
an inert backing material and encased in a thermoplastic case with inlet ports and a viewing 
window over the test and control lines. The sample is applied to the sample pad (A) and it 
migrates towards the conjugate release pad (B) where the conjugated antibodies bind the 
biomarker and migrate to the test line (C), where the bound biomarker is captured....... 134 
Figure IV.2. AuNP-antibody buffer conjugation effect on strip performance. Anti-HNE 
pAb was conjugated to AuNPs under the same conditions with 20 mM Borate buffer pH 8.5 
and 25 mM borate buffer pH 9.3, separately, and the detection of HNE adducts was 
assessed by dipping the strips on each Au-NP conjugate solution containing HNE-modified 
and non-modified HSA, OVA and KLH at 50 µg/mL. The intensity of the test lines was 
measured after 20 min after sample application and for each standard sample. The assays 
were performed in triplicate (n=3) and data is presented as mean  SEM. .................... 142 
Figure IV.3. Antigen concentration effect on strip performance (wet testing). NC strips 
previously plotted with SA369 anti-HNE pAb were dipped in AuNP-Abcam anti-HNE pAb 
conjugate solution containing HNE-modified HSA, OVA and KLH at 1.56, 6.25, 25 and 100 
µg/mL and KLH-HNE tested strips were photographed 20 min after sample application (B). 
The intensity of the test lines was measured with a cube reader after a 20 min incubation 
(A). The assays were performed in duplicate (n=2) and data is presented as mean  SEM.
 ...................................................................................................................................... 143 
Figure IV.4. Effect of different running and drying buffers composition in assay 
performance. HNE-modified and non-modified antigen solutions were prepared similarly 
in running buffers: 25 mM borate buffer pH 9.3 (A), 1% (w/v) BSA/PBST (0.1% (v/v) Tween 
20) (B) and 25 mM borate buffer pH 9.3 containing 0.1% (v/v) Tween 20 and 3% (w/v) BSA 
(C). For each of these running buffers, the detection of HNE adducts was compared by 
preparing the AuNP-SA369 anti-HNE pAb conjugates in either (a) 25 mM Borate pH 9.3, 
0.1% (v/v) Tween 20, 3% (w/v) BSA; 5% (w/v) Sucrose, (b) 25 mM Borate pH 9.3, 0.1% 
(v/v) Tween 20, 5% (v/v) BSA; 5% (v/v) Sucrose or (c) 25 mM Borate pH 9.3, 0.5% (v/v) 
Tween 20, 3% (w/v) BSA; 5% (w/v) Sucrose. An 80-µL aliquot of each HNE-modified and 
non-modified standard solution (6.25 µg/mL) was added into the sample pad and the picture 
was taken after a 20 min incubation. The assays were performed in triplicate (n=3) and data 
is presented as mean  SEM. ....................................................................................... 145 
Figure IV.5. Calibration curves represented in standard linear scale obtained from 
triplicate assays tested with HNE-modified and non-modified HSA and KLH standard 
solutions (A). As the signal is seen to saturate around the antigen concentration of 2 
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g/mL, the range 0-0.25 was investigated in more detail (B) so the differences within the 
range of 0-2.5 g/mL can be seen in greater detail. All the devices were photographed 20 
min after sample running where the increment in intensity of the test lines can be observed 
for the increasing concentrations of HNE modified KLH and HSA (C). The assays were 
performed in triplicate (n=3) and data is presented as mean  SEM. ............................. 147 
Figure IV.6. HSA-HNE detection on LFA devices. In each device concentrations from 
0.625 (bottom assays) to 10 g/mL (top assays) of HSA proteins standard treated with HNE 
at molar ratios 1:0, 1:10, 1:20, 1:40, 1:100 and 1:200 (left to right) were tested. The letter T 
on top of the window of each device stands for test line, which is where the capture antibody 
is immobilised and the gold-conjugated Ab binds if HNE is present in the sample. All the 
deviced were photographed 20 min after HSA-HNE samples were applied. These devices 
were only performed once (n=1). ................................................................................... 148 
Figure V.1. Schematic illustration of an intact IgG molecule compared to Fab, scFv, 
sdAb and diabody fragments. For each fragment, their respective gene construct/ domain 
association for each arrangement of VH and VL is depicted. .......................................... 156 
Figure V.2.  Illustration of phage display vector pSFD used in this work for the 
expression of anti-HSA-HNE Fab fragments. The map had, originally, a stuffer fragment 
of a control Fab (A), that was removed and substituted by the VHCH-VLCL genes amplified 
from sheep SA369 B cells, yield a vector of 5930 pb (B). .............................................. 159 
Figure V.3. Flowchart depicting the main steps performed for the generation of 
antibody single-chain variable fragments (scFv) (left) and antibody Fab fragments 
(right) libraries. ............................................................................................................ 162 
Figure V.4. Cloning strategy for the insertion of the heavy and light  chain gene 
fragments into the pSFD phagemid. The insertion of the  chain into the vector was 
performed first by digesting both the vector and the  chain genes, separately, with SfiI and 
XbaI restriction enzymes. After purification, both the vector and the  chain fragments were 
ligated via the action of ligase, and the resulting ligation mix was transformed into E. coli. 
Cells were grown and plated, single colonies were picked for extraction and purification of 
the  chain containing phagemid (pSFD-L), and subsequently the insertion of the heavy 
chain into the pSFD-L vector was performed. Both the pSFD-L and variable heavy chain 
fragment were digested, separately, with NotI and NocI restriction enzymes, and again, 
after purification, the ligation of the fragments was performed using the enzyme ligase. The 
vector was further transformed, cells were grown and plated, and the library containing the 
final vector (pSFD-L-H) was generated. ...................................................................... 167 
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Figure V.5. Agarose gel analysis of the DNA products resulting from the PCR 
amplification of the lambda chains (L1, L2, L3 and L4) (A) and the heavy chains (H1, 
H2, and H3) (B), and of the digested pSFD phagemid (C). The DNA bands corresponding 
to the size of 500 bp in gels depicted in A and B were excised and purified from the gels, 
and further cloned into the XbaI /SfiI digested phagemid which band (~5000 bp) was as well 
excised and purified from gel C. DNA bands corresponding to lower sizes in gels A and B, 
namely ~300 bp and 50-100 bp represent mis-priming PCR products and primers, 
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1.1. Scope  
The work reported in this thesis is concerned with the chemistry of oxidised lipids and the 
adducts they form with proteins in blood. In particular, it is focused on the capability of these 
adducts to behave as self-damage-associated patterns and to trigger the immune system 
to produce specific antibodies. These antibodies have a promising role as diagnostic 
reagents for the detection of lipid-protein adducts, and therefore, their deployment in point-
of-care tests is of great interest. In order to set the scene for the thesis, this chapter consists 
of a review of these topics, which are essential areas of knowledge needed to understand 
the significance and relevance of the research. 
 
1.2. Oxidative Stress, Reactive Species and Antioxidants 
The term oxidative stress was first coined in 1985 as the disturbance in the balance between 
the production of oxidant species and antioxidant defences, in favour of the former (Sies, 
1985). Since then, it has been a very controversial topic as the oxidative damage that arises 
from the excessive concentration of oxidant molecules seems to be linked to the onset of 
several pathologies (Surh & Packer, 2005). This damage can be manifested directly on the 
structure of biomolecules such as proteins, lipids and DNA, leading to organ and tissue 
damage, or indirectly by affecting gene expression and consequent disturbance of cell 
signalling pathways that are sensitive to changes in the cellular redox status (Birben et al., 
2012; Surh & Packer, 2005). Nevertheless, oxidant species also have a beneficial role for 
living systems as they are also involved in the defence against infectious agents and in the 
regulation of a number of cellular signalling systems and pathways. For example, the 
Keap1/Nrf2 pathway is triggered by the presence of ROS and it is believed to play a major 
role in the regulation of the expression of antioxidant related genes, such as those involved 
in the synthesis of the antioxidants NAD(P)H quinone oxidoreductase 1, heme oxygenase 
1, glutamate-cysteine ligase and glutathione S transferases (A. C. Wild, Moinova, & 
Mulcahy, 1999). Nrf2 is a nuclear factor that binds to the antioxidant response element 
(ARE) in the regulatory regions of target genes and Keap1 (Kelch ECH associating protein 
1) is a repressor protein that binds to Nrf2 and promotes its degradation by the ubiquitin 
proteasome pathway (Kansanen, Kuosmanen, Leinonen, & Levonenn, 2013). In oxidative 
stress conditions, ROS are seen to oxidize cysteine residues in Keap1, which changes its 
conformation and leads the translocation of Nrf2 to the nucleus and consequently activates 
gene expression.  This delicate balance between the beneficial and the harmful effects of 
oxidant molecules achieved by redox signalling pathways is responsible for re-establishing 
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the state of redox homeostasis of a cell, which is how, in fact, diseases are prevented or 
cured (Dröge, 2002; Ursini, Maiorino, & Forman, 2016). 
Amongst oxidant species are the reactive oxygen species (ROS) such as the superoxide 
radical (O2•ˉ), the hydroxyl radical (OH•) and the hydrogen peroxide (H2O2), produced 
enzymatically by the action of nicotine adenine dinucleotide phosphate (NADPH) oxidases 
or xanthine oxidases, and reactive nitrogen species (RNS), like nitric oxide (NO•), generated 
in biological tissues by specific nitric oxide synthases. Although less reported, there are 
also oxidant species derived from the halogens chlorine and bromine, that are commonly 
classified as reactive chlorine species (RCS) and reactive bromine species (RBS), 
respectively (Halliwell & Gutteridge, 2015; Sies, 1985). Regardless of their origin, oxidant 
molecules can also be classified as free radical species or non-radical species, depending 
on whether their atomic or molecular orbitals have, or have not, unpaired electrons 
(Phaniendra, Jestadi, & Periyasamy, 2015). Free radicals are generally more reactive, as 
the absence of paired electrons makes them to react with other molecules to become stable. 
(Halliwell & Gutteridge, 2015; Pham-Huy, He, & Pham-Huy, 2008). An extensive list of free 
radical and non-radical ROS, RNS, RCS and RBS can be found in Appendix 1. 
The main endogenous source of ROS is the electron transport chain in the mitochondria, 
where 90% of the cellular oxygen is consumed (Khansari, Shakiba, & Mahmoudi, 2009). 
During the electron transfer needed for reduction of oxygen to water, approximately 1 to 3% 
of all electrons leak from the complex I and III to produce superoxide (O2•ˉ), hydrogen 
peroxide (H2O2) and hydroxyl radical (OH•) instead of water (Birben et al., 2012). Additional 
endogenous sources of ROS include cytochrome p450, endoplasmic reticulum and 
peroxisomes, through the action of NADPH and xanthine oxidases, and phagocytic cells 
like neutrophils and macrophages that, during their encounter with pathogens release 
superoxide radicals (O2•ˉ) and hydrogen peroxide (H2O2) through the action of the enzyme 
NADPH oxidase, and hypochlorite (ClO-) via myeloperoxidases (Birben et al., 2012; 
Dahlgren & Karlsson, 1999). Among these sources of ROS, it is important to highlight 
NADPH oxidase enzymes (NOX) as they are the only enzymes that produce ROS as their 
primary function. NOX enzymes are transmembrane proteins expressed by a wide variety 
of cell types and include different isoforms. The mammalian NOX family includes seven 
isoforms and all of these isoforms are composed the catalytic subunit gp91phox (known as 
NOX2) together with the regulatory subunits p22phox, p47phox, p40phox, p67phox and the 
RAC and RAP1A GTPases (Touyz, Briones, Sedeek, Burger, & Montezano, 
2011).  Isoforms NOX1, NOX2, NOX4, and NOX5 have been identified in vascular tissue 
and NOX3, expressed in the inner ear (Lambeth, 2004). 
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Moreover, hydroxyl radicals (HO•) can also be generated by Fenton-type reactions, which 
involve the reaction of Iron (II) with hydrogen peroxide (Höhn, König, & Grune, 2013).  
Oxidants can also be produced exogenously from xenobiotics like pollutants, smoke, or 
radiation, that per se contain components that stimulate the production of ROS. For 
example, industrial pollutants such as phthalate and nonylphenol, that are found in plastics 
and cosmetic products and are seen to interfere with the hormonal system of numerous 
organisms, have been also reported to be linked to the production of O2- and H2O2 in male 
testicular tissue. Cigarette smoke, which contains alkaloids, inorganic molecules, and 
nitrosamines, was also seen to increase the number of leukocytes in plasma, and 
consequent production of ROS (Pandey & Rizvi, 2011; Shamim i. Ahmad, 2016).  
To balance the levels of oxidative species in vivo, organisms have developed defence 
mechanisms based on antioxidant species, that are stable enough to donate electrons to a 
free radical, neutralising it, and thus delaying and preventing its capacity for oxidation (Sies, 
1993). Examples of antioxidants include the enzymes superoxide dismutase (SOD), 
catalase (CAT), and glutathione peroxidase (GPx), which are synthesized in vivo, and 
vitamin E (α-tocopherol), vitamin C (ascorbic acid), carotenoids, and other phenols, 
considered to be “antioxidant nutrients”, as they can only be up taken through the diet 
(Aruoma, 1998). 
The interaction between oxidants and antioxidants is, therefore, critical for the prevention 
of oxidative damage and promotion of the cellular redox homeostasis (Figure I.1), as the 
signal damage triggers appropriate modulation mechanisms necessary for either cell 
survival or apoptosis (Wojciech & Agnieszka, 2017). 
 
Figure I.1. Schematic representation of some of the biological implications of ROS in the cell. ROS 
produced either by mitochondrial dysfunction and/or NADPH oxidases can bind to proteins and lipids affecting 
its conformation and trigger redox pathways involved the expression of oxidative stress-related genes. 
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1.3. Lipid Peroxidation 
Lipids, especially the unsaturated ones, are very susceptible to oxidative attack under 
oxidative stress conditions and undergo a process of lipid peroxidation (Figure I.2) to 
generate lipid peroxyl radicals and hydroperoxides, which can be further rearranged or 
fragmented to yield a wide variety of esterified and non-esterified lipid oxidation products 
(Ayala et al., 2014). The term lipid peroxidation is commonly used to define the oxidative 
deterioration of polyunsaturated lipids (lipids that contain at least one double bond (C=C) 
within the fatty acid chain) to yield lipid peroxides. Examples of polyunsaturated lipids are 
9,12-octadecadienoic and 5,8,11,14-eicosatetraenoic acids, also known as linoleic and 
arachidonic acids, respectively, and docosahexaenoic acids, all essential constituents of 
cell membranes. Hence, lipid peroxidation causes damage to the membrane of  lipids and, 
therefore is responsible for destructive cytotoxicity in the affected cells (Halliwell & 
Gutteridge, 2015).  
The mechanism of lipid peroxidation starts with the abstraction of a hydrogen atom from a 
methylene group (CH2) of the fatty acid, by the attack of a reactive specie – the initiation 
stage. The presence of a double bond weakens the C-H bonds on the adjacent carbon 
atom, and so the H removal gets easier. From this, a carbon radical (C-H•) is formed, which 
tends to stabilize to a conjugated diene (hydrocarbon that contains two carbon double 
bonds) by a molecular rearrangement. By further reaction with an oxygen molecule, a 
peroxyl radical, R-OO• is formed. The hydroxyl and peroxyl radicals generated can further 
abstract a hydrogen atom from adjacent fatty-acid side-chains and yield new carbonyl 
radicals that can react with O2 to form new peroxyl radicals, leading, therefore, to a chain 
reaction phenomenon – the propagation stage. When two radicals encounter and react 
with each other, they form a new bond between themselves and produce a non-radical 
specie, ending the propagation chain – termination stage (Halliwell & Gutteridge, 2015).  
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Figure I.2. Representation of the mechanism of free radical-mediated lipid peroxidation. Oxidation of 
unsaturated fatty acids such as linoleic acid starts with the abstraction of a hydrogen atom from the unsaturated 
chain to form a CH• radical, which rearranges to form a peroxyl radical. Due to its instability, peroxyl radicals 
react with other free fatty acids, to produce new radicals, in a chain reaction that only stops when two radical 
species react with each other to form a non-radical species. Examples of hydroperoxides formed from linoleic 
acid are the 9-hydroperoxyoctadecadienoate and the 13-hydroperoxyoctadecadienoate and these can further 
originate intermediate products such as 9-Peroxyoctadecadienoate, 9,10-Dioxetaneoctadecadienoate or 13-
Peroxy-9,10- Dioxetaneoctadecadienoate. 
1.3.1. Lipid Peroxidation Products 
A key feature of lipid peroxidation is the breakdown of polyunsaturated fatty acids (PUFAs) 
to yield a variety of electrophilic short-chain aldehydes that are thought to have a major role 
on human health and lifespan (Uchida, 2007). These lipid peroxidation products (LPP) can 
react covalently with macromolecules to form adducts, through which they mediate the 
activation of redox-sensitive signalling pathways involved in diverse aspects of cellular 
responses, such as detoxification and proinflammatory and anti-inflammatory responses 
(Reis & Spickett, 2012; Uchida, 2007). Examples of redox-sensitive pathways include the 
keap1/Nrf2 pathway, the nuclear factor kB (NF-kB) signalling pathway and the tyrosine 
and MAP kinases pathways , all critical in gene regulation during inflammatory and immune 
responses (Deen et al., 2018; Leonarduzzi, Robbesyn, & Poli, 2004). 
Depending on the profile of the oxidised lipid (i.e. its length, and number and position of the 
double bonds) and the type of oxidant molecule, the generated LPPs can be classified into 
five different categories (Table I.1): (1) Alkanals, when only containing a single aldehyde 
group; (2) alkenals, when, besides the aldehyde group, they also contain a double bond in 
the hydrocarbon chain; (3) -substituted alkenals, when the aldehyde contains additional 
functional groups; (4) keto-aldehydes when the aldehyde contains a keto group; and (5) 
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alkanedials, when the molecules contain two terminal carbonyl groups (Domingues et al., 
2013; Sousa, Pitt, & Spickett, 2017; Uchida, 2007). 
Table I.1. Classes of aldehydes formed by lipid peroxidation of polyunsaturated acids and 
corresponding examples. Nomenclature is based on the length, and number and position of the double bonds. 
Alkanals Alkenals -substituted Alkenals Ketoaldehydes Alkanedials 
2-hydroxybutanal Acrolein 4-hydro-2-hexenal 4-Oxononemal Glyoxal 
2-hydroxyheptanal Crotonaldehyde 4-hydroxy-2-nonenal Methyl glyoxal Malondialdehyde 
Pentanal 2-Pentanal 4-hydroxy-2,6-nonadienal - - 
Hexanal 2-Hexenal 4-hydroxy-2,6-dodecadienal - - 
Alkanals, when compared to the other classes of oxidised lipids, are fairly simple molecules. 
Because they only present a single carbonyl functional group, these molecules can only 
react with one amine group, yielding a single adduct. Butanal, hexanal and nonanal are 
listed as the major alkanals generated by lipid peroxidation (Sousa et al., 2017). Alkenals, 
on the other hand, due to the presence of the two electrophilic reaction centres, are much 
more reactive molecules, and this bi-reactivity is particularly interesting as it enables the 
formation of cross-link adducts, which are likely to have a bigger impact on the normal 
functioning of a cell. -substituted alkenals, such as the ones containing the functional 
groups hydroperoxyl (-OOH), epoxy, hydroxyl (4-hydroxyalkenals), or keto (4-oxo-
alkenals), at the C4 position, are considered to be the most prominent class of lipid 
peroxidation-specific aldehydes (Sousa et al., 2017). Belonging to -substituted alkenals 
there is the very well-studied aldehyde 4-hydroxy-2-nonenal, considered to be one the most 
cytotoxic LPPs (Benedetti, Comporti, & Esterbauer, 1980). Ketoaldehydes, including 
ketoalkanals and ketoalkenals, are another important class of reactive aldehydes, of which 
4-oxo-2-nonenal (ONE) is part. ONE is originated from the peroxidation of n-6 PUFAs and
is able to form three possible crosslink molecules as it contains a ketone, a carbonyl group 
and a double bond in its structure (Uchida, 2003b). Alkanedials, or di-aldehydes, are 
molecules containing two terminal carbonyl groups and, like -substituted alkenals, are 
bifunctional and able to crosslink proteins and DNA (Sousa et al., 2017). 
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1.3.1.1. 4-Hydroxynonenal (HNE), the Most Toxic Lipid Peroxidation Product 
4-hydroxy-trans-2-nonenal, or hydroxynonenal, usually abbreviated to HNE, deserves 
special attention as it has been reported to be the most toxic, reactive and abundant LPP 
(Castro, Jung, Grune, & Siems, 2017). This product was first discovered and detected in 
the 1960s by Schauenstein et al., but it was only recognised as a cytotoxic product 20 years 
later (Ayala et al., 2014; Benedetti et al., 1980). This compound falls into the category of γ-
substituted alkenals and it is a major product of the decomposition of -6 polyunsaturated 
fatty acids, such as linoleic and arachidonic acid, through either enzymatic or non-
enzymatic pathways (Spickett, 2013). By the enzymatic process, HNE can result from 13-
hydroperoxyoctadecadienoic acid (13-HPODE), which is a product of oxidation of linoleic 
acid, via the action of 15-lipoxygenase 1 (15-LOX-1) or from 15-
hydroperoxyeicosatetraenoic acid (15-HPETE), a product of oxidation of arachidonic acid,  
by the action of 15-lipoxygenase 2 (15-LOX-2) (Wojciech & Agnieszka, 2017). In the non-
enzymatic process, the production of HNE involves several oxygen radical-dependent 
reactions involving hydroperoxides, alkoxyl radicals, epoxides and fatty acyl groups. The 
main reaction is believed to be the beta-cleavage reaction of lipid peroxyl radicals, which 
leads to the cyclization of peroxyl radicals to form dioxetane, for subsequent chain cleavage 
(Ayala et al., 2014; Wojciech & Agnieszka, 2017). 
The levels of HNE generated during lipid peroxidation depend primarily on the availability 
of endogenous PUFAs, but exogenous PUFAs, derived from food, can also play a major 
role. In fact, a study revealed that in western diets, where the ratio of -6: -3 fatty acids is 
around 15:1, the levels of HNE were increased and so did the onset of several chronic 
inflammatory diseases (Patterson, Wall, Fitzgerald, Ross, & Stanton, 2012). Values 
reported for plasmas, cells, and subcellular fractions showed that in physiological conditions 
(0.1-1 μM), HNE is thought to be beneficial to cells, as it can act as a signalling molecule 
stimulating the synthesis of detoxifying enzymes and cell resistance to oxidative stress 
(Hermann Esterbauer, Schaur, & Zollner, 1991). Conversely, at higher concentrations (10-
60 μM), it has been reported that this aldehyde starts promoting organelle and protein 
damage, which leads to induction of autophagy, senescence, or cell cycle arrest; 
nevertheless, cells can subsist. At concentrations above 100 μM, HNE was seen to induce 
cell dysfunction and apoptosis by inhibiting glycolytic enzymes, mitochondrial respiration 
and even DNA and protein synthesis (Barrera et al., 2014; Hermann Esterbauer et al., 1991; 
Schaur, 2003; Shoeb, Ansari, Srivastava, & Ramana, 2013; Wojciech & Agnieszka, 2017; 
Zhang & Forman, 2017).  
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When HNE is present at high concentrations, it can react with proteins and/or DNA to form 
adducts, which, therefore, results in a variety of cytotoxic and genotoxic consequences. 
This reactivity is due to the presence of the hydroxy group, the C=C double bond and the 
C=O carbonyl group, all electrophilic centres for nucleophilic attack. HNE can form Schiff’s 
base adducts between its carbonyl group and the free amino groups of Lys and Arg 
residues, and/or Michael adducts between its β carbon and the nitrogen lone pair of the His 
and Lys residues, or the sulfhydryl group of Cys residues (Figure I.3) (Domingues et al., 
2013). HNE can also contribute to protein crosslinking due to its bi-reactivity, and according 
to the literature, it is estimated that 1-8% of the HNE formed in cells ends up covalently 
bound to proteins (Zhong & Yin, 2015). 
 
Figure I.3. Chemical structure of 4-hydroxy-2-nonenal (HNE) and reaction mechanisms involved in the 
formation of Michael and Schiff’s base adducts. This aldehyde contains functional groups with a very high 
reactivity towards nucleophilic residues of peptides/proteins, namely the C=C double bond and the C=O 
carbonyl group, allowing HNE to form Michael adducts with cysteine, lysine or histidine residues and/or Schiff’s 
base adducts with lysine amino acids. 
 
Due to its amphiphilic nature, HNE is able to diffuse across cell and organelle membranes 
and covalently modify cytoplasmic or nuclear compounds far from the site of its generation. 
If formed outside the cells (i.e., in an inflammatory site or in the plasma), HNE can react 
with stromal proteins or proteins belonging to adjacent cells, that do not undergo lipid 
peroxidation. HNE has also been reported to mediate several pathological events in 
humans, including cellular growth inhibition and apoptosis induction (Barrera et al., 2014; 
Nakashima et al., 2003; Xiao, Zhong, Xia, Tao, & Yin, 2017).  
Regarding its metabolism, HNE has a half-life of less than 2 min in physiological conditions 
and can be metabolized by glutathione-S-transferase (GST), alcohol dehydrogenase (ADH) 
and aldehyde dehydrogenase (ALDH), depending on the stress level, to its corresponding 
alcohol, 1,4-dihydroxy-2-nonene (DHN), corresponding acid, 4-hydroxy-2-nonenoic acid 
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(HNA), or to an HNE-glutathione conjugate product (Ayala et al., 2014; Chapple, Cheng, & 
Mann, 2013). 
Elevated levels of HNE adducts have been found in chronic liver diseases (Poli, Biasi, & 
Leonarduzzi, 2008), Alzheimer’s disease (Reed, Pierce, Markesbery, & Butterfield, 2009), 
systemic lupus erythematosus (Khan, Moinuddin, Mir, Isalma, & Alam, Khursheed, Ali, 
2016), cancer (Zhong & Yin, 2015), cardiovascular diseases, diabetes, and Parkinson’s 
disease (Ayala et al., 2014; Csala et al., 2015; Shoeb et al., 2013), providing evidence that 
HNE is highly present in cells and tissue and may contribute to the progression of many 
diseases. A very succinct table showing the concentration of different aldehydes in the 
serum of healthy individuals and individuals with diabetes, rheumatoid arthritis and lung 
cancer can be found in Table I.2. 
 
Table I.2. Concentration of different aldehydes in serum or plasma collected from healthy and diseased 








Lung cancer   
Glyoxal 1.04 μM 2.75 μM 1.34 μM - A  
Methylglyoxal 146.5 nM 299 nM 145 nM - B  
Acetaldehyde 1279 nM   - C  
Propionaldehyde 135 nM   - C  
Acrolein 42.2 nM 68.7 nM 76.3 nM - B  
 1.26 μM 6.35 μM 2.92 μM  A  
Malondialdehyde 5.54–6.56 µM   - D  
 0.36–1.24 μM   - E  
 15.1 μM 25.6 μM 37 μM - A  
 0.44–0.89 μM    E  
Crotonaldehyde 61.3 nM   - B  
Valeraldehyde 7 nM   - C  
Hexanal 17 nM   - C  
 1.04-2.06 μM   2.28–25.3 μM F  
2-Hexanal 59.5 nM 59.2 nM 61.7 nM - B  
Heptanal 0.02–0.91 μM   0.16–3.91 μM F  
Hydroxynonenal 0.96 μM 1.27 μM 1.78 μM  A  
 82 nM    G  
 68.9-107 nM    H  
 0.65 μM    I  
a Detection methods: A – HPLC–fluorescence detection of difurylimidazole derivatives; B – LC-MS with 
peroxyoxalate chemiluminescence detection after fluorescence labelling with 4-(N,N-dimethylaminosulfonyl)-7-
hydrazino-2,1,3-benzoxadiazole; C – HPLC of fluorescent decahydroacridine derivatives; D – HPLC-DAD, 
HPLC-fluorescence, LC-DAD or LC/MS-SIM; E - HPLC analysis of the thiobarbituric acid (TBA) derivative; F - 
Derivatization with 2,4-dinitrophenylhydrazine (DNPH), extraction with DLLME-SFO, analysis by HPLC; G – 
HPLC of the oxime-bis-tert-butyldimethylsilyl derivative; H – Derivatization with dinitrophenylhydrazine (DNPH), 
analysis by LC; I – DNPH derivitization, SPE of hydrazine and HPLC with detection at 370 nm. 
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Therefore, as biomarkers of oxidative stress in vivo, HNE-protein adducts may deserve a 
place in medical diagnostic testing (Requena et al., 1996). 
Figure I.4. Schematic illustration of the effects of HNE inside and outside the cell. HNE mediates cell 
signaling pathways like Nrf2/keap1 involved in processes such as autophagy, proliferation and apoptosis, and 
can react with protein and/or lipids leading to conformational changes and, therefore, protein and lipid damage. 
1.4. Protein Lipoxidation 
Proteins can undergo a wide variety of oxidative post-translational modifications (oxPTM), 
by reaction with the LLPs above mentioned. This phenomenon is known as protein 
lipoxidation, and the protein-lipid adducts therefrom are called lipoxidation products 
(Domingues et al., 2013). The mechanism through which these adducts are formed 
depends on both the functional groups of the LPPs and the availability of specific amino 
acids but, generally, LPPs are seen to react most frequently with four chemical groups: the 
free amine group (NH2-) of lysine residues, the imidazole group of histidine residues, the 
guanidine group of arginine residues and the thiol (SH-) group of cysteine residues. The 
order of reactivity of nucleophilic amino acids towards electrophilic compounds is reported 
to be Cys>>His>Lys; however, factors including solvent accessibility and nucleophilicity can 
also affect their reactivity (Aldini et al., 2015). Michael adducts, generated by Michael 
addition, are formed by reaction of the electrophilic carbon located in the  position with 
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respect to the ,  unsaturated carbonyl group with the nitrogen lone pair of the 
histidine/lysine or the thiol group of cysteines (Figure I.5) (Domingues et al., 2013).  
 
Figure I.5. Mechanism of Michael adduct formation between an aldehyde and a cysteine residue. The 
Michael reaction starts with the attack of the nucleophile (in this case a cysteine residue) to the aldehyde (in 
this case the LPP acrolein) at the electrophilic alkene carbon, yielding an enolate ion. The enolate then 
deprotonates a water molecule recreating hydroxide and the energetically more favourable carbonyl group. 
 
Although Michael adducts are theoretically reversible, Michael addition to cysteine and 
histidine residues is seen almost as irreversible, as the rate of the reverse reaction is 
considerably lower when compared to the rate for the formation of the adduct. However, for 
Michael adducts to Lys residues the same is not observed, meaning that for its stabilization, 
a reduction reaction with NaBH4 is needed (Domingues et al., 2013). 
Schiff’s base adducts, on the other hand, are formed by condensation of an aldehyde or a 
ketone with the primary amine of Arg or Lys residues. In more detail, the reaction starts with 
the formation of a carbinolamine intermediate that rearranges and loses water to yield a 
Schiff base (Figure I.6). Like Michael adducts, Schiff’s base adducts are reversible and can 
always be hydrolysed back to their aldehydes or ketones and amines by aqueous acid or 
base conditions (Vistoli et al., 2013).  
Bi-functional lipid peroxidation products, as mentioned before, have the capability of 
reacting via the two different functional groups and can therefore form Michael and Schiff’s 
base adducts, promoting protein cross-linking (Aldini et al., 2015).  
The importance of lipoxidation has attracted a great deal of attention in the recent years, 
due its recognition as a mechanism for regulating protein function in health and disease, 
especially as lipoxidation adducts may interact or compete with other modifications, 
including oxidative modifications or adduct formation with drugs in therapeutic regimes of 
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Figure I.6. Mechanism of Schiff base adduct formation between a ketone and a lysine residue. The Schiff 
base formation mechanism involves an initial attack from a nucleophile ((in this case a lysine residue) to the 
carbonyl group, followed by transfer of a proton from a weak acid to a strong base. After protonation of the -OH 
group, a molecule of water is released, allowing the formation of a double bond. 
 
1.4.1. Biological Occurrence of Lipoxidation Adducts 
The accumulation of lipoxidation products in tissues has been reported to increase the level 
of inflammation in the body through the activation of specific cell receptors called RAGE 
(receptor for advanced glycation end products), seen to be involved in modulation of 
proinflammatory signals (Bengmark, 2007). In particular, RAGE binds to proinflammatory 
cytokine-like mediators of the S100/calgranulin family, which encompasses polypeptides 
released by inflammatory cells, and to the nuclear protein amphoterin, that when released 
exerts proinflammatory activities (Hofmann et al., 1999; Hori et al., 1995). Moreover, the 
binding of RAGE to glycated and lipoxidation products in vascular cells, such as endothelial 
cells and neuronal cells, and inflammatory cells like monocytes, may activate the signalling 
pathways of erk1/2 (p44/p42), p38 and SAPK/JNK MAP kinases, rho GTPases, 
phosphoinositol-3 kinase and of NF-B, all linked to inflammation status (Chavakis, 
Bierhaus, & Nawroth, 2004). Tyrosine kinase receptors, such as the epidermal growth factor 
receptor (EGFR) and the platelet-derived growth factor receptor (PDGFR), have also been 
recognized as targets of electrophilic oxidised lipids (Leonarduzzi et al., 2004). LPPs like 
acrolein and 4-HNE elicit PDGFR modification and subsequent dysfunction, leading to the 
defective proliferation of smooth muscle cells, which could be implicated in the 
pathogenesis of fibroatheroma and vulnerable plaque (Uchida, 2007). However, 
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lipoxidation has also been reported to occur in healthy individuals, where the formation of 
lipoxidation products can even induce gain of protein function or activity, leading to 
beneficial effects (Levonen et al., 2004; Martín-Sierra, Laranjeira, Domingues, & Paiva, 
2019). Bacterial proteins SoxR and OxyR are transcriptional activators that respond to 
superoxide and H2O2, respectively, and by getting oxidized activate directly the transcription 
of several genes including catalase (katG), alkyl hydroperoxide reductase (ahpCF) genes, 
glutathione reductase (gorA), glutaredoxin 1, and a ferric uptake regulator (Halliwell & 
Gutteridge, 2015).  
Lipoxidation products are particularly associated with ageing and age-related diseases such 
as cancer, atherosclerosis, diabetes, chronic obstructive pulmonary disease, systemic 
lupus erythematosus and neurodegenerative diseases (including Huntington’s, Parkinson’s 
and Alzheimer’s diseases) (Baraibar & Friguet, 2013).  
In diabetes mellitus, the high level of glycoxidation and lipoxidation products in plasma and 
tissue proteins suggests that oxidative stress is increased, however, it is still not clear 
whether oxidative stress has a primary role in diabetic complications or it is a secondary 
indicator of end-stage tissue damage in diabetes (Baynes & Thorpe, 1996; Dröge, 2002). 
Superoxide was seen to be generated by the process of glucose autoxidation, and 
furthermore, in hyperglycaemia conditions, low-density lipoprotein (LDL) peroxidation was 
reported to occur in endothelial cells and account for the generation of LPPs (Afonso & 
Spickett, 2018; Dröge, 2002). Lipoxidation adducts to apolipoprotein B of LDL (lysine-MDA, 
the cross-link lysine-MDA-lysine, lysine-HNE, and histidine-HNE) were already reported, as 
well as a significant increment in the levels of HNE-modified human serum albumin (HNE-
HSA) in sera of patients with type 2 diabetes (Jakus, Bauerova, Michalkova, & Carsky, 
2000; Lyons & Jenkins, 1997; Toyokuni et al., 2000) 
Regarding cancer, the role of lipid peroxidation and lipoxidation is still not completely 
understood, as lipid composition can differ between each type of cancer cell. 
Nevertheless, increased incidence of HNE-protein adducts has been observed in human 
liver, kidney and colon cancer tissues (Zhong & Yin, 2015). Moreover, studies in astrocytic 
and ependymal glial tumours showed the incidence of HNE-positive tumour cells was 
directly related to increasing grades of malignancy (Martín-Sierra et al., 2019).  
In atherosclerosis, one of the first events that occurs is the invasion of the artery wall by 
monocytes and macrophages, cells that possess the scavenger receptor to oxidised LDL 
(oxLDL) and that, by binding to oxLDL, become activated and stimulated to produce even 
more ROS. HNE, MDA, methylglyoxal and glyoxal have been reported to directly modify 
the structure of LDL, changing its metabolism towards macrophages. In particular, protein 
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carbonyls, MDA and HNE-adducts on Lys were detected in atherosclerotic plaque, but the 
total extent of lysine modification by these compounds was less than 1% of the lysine 
residues in plaque proteins (Baynes & Thorpe, 2000). 
In autoimmune diseases, the presence of lipoxidation adducts was also observed, namely 
in systemic lupus erythematosus (SLE), where catalase and HSA were reported to be 
modified by HNE. However the actual site of modification was not reported (D’souza et al., 
2008; Grune et al., 1997; Khan et al., 2016). SLE patients were also seen to have elevated 
levels of anti-oxLDL autoantibodies that cross-react with phospholipids, which suggests the 
antigen might be oxidised on both the protein and lipid structures of LDL (Kurien, Hensley, 
Bachmann, & Scofield, 2006). Regarding neurological diseases, increased levels of 
modified proteins were found in neuronal cytoplasmin disease compared to age-matched 
control samples. Carbonyls were confirmed in creatine kinase BB, glutamine synthase, 
ubiquitin carboxy-terminal hydrolase L-1, α-enolase and dihydropyrimidinase-related 
protein 2, although the nature of the carbonyl formation was not confirmed (Domingues et 
al., 2013). 
While it can be seen that there is abundant evidence of protein lipoxidation in the pathology 
of several diseases, they are in most of the cases focused on HNE and MDA adducts, as 
most of the detection methods (at least antibody-based ones) are directly targeted to these 
products. Development of improved methods to identify and characterize electrophilic lipid–
protein adducts are still in great demand, as well as the need to understand the exact 
relation between redox status and protein lipoxidation in the triggering of antioxidant and 
adaptive response (Vasil’ev, Tzeng, Huang, & Maier, 2014).  
 
1.4.2. Detection of Lipoxidation Adducts 
Given the importance of lipoxidation products in the pathology of human disease, there has 
been a great effort to develop technologies to specifically detect lipid-protein adducts in 
biological and clinical samples. Mass spectrometry (MS) is one of the techniques that has 
been used for many years for the study of proteins-lipid adduct. As MS analysis is based 
on determining the mass-to-charge (m/z) ratio of ionized analytes, and oxPTMs change the 
m/z ratio of the intact proteins, MS is seen as a powerful method not only for detecting but 
to characterize lipoxidation products (Verrastro, Pasha, Jensen, Pitt, & Spickett, 2015). 
When operated in tandem mode (MS/MS), MS not only provides detailed structural 
information of the protein-lipid adduct, it can also be used to confirm the location of the 
oxidative post-translational modification in the peptide backbone (oxPTM) (Aldini et al., 
2015). Adducts can be detected by MS analysis with either matrix assisted laser 
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desorption/ionization (MALDI), or electrospray (ESI), often coupled to liquid 
chromatography (LC–MS), in positive ion mode (Bollineni, Hoffmann, & Fedorova, 2011). 
Modified peptides are typically recognized in the MS spectrum based on the mass shift 
versus the native peptide: if it is Michael adduct the mass shift caused by the modification 
is equal to the molecular weight of the LPP, if it is a Schiff’s base adduct the difference is 
then equal to the molecular weight of the LPP minus 18 amu, owing to loss of H2O during 
adduct formation (Aldini et al., 2015). The characterization of the adducts can be performed 
by following either a top-down strategy, that involves analysis of intact proteins and 
fragmentation within the mass spectrometer, or a bottom-up proteomic approaches that 
consist of enzymatically digesting the protein (usually using trypsin) to a peptide mixture, 
before MS analysis (Loizides-Mangold, 2013). 
Several studies following these approaches for the detection of HNE, MDA and acrolein 
adducts have already been published and there has been extensive characterization of 
these adducts in vitro and in vivo (Domingues et al., 2013). Nevertheless, for the 
identification of protein lipoxidation adducts in more complex samples, such as cells, tissues 
or even biological fluids, untargeted approaches are not always appropriate, and label-
dependent methods (involving chemical probes) are required (Domingues et al., 2013). 
Because most of the existing derivatization methods exploit the high reactivity of the free 
carbonyl groups of the adducts, carbonyl-reactive reagents such as 2,4-
dinitrophenylhydrazine (DNPH) are commonly used. DNPH has been extensively used due 
to its convenience, low expense and relative simplicity, however this method is not 
completely specific to lipoxidation products, as other carbonyls formed by direct oxidative 
attack on the protein will be detected as well (Domingues et al., 2013). Other labelling 
reagents have been reported for detecting carbonyls, like fluorescein derivatives or biotin-
based hydroxylamine-functionalized reagents (Vasil’ev et al., 2014); nevertheless it is 
important to note that these labelling methods cannot be used to identify lipoxidised proteins 
in vivo in humans, as they require the presence of an artificially labelled lipid in the tissue 
of interest. 
It is essential to understand the requirements and limitations of the techniques used and 
select appropriate approaches to address the research question. Although MS approaches 
are being developed and applied (Afonso & Spickett, 2018; Aldini et al., 2006; Shibata et 
al., 2017), they have the limitation of requiring expensive specialist equipment and being 
challenging to perform. Moreover, their translation for early diagnostic screening tools in 
clinical settings continues to be difficult, owing to factors such as lack of well-established 
validation protocols for oxPTMs, the wide variety of methodologies, and complex data 
analysis (Verrastro et al., 2015). 
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Therefore, antibody-based techniques remain attractive in the field of oxidative stress, as 
immunoassays have the advantage of combining high sensitivity, relative simplicity, 
accessibility and rapidity in one single platform, which is the ultimate goal in terms of 
healthcare diagnostics. Antibodies specific to HNE, HHE, MDA, acrolein, crotonaldehyde 
and methylglyoxal have been used both in enzyme-linked immunosorbent assays (ELISA) 
and immunohistochemistry methods, and the identification and detection of LPPs and 
lipoxidation adducts has seen to be successful (Zarkovic, Jakovcevic, & Zarkovic, 2017). 
Regarding HNE, the first generated antibodies against this lipid peroxidation oxidation 
product were in the late 1980s, when Palinski et al (1989) and Jurgens et al (1990) produced 
antibodies against HNE-treated LDL (Jurgens, Ashy, & Esterbauer, 1990; Palinski et al., 
1989). Subsequently other groups adopted different approaches and raised antibodies 
against alternative immunogens, such as HNE-treated keyhole limpet haemocyanin (KLH) 
(Hartley, Kroll, & Petersen, 1997; Toyokuni et al., 1995; Uchida, Szweda, Chae, & 
Stadtman, 1993; Waeg, Dimsity, & Esterbauer, 1996), a synthetic peptide Gly3-His-HNE-
Gly3 conjugated to KLH (Uchida, Itakura, et al., 1995), or HNE-modified HSA (Khan et al., 
2016; Khatoon, Moinuddin, Alam, & Ali, 2012).The majority of these were polyclonal sera 
able to recognize HNE adducts on a variety of proteins but some monoclonal antibodies 
were also produced (Toyokuni et al., 1995; Waeg et al., 1996). In some cases, specificity 
for a specific modified residue or adduct was reported, as is the case of antibodies specific 
to histidine (Toyokuni et al., 1995; Waeg et al., 1996) or cysteine adducts (Hartley et al., 
1997), while other antisera showed broader specificity. Monoclonal antibodies to MDA–
lysine adducts of LDL and polyclonal antibodies to MDA–lysine adducts of KLH were also 
developed for ELISA immunohistochemistry protocols and similar approaches were used 
for acrolein and HHE-adducts (Haberland, Fong, & Cheng, 1988; Uchida et al., 1998; 
Yamada et al., 2004). Another interesting antibody available in the field is the mAb EO6 
autoantibody, found in apoE-deficient mice, that has been shown to be specific to oxidised 
phospholipids (oxPL) and low-density lipoprotein-oxPL adducts (Hörkkö et al., 1999). 
Currently, there is a vast offer of commercial anti-HNE antibodies, from several companies, 
that derive in most cases from the original clones listed below in Table I.3.  
However, even though all these antibodies have been found to detect different kinds of 
lipoxidation adducts, one of the limitations of immunoassays is the dependence on the 
antibody specificity. Some of the reagents are polyclonal and likely to have cross-reactivity 
to similar adducts (Sousa et al., 2017). Moreover, none of the immunoassays are able to 
provide information about precise site of modification within the protein, or on the kind of 
protein that is modified.  
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Table I.3. List of the first antibodies generated against the lipid peroxidation product 4-HNE. 
Immunogen Animal Clonality Reference Year 
4-HNE-LDL Guinea Pig Polyclonal Palinski et al 1989 
4-HNE-LDL Rabbit Polyclonal Jurgens et al 1990 
4-HNEreduced-LDL Guinea Pig Polyclonal Palinski et al 1990 
4-HNE-KLH Rabbit Polyclonal Uchida et al 1993 
Gly3-His-HNE-Gly3 Rabbit Polyclonal Uchida et al 1995 
4-HNE-KLH Mouse Monoclonal Toyokuni et al 1995 
4-HNE-KLH Mouse Monoclonal Waeg et al 1996 
4-HNE-KLH Rabbit Polyclonal Hartley et al 1997 
4-HNE-HSA Rabbit Polyclonal Khatoon et al 2012 
 
 
1.5. Oxidation and Immunity 
Recent hypotheses have indicated that oxidative stress and oxidised biomolecules are 
involved in a process of sterile inflammation (i.e., inflammation in the absence of 
pathogens), activating the innate and adaptive immune responses. The modification of 
“self” biomolecules by oxidised lipids is seen to generate oxidation-specific epitopes (OSEs) 
that share a molecular identity with both pathogen-associated molecular patterns (PAMPs) 
on microbial pathogens, and damaged-associated molecular patterns (DAMPs) on 
apoptotic cells, making them to be recognized by a variety of pattern recognition receptors 
(PRR), that trigger signalling pathways to induce the secretion of inflammatory chemokines 
and cytokines. OSEs have a crucial role in physiological processes, as they target 
oxidatively modified endogenous molecules as damaged by oxidative stress, allowing the 
host to identify dangerous biological waste and maintain homeostasis (Uchida, 2013). 
OSEs including OxPLs and MDA-protein adducts have been reported on the surface of 
apoptotic cells, microvesicles and damaged structures such as OxLDLs (Leibundgut, 
Witztum, & Tsimikas, 2013).  
PPRs for OSEs encompass a wide set of molecules such as toll-like receptors (TLRs), 
nucleotide-binding oligomerization receptors domain-like receptors (NODs), scavenger 
receptors (SR; e.g., CD36 and SR-A1), RAGEs, and many others. They are mostly cell-
associated, located at the surface of antigen presenting cells, but soluble PPRs 
like components of the complement system, lectins, and pentaxins have also been reported 
(Foell, Wittkowski, & Roth, 2007). Detailed studies have shown that CD36 is the major SR 
for OxLDL and accounts for most of the binding and uptake of OxLDL by macrophages, 
and LOX1 to mediate MDA-induced nitric oxide (NO) production and binding to HNE 
adducts with ApoB100 protein in oxLDL (Binder, Papac-Milicevic, & Witztum, 2016). Toll-
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like receptors (TLR) have also been reported to recognize and respond to OSEs, namely 
TLR1, TLR2 and TLR4-6 heterodimer. Sensing of oxidised phosphatidylcholine (oxPC) 
seems to be important for the TLR4-mediated effects, OxPLs were seen to stimulate 
macrophages via a TLR2 pathways, chemokine secretion by macrophages stimulated with 
oxLDL was shown to require the cooperation of CD36 with a TLR4-TLR6 heterodimer 
and oxidised cholesteryl esters (OxCEs) were seen to trigger pro-inflammatory macrophage 
responses via TLR4. TLRs have not, however, been seen to be directly implicated in 
chemokine secretion induced by MDA or HNE (Weismann & Binder, 2012). 
Regarding soluble PPRs, C-reactive protein and complement factor H have been seen to 
bind to PC and PC-OxPL found in oxLDL, and MDA-epitopes, respectively, and more 
recently, milk fat globule-epidermal growth factor 8 (MFG-E8) has been shown to 
specifically recognize oxPC and oxidised phosphatidylethanolamine (oxPE) (Miller et al., 
2012). 
OSEs have also been identified as major targets of natural IgM antibodies (Binder et al., 
2016; Miller et al., 2012). Levels of IgMs specific for oxLDL and MDA-LDL were found to be 
higher in cord blood samples when in comparison with matched maternal blood samples. 
Studies have also reported several OSEs, including PC-oxPL, MDA and HNE adducts to 
be bound to up 30% of all natural IgM found in the plasma of wild-type mice (Grönwall et 
al., 2016). Furthermore, several natural monoclonal IgM antibodies with specificity to OSEs 
have been characterized, as is the case for the E06 mAb that was originally cloned from 
the spleens of atherosclerosis-prone apolipoprotein E (Apoe−/−) mice and showed specificity 
to PC-oxPL (Hörkkö et al., 1999).  
Despite the clear evidence that lipoxidation adducts are linked to the main inflammatory 
mechanisms, the exact biological consequences of lipoxidation adducts in pathology is still 
far from being understood. Undoubtedly, interdisciplinary studies combining different 
analytical techniques, cell biology, and immunology could help clarify the role of lipid-
derived DAMPs in disease aetiology.  
 
1.6. Antibodies 
As aforementioned, OSEs represent an important class of endogenous “danger signals” 
likely to exert positive selection pressure for natural antibody-producing B cells, 
and antibodies to these epitopes could present a promising strategy to target therapeutic 
molecules to active sites of inflammation. For better understanding how the immune system 
responds to these structures and how anti-HSA-HNE antibodies were generated in this 
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project, the following topics of this introduction are focused on immune responses that lead 
to the development of such specific molecules and how can these be generated and further 
refined for commercial application. 
 
1.6.1. Innate and Adaptive Immunity 
Upon infection by foreign pathogens, the immune system has the capability of triggering 
two different kinds of responses. Up to 12 hours after infection, the immune responses are 
based on the action of physical and chemical barriers, such as epithelial and antimicrobial 
substances, phagocytic cells such as neutrophils and macrophages, blood proteins, and 
cytokines, in what is known as innate immunity. After a day, and up to a week after infection, 
the immune responses start to develop specificity and memory capacity, via the production 
of antibodies that bind specifically to extracellular pathogens, so subsequent infections with 
the same pathogen can be easily fought. This delayed response is what constitutes 
adaptive immunity (Abbas, Lichtman, & Pillai, 2007).  
For a B lymphocyte to start producing antibodies it needs first to be activated via interaction 
with the antigen/OSEs and helper T cells (TH cells), and this activation takes place 
in peripheral lymphoid organs (lymph nodes and the spleen). When the antigen binds to the 
B cell receptor (BCR) it gets internalized through receptor-mediated endocytosis and is 
degraded and presented to T cells as peptides in a complex with major histocompatibility 
complex (MHC) class II molecules. Upon recognition of these peptide:MHC complexes by 
the TH cell, several signals such as the activation of CD40 on B cells and production of 
various cytokines by TH cells (IL-21, IL-6, TGF-β, IFN-γ, and IL-4) will cause B cells to 
migrate to different areas of the lymph nodes (Figure I.7), and proliferate and differentiate 
into antibody-secreting plasma cells that secrete different classes of antibodies with 
different functions (Murphy & Weaver, 2017).  
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Figure I.7. Illustration of the B cell affinity maturation process in a lymph node. Once B cells present the 
antigen to T helper cells and these receive co-stimulatory signals the selected B cells enter the dark zone of the 
follicle and undergo somatic hypermutation (SHM). After one or possibly more cycles of proliferation, B cells 
migrate to the light zone and, in the light zone, the mutated B cell receptors (BCR) are now exposed to antigens 
that are incorporated into immune complexes on the follicular dendritic cells (FDC). If the affinity of the BCR is 
very low, the B cell will not receive survival signals and will undergo apoptosis, and the surviving B cells can 
either re-enter the dark zone and undergo further proliferation and SHM, exit the follicle as plasma cells or they 
can exit as memory B cells. Adapted from: Heesters, Myers, & Carroll, 2014 
1.6.2. Molecular Structure and Functional Features 
All human antibody molecules share the same basic structural characteristics but display 
remarkable variability in the regions where the antigen binds. They are all Y-shaped 
molecules with a symmetric core structure containing two identical light chains and two 
identical heavy chains, covalently linked by disulphide bonds (Figure I.8). Each heavy and 
light chain has a molecular weight of approximately 50 kDa and 25 kDa, respectively, 
making an antibody of 150 kDa. Each antibody molecule has two antigen binding sites 
located at the amino terminal variable regions (known as VH and VL, respectively for variable 
regions located on heavy and light chains), where sets of complementarity-determining 
regions (CDRs) exists. These CDRs constitute a paratope, i.e., the antibody sequence that 
recognises antigen. The region on the antigen to  which the paratope binds is called epitope 
(Schroeder Jr & Cavacini, 2010).  
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Figure I.8. General representation of the antibody structure. 3D structure of an IgG antibody (PDB: 1IGT) 
illustrated as a ribbon diagram of the backbones of the polypeptide chains, where the heavy chains are depicted 
in green and the light chains in blue (A). Each heavy chain consists of three constant regions (CH) and one 
variable region (VH) while each light chain is composed of one constant (CL) and one variable region (VL). The 
two antigen-binding sites are formed by the juxtaposition of VL and VH domains. The bottom section of the 
antibody is the Fc region to which two arms, the Fab regions, are attached. The two heavy chains are linked to 
each other by disulphide bonds, and each heavy chain is linked to a light chain by a disulphide bond (B). The 
structure in panel B was taken from https://bxcell.com/antibody-structure/. 
The carboxy-terminal constant regions (CH and CL respectively for heavy and light chains), 
are, as the name states, constant, and only the CH regions are seen to mediate effector 
functions. There are 5 different classes of antibodies: IgG, IgM, IgD, IgE and IgA, being IgG 
by far the most abundant Ig in serum. It is also important to note that there are two types of 
light chains, known as lambda () and kappa (), and they can be found in any of these five 
major classes of antibodies (Abbas et al., 2007; Murphy & Weaver, 2017). No functional 
difference has been found between these two chains, however the ratio of  to  seems to 
be different from species to species: for mice it is 20:1, for humans 2:1 and for cattle 1:20 
(Sun et al., 2012). 
1.6.3. Antibody Variability 
The diversity of antibody repertoires arises mainly from two genetic events that involve 
recombination and mutation of the immunoglobulin genes. In a first instance, variability is 
generated by gene rearrangement mechanisms that occur due to the fact that, unlike most 
genes, the complete DNA sequence of the variable-region exon is encoded by two separate 
DNA fragments; then, upon rearrangement, the diversity is further enhanced by somatic 
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hypermutation processes, that introduce point mutations into those same V-regions genes 
(Murphy & Weaver, 2017).  
The rearrangement that produce the complete Ig light chain and heavy chain genes, also 
known as V(D)J recombination is depicted in Figure I.9, and occurs during B cell’s 
maturation. For the light chain, the rearrangement encompasses the variable (V) and joining 
(J) gene segments; whereas for the heavy chain there is a third gene segment involved 
called the diversity, of D gene segment. Because there are multiple copies of the V, D and 
J gene segments and each of which can be rearranged in many different formulas, several 
millions of immunoglobulin V regions can actually be formed; and this is the principle in 
which all the in vitro cloning techniques are based on for the generation of recombinant 
antibodies libraries (Abbas et al., 2007). 
Somatic hypermutation, on the other hand, occurs only in activated B cells, after the 
initiation of an immune response has been triggered, as a mechanism of affinity maturation 
for production of antibodies with greater affinity. Somatic hypermutation introduces 
mutations in the V regions via an enzyme called activation-induced cytidine deaminase, 
that might change from one to a few amino acids, leading to the formation of closely related 
B cell clones that only differ subtly in specificity and antigen affinity (Reynaud, Garcia, Hein, 
& Weill, 1995). 
In humans, the Ig variable regions accumulate mutations at a rate of about one base pair 
change per 103 base pairs per cell division, which is known to be 1 million-fold higher that 
the spontaneous rate of mutations in most of other genes (Z. Li, Woo, Iglesias-Ussel, Ronai, 
& Scharff, 2004). Although these mutations may be both transitions (e.g., C to T, G to A) 
and transversions (e.g., C to A or G; G to C or T), there seem to be preferentially targeted 
motifs like the WRCY (W = A or T, R = A or G, C, Y = T or C) and WA, that are referred to 
as hot spots (Peled et al., 2008). Nevertheless, nucleotide changes tend to be clustered in 
the CDRs of the V-regions, whereas silent or neutral mutations, that do not alter the amino 
acid sequence seem to occur in frame work regions (Jenne, Kennedy, & Reynolds, 2006). 
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Figure I.9. Somatic DNA recombination of the V-region genes. Light-chain V region genes are constructed 
from the variable (V) and joining (J) gene segments of the genomic DNA to form a complete light-chain V-region 
exon. The light-chain constant region (C) is encoded in a separate exon and is joined to the V-region exon by 
splicing of the light-chain RNA to remove the V-to-J and the J-to-C introns. Heavy-chain V regions are first 
constructed from the diversity (D) and the J gene segments, and then the V gene segment joins to the combined 
DJ sequence, forming a complete VH exon. A heavy-chain C region gene is encoded by several exons, that 
together with the leader sequence, are spliced to the V-domain sequence during processing of the heavy-chain 
RNA transcript. The leader sequence is later removed after translation, and the disulphide bonds that link the 
polypeptide chains are formed. The hinge region is shown in purple. From Murphy, K., Travers, P., Walport, M., 
& Janeway, C. (2008). Janeway's immunobiology. New York: Garland Science. 
1.6.4. Polyclonal, Monoclonal and Recombinant Antibodies: 
Distinguishing characteristics and applications 
When considering the use of antibodies for a certain application, whether it is biomedical 
research, diagnostics, therapy or even medicine, the first choice to be made is the type of 
antibody to use. There are polyclonal antibodies (pAbs), a mixture of antibodies that 
recognize different epitopes on the same antigen, monoclonal antibodies (mAbs), that only 
recognize a single epitope per antigen, and even recombinant antibodies (rAbs), that are 
tailor-made mAbs generated in vitro from a unique set of genes. Each type comes with their 
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own unique advantages and disadvantages and is produced by very different methods, 
making them suitable for different applications. 
pAbs are a heterogeneous mixture of antibodies, meaning each antibody recognizes a 
different epitope on the same antigen. Therefore, pAbs are more suitable for detection 
methods, namely detection of low concentration antigens, as the target antigen will bind to 
more than one antibody molecule on its multiple epitopes, so that its signal is effectively 
amplified. This is, however, a disadvantage for quantification studies. Another characteristic 
of pAbs is their tolerance for changes in the antigens, i.e. polymorphisms, heterogeneity of 
glycosylation, or slight denaturation. Minor changes in the structure of the antigen will not 
drastically affect their binding to the antibodies, and for this reason pAbs are often preferred 
over mAbs for detection of denatured proteins. pAbs are also known for being more robust 
and more stable over a broader range of pH and buffer compositions than mAbs (Lipman, 
Jackson, Trudel, & Weis-Garcia, 2005). However, pAbs have a great degree of batch-to-
batch variability, as their production depends always on the immunisation of an animal, and 
often present cross-reactivity to other serum proteins (Leenaars & Hendriksen, 2005). 
mAbs, on the other hand, are generated from a single B-cell clone and therefore only 
recognize a single epitope per antigen, which makes them highly monospecific and very 
suitable for quantification applications (Lipman et al., 2005). They are also less likely to 
cross-react with other proteins and present a high degree of homogeneity, which means 
they provide higher reproducibility, not only between batches but also between 
experiments. However, traditional methods for developing mAbs are dependent on animal 
immunisation, as for pAbs, and on creation or screening of immortalized hybridoma cell 
lines, which can cause a bottleneck in mAb production. Moreover, traditional mAbs are 
mostly limited to murine sources because the myeloma cell lines required for 
immortalization are not commonly available for other species. MAbs are less flexible in 
terms of epitope recognition, which might be an inconvenience when the target is not shared 
across a range of species (Baird et al., 2009; Laffly & Sodoyer, 2005). 
Recombinant antibodies, as opposed to the two other types aforementioned, are generated 
in vitro and were developed with the aim of overcoming the disadvantages of the pAbs and 
combining the advantages of the mAbs. RAbs are selected from antibody synthetic libraries 
of generally 108 antibodies clones whose DNA variability is induced in vitro, which increases 
the chances of producing a highly specific, sensitive and stable antibody. Moreover, 
production of rAbs in vitro, despite being very challenging, is robust and can overcome the 
batch-to-batch variability of the pAb. rAbs can be very useful for analysing the proteome of 
a cell, as they can give a very sensitive readout of the relative abundance of a given protein 
in a cell lysate (Holt, Enever, Wildt, & Tomlinson, 2000; Laffly & Sodoyer, 2005). 
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1.6.5. Production of Antibodies  
1.6.5.1. Generation of Polyclonal Antibodies by Immunising Animals 
Immunising and bleeding animals to produce polyclonal sera is a technically straightforward 
procedure, but one needs to remember that animals must always be injected and bled as 
safely and painlessly as possible. All immune systems of living species display the property 
of self-tolerance, i.e., the immune system of an animal is normally not triggered by a self-
antigen/protein, in order to protect the animal from autoimmune damage. 
Therefore, immunisations should always be done in animals that are as far in evolutionary 
distance from the source of the antigen as possible. Immunisation of closely related species 
might result in a predominant IgM response due to the lack of T cell recruitment (Lipman et 
al., 2005). 
The choice of animal is usually based on how much serum will be needed, the species from 
which the target antigen is isolated, whether mAbs will be further needed and how much 
antigen is available. Rabbits, mice, rats, hamsters and guinea pigs are commonly used in 
the laboratory because of their small size, and they usually yield bleeds of 100-200 L (for 
mouse) to 25 mL (for rabbits). Nevertheless, for most of the commercial applications, larger 
animals like pigs, horses, sheep and donkeys are used, because larger volumes of serum 
can be obtained. In case of shortage of antigens, small rodents are preferred because they 
generally respond better to low doses than larger animals. 
Before proceeding to the immunisation, the form and dosage of the antigen needs also to 
be considered. Particulate antigens, like cells bacteria and virus, are usually much better 
immunogens than soluble molecules due to their mechanism of phagocytosis. 
Nevertheless, most soluble antigens can be made more immunogenic by coupling them 
chemically to larger biomolecules, beads or even cells. The valency of an antigen has a 
strong impact on its immunogenicity as phagocytosis is triggered by particles> 0.5 μm 
(Martínez-Riaño et al., 2018) . 
Regarding the dose, the optimum amount to achieve the strongest response will vary from 
host to host. For example, for a sheep, an initial dose of 0.5 to 1 mg of a pure soluble protein 
antigen in adjuvant (stimulators of the immune response usually injected together with the 
target antigen) is applied and for further injections this amount can be lowered or kept the 
same (Harlow & Lane, 1988).  
Usually, antibodies start to be detected in the serum 5 to 7 days after the immunisation and 
persist at low levels for a few days, reaching a peak titre around day 10 (Harlow & Lane, 
1988). However, the primary responses are generally very weak, requiring a secondary 
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immunisation, 2 to 3 weeks later, from which the response is usually different. The number 
of B cells expressing surface antibodies increases exponentially, reaching a peak between 
days 3 and 4, and antibodies in the serum reach a peak around days 10-14. Typically, high 
levels of antibody persist for about 2- 4 weeks after the second injection. After a third 
immunisation, the immune response appears to be very similar to the one obtained with the 
previous injection, but the quality of the antibodies in the serum is improved due the 
maturation process of the B cells (Harlow & Lane, 1988). Further boosts might be 
administrated but extended intervals are needed so the circulating level of antibody drops 
enough to prevent rapid clearance of the newly injected antigen (Harlow & Lane, 1988). 
Serum samples, taken 7-14 days after each injection, can be assessed by ELISA or another 
immunoassay technique, against the immunogen, and by comparing the different antibody 
titres of the different immunisations, the immune response of an animal over time can 
inferred. 
 
1.6.5.2. Generation of Monoclonal Antibodies by Hybridoma Technology 
More than four decades ago César Milstein and Georges J. F. Köhler described the 
hybridoma technology for generating monoclonal antibodies (mAbs), revolutionising not 
only biomedical research and diagnostics but also the generation of an arsenal of therapies 
for many diseases (Köhler & Milstein, 1975). mAbs were first recognized in sera of patients 
with multiple myeloma in which clonal expansion of malignant plasma cells produced high 
levels of an identical antibody resulting in a monoclonal gammopathy. The hybridoma 
technology was then based on fusing B cells from an immunized animal (typically a mouse) 
with a myeloma cell line and growing the hybrid cells under conditions where unfused 
normal and tumour cells cannot survive. Hybrid cells are then grown as single cell clones 
and tested for the secretion of the antibody of interest. 
The selection of the hybrid clones is done by using a medium containing hypoxanthine, 
aminopterin and thymidine (HAT medium), compounds known to be related to biosynthesis 
of nucleotides. In the presence of aminopterin, tetrahydrofolate cannot be produced, which 
results in a defect in de novo purine synthesis; however, the myeloma cells used for this 
protocol lack the gene for expressing the enzyme hypoxanthine-guanine 
phosphoribosyltransferase (HGPRT), which allows them to survive using de novo purine 
synthesis, and therefore only the hybrid cells expressing the HGPRT gene from the 
myeloma cells will survive in medium containing aminopterin (Milstein, 1999). 
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1.6.5.3. Generation of Recombinant Antibodies by Phage Display 
Technology 
The phage display technique, created by George Smith in 1985 for displaying polypeptides, 
is based on the direct linkage between phage phenotype and its encapsulated genotype, 
which allows the display of molecule libraries on the surface of phage (Smith, 1985). DNA 
encoding millions of variants of peptides, proteins or fragments can be cloned into the phage 
genome, as a fusion to the gene encoding one of the phage coat proteins, and upon 
expression, the coat protein fusion will be incorporated into new phage particles that are 
assembled in the bacterium, as illustrated in Figure I.10 (Brien, Aitken, Chames, 
Hoogenboom, & Henderikx, 2002).  
 
Figure I.10. Principle of phage display technology. The genetic information of the desired antibody is 
inserted into the phage DNA and ends up being expressed as part of the capsule protein on the surface of the 




Phages expressing the desired molecules can be retained by interaction with the target 
(while unbound phages are washed away) and be recuperated for further infection of a new 
batch of bacteria for replication and enrichment of those same clones from the library. This 
selection process, commonly referred to as biopanning, illustrated in Figure I.11, is usually 
repeated 2-4 times, depending on the antibody fragment format and on the type of phage 
display library (Teixeira & Gonzalez-Pajuelo, 2018). In the end each pool of enriched 
phages collected after each round of panning can be subjected to affinity analysis by 
immunoassays, so the enrichment can be confirmed, and individual clones can be selected 
for expression. 
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Figure I.11. Schematic representation of the phage display process. Once the antibody library is generated, 
phages expressing the different clones are incubated with the target antigen for positive selection, in a process 
called biopanning. After elution from the antigen, the phages are recovered, used to infect new bacteria for 
amplified and the generation of a more enriched library. This process is usually performed 2-4 times to allow a 
sufficient enrichment of the specific phages. 
 
Phage display was not only a key stepping stone for the development of tailor-made 
antibodies, bypassing the classical approach of the hybridoma technology, but also a 
valuable tool to target novel antigens, and therefore characterize human immune libraries 
and to study autoimmune diseases (Brien et al., 2002). Synthetic libraries, in particular, 
because they are not constrained by the immune system, avoid bias caused by any 
tolerance mechanisms, and therefore screening synthetic peptide phage-libraries is a great 
approach for obtaining a range of affinity-selected phage clones specific to autoantibodies 
and to target unique self-epitopes (Hust & Lim, 2002). 
 
1.7. Antibodies Specific to Lipoxidation Products as Promising 
Diagnostic Tools 
Given the very low concentrations and short half-lives of reactive species (half-life for O2•– 
and H2O2 were reported to be 200 ns in cells (Schmitt et al., 2014)), the in vivo oxidative 
stress levels can only be determined indirectly mainly via the measurement of metabolites 
 
63 of 260 
of ROS/RNS, levels of antioxidants, and biomarkers of oxidative damage, such as DNA 
damage, protein carboxylation, and LPPs, that are more stable than free radicals (Kumar 
Maurya & Chandra, 2017). In detail, clinically tested biomarkers so far include MDA, HNE 
and acrolein-lysine adducts, F2-isoprostane (markers of lipid peroxidation), 8-oxo-7,8-
dihydro-2′-deoxyguanosine (8-oxodG, a marker of oxidative DNA damage), carboxymethyl-
lysine, pentosidine (markers of glycol-oxidation), nitrotyrosine, nitrite/nitrate (markers of 
nitro-oxidation), and bilirubin oxidative metabolites (a marker of haem oxygenase activity) 
(Tsukahara & Kaneko, 2014). Studies reporting the detection of these biomarkers use 
mainly analytical techniques like HPLC, GC and MS, but a recent growth in the use of ELISA 
assays for the detection of oxidative modified molecules has also been gaining attention 
(Hsieh, Dantzler, & Weigl, 2017; Noiri & Tsukahara, 2005; Satoh et al., 1999; Uchida, 
Osawa, Hiai, & Toyokuni, 1995; Weber et al., 2013). Nevertheless, these techniques are 
still too time consuming for diagnostic or even clinical use, posing the need for the 
development of easier, more rapid and sensitive assays, such as point-of-care (PoC) tests. 
PoC testing is one way of dealing with decreasing healthcare budgets by reduce the 
expensive care in hospitals and encouraging more patients to be assessed and treated in 
primary care or the community. The total in vitro diagnostics (IVD) market is estimated to 
be worth in excess of US$ 51 billion annually (2011 data) with growth estimated at 7% per 
annum, of which approximately US$15 billion was PoC testing. Of the total PoC testing 
market in 2011, 55% of it was in the US, 30% in Europe and 12% in Asia, largely dominated 
by glucose testing and home pregnancy tests (St John & Price, 2014). 
As regards oxidative stress diagnostics, there are four assays that bring laboratory testing 
to the near-patient testing fields: the FORD (Free Oxygen Radicals Defense) test that 
measures the presence of antioxidants based on a colorimetric reaction, the FORT (Free 
Oxygen Radicals Testing) test for measuring hydroperoxyl molecules, also based on a 
colorimetric reaction, the BAP (biological antioxidant potential) test for measuring the 
reducing/antioxidant balance on blood samples based on the reduction of Fe3+ ions, and 
lastly, the dROMs (derivatives of reactive oxygen metabolites) test for measurement of 
hydroperoxides present in blood, through the formation of alkoxyl (RO.) and peroxyl (ROO.) 
radicals (Palmieri & Sblendorio, 2007). According to data from 2007, FORT’s manufacturers 
have full IVD certification and CE mark, FORD’s has both the IVD and Self Testing 
Certification, BAP’s has the CE mark, while dROMs had still its patent pending. Both FORD 
and FORT were tested in blood from patients with newly diagnosed type 2 diabetes, where 
FORT and FORD levels were seen to be increased and decreased, respectively, in diabetic 
patients, with interassay coefficients of variation of 6.2% and 6.6%, respectively for the 
FORT and FORD (Pavlatou, Papastamataki, Apostolakou, Papassotiriou, & Tentolouris, 
2009). 
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Apart from these four assays, another reported, yet non-patented, PoC test developed is a 
rapid lateral flow assay (LFA) that combines electrochemical and colorimetric detection for 
the measurement of 8-hydroxy-2′-deoxyguanosine (8-OHdG), a DNA oxidative damage 
biomarker (Kaneko et al., 1970). Nevertheless, despite the substantial number of antibodies 
specific to lipoxidation products and the very optimistic growth potential for POC testing, so 
far, no rapid diagnostic tools have been developed for the detection of these oxPTMs. LFA 
technology, that detect analytes via the use of specific antibodies in only a few minutes, can 
therefore be a promising approach for the assessment of oxidative stress levels in vivo. 
Information on the functioning of LFAs can be found in the introduction in CHAPTER IV. 
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1.8. Aims of the Project  
The strong association between lipoxidation adducts and the development of inflammation 
responses identifies these adducts as powerful biomarkers for oxidative stress-related 
pathologies. However, although there is a vast diversity of antibodies specific to many lipid 
peroxidation products, no attempt has been made, so far, to apply these molecules to the 
development of rapid diagnostic tests. The overall aim of this project was to understand the 
immunogenic impact of lipoxidation adducts, as immunogenic, to determine the neo-
antigenic epitopes formed when self-proteins are made, and to make antibodies suitable 
for the deployment in a prototype diagnostic test. To meet this aim, the work was divided in 
four main tasks, which are detailed in four chapters: 
• Chapter II describes the development of synthetic methods for the preparation of 
lipoxidised proteins and peptides, and the subsequent characterisation and validation 
of the adducts via mass spectrometry and immunoassays.  
 
• Chapter III reports the application of the lipoxidation adducts (neo antigens) generated 
in the work described in Chapter II for the generation of polyclonal antibodies through 
the immunisation of different animals. The immunogenicity of different types of adducts 
was investigated, and the general structure of the adduct-based epitopes recognised 
by the generated antibodies was characterised. 
 
• Chapter IV describes the work performed for the development of a lateral flow assay for 
the detection of HNE adducts, in order to evaluate the diagnostic utility of the in-house 
generated antibodies. 
 
• Chapter V describes the use of phage display technology for the generation of 
monoclonal antibody fragments through the construction of Fab and scFv libraries 
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CHAPTER II  
GENERATION, DETECTION AND CHARACTERIZATION 
OF HNE ADDUCTS ON INTACT HUMAN SERUM 
ALBUMIN AND HUMAN SERUM ALBUMIN SEQUENCE 
PEPTIDES 
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2.1. Introduction 
2.1.1. Principles of Mass Spectrometry and Instrumentation 
Mass spectrometry (MS) is an analytical technique that measures the mass-to-charge ratio 
(m/z) of ionized analytes, and, consequently can be used to measure the molecular mass 
of proteins/polypeptides and detect the presence of PTMs. Conventionally, a mass 
spectrometer is composed of an ion source used to ionise the sample, a mass analyser to 
measure the m/z ratio, and a detector that is responsible for converting the ions into 
electrical signals (Aebersold & Domon, 2006). Regarding the ion sources, electrospray 
ionisation (ESI) and matrix-assisted laser desorption/ionization (MALDI) are, possibly, the 
two most commonly used methods (Aebersold & Mann, 2003). In ESI, the ionisation occurs 
through the use of a strong electric field that converts the macromolecules into small 
droplets, which later, by application of a direct flow of dry gas, desolvate and create the 
molecular ions; in MALDI, the sample is ionised by being mixed with matrix first, and then 
fixed to a metal plate, that upon receiving a pulsed laser radiation, causes the ablation of 
the sample from the matrix due to the action of a hot plume of gases, creating the molecular 
ions. As both ESI and MALDI are soft ionisation methods, they can be used to generate 
molecular ions, which facilitates the analysis of biomolecules such as proteins (Pitt, 1998).  
Once the ions have been generated, they are transferred to the mass analyser where they 
are separated according to their m/z, through the action of an electrical or sometimes 
magnetic field, depending on the type of mass analyser. MALDI is usually coupled to time-
of-flight (TOF) analysers that measure the m/z of intact peptides, whereas ESI is usually 
coupled to a combination of ion traps and triple quadrupole instruments, in what is denoted 
as tandem mass spectrometry (MS/MS). The use of two or more mass analysers is typically 
applied when structural information is required, something that is achieved by the 
generation of fragmentation patterns. In a simple manner, tandem MS relies on the first 
analyser to select specific molecules (the precursor/parent ions), which while moving 
through a collision cell, get fragmented by the collision with an inert gas (usually nitrogen 
or argon), and then proceed to the second mass analyser for further analysis. Depending 
on the collision energy applied, the breakage of the peptide bonds may occur closer to the 
N terminus or the C terminus of the peptide, producing characteristic fragment ions 
(Verrastro et al., 2015). Tandem MS has, therefore, been an extremely useful tool for the 
identification and localisation of lipoxidation sites in peptides, as reported in the literature 
(Annibal et al., 2016; Milic et al., 2015; Vasil’ev et al., 2014). 
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2.1.2. Human Serum Albumin: The Most Abundant Protein of the 
Human Sera 
Human serum albumin (HSA) is a monomeric multi-domain macromolecule present in the 
human plasma. It is known to regulate plasma osmotic pressure, modulate fluid distribution 
between different body compartments, serve as carrier for endogenous and exogenous 
substances in plasma, such as bilirubin and fatty acids, and to act as free radical scavenger 
(Anraku, Chuang, Maruyama, & Otagiri, 2013; Fanali et al., 2012; Petersen, Ha, Harohalli, 
Feix, & Bhagavan, 2000; Rippe, Kamiva, & Folkow, 1979). HSA is also the most abundant 
protein in human plasma, accounting for 55-60% of the total protein content, at a typical 
concentration of approximately 3.5–5.0 g/dL (Turell, Radi, & Alvarez, 2013).  
HSA is synthesized in the hepatic cells as preproalbumin, which has an N-terminal peptide 
that is removed before the nascent protein is released from the rough endoplasmic 
reticulum. The product, also called proalbumin, is in turn cleaved in the Golgi vesicles to 
produce the secreted albumin, which is composed of 585 amino acids with a molecular 
weight of 66,700 Da (Fanali et al., 2012). Structurally, HSA resembles a globular heart-
shaped protein composed of approximately 67% α-helices, 23% extended chains, and 10% 
β-turns, characterized by having no carbohydrate moiety, a scarcity of Trp, Gly, Ile and Met 
residues and an abundance of charged amino acids such as Cys, Leu, Glu, and Lys 
(Anguizola et al., 2013). 
Because HSA is a negative acute-phase protein, in stressful conditions or acute infections 
the concentration of the hepatic HSA mRNA is depressed, and HSA is only synthesized in 
a suitable nutritional, hormonal, and osmotic environment (Fanali et al., 2012). Hepatic 
cytokines such as interleukin-6 (IL-6) and tumour necrosis factor alpha (TFN-α) appear to 
be the main regulatory agents, but hormones such as insulin and amino acid deficiencies 
can also play an important role in HSA synthesis. Studies have shown that levels of HSA 
may decrease to around 1.5 g/L (Fanali et al., 2012). 
Because of its abundance and because it is subject to post-translational modifications, this 
protein is also considered a very valuable biomarker for diagnosis of many diseases and 
for the assessment of therapeutic responses (Gundry, Fu, Jelinek, Van Eyk, & Cotter, 2007; 
Otagiri & Giam Chuang, 2016). Particularly in oxidative stress-related conditions such as 
chronic liver and kidney diseases and diabetes, the formation of oxPTMs on HSA has been 
reported (Boisvert, Koski, & Skinner, 2010; Musante et al., 2007; Oettl et al., 2013). 
However, the determination of the HSA levels per se in blood can also constitute a method 
for assessing in cancer patients the severity and progression of the tumour, and their 
prognosis (Lam, Leung, & Tse, 2007).  
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2.1.3. HSA Modifications 
HSA has been reported to undergo many different types of modifications, including 
acetylation, namely on Lys199, Lys402, Lys519 and Lys 545 (Liyasova, Schopfer, & 
Lockridge, 2010), glycation on Arg410 and Arg525 via a Schiff’s base reaction (Ahmed, 
Dobler, Dean, & Thornalley, 2005), nitration and nitrosylation at Trp and Tyr residues, and 
oxidation on Cys, Met and Lys residues (Fanali et al., 2012). In fact, oxidation of HSA is a 
feature in many pathological conditions characterized by oxidative stress, as 
aforementioned, and it is believed to be an age-related consequence (Era, Kuwata, Imai, 
Hayashi, & Masaru, 1995). Moreover, HSA has the interesting feature of only containing a 
single free cysteine in its structure, Cys34, which represents the largest fraction of free thiol 
in human plasma (Turell et al., 2013). In 70-80% of healthy individuals, this residue is seen 
in the form of free sulfhydryl group, while in 25-30% it forms a mixed disulphide bond either 
with cysteine/homocysteine or glutathione. Cys34 can also be oxidized to either sulfonic 
acid or sulfinic acid, irreversible modifications that have seen augmented in several 
pathologies (Turell, Botti, Carballal, Radi, & Alvarez, 2009; Turell et al., 2013).  
HSA has also been implicated in the formation of protein carbonyls, when subjected to 
oxidative stress conditions (Aćimović, Jovanović, Srećković, Penezić Romanjuk, & Mandić, 
2013; Temple, Yen, & Gronert, 2006). A study has identified HSA as the major carbonylated 
protein in bronchoalveolar lavage fluid of older smokers, reporting HSA adducts to acrolein 
and crotonaldehyde at Cys34, His39, Lys351, Lys525, Lys541 and Lys545 (Rossi, 
Colombo, Carini, Milzani, & Dalle-donne, 2010). The reactivity of HSA to HNE and HHE has 
also been extensively characterized with adducts being identified at Cys34, His146, Lys199, 
His242 and His288 (Aldini et al., 2006; Q. Liu, Simpson, & Gronert, 2012). 
 
2.1.4. Chapter II Aims  
The aim of the work described in this chapter was to generate, detect and characterize HNE 
adducts in both intact HSA protein and HSA sequence peptides, for later use as antigen for 
generation of anti-HSA-HNE antibodies. For this purpose, both the intact protein and the 
synthesized peptides were treated with HNE at different molar ratios on aqueous solutions 
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2.2. Reagents 
Human serum albumin (product code: A1653) and albumin from chicken egg white (product 
code; A5503) were obtained from Sigma-Aldrich. Alpha-1 antitrypsin (A1AT) from human 
plasma (≥95% (SDS-PAGE)) was purchased from Merck (Germany). 4-hydroxynonenal-
diethylacetal (HNE-DEA) was generously supplied by Prof. Giancarlo Aldini from University 
of Milan. HNE was prepared from HNE-DEA by 1mM aqueous HCl hydrolysis (1 h at room 
temperature) and quantified by UV spectroscopy (λmax=224 nm; ε=13,750 L mol-1cm- 1). 
Fluorenylmethyloxycarbonyl (Fmoc) protected amino acids were purchased from Intavis 
(20×1 cartridge of 0.5 mmol of Fmoc-Ala-OH, Fmoc-Arg (Pbf)-OH, Fmoc-Asn(Trt)-OH, 
Fmoc-Asp(OtBu) OH, Fmoc-Cys (Trt)-OH, Fmoc-Gln (Trt)-OH, Fmoc-Glu (tBu)-OH, Fmoc-
Gly-OH, Fmoc-His (Trt)-OH, Fmoc-Ile-OH, Fmoc-Leu-OH, Fmoc-Lys (Boc)-OH, Fmoc-Met-
OH, Fmoc-Phe-OH, Fmoc-Pro-OH, Fmoc-Ser(OtBu)-OH, Fmoc-Thr (tBu)-OH, Fmoc-Val-
OH). Fmoc-PAL-PEG-PS resin was acquired from Thermo Fisher Scientific (UK) and 1-
methyl 2-pyrrolidinone (NMP), dimethylformamide (DMF), 1,3-diisopropylcarbodiimide 
(DIC), 1-hydroxybenzotriazole (HOBt), acetonitrile, formic acid, dichloromethane (DCM), 
and ethanol were purchased from Rathburn chemicals Ltd (Walkerburn, Scotland). 
Trifluoracetic acid (TFA), triisopropylsilane (TIPS) and piperidine were obtained from 
Sigma. Commercial goat polyclonal antibody anti-HNE (Ab46544) was purchased from 
Abcam, and 3,3′,5,5′-tetramethylbenzidine (TMB) and HRP-labelled anti-goat IgG were 
purchased from Sigma Aldrich (UK). All solvents were of LC-MS grade and all solutions 
were prepared using ultra-pure Milli-Q water. All other reagents were of analytical grade. 
 
2.3. Materials and Methods 
2.3.1. Solid-Phase Peptide Synthesis 
Synthetic peptides were synthesized by fluorenylmethyloxycarbonyl (Fmoc) chemistry on a 
Liberty Automated Synthesizer controlled by Pepdriver software. The Fmoc-PAL-PEG-PS 
resin was loaded into the reaction vessel at final concentration of 0.1 mM and the Fmoc 
protected amino acid derivatives were individually added into flasks at final concentrations 
of 0.2 M in dimethylformamide (DMF).  
The peptide synthesis was performed by cycles of coupling, deprotection and washes. 
Once the resin was swollen in DMF, the first amino acid was added in the presence of 1,3-
diisopropylcarbodiimide (DIC) and 1-hydroxybenzotriazole (HOBt), for activation of the 
carboxylic group (coupling step) and then 20% v/v piperidine in DMF was added for removal 
of the Fmoc group (deprotection step). The resin was drained and washed with DMF at the 
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end of each step to remove excess reagents. This process was repeated sequentially for 
each peptide sequence and the list of specific reagents and corresponding volumes used 
for each synthesized peptide is in Appendix 2, Appendix 3 and Appendix 4. 
Once the synthesis was finished, the resin was transferred to a 25-mL fritted filtration 
column (Fisher Scientific, UK) and washed twice with dichloromethane (DCM) and twice 
with ethanol and then freeze-dried for 1-2h. The resin-bound peptides were cleaved from 
the resin with a trifluoracetic acid (TFA) containing mixture (0.5 mL of H2O, 0.5 mL of TIPS 
and 20 mL of TFA) at room temperature for 2 h. TFA and solvents were further removed on 
the rotary evaporator to leave a crude residue. Solid crude peptides were then precipitated 
in cold diethyl ether, dried under a stream of air, dissolved in 50:50 (v/v) H2O/Acetonitrile 
(ACN) and freeze-dried overnight to yield a white solid. 
For synthesis of biotinylated peptides, the same protocol was applied but the resin used 
was the Fmoc-PEG Biotin NOVATagTM from Merck Millipore (Darmstadt, Germany).  
 
2.3.2. Peptide Purification by High Performance Liquid 
Chromatography 
Crude peptides were purified on a Kinetix® C18 HPLC column, pore size 100 Å, dimensions 
250 x 4.6 mm (Phenomenex) in a Dionex Ultimate 3000 HPLC system (Thermo Fisher, UK) 
, using a linear gradient from 95% solvent A (5% v/v acetonitrile, 95% v/v water, plus 0.1% 
TFA) to 100% of solvent B (100% acetonitrile plus 0.1% TFA) for approximately 30 min at 
a flow rate of 2.5 ml/min.  
After column equilibration for 5 min, the crude peptide was dissolved in solvent A at a 
concentration of 1 mg/mL and aliquots of 200 L were injected using the automated HPLC 
injector. The absorbance (Abs) was monitored at 230 nm and 280 nm. The main HPLC 
peaks were collected for further assessment by MS. Once the identity of the desired peptide 
was confirmed, an automated sequence of injections was set up and executed to purify all 
the peptide solution. The HPLC fractions of interest were collected, combined and freeze-
dried overnight, and peptides were stored at -20°C until further use. 
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2.3.3. Liquid Chromatography-Electrospray Mass Spectrometry 
Analysis to Confirm Synthetic Peptide Identity  
To confirm the molecular mass of the synthesized peptides, 0.1-0.5 g of the dried peptide 
stock was dissolved in 200 µL of solvent A (5% v/v acetonitrile, 95% v/v water plus 0.1% 
formic acid) and analysed by LC-ESI-MS in positive ion mode, using a Waters 2690XE 
HPLC coupled to a ZMD2000 Quadrupole Mass Spectrometer (MS). Separations were 
carried out on a reversed-phase elution with a Kinetex® C18 column (pore size: 100 Å; 
dimensions: 100 x 2.10 mm), using a 21-min linear gradient from 95% of Solvent A (5% v/v 
acetonitrile, 95% v/v water, plus 0.1% formic acid) to 90% of Solvent B (100% acetonitrile 
plus 0.1% formic acid), followed by a 7-min equilibration period. Samples were injected in 
volumes of 100 µL, and a flow rate of 0.3 mL/min was used. 
ESI-MS analyses were carried out by setting the ESI source to positive-ion mode and using 
capillary temperature of 150C, capillary potential of +2.5-4.0 kV, cone at 70 V, extractor at 
1-5 V and RF lens at 0.5 V. The flow rate of the nebulizer gas (nitrogen) was 5 L/min and 
acquisition was performed using 1-minute scans within the m/z of 200-2000 Da. 
 
2.3.4. Generation of HNE Adducts on HSA, HSA Peptides, OVA and 
A1AT 
For the generation of HNE adducts, 0.1 mL aliquots of each protein/peptide (at a 
concentration of 10 mg/mL in PBS) were reacted with HNE (stock concentration of 5.2 
mg/mL in 1 mM HCl) at a molar ratio of 1:1, 1:5 or 1:10 for 2 h at 37°C. The concentration 
of each reaction was then adjusted to 1 mg/mL by addition of 0.9 mL of PBS. All the 
reactions performed in this chapter were all done using the same batch of HNE and each 
of these HNE reactions was performed in triplicate (n=3). 
 
2.3.5. Identification of HNE Modifications on Synthetic HSA Peptides 
by LC-MS/MS  
Peptides were individually analysed using an Ultimate 3000 HPLC system (Thermo 
Scientific, UK) coupled to a 5600 TripleTOF MS (ABSciex, Warrington, UK). Briefly, each 
purified peptide was resuspended in 2% v/v acetonitrile 0.5% v/v formic acid and loaded 
onto a C18 trap column (C18 PepMapTM, 5 µm, 0.5 x 5 mm, Thermo Scientific, UK) at 30 
µL/min in 2% v/v acetonitrile 0.5% v/v formic acid followed by a 4 minute wash, before 
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separation on a nano-HPLC column (C18 PepMapTM, 5 µm, 0.075 x 150mm, Thermo 
Scientific, UK) at 300 nL/min using a gradient elution running from 2% to 45% aqueous 
acetonitrile, 0.1% v/v formic acid over 45 minutes. Ionization of the peptides was achieved 
by electrospray using a voltage of 2.4 kV, a source temperature of 150°C, declustering 
potential of 100V, nebulizer gas flow of 15 L/min and a curtain gas setting of 25 psi. Survey 
scans were collected in positive mode from m/z 350 to 2000 Da using high-sensitivity TOF-
MS mode. All the LC-MS/MS experiments ware performed in triplicate (n=3). 
 
2.3.6. Identification of HNE Modifications on HSA by Matrix-Assisted 
Laser Desorption/Ionization Time-of-Flight (MALDI-TOF) MS 
The analysis of native HSA and HNE modified HSA samples by MALDI-TOF MS was 
performed on a Bruker Autoflex Speed MS (Bruker, MA, USA) using a sinapinic acid matrix 
(10 mg/mL in 70:30 (v/v) water/acetonitrile with 0.1% TFA) as the matrix in positive ion 
mode. A 20 μL aliquot of each sample was desalted using a mixed bed ion exchange 
resin  (Amberlite MB-9L from Sigma-Aldrich), and 1 μL of desalted sample was spotted onto 
the MALDI plate and allowed to dry naturally. Finally, 1 μL of matrix solution was spotted 
onto the dry sample and allowed to dry at room temperature before analysis. MALDI-TOF 
analysis were only performed once (n=1). 
 
2.3.7. Identification of HNE Modifications on HSA by LC-MS/MS of 
Tryptic Digested HSA Peptides Modified by HNE  
HNE-modified HSA samples (50 μg) were digested with trypsin according to the Filter Aided 
Sample Preparation (FASP) protocol. Briefly, proteins were reduced with dithiothreitol 
(DTT) (100 mM, 1 h, at room temperature), transferred onto a Microcon centrifugal filter (30 
KDa cut-off) by centrifugation at 14 000 × g, alkylated in situ with iodoacetamide (50 mM, 
20 min in the dark), washed twice with urea buffer (8 M Urea, 100 mM Tris-HCl, pH 8.5) 
and two times with ammonium bi-carbonate buffer (50 mM) before digestion with trypsin 
(1:25 enzyme to protein ratio w/w) overnight at 37°C in a humidified environment. Peptides 
were recovered in ammonium bicarbonate buffer (50 mM), dissolved at 250 ng/μL in 3% 
(v/v) acetonitrile in water and used for LC-MS analysis using a nano-ACQUITY UPLC 
system (Waters GmbH, Eschborn, Germany) coupled online to an LTQ Orbitrap XL ETD 
mass spectrometer equipped with a nano-ESI source (Thermo Fischer Scientific, Bremen, 
Germany). Eluent A was formic acid (0.1% v/v) in water and Eluent B was formic acid (0.1% 
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v/v) in acetonitrile. Samples (10 μL injection) were diluted in Eluent A and loaded onto the 
trap column (nano Acquity Symmetry C18; internal diameter 180 μm, length 20 mm, particle 
diameter 5 μm) at a flow rate of 10 μL/min. The separation was performed using a BEH 130 
column (C18 column, internal diameter 75 μm, length 100 mm, particle diameter 1.7 μm) at 
a flow rate of 0.4 μL/ min, with a linear gradient from 3% to 30% of eluent B over 18 min 
and then to 85% of eluent B over 1 min. The transfer capillary temperature was set to 200°C 
and the tube lens voltage to 110 V. An ion spray voltage of 1.6 kV was applied to a PicoTip 
online nano-ESI emitter (New Objective, Berlin, Germany). The precursor ion survey scans 
were acquired on an Orbitrap MS with resolution of 60,000 at m/z 400 across a range from 
m/z 400 to 2000. CID tandem mass spectra (isolation width 2.00, activation Q 0.250, 
normalized collision energy 35.0%, activation time 30.0 ms) were recorded in the linear ion 
trap by data-dependent acquisition (DDA) for the top six most abundant ions in each survey 
scan with a dynamic exclusion of 60 s using Xcalibur software 3.0 (Thermo Fischer 
Scientific, Bremen, Germany). All LC-MS/MS experiments were performed in triplicate 
(n=3). 
 
2.3.8. Identification of Tryptic Peptides of HSA Modified by HNE Using 
Sequest Search Engine 
HNE modifications were identified using the Sequest search engine (Proteome Discoverer 
1.4, Thermo Scientific) against Homo sapiens (Human) database, allowing up to two missed 
cleavages and a mass tolerance of 10 ppm for precursor ions and 0.8 Da for product ions. 
Oxidation of methionine and cysteine, carbamidomethylation (CAM) of cysteine, HNE 
Michael adducts (on cysteine, lysine and histidine) and Schiff's base adducts (on lysine) 
were used as variable modifications and results were filtered for rank 1 peptides and score 
vs. charge states corresponding to Xcorr/z 2.0/2, 2.25/3, 2.5/4, 2.75/5. 
 
2.3.9. Identification of HNE Modifications on HSA, OVA and A1AT by 
direct ELISA 
96-well microtiter plates (Corning, MA, USA) were coated with 100 μL of both HNE treated 
and non-treated proteins in a concentration range from 0 to 1 μg/mL, overnight at 4°C. 
Following aspiration of the antigen solution, the plates were washed three times with tris-
buffered saline, 0.1% Tween 20 (TBST), and the wells were blocked with 120 μL of 1% 
(w/v) BSA/PBS for 1 h at room temperature. After another three-wash step with TBST, 100 
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μL of the anti-HNE pAb (Ab46544; Abcam) was added to each well and the plate was left 
to incubate for 1 h with shaking at room temperature. The wells were once again washed 
three times with TBST and the plate was further incubated with 100 μL of mouse anti-goat 
IgG (AP labelled) in 1% (w/v) BSA/ PBST, for 1 h with shaking at room temperature. The 
detection was done using pNPP (Thermo Fisher Scientific, USA) and the absorbance was 
read at 405 nm using a microplate reader. The assay was performed in duplicate (n=2), 
with technical triplicates. 
 
2.3.10. Statistical Analysis 
Data depicted in Figure II.14 were analysed in two different ways as the assay was only 
performed in duplicate (n=2). Firstly, data was analysed individually using o one-way 
analysis of variance (ANOVA) tests with Microsoft Excel to assess significative differences 
between the three HNE molar ratios used on each individual set of proteins. Secondly, 
combined data was analysed with software R using the non-parametric Kruskal-Wallis rank 
sum test (non-parametric alternative to one-way ANOVA test) as the data did not meet the 
criteria required for one-way ANOVA tests. For the combined data Post hoc Dunn tests was 
further performed for multiple comparison of groups and a significance threshold was set to 
0.0083 – Bonferroni Correction –, since six different tests were performed. 
 
2.3.11. SDS-PAGE of HNE Modified Proteins 
Sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–PAGE) was performed 
to evaluate the profile of the modified and non-modified proteins. Samples were prepared 
in Laemmli buffer 4% SDS, 20% glycerol, 10% 2-mercaptoethanol, 0.004% bromophenol 
blue and 0.125 M Tris HCl, pH 6.8) and heated at 100◦C for 5 min. Samples were loaded 
onto a 12% acrylamide gel, prepared using 40% acrylamide/bis (29:1), 10% ammonium 
persulfate and 10% SDS stock solutions (following the standardized Bio-Rad protocol), and 
run at 100 mV using as running buffer 192 mM glycine, 25 mM Tris-HCl and 0.1% SDS, pH 
8.3. Gels were stained with Coomassie Brilliant Blue (Pharmacia, Uppsala, Sweden). 
Images were acquired with the Gel Doc EZ System from Bio-Rad (CA, USA). 
 
2.3.12. Western Blotting of HNE Modified Proteins 
For the western blot analysis, HNE treated proteins were run on 12% SDS-PAGE gels and 
separated following the conditions described before. Proteins were transferred from the gel 
 
76 of 260 
to polyvinylidene fluoride (PVDF) membranes using the Trans-Blot Turbo Transfer System 
(Bio-Rad, CA, USA). The membranes were blocked overnight at 4°C with AdvanBlock-PF 
blocking solution (Advansta, Inc, CA, USA) and then incubated with the primary antibody 
(Abcam anti-HNE, dilution 1:10000), for 1h at room temperature. The membranes were 
then washed with AdvanWash washing solution (Advansta, Inc, CA, USA) three times for 
10 min and incubated with the secondary antibody (HRP-labelled anti-sheep and anti-goat, 
dilution 1:10000). The detection was carried out with WesternBright Sirius ECL (Amersham, 
UK), using the ChemiDoc™ XRS+ System (Bio-Rad, CA, USA). The results were 
interpreted by densitometry analysis using the software ImageJ, Version 1.48. 
 
2.3.13. Bio-layer Interferometry 
OctetRED96 (FortéBio Inc.) was used to measure the association and dissociation rates of 
the commercial antibody anti-HNE to the modified HNE-modified biotinylated 31LQQCPFE37 
peptide through bio-layer interferometry. The binding assay was performed in a 96-well 
plate using Dip and Read™ Streptavidin coated biosensors. The peptide 31LQQCPFE37 was 
resynthesized with a biotin tag at the C-terminal for immobilization to the streptavidin 
biosensors. The biotinylated peptide was reacted with HNE as mentioned before, and the 
HNE-peptide adduct was purified by reverse-phase HPLC. The ligand concentration used 
for the assay was 2 µg/mL, and all the steps were performed at 30°C with the plate shaking 
speed set at 1000 rpm. The antibody and antigens solutions were diluted in a Kinetics Buffer 
from FortéBio Inc, containing PBS + 0.1% w/v BSA, 0.02% v/v Tween20 and 0.05% w/v 
sodium azide, at pH 7.4 and used as a ligand for the anti-HNE commercial pAb.  
Eight Dip and Read™ Streptavidin coated biosensors were dipped into the biotinylated 
31LQQCPFE37-HNE adduct solution for 10 min, and the association data was acquired for 
15 min from solutions of pAb anti-HNE where the concentration was varied between 64 nM 
to 1 nM by 1:2 serial dilution. After the equilibrium was reached, the dissociation step was 
carried out over 20 min in Kinetics Buffer (provided from ForteBio). The assay data were 
processed using Data Analysis (version 6.3, ForteBio) to obtain kinetic values. Briefly, a 
buffer blank was used as a reference cell subtraction and the data series was evaluated 
using a global fit algorithm for 1:1 binding interaction, assuming that an immobilized ligand 
protein and analyte bind to each other with an association rate constant (Kon) and dissociate 
with a dissociation rate constant (Kdis). The association rate = Kon [ligand][analyte] and the 
dissociation rate = Kdis [ligand-analyte]. At equilibrium, forward and reverse rates are equal. 
Hence, the equilibrium dissociation (or affinity) constant, KD, is equal to Kdis/Kon = 
[ligand][analyte]/[ligand-analyte]. 
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2.4. Results 
2.4.1. Design of Key Model HSA Sequence Peptides 
The use of synthetic peptides as a means to generate antibody reagents is a very common 
procedure when specific targeted antibodies are desired. By immunizing with a particular 
sequence of a protein, antibodies can be raised against unique regions such as highly 
conserved regions, active sites or even regions of post translation modification. 
As stated before, one of the aims this chapter was to synthesize key peptides from HSA 
which can be, in theory, highly subjected to HNE modifications, and identify and 
characterize those same HNE adducts. According to the literature, Cys34, His146 and 
Lys199 were reported to be the three most reactive HNE-adduction sites on HSA (Aldini et 
al., 2006), and therefore, peptide sequences containing these three residues were 
synthesized for further assessment. The red, blue and purple peptide chains highlighted in 
both panels A and B of Figure II.1 represent the peptide sequences containing the residues 
Cys34, His146 and Lys199, respectively, which are located on the surface of the protein, 
making the amino acids prone to be attacked and consequently more easily modifiable by 
HNE. Cys34 and the adjacent amino acids (red sequence) are rearranged in a -pleated 
sheet, while His146 and Lys199 together with its respective adjacent amino acids (light blue 
and purple, respectively) are part of -turns. These characteristics are important when 
considering the generation of antibodies as the response of the immunity system is dictated 
by the structural differences between the antigen and the host's self-proteins (Benjamin et 
al., 1984). According to Aldini et al, HNE forms Michael adducts with Cys34 and His146, 
while with Lys199 yields a Schiff’s base adduct (Aldini et al., 2006). HSA sequences 
containing these three amino acid residues were therefore synthesized for assessment of 
HNE-adducts formation.  
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Figure II.1. Location of Cys34 (red), His146 (light blue) and Lys199 (purple) residues in the 3D molecular 
structure of human serum albumin (PBD FILE: 1AO6) (A) and in the amino acid sequence (B). Peptides 
31LQQCPFE37, 141EIARRHPYFYAPEL154, 198LKCASLQK205 containing these three key amino acids were 
selected for chemical synthesis and HNE treatment. 
  
2.4.2. Synthesis of HSA Peptide Sequences 
Three HSA peptide sequences containing the three most reactive HNE-adduction sites 
were synthesized by FMOC chemistry using a solid phase peptide synthesis method 
according to well-established methods (Behrendt, White, & Offer, 2016). The amino acid 
sequences, chemical formulas and monoisotopic masses of each individual peptide and 
respective HNE adduct are presented in Table II.1. Due to the resin used, all the 
synthesised peptides have an amide group at the C-terminal, and both the 
41EIARRHPYFYAPEL154 and 198LKCASLQK205 peptides have as well an acetyl group at the 
N-terminal to avoid reaction between the HNE and the common free amine at the free 
peptide N-termini. Each peptide purified by reverse-phase liquid chromatography and their 
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Table II.1. List of key HSA peptides synthesized based on a study where the residues Cys34, Lys199 
and His146 were identified as the most reactive HNE-adduction sites of HSA (Aldini et al., 2006). For each 
peptide, their corresponding amino acid sequence, chemical formula, average molecular weight and 
monoisotopic mass is presented, together with the monoisotopic mass of the expected HNE adduct (MA for 
Michael adduct and SB for Schiff’s base). Both the 41EIARRHPYFYAPEL154 and 198LKCASLQK205 peptides have 
an amide group at the C-terminus and an acetyl group at the N- terminus, while the 31LQQCPFE37 has only the 
amide group at the C-terminus. 
 
*Monoisotopic mass of HNE: 156.1150 
 
The HSA peptide sequence 31LQQCPFE37 was selected based on the presence of Cys34, 
the only free cysteine present in the whole protein. Upon completion of the synthesis of the 
peptide, the crude solution was loaded on a reverse-phase chromatography column for 
peptide purification (Figure II.2 A) and its mass was confirmed by ESI-MS (Figure II.2 B). 
 
Figure II.2. HPLC chromatogram (A) and MS spectra (B) obtained for purified 31LQQCPFE37 HSA peptide 
(monoisotopic mass: 862.40). The crude peptide was initially dissolved in 5% v/v acetonitrile, 95% v/v water, 
plus 0.1% TFA, to a concentration of 1 mg/mL, all eluted peaks were collected for MS analysis and once the 
peak corresponding to the HSA peptide was identified further HPLC runs were set up for purification of that 
single product. In the end all the fractions were combined, the peptide was freeze dried, and analytical runs by 
HPLC (A) and ESI-MS (B) were performed for confirmation of purity. 











1018.5144 (Single MA) 
1174.6295 (Double MA) 
AcNH2-141EIARRHPYFYAPEL154-CONH2 
C85H123N23O28 




1086.6455 (Single MA) 
1242.7606 (Double MA) 
1068.6305 (Single SB) 
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The mass spectrum (MS) depicted in Figure II.2 B exhibits a peak at m/z 863.0 which 
corresponds to the protonated pseudo molecular ion, [M+H]+, suggesting that the peptide 
was successfully synthesized. The peak at m/z 885.0 was identified as the sodiated 
molecular ion, [M+Na]+ and the other minor peaks observed at lowers m/z correspond to 
impurities that co-eluted with the peptide. 
The HSA peptide sequence 141EIARRHPYFYAPEL154 was selected based on the presence 
of His146, considered to be one of the most HNE-reactive sites. Again, once the synthesis 
of the peptide was completed, the crude solution was loaded on a reverse-phase 
chromatography column for peptide purification (Figure II.3 A) and its mass was confirmed 
by ESI-MS (Figure II.3 B). 
 
Figure II.3. HPLC chromatogram (A) and MS spectra (B) obtained for purified 141EIARRHPYFYAPEL154 
HSA peptide (monoisotopic mass:1801.93). The crude peptide was initially dissolved in 5% v/v acetonitrile, 
95% v/v water, plus 0.1% TFA, to a concentration of 1 mg/mL, all eluted peaks were collected for MS analysis 
and once the peak corresponding to the HSA peptide was identified further HPLC runs were set up for 
purification of that single product. In the end all the fractions were combined, the peptide was freeze dried, and 
analytical runs by HPLC (A) and ESI-MS (B) were performed for confirmation of purity. 
 
The MS in Figure II.3 B shows two main peaks at m/z 601.5 and 901.9, corresponding to 
the ion [M+2H]2+ and [M+3H]3+, respectively, confirming the correct synthesis of the peptide. 
The peaks at m/z 595.9 and 620.2 are again thought to be impurities or peptide fragments. 
The peptide sequence 98LKCASLQK205, was selected for synthesis due the presence of the 
residue Lys199, another amino acid considered to be one of the most HNE-reactive sites. 
The peptide was purified by reverse phase liquid chromatography (Figure II.4 A) and the 
mass was confirmed by ESI-MS (Figure II.4 B). 
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Figure II.4. HPLC chromatogram (A) and MS spectra (B) obtained for purified 198LKCASLQK205 HSA 
peptide (monoisotopic mass: 930.53). The crude peptide was initially dissolved in 5% v/v acetonitrile, 95% 
v/v water, plus 0.1% TFA, to a concentration of 1 mg/mL, all eluted peaks were collected for MS analysis and 
once the peak corresponding to the HSA peptide was identified further HPLC runs were set up for purification 
of that single product. In the end all the fractions were combined, the peptide was freeze dried, and analytical 
runs by HPLC (A) and ESI-MS (B) were performed for confirmation of purity. 
 
The peptide 198LKCASLQK205 was identified on the MS spectra (Figure II.4 B) by the peaks 
observed at m/z 930.6 and 465.7 corresponding to the ions [M+H]+ and [M+2H]2+, 
respectively. The ion peak observed at m/z 620.6 is an impurity co-eluted with peptide of 
interest. 
 
2.4.3. Detection of HNE Modifications on HSA Peptides by LC-MS 
Purified peptides 31LQQCPFE37, 141EIARRHPYFYAPEL154 and 198LKCASLQK205 were 
individually incubated with HNE at a 1:10 protein:HNE molar ratio and the reaction products 
were analysed by ESI-MS. 
The total ion chromatogram (TIC) obtained for the HNE-treated 31LQQCPFE37 peptide 
depicted in Figure II.5 A shows the presence of one main peak (retention time (RT): 35 
min) followed by four other minor peaks with longer RTs. As seen in the extracted-ion 
chromatogram (XIC) in Figure II.5 B, the main peak (RT: 35 min) corresponds to the elution 
of the non-modified peptide (m/z 863.413) but comprises as well the elution of an HNE-
modified form of the peptide with an m/z = 1019.534 (Figure II.5 C), that corresponds to 
the formation of an HNE Michael adduct. The peaks with longer RTs relates to the formation 
of a double HNE-modified peptide (Figure II.5 D) as seen by the presence of a product with 
an m/z = 1175.656, that corresponds to the formation of two HNE Michael adducts. It is 
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worth noting that the addition of a single HNE molecule to the peptide seemed to not affect 
the elution time of the peptide, as it eluted at a very similar time to the non-modified peptide, 
but the addition of two HNE molecules makes the peptide to bind more strongly to the 
column and to only elute 5-7 s later. 
 
Figure II.5. Identification of the products formed by reacting peptide 31LQQCPFE37 with HNE at a peptide-
HNE molar ratio of 1:10; and their respective difference in the retention time. The TIC chromatogram of 
the total reaction products (A) show a main peak at Rt 35 min corresponding to the prediction of the non-modified 
peptide (m/z 863) (B) and one HNE Michael adduct (m/z 1019), and a few other peaks with longer RT 
corresponding to a two HNE Michael adduct (m/z 1175). The experiment was performed in triplicate (n=3). 
 
Regarding the peak at RT 35.736 min, the spectrum in Figure II.6 A confirms the co-elution 
of both non-modified peptide and one Michael Adduct (MA)-HNE-peptide species in the 
same elution peak. The formation of a MA-HNE-peptide adduct is confirmed by the 
presence of the ions peak at m/z 1019.5 (corresponding to the protonated molecular ion 
[M+HNE+H]+), while the presence of the non-modified 31LQQCPFE37 peptide is confirmed 
by the presence of the ions peaks [M+H]+ m/z 863.4 and [M+2H]2+ m/z 432.19, which 
correspond to the predicted mass of the native peptide. 
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The formation of a double MA-HNE-peptide adduct (predicted m/z 1174) is shown in the 
MS spectrum relative to the peak at RT 40.397 min (Figure II.6 B). The ion peaks at m/z 
1175.65 and 579.31 correspond to the protonated molecular ion [M+2HNE+H]+ and to the 
double charged molecular ion [M+2HNE-18+2H]2+, respectively. This last molecular ion 
suggests that one of the MA adducts suffered a rearrangement to a Schiff’s Base adduct 
due to the loss of 18 amu (equivalent to a molecule of water). The presence of the ion peaks 
at m/z 863 ([M+H]+), m/z 1019.5 ([M+HNE+H]+) and m/z 510.24 ([M+HNE+2H]2+) show that 
the non-modified peptide and the single MA-HNE-peptide adduct are also co-eluting with 
the double- MA-HNE-peptide adduct. 
 
Figure II.6. Identification of HNE Michael adducts on peptide 31LQQCPFE37 by MS, following a 2 h 
reaction with HNE at a peptide-HNE molar ratio of 1:10. The formation of a single MA-HNE-peptide adduct 
was confirmed by the ion peak at m/z 1019.5 ( [M+HNE+H]+ ), and by the ion peak at m/z 501.24 
([M+HNE+2H]2+) (A). The ions peaks at m/z 1175.6 and m/z 579 correspond to the protonated molecular ion 
[M+2HNE+H]+) and to the double charged molecular ion [M+2HNE+2H]2+, respectively, confirming the formation 
of a double MA-HNE-peptide adduct (B). The experiment was performed in triplicate (n=3). 
 
A Schiff’s base (SB)-HNE-peptide adduct was also identified in the MS data (Figure II.7 A), 
by the observation of an ion peak with a RT of 43.817 min relative to the ions [M+HNE-18 
+H]+ m/z 1001.5 and the [M+HNE-18+2H]2+ m/z 501.2. Again, the ion peak regarding the 
non-modified peptide (m/z 863.4) is observed. Moreover, a Michael and Schiff’s base 
adducts within the same peptide was also identified by MS spectrum in Figure II.7 B, by 
observation of a peak with a RT of 44.240 min with m/z 579.3102 corresponding to the 
double protonated ion [M+2HNE-18+2H]2+. This species is; however, co-eluting with the 
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Schiff’s base adduct (m/z 1001.522), the double MA adduct (m/z 1175.65) and the non-
modified peptide (m/z 863.41). 
 
Figure II.7. Identification by LC-MS of a Schiff’s base (A) and a double MA (B) adducts formed on peptide 
31LQQCPFE37, followed reaction with HNE at peptide-HNE molar ratio of 1:10. The MS spectrum of the 
peak with an RT of 43.817 shows the ion peaks with m/z 1001.5 and m/z 501.2, which correspond to the single 
([M+HNE-18+H]+) and double ([M+HNE-18+2H]2+) protonated ions relative to the predicted mass of a Schiff’s 
base adduct, and the MS spectrum of the peak with a RT of 44.240 depicts the molecular ion m/z 579.3102 
relative to the predicted mass of both a Michael and Schiff’s base adducts [M+2HNE-18+2H]2+. The ion peaks 
with m/z 1175.6560, 1001.5235 and 863.4132 suggest the co-elution of this adduct with other products, namely 
the non-modified peptide, the MA-HNE and SB-HNE peptide adducts. The experiment was performed in 
triplicate (n=3). 
 
Regarding the 141EIARRHPYFYAPEL154 peptide, the TIC obtained for the HNE-peptide 
reaction products (Figure II.8 A) shows the presence of two main peaks with RTs of 32 
(Figure II.8 B) and 37 min (Figure II.8 C) corresponding to the non-modified peptide 
(predicted m/z 1801.9) and to a Michael adduct (predicted m/z 1957), respectively. Figure 
II.8 shows the deviations in the elution patterns between the non-modified peptide (Panel 
B) and the HNE-peptide adduct (Panel C), suggesting that the addition of an HNE molecule 
changes the hydrophobicity of the peptide, and consequently its retention time. 
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Figure II.8. Identification by LC-MS of the products formed by reacting peptide 141EIARRHPYFYAPEL154 
with HNE at a peptide-HNE molar ratio of 1:10; and their respective difference in the retention time. Panel 
A shows the total ion chromatogram of the total reaction products and panels B and C show the TICs relative 
to the prediction mass of the non-modified peptide and MA-HNE-peptide adduct, respectively. The experiment 
was performed in triplicate (n=3).  
 
The MS spectrum depicted in Figure II.9 shows two main ions peaks at m/z 980.5313 and 
653.6792, which correspond to the predicted mass of a double charged molecular ion 
([M+HNE+2H]2+) and the triple charged molecular ions ([M+HNE+3H]3+), respectively, 
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Figure II.9. Identification by LC-MS of a Michael adduct formed on the peptide 141EIARRHPYFYAPEL154 
followed reaction with HNE at a peptide-HNE molar ratio of 1:10. MS spectrum relative to the peak with an 
RT of 37.740 min reveals the ions peaks at m/z 980.5313 and 653.6792, which correspond to the double 
([M+HNE+2H]2+) and triple ([M+HNE+3H]3+) charged ions regarding the predicted mass of the an MA-HNE-
peptide adduct (m/z = 980.53). The experiment was performed in triplicate (n=3). 
 
Regarding peptide 198LKCASLQK205 , the MS of its reaction products with HNE (Figure 
II.10), shows three molecular ion peaks of m/z 1008.5941, m/z 1087.1615 and m/z 
1165.2288 (present in the panels A, B and C, respectively), which correspond to the three 
different Michael adducts. These appear to be doubly charged molecular ions, which 
suggests that the peptide may have dimerized in the solution. Nevertheless, the peaks of 
m/z 1859.06, m/z 672.72 and m/z 504.79 observed in Figure II.10 A, correspond to the 
double, triple and quadruple protonated molecular ions, respectively, which are consistent 
with the presence of a dimerized peptide containing a single HNE-MA-peptide adduct. The 
same is observed for the double HNE-MA- adduct to the dimerized peptide (in Figure II.10 
B) by the presence of the peaks of m/z 1087.1615, m/z 724.7648 and m/z 543.8180, which 
correspond the double, triple and quadruple protonated molecular ions, respectively. In 
Figure II.10 C the observed peaks at m/z 1165.2288, m/z 777.1412 and m/z 583.0994 are 
consistent with the triple HNE-MA adduct of the dimerized peptide. In the same panel a 
peak at m/z 622.39 is also observed, which was not identified.  
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Figure II.10. Identification by LC-MS of the products formed by reacting peptide 198LKCASLQK205 with 
HNE at a peptide-HNE molar ratio of 1:10; and their respective difference in the retention time. TIC in 
panel A represents the total elution profile of all the reaction products formed and the XICs regarding peaks at 
RT 25 min (B), 30 min (C), 33 min (D) and 36 min (E) correspond to the prediction of the non-modified peptide 
(m/z 930.534), the single MA-HNE-peptide adduct (m/z 1008.595), the double MA-HNE-peptide adduct (m/z 
1086.660) and the triple MA-HNE-peptide adduct (m/z 1164.724), respectively. The experiment was performed 
in triplicate (n=3). 
 
When analysing the MS spectra of each MA adduct (Figure II.11), the molecular ion peaks 
of m/z 1008.5941, m/z 1087.16.15 and m/z 1165.2288 (present in the panels A, B and C, 
respectively), that corresponds, respectively, to the three different Michael adducts, appear 
to be doubled charged molecular ions, which suggest that the peptide has dimerized in the 
solution. Nevertheless, the peaks of m/z 1859.06, m/z 672.72 and m/z 504.79 observed in 
Figure II.11 A, correspond to the double, triple and quadruple protonated molecular ions, 
respectively, which are consistent with the presence of a dimerized peptide containing a 
single HNE-MA-peptide adduct. The same is observed for the double HNE-MA-adduct to 
the dimerized peptide (Figure II.11 B) by the presence of the peaks of m/z 1087.1615, m/z 
724.7648 and m/z 543.8180, which correspond to the double, triple and quadruple 
protonated molecular ions, respectively, and for the triple HNE-MA-adduct to the dimerized 
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peptide (in Figure II.11 C) by the presence of peaks m/z 1165.2288, m/z 777.1412 and m/z 
583.0994 that correspond to the double, triple and quadruple protonated molecular ions. 
 
 
Figure II.11. Identification by LC-MS of Michael adducts formed on peptide 198LKCASLQK205 followed 
reaction with HNE at peptide-HNE molar ratio of 1:10. Panel A shows the MS spectrum relative to the peak 
with an R.T. of 29.944 showing the ion peak relative to the predicted single Michael adduct (m/z = 1087.1615); 
Panel B shows the MS spectrum relative to the peak with an R.T. of 33.707 showing the ion peak relative to the 
predicted double Michael adduct (m/z = 1165.2288); Panel C shows the MS spectrum relative to the peak with 
an R.T. of 36.848 showing the ion peak relative to the predicted triple Michael adduct (m/z = 1165.2288). The 
experiment was performed in triplicate (n=3). 
 
2.4.4. Detection of HNE Modifications on Intact HSA by LC-MS/MS 
The structural modifications of HSA by HNE were also characterized digesting the native 
HSA and HNE-modified (1:10) HSA samples with trypsin and analysing the generated 
peptides by LC-MS/MS. The Sequest search engine provided 81% protein sequence 
coverage, from which 15 peptides containing HNE adducts were identified, of which 8 were 
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Michael adducts and 3 were Schiff’s Bases (Table II.2). The HNE-modified peptides were 
identified based on their m/z, which were determined with mass accuracy ≤5 ppm, and an 
increase of the retention times over the unmodified peptides. Since after trypsinization, the 
generated peptides were treated with iodoacetamide to block the thiols groups of cysteine 
residues, most of the unmodified cysteine-containing peptides were identified as 
carbamidomethylated (CAM), and the exact location of some of the identified HNE 
modifications could not be determined because of the neutral loss of the HNE moiety during 
MS/MS fragmentation. Examples of this are His105 and Lys106 from peptide 
99NECFLQHKDDNPNLPR114 and His67 and Lys73 from peptide 
52TCVADESAENCDKSLHTLFGDKLCTVATLR81; however, the manual annotation of the 
MS spectra, the m/z of the modified peptides and the differences observed in the retention 
times between the modified and equivalent unmodified peptides allowed the confirmation 
of HNE modification on peptides (Table II.2). As the covalent adduction of HNE molecules 
to peptides is typically seen to increase the overall hydrophobicity of the peptides, changes 
in their retention time on a HPLC column can usually be used to confirm the modifications. 
It should be noted that the LC-MS/MS data report on the total variety of modifications 
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Table II.2. Tryptic peptides of HNE-modified HSA identified using the Sequest database search engine 
(Proteome Discoverer 1.4, Thermo Scientific). Oxidation of methionine and cysteine, carbamidomethylation 
(CAM) of cysteine, HNE Michael adducts (on cysteine, lysine and histidine) and Schiff's base adducts (on lysine) 
were used as variable modifications and results were filtered for rank 1 peptides and score vs. charge states 
corresponding to Xcorr/z 2.0/2, 2.25/3, 2.5/4, 2.75/5. 
HSA Peptide Sequence Modifications a 
Theo. MH+ 
[Da] b 






2xCAM C53; C62; 1xHNE MA 
H67 
2653.2120 3 885.0750 0.37 35.0 
2xCAM C53; C62 2497.0970 3 833.0372 -0.28 27.4 
65SLHTLFGDK73 
1xHNE MA H67 1173.6514 2 587.3284 1.42 35.3 
- 1017.5364 2 509.2706 2.08 22.6 
52TCVADESAENCDKSLHTLFGDKLCT
VATLR81 
3xCAM C53; C62; C75; 1xHNE 
MA H67/K73 
3567.7128 4 892.6862 -3.04 39.2 
3xCAM C53; C62; C75; 3411.5978 3 1137.8713 -0.67 33.8 
94QEPERNECFLQHKDDNPNLPR114 
1xCAM C101; 1xHNE MA 
H105 
2792.3421 3 931.4533 -1.39 27.8 
1xCAM C101 2636.2270 3 879.4126 1.22 20.2 
99NECFLQHKDDNPNLPR114 
1xCAM C101; 1xHNE MA 
H105/K106 
2153.0444 3 718.3517 1.57 28.8 
1xCAM C101 1996.9294 2 998.9680 0.17 20.9 
115LVRPEVDVMCTAFHDNEETFLK136 
1xCAM C124; 1xHNE MA 
H128 
2806.3790 3 936.1309 0.15 40.5 
1xCAM C124 2650.2640 3 884.0940 -1.51 35.3 
115LVRPEVDVMCTAFHDNEETFLKK137 
1xCAM C124; 1xHNE MA 
H128 
2934.4740 4 734.3732 0.70 38.3 
1xCAM C124 2778.3590 3 926.7914 -0.43 33.1 
226AEFAEVSKLVTDLTK240 
1xHNE SB K233 1788.9993 2 895.0037 -0.55 47.3 
- 1650.8949 2 825.9522 -1.54 39.3 
241VHTECCHGDLLECADDR257 
3xCAM C245; C246; C253; 
1xHNE MA H242 
2242.9526 3 748.3223 -0.11 26.1 
3xCAM C269; C270; C277 2086.8375 3 696.2834 0.65 19.2 
241VHTECCHGDLLECADDRADLAK262 
3xCAM C245; C246; C253; 
1xHNE MA H242 
2741.2328 3 914.4163 -0.74 26.7 
3xCAM C245; C246; C253 2585.1177 3 862.3770 0.27 22.7 
241VHTECCHGDLLECADDRADLAKYI
CENQDSISSK274 
2xCAM C245; C246; 
1xOxidation C265; 1xHNE MA 
H247 
4067.8089 4 1017.7064 1.05 27.0 
2xCAM C245; C246; 
1xOxidation C265 
3911.6939 4 978.6787 0.02 23.5 
373VFDEFKPLVEEPQNLIK389 
1xHNE SB K378 2183.1998 2 1092.1036 -0.21 48.4 
- 2045.0954 2 1023.0520 -0.80 38.3 
501EFNAETFTFHADICTLSEK519 
1xCAM C514; 1xHNE MA 
H510 
2416.1377 2 1208.5740 -1.34 42.1 
1xCAM C514 2260.0227 2 1130.5161 -1.13 35.7 
501EFNAETFTFHADICTLSEKER521 
1xCAM C514; 1xHNE MA 
H510 
2701.2814 3 901.1012 -3.03 39.8 
1xCAM C514 2545.1664 2 1273.0881 -1.13 33.7 
542EQLKAVMDDFAAFVEK557 
1xHNE SB K545 1979.0194 2 990.0121 1.15 47.3 
- 1840.9150 2 920.9618 -0.88 41.7 
a For each peptide, top line (white background) corresponds to the modified peptide, and the bottom line (grey 
background) to the non-modified peptide. 
b Theoretical mass 
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2.4.5. Detection of HNE Modifications on Intact HSA by Direct Infusion 
ESI-MS 
Native and HNE treated (1:10) HSA samples were analysed by direct infusion on a 
quadrupole mass spectrometer equipped with an electrospray ionization source to evaluate 
changes in the protein mass and assess the number of HNE adducts formed on intact 
protein. Positive-ion ESI mass spectra of native and HNE-modified HSA are depicted in 
Figure II.12 A and D, respectively. Both spectra were smoothed (panels B and E, 
respectively for native and HNE modified HSA) and the peaks were centred (panels C and 
F, respectively for native and HNE modified HSA). 
The spectrum of the native HSA (Figure II.12 A) shows multiply charged peaks ranging 
from m/z 1075 to m/z 1858, which corresponds to the addition of 62 to 36 protons, 
respectively; and for the modified protein (Figure II.12 D), even though ion peaks are quite 
broad, the spectrum shows multiply charged peaks ranging from m/z 1164 to m/z 1877, 
which correspond to the addition of 58 to 36 protons. By deconvoluting the spectra, the 
molecular weights of the non-modified and modified species were calculated to be 66749.11 
Da and 67481.26 Da, respectively, meaning that the HNE-modified HSA is 732.15 Da 
bigger. Because HNE contains three functional groups – aldehyde, C=C double bond and 
one hydroxyl group – it can react with more than one amino acid, either via Michael or Schiff 
base mechanisms. If the adducts were all formed via Michael addition, this result suggests 
the presence of 4.69 molecules of HNE per molecule of HSA. If the adducts, or some of 
them, were formed via Schiff base addition, which involves a loss of 18 Da (loss of H2O) in 
the reaction, this would increase the number of HNE molecules added up to 5.3. 
Nevertheless, the mass increment between the two forms shows the generation of HNE 
adducts on HSA was possible under these conditions. 
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Figure II.12. Direct infusion ESI-MS analysis of native HSA (A) and HNE-modified HSA (D). Both spectra 
were smoothed (Panels B and E, respectively for native HSA and HNE-modified HSA) and the peaks were 
centred (Panels C and F, respective for native HSA and HNE-modified HSA). ESI-MS spectrum of the native 
HSA shows multiply charged peaks ranging from m/z 1075-1858 and the spectrum of the modified HSA shows 
multiply charged peaks ranging from m/z 1164 to m/z 1877.  
 
 
2.4.6. Detection of HNE Modifications on Intact HSA by MALDI-TOF-
MS 
As MALDI-TOF-MS allows the analysis of large proteins, the formation of HNE adducts on 
HSA (sample treated with HNE at a protein:HNE molar ratio of 1:10) could also be confirmed 
by this method. The data in Figure II.13 A shows that the HNE-modified HSA was shifted 
by +477 Da compared to native HSA (Figure II.13 B), which corresponds approximately to 
the addition of 3 molecules of HNE per HSA molecule on average, assuming the adducts 
were formed via Michael addition (+156.1 Da). Nevertheless, this number could be slightly 
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higher if there were a mixture of different adducts being formed on HSA, as suggested by 
the MS/MS data described above. 
 
Figure II.13. MALDI-TOF-MS spectra of HSA treated with HNE at a protein:HNE molar ratio of 1:10 (A) 
and native HSA (B). The difference in mass between the peak representing the modified protein and the peak 
representing the native form correspond to the addition of ∼3 molecules of HNE per HSA. 
 
 
2.4.7. Detection of HNE Modifications on Intact Proteins by Direct 
ELISA Assay 
Prior to initiating the immunization protocol, the reactivity of HNE towards three different 
proteins was assessed by direct ELISA using a commercial polyclonal antibody (pAb) anti-
HNE. This commercial antibody was generated by immunization of HNE-treated keyhole 
limpet hemocyanin (KLH), a protein found in the haemolymph of the giant keyhole limpet 
Megathura crenulata, to avoid cross-reactivity to human or mammalian proteins, which was 
thought to make the results more reliable by limiting false positives. 
HSA, A1AT and OVA were treated individually with the aldehyde at a protein:HNE molar 
ratios of 1:1, 1:5 and 1:10, before being coated onto the immunoassay plate. 
The plot depicted in Figure II.14 shows HNE adducts were formed in all three proteins when 
treated with HNE at protein:HNE molar ratios of 1:5 and 1:10, but when observing the data 
regarding the 1:1 molar ratio, only A1AT seems to have been modified.  
Comparing the three proteins, A1AT appears to be the protein with a higher number of HNE 
adducts whilst HSA the one with the lowest number of HNE modifications. When looking in 
detail to the data gathered when the antigen was plated at the concentration of 1 µg/mL, 
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A1AT appears to be three times more modified than HSA, as seen by the absorbance 
values acquired when both proteins as treated at a 1:10 protein-HNE molar ratio.  
Statistical data obtained from both individual sets of experiments – as this assay was only 
performed in duplicate – showed there was statistical difference between all the three 
modified and respective non-modified proteins (Appendix 8 A); however, as the combined 
data did not meet the criteria of normal distribution and equal variance, which are needed 
for performing a single way ANOVA analysis, the non-parametric Kruskal-Wallis rank sum 
test was used (Appendix 8 B). The p values obtained by this test indicate only A1AT-HNE 
and OVA-HNE are significatively different from A1AT and OVA, respectively, as opposed 
to HAS-HNE and HSA. Using the Dunn test to determine where exactly the statistical 
difference occurs within the HNE modified A1AT and OVA, it was possible to infer that the 
significant difference occurs between non-modified A1AT and A1AT-HNE (1:10) and OVA-
HNE (1:1) and OVA-HNE (1:10) –  p values of  0.0024 and 0.0049, respectively (Appendix 
8 C). 
 
Figure II.14. Identification of HNE adducts on A1AT, HSA and OVA by direct ELISA using the commercial 
anti-HNE polyclonal antibody from Abcam. Each protein was individually incubated with HNE at three 
different protein-HNE molar ratios (1:1, 1:5 and 1:10) for 2h at 37°C, and different concentrations from these 
batches, ranging from 0 to 1 g/mL, were adsorbed onto an ELISA plate (A). The data obtained when using 1 
g/mL of each modified and non-modified antigen was isolated and represented in a graph bar for ease of 
understanding (B). The assay was performed in duplicate (n=2), with SEM of technical triplicates; * p<0.0125. 
 
Nonetheless, the ELISA assay confirms the aldehyde is able to modify the proteins 
regardless of their origin or size, which is in agreement with several studies found in the 
literature. The protein:HNE molar ratio of 1:10 was chosen for further experiments since 
statistically significant differences were observed for all these three batches of modified 
proteins. 
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2.4.8. Detection of HNE Modifications on Intact Proteins by SDS-PAGE 
and Western Blotting  
To complement the results obtained by ELISA, the same three proteins, non-modified 
(Figure II.15 A) and HNE-modified at the same molar ratios (Figure II.15 B), were 
subjected to SDS-PAGE gel and western blotting analysis with the same commercial anti-
HNE pAb (Figure II.15 C). 
 
Figure II.15. SDS-PAGE (A and B) and western blotting analysis (C) of non-modified and HNE modified 
HSA, OVA and A1AT. Non-modified proteins are represented in panel A whereas HNE modified HSA, OVA 
and A1AT at three different molar ratios (1:1, 1:5 and 1:10) are depicted in panel B. The HNE modifications on 
the three proteins were also confirmed by western blotting analysis using the Abcam anti-HNE (C). The 
experiment was only performed once (n=1). 
 
Visual interpretation of the SDS-PAGE gel depicted in Figure II.15 B shows that, regarding 
HSA (MW: 66.5 kDa), there is an increment of the molecular weight of the protein band as 
the protein-HNE molar ratio is increased, suggesting HNE is forming adducts on the protein. 
For OVA (MW: 45 kDa), no major changes can be observed in the protein bands; however, 
for the 1:5 molar ratio, the protein band detected seems to be stronger than the bands 
observed for 1:1 and 1:10 molar ratios. For A1AT (54 kDa), the protein band seems to 
decrease its intensity with increasing concentration of HNE, but the onset of high molecular 
weight bands can be seen. This phenomenon was also observed for HSA, which suggests 
in the presence of high concentrations of HNE induced the formation of protein crosslinks 
and aggregation.  
The formation of HNE adducts on HSA, OVA and A1AT, in all the three protein:HNE molar 
ratios tested, was further confirmed by western blotting using a commercial antibody 
specific to HNE (Figure II.15 C). The blot shows as well increasing intensities of the bands 
with increasing protein:HNE molar ratios, suggesting, as expected, the formation of a 
greater number of HNE modifications with increasing concentrations of HNE. Regarding 
HSA and OVA, the detection top bands by the anti-HNE pAb confirms the formation of HNE-
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crosslinks with more than one molecule of HSA or OVA, as the SDS-PAGE implied. 
Although quantitative studies were not done for this western blot, densitometry analysis will 
be shown later for this and other western blot experiments in 3.4.4. Enrichment and 
Characterization of SA269 anti-HSA-HNE Antibodies using Protein G and KLH-HNE 
Conjugated Resins. 
 
2.4.9. Kinetic and Affinity Characterization of anti-HNE pAb to HNE 
treated 31LQQCPFE37 Peptide 
The development of a lateral flow assays relies mainly on the sensitivity of the antibodies 
used for the capture and detection of the target analyte; therefore, target binding 
characterization is an essential analytical step for the selection of high affinity (KD < 1 nM) 
and highly specific antibody molecules. As preliminary experiment, the kinetic parameters 
of the commercial anti-HNE antibody were tested with the HNE-modified biotinylated 
31LQQCPFE37 peptide using FortéBio Octet assay with “Dip and ReadTM Streptavidin 
Biosensors”. For this purpose, the peptide 31LQQCPFE37 was re-synthesized with a biotin 
tag in the C-terminal (MW: 1291.63), purified by reverse-phase chromatography and its 
mass was confirmed by LC-MS (Figure II.16). The peaks at m/z 1262.6338 and 646.8129, 
which correspond to the single and double charged ions ([M+H]+) and ([M+2H]+2) of the 
peptide, confirmed the correct synthesis and purification of the peptide. 
 
Figure II.16. MS analysis of synthetic biotinylated 31LQQCPFE37 peptide (A) and corresponding structure 
(B). Ion peaks at m/z 1292.6338 and 646.8129 correspond to the single and double charged ions ([M+H]+) and 
([M+2H]+2), respectively, of the peptide. The experiment was performed in triplicate (n=3). 
 
The biotinylated 31LQQCPFE37 (biot-31LQQCPFE37) peptide was further reacted with HNE 
under the same conditions, for generation of HNE adducts, and its corresponding reaction 
products were analysed by LC-MS. Figure II.17 A and B show, respectively, the formation 
of one MA and one SB. 
 
97 of 260 
 
Figure II.17. Identification by LC-MS of HNE adducts formed on biotinylated 31LQQCPFE37 peptide 
followed reaction with HNE at peptide-HNE molar ratio of 1:10. An HNE-MA-peptide adduct was confirmed 
by the presence of the ion peaks m/z 1448.7535 and 724.8722, that correspond to the single and double ion 
species, respectively (A), and a Schiff’s base adduct was confirmed by the ion peaks m/z 1430.7405 and 
715.8655, which correspond as well the single and double ion species, respectively (B). The experiment was 
performed in triplicate (n=3). 
 
Once the formation of HNE adducts was confirmed, the purified HNE-adducted form of the 
biot-31LQQCPFE37 peptide (HNE-biot-31LQQCPFE37) was immobilized onto a streptavidin 
plate for calculation of association and dissociation constants of the Abcam anti-HNE pAb, 
by bio-layer interferometry. The traces depicted in Figure II.18 show the interference in the 
wave light caused by the association and dissociation of HNE-biot-31LQQCPFE37 peptide 
when using different antibody concentrations. The higher the concentration of antibody, the 
faster the association and dissociation steps. 
 
 
Figure II.18. Kinetic and affinity analysis of Abcam anti-HNE pAb to immobilized HNE-biotinylated-
31LQQCPFE37 peptide. Kinetic constants were calculated testing eight different antibody concentrations (64, 
32, 16, 8, 4, 2 and 1 nM) and the the binding curves (red lines) were fit using a global fit algorithm for 1:1 binding 
interaction in the Octet Data Analysis software v. 7.0. The assay was performed only once (n=1).  
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The assay data was processed using Data Analysis (ForteBio) to obtain the kinetic values, 
using a global fit algorithm for 1:1 binding interaction, which fits multiple concentrations to 
one set of constants. The KD obtained for interaction between the Abcam anti-HNE pAb and 
the HNE-biot-31LQQCPFE37 peptide was 3.09 x10-9 M (10 nM), which is considered a high 
affinity binding.  
 
2.5. Chapter II Discussion, Conclusions and Future Work 
When evidence for a correlation between oxidative stress and the onset of several chronic 
diseases began to emerge, the need to develop novel detection and identification strategies 
for oxidation products became more crucial. It is now clear that lipid oxidation products in 
particular can react and form covalent adducts with different molecules, altering their 
structure and modifying their function in a process called lipoxidation, and emphasizing the 
need to detect not only free radicals and antioxidants, but also oxidized lipid-protein-
adduction products. HSA-HNE adducts, in particular, are of very great interest as they can 
serve as blood markers of oxidative stress in vivo. 
High resolution MS approaches led the identification of 11 HNE modifications on intact HSA, 
from which 8 were formed via Michael addition and 3 via Schiff’s base reaction, confirming 
the in vitro reactivity of this lipid peroxidation product towards HSA. Apart from the HNE 
modification on peptide 115LVRPEVDVMCTAFHDNEETFLK136 (possibly localised at 
His128), all the other HNE modifications identified in this study had already been reported 
by Aldini et al (Aldini et al., 2006), Liu et al (Q. Liu et al., 2012), and Szapacs et al (Szapacs, 
Riggins, Zimmerman, & Liebler, 2006), reinforcing not only the veracity of this study, but 
also the accuracy of MS strategies in the detection of lipoxidation products. However, in all 
three studies, the residue Cys34, known to be the only free cysteine of HSA, was also 
identified as HNE-modified, that was not observed in this study. This residue is as well 
known to be the largest fraction of thiol in blood serum (~80%) (Rossi et al., 2010) and 
therefore is commonly used as an indicator of the oxidative stress in serum; however, 
because the HSA used in our studies comes from a commercial source and had probably 
been extensively exposed to the atmospheric oxygen, this might have caused the possible 
oxidation of Cys34, biasing the formation of HNE adducts. Another possible explanation for 
the non-identification of the HNE-Cys34 adduct relies on the 81% of protein sequence 
coverage achieved by the search engine used, which could have missed the protein 
sequence including the Cys34 residue. Apart from the HNE modifications identified in the 
work described in this chapter, Liu et al has also identified HNE adducts on residues 
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Lys162, Lys199, Lys212, Lys262, His288, Lys351, His367, Lys414 and Lys525, possibly 
due to the longer HNE reaction times used in these experiments (3h) (Q. Liu et al., 2012). 
In addition to MS, antibody-based techniques confirmed the formation of HNE adducts on 
HSA, and as well on OVA and A1AT (as control), either by ELISA and western blotting, 
suggesting different intact proteins are susceptible to HNE modifications and can be used 
directly as immunogens. However, the use of specific peptide sequences as immunogens 
is also a strategy very much applied for the generation of antibodies, namely for generating 
“highly-specific“ polyclonal antibodies (Burdon & van Knippenberg, 1988) – which in this 
case might be translated as specificity to a particular HNE adduct on HSA. Therefore, the 
formation of HNE adducts on peptides containing target amino acids was well assessed in 
this work. In all the three synthesised peptides HNE adducts were identified, but their exact 
location was, unfortunately, not achieved. Regarding peptides 31LQQCPFE37 and 
98LKCASLQK205 in particular, more than one adduct was identified (in each sequence), 
suggesting the excess of HNE used allowed the modification of other nucleophilic amino 
acids as well. In fact, in 31LQQCPFE37 we believe the second HNE adduct identified might 
be located on the NH2 group of the N-terminus of the peptide, as this was not acetylated, 
and there are no other potentially reactive amino acids in the peptide sequence. 
The affinity of the anti-HNE commercial pAb towards one of the synthesised peptides was 
then measured via a bio-layer interferometry (BLI) assay, as the adsorption of single 
peptides to ELISA plates is not viable. The peptide 31LQQCPFE37 was biotinylated and 
reacted with HNE, and then linked to a streptavidin plate for the kinetic measurements. The 
affinity of an antibody is commonly measured by its equilibrium dissociation constant (KD), 
that is a ratio of kdis/kon, between the antibody and its antigen, and therefore, the lower the 
KD value, the higher is the affinity of the antibody for its target, and the less antibody is 
required in an immunoassay for detection of the analyte. The commercial antibody 
presented a KD of 3.09 x10-9 M towards the modified peptide, which makes this antibody a 
high affinity antibody. High affinity antibodies generally a KD in the low nanomolar range 
(10-9) and very high affinity antibodies a KD in the picomolar (10-12) range. However, this 
kinetic measurement was not performed for the neither of the other two peptides, not 
allowing to establish any type of correlation between affinity antibody and specific adducts. 
It would be of great interest for future work to compare the KDs of different commercial anti-
HNE antibodies towards His, Cys and Lys-HNE specific adducts and understand if the 
immunization methodology applied influences the affinity/specificity of the antibody. 
Another possible idea for future work regarding the MS approaches followed in this work 
would be to test a gentler collision energy on the mass analyser, like electron capture 
dissociation, in order to identify the exact location of the HNE adducts within the HSA amino 
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acid sequence, and equally important, to compare this study using freshly purified HSA to 
assess the differences in HNE modifications.  
Nevertheless, either by using the intact protein or by chemically synthesising peptides, the 
formation of HNE adducts on HSA was confirmed, opening the possibility of using these 
adducts as immunogens to trigger the production of polyclonal antibodies. 
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CHAPTER III  
GENERATION AND CHARACTERIZATION OF ANTI-
HSA-HNE POLYCLONAL ANTIBODIES AND 
IMMUNOASSAY DEVELOPMENT 
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3.1. Introduction 
3.1.1. Generation of anti-HNE Antibodies by Immunisation 
Antibodies have undoubtedly become one of the most desirable classes of biomolecules 
for several industries, due to their high sensitivity and specificity towards specific targets. 
Particularly in the last 20-30 years, with the development of hybridoma and phage display 
technologies for generation of monoclonal antibodies, these molecules have been highly 
produced for application in scientific research, namely for laboratory assays such as 
radioimmunoassays and enzyme-linked immunosorbent assays (ELISA), in diagnostics, 
and even for immunotherapy (Sifniotis, Cruz, Eroglu, & Kayser, 2019). Regarding 
diagnostics and what concerns oxidative stress-related disorders, there has been a great 
interest in developing antibodies specific to lipid oxidation products such as HNE (Toyokuni 
et al., 1995), ACR (Uchida et al., 1998), MDA (Sevilla et al., 1997) and HHE (Yamada et 
al., 2004) for scientific purposes, but further deployment of these reagents in diagnostic 
assays for commercial application has not been accomplished yet.  
With the exception of synthetic recombinant antibody production methods, virtually all 
antibodies are derived from active immunization of animals with an immunogen; however, 
not all molecules are considered immunogenic. In order to induce a good antibody response 
in a host animal, immunogens need to be bigger than 3000-5000 Da, so they can 
simultaneously bind to antibodies on the surface of B cells and to class II-T cell receptors 
(Harlow & Lane, 1988). Since most of the lipid oxidation products, including HNE, are of 
very small molecular weight, the generation of specific antibodies towards these products 
is considerably more challenging. To overcome this issue, these small molecules must be 
coupled to bigger molecules, also known as carrier proteins, which can elicit a much better 
immune response. Another very common strategy to trigger the immune system to produce 
antibodies, quite often used when working with lipid peroxidation products, is to chemically 
synthesize peptide sequences of proteins of interest, react them with the lipid oxidation 
product, and couple the modified the lipoxidised peptide to a carrier protein, so antibodies 
can be generated specifically against a certain peptide sequence. This strategy can be 
particularly useful when studying lipoxidation adducts, as the immunization of HNE-modified 
peptide sequences containing single and known nucleophilic residue may lead to the 
generation of antibodies specific to a certain type of lipoxidation adduct. For example, 
Uchida et al in 1995 generated an anti-HNE-His antibody by immunizing rabbits with HNE-
conjugated to the heptapeptide Gly3-His-Gly3 covalently bound to a carrier protein (Uchida, 
Itakura, et al., 1995).  
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Equally important to the size of the antigen is its source, as animals develop immunological 
tolerance to self-molecules (Burdon & van Knippenberg, 1988). If antigens are very similar 
to host molecules, animals might not respond as B and T cells that display receptors specific 
to self-proteins have been previously eliminated from the system. Therefore, for the best 
immune response, antigens should be different from host molecules, ideally from a different 
animal species, so the immune cells recognize it. Non-human carrier proteins like keyhole 
limpet haemocyanin (KLH) and bovine serum albumin (BSA) are very often used in 
immunization protocols has they are very large proteins and do not cross-react to human 
proteins. 
Once the immunization protocol is finished, antisera are relatively quick and inexpensive to 
produce, but the specificity and affinity of the desired antibodies entirely depend on further 
processing of the antiserum (Harlow & Lane, 1988). The whole IgG fraction is usually 
obtained from the serum by affinity chromatography, which is based on specific and 
reversible binding of the Fc regions of the IgG to lectins, such as Protein A or Protein G. 
However, if only a specific population of IgG is desired, then their capture requires 
immobilization of the immunogen onto a solid support to allow the specific antibodies to 
bind to the antigen. For both strategies, after extensive washing of the solid phase, which 
removes everything that does not bind to the antigen, specific antibodies can be eluted by 
disruption of immunological binding by either low pH or high concentrations of a competitor 
molecule (H. F. Liu, Ma, Winter, & Bayer, 2010).  
The first anti-HNE antibody generated was raised by immunization of rabbits with HNE-
treated KLH (Uchida et al., 1993) but other anti-HNE pAbs have been raised by coupling 
HNE to bovine serum albumin (BSA) (Satoh et al., 1999; Uchida, Itakura, et al., 1995). As 
regards the application of anti-HNE antibodies to immunoassays for detection of HNE-
protein adducts, ELISAs have been by far the most developed assay. They are fairly easy 
and inexpensive to develop, rapid to perform, and can be designed in different ways; 
however, the accuracy of the test entirely relies on the sensitivity and specificity of the 
antibodies, which is not always consistent due to the complexity of the tested matrices. For 
example, a comparative study of two different anti-HNE primary antibodies in serum 
samples of obese patients have showed differences in the quantification range of HNE-
protein adducts in plasma/serum between both direct ELISAs, even when both antibodies 
were stated to be specific to the HNE-His epitope (Weber et al., 2013). Nevertheless, 
Uchida et al in 1999 reported the development of a rapid competitive ELISA assay for 
quantification of acrolein and HNE modified proteins by using mAbs specific for the acrolein-
modified FDP-lysine (N-(3-formyl-3,4-dehydropiperidino)-L-lysine) residue (mAb5F6) and 
the HNE-modified histidine residue (mAb HNEJ-2), and the results were very consistent. 
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Another direct ELISA developed for the detection of HNE adducts using the same anti-HNE-
His mAb was tested in human osteosarcoma cell cultures and was shown to be able 
to determine HNE-His conjugates when cells were treated with less than 3 nmol of HNE/105 
cells: however, the assay showed elevated background values due to the presence of 
several cell contaminants (Borovic, Rabuzin, Waeg, & Zarkovic, 2006). Regardless of the 
background, the authors stated that the assay had a sensitivity of 8.1 pmol HNE–His/mg of 
protein and an inter-assay precision of 12%, when tested with human osteosarcoma cell 
cultures (Borovic et al., 2006). 
As none of these anti-HNE antibodies seem to be fully characterized in terms of epitope 
binding and even results obtained with monoclonal antibodies seem to be variable, there is 
still a very big window open for research and development in this field. 
 
3.1.2. Chapter III Aims  
As HSA was found to be one of the major nucleophilic target of HNE in the human sera 
(Aldini, Vistoli, et al., 2008), the aim of this section of the project was to generate antibodies 
with specificity to only HNE adducts on HSA and deploy these molecules in a immunoassay 
for rapid detection of HNE-HSA adducts.  
To accomplish this aim, the HNE adducts formed on intact HSA and on 31LQQCPFE37 
peptide, confirmed in Chapter II, were prepared for immunization and administrated, 
separately, on different animals. After each vaccination, polyclonal sera were collected for 
screening by ELISA against different HNE-modified and non-modified target proteins, and 
subsequently, the potential anti-HSA-HNE antibodies were purified by different strategies. 
After epitope characterization, purified anti-HSA-HNE antibodies were applied on a 
sandwich immunoassay for assessment of specificity and sensitivity. 
 
3.2. Reagents 
Human serum albumin (A1653) and albumin from chicken egg white (A5503) were obtained 
from Sigma-Aldrich. ImjectTM mcKLH (in PBS) and CarboxyLink™ coupling resin were 
purchased from Thermo Fischer Scientific (UK). 4-hydroxynonenal diethylacetal (HNE-
DEA) was generously supplied by Prof. Giancarlo Aldini from University of Milan. HNE was 
prepared from HNE-DEA as stated before in 2.2 Reagents. Commercial goat polyclonal 
antibody anti-HNE (Ab46544) was purchased from Abcam, and 3, 3′, 5, 5′-
tetramethylbenzidine (TMB) and HRP-labelled anti-goat IgG were purchased from Sigma 
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Aldrich (UK).  NHS-Activated Sepharose 4 Fast Flow columns and HiTrap Protein G HP 
columns were purchased by GE Healthcare (UK). Fluorenylmethyloxycarbonyl (Fmoc) 
protected amino acids were purchased from Intavis (20×1 cartridge of 0.5 mmol of Fmoc-
Ala-OH, Fmoc-Arg (Pbf)-OH, Fmoc-Asn(Trt)-OH, Fmoc-Asp(OtBu) OH, Fmoc- Cys (Trt)-
OH, Fmoc-Gln (Trt)-OH, Fmoc-Glu (tBu)-OH, Fmoc-Gly-OH, Fmoc-His (Trt)-OH, Fmoc-Ile-
OH, Fmoc-Leu-OH, Fmoc-Lys (Boc)-OH, Fmoc-Met-OH, Fmoc-Phe-OH, Fmoc-Pro-OH, 
Fmoc-Ser(OtBu)-OH, Fmoc-Thr (tBu)-OH, Fmoc-Val-OH). 1-methyl 2-pyrrolidinone (NMP), 
dimethylformamide (DMF), 1,3-diisopropylcarbodiimide (DIC), 1-hy- droxybenzotriazole 
(HOBt) acetonitrile, formic acid, dichloromethane (DCM), and ethanol, were purchased from 
Rathburn chemicals Ltd (Walkerburn, Scotland). Trifluoracetic acid (TFA), triisopropylsilane 
(TIPS) and piperidine ≥99.5% was obtained from Sigma (UK). Sodium chloride (NaCl), 
Sodium Phosphate (Na2HPO4), potassium phosphate (KH2PO4), Glycine, Tween 20 and 
Trizma® (TRIS base) were purchased from Sigma Aldrich (UK). All solutions were prepared 
using ultra-pure Milli-Q water. 
 
3.3. Materials and Methods 
3.3.1. Preparation of HSA-HNE Adducts for Immunization 
For the generation of HNE adducts, 5 mg of HSA were reacted with HNE (stock 
concentration of 5.2 mg/mL in 1 mM HCl) at a molar ratio of 1:10 in 1 mL of phosphate 
buffer saline buffer (PBS; 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8mM KH2PO4, 
pH 7.4) for 2 h at 37°C. Once the 2 h were completed, the concentration of the reaction mix 
was adjusted to 1 mg/mL by addition of 4 mL of PBS. 
 
3.3.2. Preparation of KLH-peptide-HNE Conjugate for Immunization 
HNE-modified 31LQQCPFE37 peptide was conjugated to KLH before sheep immunization, 
according to the protocol recommended by the manufacturer (Thermo-Scientific). The 
carrier protein, KLH, was activated with maleimide and reconstituted to 10 mg/mL in distilled 
water. It was then incubated with an equal volume of 10 mM sulfosuccinimidyl-4 -[N-
maleimidomethyl] cyclohexane-1- carboxylate at room temperature for 1 h, with gentle 
periodic mixing. After equilibrating the PD-10 column (Thermo Scientific, UK) with 
conjugation buffer (100 mM ethylenediaminetetraacetic acid, 83 mM sodium phosphate, 
100 mM sorbitol and 900 mM NaCl, pH 7.2), the excess cross-linker was removed by 
desalting. To ensure efficient conjugation, the peptide was prepared in a 10-molar excess 
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to KLH, by adding the molecular weight equivalents of the peptide and protein. The peptide 
was reconstituted to 1 mg/mL in conjugation buffer and incubated for 2 h with the collected 
column eluate. Again, PD-10 columns were equilibrated with conjugation buffer, and the 
conjugated peptide-KLH mixture was filtered through the column to remove any excess 
unconjugated peptide.  
 
3.3.3. Generation of anti-HSA-HNE Polyclonal Antibodies  
The immunization protocol was performed by the subcontracted company Orygen in 
Edinburgh, UK, that was responsible for administrating the initial immunization with 1 
mg/mL of immunogen and further three (or, in some cases, four) boosts (one 28 days days) 
with 0.25 or 0.50 mg/mL of the immunogen, in each respective animal.  
For generation of anti-HSA-HNE polyclonal sera, the effect of the stability of the adducts 
was tested by immunizing two sheep (SA350 and SA369) with non-reduced HSA-HNE 
adducts and two other sheep (SA351 and SA352) with NaBH4-reduced HSA-HNE adducts. 
For generation of anti-HNE-modified 31LQQCPFE37 conjugated peptide, two sheep (SA414 
and SA415) and two rabbits were used (rabbits RA511 and RA512). Before the start of 
each immunization protocol, a pre-immune bleed was collected for further control analysis. 
Seven days after each injection a bleed (∼300 mL) was collected. 
Table III.1. List of the immunizations performed for the generation of anti-HSA-HNE antibodies. 
Immunogen Animals immunised 
HSA-HNE (reduced addct) 2 sheep (SA351 and SA352) 
HSA-HNE (non-reduced adduct) 2 sheep (SA350 and SA369) 
HNE- modified 31LQQCPFE37 2 sheep (SA414 and SA415) and 2 rabbits (RA511 and RA512) 
 
3.3.4. Polyclonal Sera Screening by Direct ELISA 
The collected bleeds were screened for antibody binding by direct ELISA by coating 96-
well microtiter plates (Corning, MA, USA) with 100 μL of the target antigen at 1 μg/mL, 
overnight at 4°C. Following aspiration of the antigen solution, the plates were washed three 
times with tris-buffered saline, 0.1% Tween 20 (TBST), and the wells were blocked with 120 
μL of 1% (w/v) BSA/PBS for 1 h at room temperature. After another three-wash step with 
TBST, 100 μL aliquots of each bleed were added to the wells in 4-fold dilution factors in 1% 
(w/v) BSA/PBST (1/400, 1/1600, 1/6400, 1/25,600, 1:102,400 and 1/409,600) and the plate 
was incubated for 1 h with shaking at room temperature. The wells were once again washed 
three times with TBST and the plate was further incubated with 100 μL of 1:25,000 dilution 
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of mouse anti-sheep IgG or mouse anti-rabbit conjugated to alkaline phosphatase in 1% 
(w/v) BSA/ PBST, for 1 h with shaking at room temperature. The detection was done using 
pNPP (Thermo Fisher Scientific, USA) and the absorbance was read at 405 nm using a 
microplate reader. A schematic illustration of the assay is depicted below in Figure III.1. 
 
Figure III.1. Illustration of the direct ELISA assay performed for the detection of anti-HNE antibodies 
generated by animal immunization. The HNE-modified antigen was coated on a 96 well plate, to which the 
sera was added (after blocking). The detection was performed using an alkaline phosphatase labeled antibody 
anti-species. 
 
3.3.5. Selective Capture of anti-HSA-HNE Antibodies  
Selective enrichment of anti-HSA-HNE antibodies from crude serum of sheep SA369 was 
carried out by following two different affinity purification approaches. The first approach 
involved a first affinity chromatographic step using a HiTrapTM NHS-activated column 
modified with HNE-treated HSA (1 mL) for purification of the mixture of anti-HSA and anti-
HSA-HNE antibodies, and a second affinity purification with a HiTrapTM NHS activated 
column modified with HSA (1 mL) for depletion of the anti-HSA antibodies. Anti-HSA-HNE 
pAbs were collected from the unbound fraction of the second purification run. 
The second approach consisted of a first purification step with a HiTrapTM Protein G column 
(1 mL) for purification of the whole population of antibodies, and later, for the specific 
purification of anti- HNE antibodies a HiTrapTM NHS activated column modified with HNE- 
treated KLH was used. For both approaches, the columns were equilibrated with 5 column 
volumes of PBS pH 7.4, prior to loading of 10 mL of crude serum (previously centrifuged 
and filtered). Washing for removal of non-specific binding compounds was achieved by 
increasing the salt concentration to 1M NaCl for 2 column volumes. After re- equilibration 
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into PBS, the elution of bound antibodies was triggered by decreasing the pH to 2.5, using 
a 0.1M Glycine-HCl aqueous buffer. Column flow through and eluate were continuously 
collected as 5 and 2 mL fractions, respectively, in a FRAC 950 fraction collector from GE 
Healthcare. The collected samples containing the antibody of interest were combined 
neutralized by adding 60 μL of 1M Tris-HCl pH 9.0, per each 5 mL, and then placed in 
dialysis tubing overnight in 2 L of PBS. After dialysis, samples were loaded onto the second 
NHS modified column (KLH-HNE or HSA-modified) for depletion of anti-HSA anti- bodies. 
The same elution and dialysis methods were applied. The chromatographic runs with both 
columns were performed on an ÄktaTM Purifier 10 system from GE Healthcare. The data 
collection and processing were accomplished using Unicorn 5.1 software. Chromatographic 
parameters such as conductivity and UV absorbance at 280 nm were measured 
continuously. The concentration of the eluate samples from both columns was calculated 
by measuring the absorbance at 280 nm using a spectrophotometer, and then dividing that 
value by 1.4 (extinction coefficient of IgG). 
 
3.3.6. SDS-PAGE 
Sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–PAGE) was performed 
to characterise the SA369 polyclonal serum and the different enriched populations of anti-
HSA-HNE pAbs. Samples were prepared in Laemmli loading buffer, heated at 100°C for 5 
min, and loaded onto a 12% acrylamide gel, prepared from 40% acrylamide/bis stock 
solution (29:1) (Bio-Rad, UK) and run at 100mV using 192mM glycine, 25mM Tris–HCl and 
0.1% SDS, pH 8.3. Gels were stained with Coomassie Brilliant Blue (Pharmacia, Uppsala, 
Sweden). Images were acquired with the Gel Doc EZ System from Bio-Rad (CA, USA). 
 
3.3.7. Western Blotting using the SA369 anti-HSA-HNE Polyclonal 
Antibody  
For the Western blot analysis, samples were separated on 12% SDS-PAGE gels according 
to the conditions described before. Proteins were transferred from the gel to PVDF 
membranes using the Trans-Blot Turbo Transfer System (Bio-Rad, CA, USA). The 
membranes were blocked overnight at 4 °C with AdvanBlock-PF blocking solution 
(Advansta, Inc, CA, USA) and then incubated with the primary antibodies (either the in-
house enriched anti-HNE pAb or the Abcam anti- HNE pAb, dilution 1:10,000), for 1 h at 
RT. The membranes were washed with AdvanWash washing solution (Advansta, Inc, CA, 
USA) three times for 10 min and incubated with the secondary antibody (HRP-labelled anti-
 
109 of 260 
sheep and anti-goat, dilution 1:10,000). Detection was performed using the WesternBright 
Sirius ECL reagent (Amersham, UK), and images acquired using the ChemiDoc™ XRS + 
System (Bio- Rad, CA, USA). The results were interpreted by densitometry analysis using 
the software ImageJ, Version 1.48. 
 
3.3.8. Sandwich ELISA for Detection of HNE adducts 
A sandwich ELISA using the SA369 pAb as capture antibody and the Abcam anti-HNE pAb 
as detection antibody was developed for the detection of HNE adducts (Figure III.2). 96-
well ELISA plates were coated overnight at 4 °C with 100 μL per well of the capture antibody 
(SA396 anti-HSA-HNE pAb) solution at 1 μg/mL. Plates were washed three times with 
TBST (20mM Tris, 137mM NaCl 0.05% Tween-20 pH 7.6) and blocked with 120 μL of 1% 
(w/v) BSA/PBS (137 mM sodium chloride, 2.7mM potassium chloride, 8mM disodium 
hydrogen phosphate, 1.5 mM potassium dihydrogen phosphate, pH 7.4), for 1 h at room 
temperature. Plates were once again washed three times with TBST, and then incubated 
with 100 μL of the antigen (KLH, HSA or OVA previously treated with HNE at a protein:HNE 
1:10M ratio for 2 h at 37 °C and prepared in 1% (w/v) BSA/PBST at a range of 0–20 μg/mL) 
for 1 h with shaking. After another three wash steps with TBST, the plates were incubated 
with 100 μL of the detection pAb (Abcam anti-HNE HRP-la- belled (dilution: 1/2000)) for 1 
h. TMB substrate solution (100 μL) was used for detection and its reaction was stopped 
after 15–30 min by addition of 50 μL of stopping solution (1M HCl). Absorbance was read 
at 450 nm. 
 
Figure III.2. Illustration of the sandwich ELISA assay developed for the detection of HNE adducts on 
proteins. The in-house sheep SA369 pAb was used as capture antibody and the Abcam anti-HNE pAb as 
detection antibody. 
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3.3.9. Statistical Analysis  
Data from the ELISA assays shown in Figure III.14 A and B were both analysed with 
Microsoft Excel program, using a Student’s t-Test: Paired Two Sample for Means for 
comparing individual concentrations of non-modified vs modified antigen in Figure III.14  A, 
and one-way ANOVA tests to assess in Figure III.14  B significative differences between 
HNE modified and non-modified HSA. 
 
3.3.10. HRP-Labelling of Antibodies 
Enriched anti-HSA-HNE pAbs and commercial anti-HNE pAb were labelled separately with 
horseradish peroxidase (HRP), for direct detection on the membrane immunoassays, using 
a commercial labelling kit from Innova Biosciences. The conjugation was performed 
according the manufacturer’s instructions, by mixing the 10 µl of antibody solution (2 
mg/mL) with 1 µl of LL-modifier reagent. After a 3 h incubation at room temperature with 
the Lightning-Link® mix, 1 µl of LL-quencher reagent was added. The conjugate was stored 
at 4ºC. 
 
3.3.11. Design and Synthesis of Peptide Arrays  
The sequence of HSA, including the 18-residue signal peptide and 6-residue pro-peptide 
(accession number P02768) and ovalbumin (OVA) (accession number P01012) was 
divided into 15-mer peptides with sequential peptides overlapping by 13 amino acids, and 
each peptide was synthesised on commercially available derivative membranes (amino-
PEG500-UC540 Sheets) based on conventional Fmoc chemistry, using the Intavis ResPep 
SL peptide synthesiser (INTAVIS, Köln, Germany). Peptides were cellulose-coupled to the 
C-termini and the principle of the peptide arrays is depicted in Figure III.3. 
The membranes were initially washed with DMF and ethanol, the coupling of the amino 
acids was achieved by pre-activation in 0.5M amino acid (in NMP), 1.1M activator (HOBt) 
and 1.1M of DIC in DMF. Any unreacted free amino groups were blocked by washing the 
membranes with 10% acetic anhydride in DMF (capping solution). The peptides were built 
one amino acid at a time, starting from the C-terminus to the N-terminus. In the last coupling 
cycle, the capping step was omitted and the final Fmoc-deprotection was carried out with 
20% piperidine in DMF. The HSA and OVA sequences of each synthesised peptide and 
their localization on the peptide array are shown in Appendix 5 and Appendix 6, 
respectively. Once the synthesis was completed, the membrane was treated with a mixture 
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of TFA/TIPS/H2O (18:1:1) for 1–2 h for final sidechain deprotection, and then washed with 
DCM for 30 min. Finally, the membranes were washed with ethanol and water, in cycles of 
5 min and once dried they were stored in a sealed container at RT. In the text, HSA residues 
are numbered from the start of the mature protein sequence, without the signal and pro-
peptides. 
Figure III.3. Schematic representation of a peptide array. The membrane is firstly incubated with HNE and 
subsequently with the primary and the HRP-labelled secondary antibody. After incubation with the substrate, 
the peptide spots to which the antibody is bound develop a blue colour. 
3.3.12. Epitope Mapping on Peptide Arrays 
The cellulose membranes were initially washed 3 times for 10 min with PBS for rehydration 
and for the HNE adduct formation, the membranes were then incubated with 0.02 mM HNE 
in PBS for 2 h at 37 °C (for negative controls this step was omitted). Subsequently, 
membranes were washed twice with PBS containing 0.1% (v/v) Tween 20 (PBST) for 30 
min and blocked with 20 mL of blocking solution (5% skimmed milk powder in PBST) for 1 
h. The blocking reagent was discarded and a 20 mL aliquot of 100 ng/mL of HRP-
conjugated anti-HNE antibody in blocking agent was added. After a 1 h incubation the 
membranes were washed with 3 volumes of PBST (3×5 min) and incubated with 5 mL of 
TMB for 15–30 min, until color is observed and the signal was completely developed. The 
membranes were washed with two volumes of water, allowed to drip dry and then scanned 
using a GS-800TM Calibrated Densitometer from Bio-Rad (CA, USA). The regeneration of 
the membranes was accomplished by incubation with 20 mL of 1% SDS in 100 mM Tris-
HCl, pH 6 + 140 μl of β-mercaptoethanol. 
 
112 of 260 
3.4. Results 
3.4.1. ELISA Screening of anti-HSA-HNE Polyclonal Sera  
For the generation of anti-HSA-HNE polyclonal antibodies two sheep were immunized with 
non-reduced HSA-HNE adducts (sheep SA350 and SA369) and two other sheep were 
immunized with NaBH4-reduced HSA-HNE adducts (sheep SA351 and SA352). Sera 
collected every month (7 days after an immunization) from the four immunized sheep, 
together with their respective pre-immune bleeds, were tested by ELISA against HSA-HNE 
and OVA-HNE coated microwell plates (Figure III.4). As seen in Figure III.4 A, all the four 
sheep responded well to the immunization by producing sera specific to HSA-HNE. In 
general, the three bleeds show increased binding to the antigen over time and no binding 
is observed for the pre-immune bleeds. For sheep SA350 and SA369, for the 1/1600 
dilution, the Abs values start to decrease, which is due to a phenomenon known as “the 
hook effect” (D. Wild, John, & Sheehan, 2013). This suggests that, for the dilution in 
question, the concentration of antibodies and other proteins is so high that the binding of 
the antibodies to the antigen cannot be established. The higher concentration of antibodies 
produced by these two sheep might be related to the absence of adducts reduction, as it is 
the only existing difference between the two immunized immunogens. 
 As HNE is a very small molecule (MW: 156.1 Da) located on the surface of a very large 
protein (HSA MW: 66.5 kDa), the majority of the antibodies are likely to be generated 
against HSA. Therefore, the screening performed against HSA-HNE does not necessarily 
indicate the production of antibodies specific to HNE adducts on HSA. Thus, to discriminate 
the anti-hapten-specific antibodies (anti-HNE) from the anti-carrier specific antibodies (anti-
HSA), all the bleeds collected from the four sheep were tested again by ELISA this time 
against HNE-modified (OVA) (Figure III.4 B). OVA was chosen as the carrier protein 
because, despite its name, it does not have any sequence similarity to HSA, but it has a 
similar molecular weight. The data shows that, in fact, only sheep SA369 exhibits a good 
immune response against HNE, as revealed by antibody titers >1/20,000 achieved by direct 
binding ELISA. 
Regarding sheep SA350, which as well immunized with non-reduced HSA-HNE adducts, a 
small response to OVA-HNE was registered, different from the binding of the pre-immune 
bleed, however the titer of anti-HNE antibodies is very low. About sheep SA351 and SA352, 
none of the post-immunization collected bleeds showed binding to HNE adducts on OVA, 
being the absorbances values acquired the same level as the one obtained for the pre-
immune bleeds. 
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Figure III.4. Screening of anti-HSA-HNE polyclonal sera collected from sheep SA350, SA369, SA351 and 
SA352, by ELISA against HSA-HNE (A) and OVA-HNE (B). Sheep SA350, SA369 were immunized non-
reduced HSA-HNE adducts and sheep SA351 and SA352 were immunized with NaBH4-reduced HSA-HNE 
adducts. All the three post-immunization bleeds were screened against their respective pre-immunization 
collected bleed, as a control. The assays were only performed once (n=1), as the aim of this assay was to only 
assess the presence of target antibodies, in order to proceed to their purification. 
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3.4.2. ELISA Screening of anti-KLH-31LQQCPFE37-HNE Polyclonal Sera 
Screening 
A second more targeted strategy for the generation of antibodies specific to HNE adducts 
on HSA involved the immunization of two sheep (SA414 and SA415) and two rabbits 
(RA511 and RA512) with HNE-modified 31LQQCPFE37 peptide, which is the HSA sequence 
that contains the only free cysteine on the protein, and therefore has an enormous potential 
of being HNE modified in vivo. Because the modified peptide has a considerably low size 
(MW of 1019 Da for an HNE-MA adduct), in order to trigger a good immune response, the 
peptide was coupled to a carrier protein, KLH, before being used for immunization. 
As for the previous reported immunization process, three post-immunization bleeds were 
collected and tested together with the pre-immune bleed, by ELISA against HNE-modified 
biotinylated 31LQQCPFE37 peptide (Figure III.5). 
 
 
Figure III.5. Screening of the antibodies present in the pre-immune bleed and in three post-immunization 
bleeds collected from rabbit RA511 and RA512 and sheep SA414 and 415 immunized with KLH-
31LQQCPFE37-HNE. The binding to Biotinylated-31LQQCPFE37-HNE modified HSA was accessed by ELISA 
assay. The assays were only performed once (n=1), as the aim of this assay was to only assess the presence 
of target antibodies, in order to proceed to their purification. 
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The ELISA data show a very weak response to the HNE-modified peptide for all of the 
bleeds collected either from the rabbits or sheep. Nevertheless, when comparing both 
species, rabbits seemed to have responded better, as seen by the higher absorbance 
values obtained for the smallest dilution of 1/400.  
Sheep SA414’s post-immunization bleeds do not reveal any binding to the modified peptide, 
as their absorbance values are of the same order of magnitude as the pre-immune bleed, 
and for SA514, even though a small increase in the binding is observed after the second 
boost, the titers appear to constant after the third and last immunization. 
Consequently, as the antibody titers obtained from this peptide immunization are very low, 
both sheep SA414 and SA415 and rabbits RA511 and RA512 were terminated, and further 
work was carried out using only bleeds collected from sheep SA369, immunized with non-
reduced HSA-HNE adducts, whose sera samples showed a much higher antibody titer to 
work with. 
 
3.4.3. Enrichment and Characterization of SA369 anti-HSA-HNE 
Antibodies using HSA and HSA-HNE-conjugated Resins 
In order to purify from the SA369 serum only the polyclonal antibody population specific to 
HSA-HNE and, possibly HNE only, a two-step chromatography purification was executed. 
This strategy involved an initial chromatography step using an HSA-HNE coupled resin for 
recovery of all anti-HSA and anti-HSA-HNE antibodies (Figure III.6 A), followed by a 
second chromatographic step with an HSA-coupled resin, for the depletion of antibodies 
with affinity for unmodified HSA (Figure III.6 B). The enrichment of anti-HNE/HSA-HNE 
antibodies with the first chromatographic run yielded a very tall and sharp elution peak 
around minute 37 (Figure III.6 A), which corresponds to all the antibody population that 
was bound to immobilized HNE-modified HSA. However, from the second chromatographic 
run with the HSA-coupled resin, one can see that the majority of the antibodies collected 
was specific to HSA, as seen by the very tall peak around minute 20 (Figure III.6 B). The 
antibody fraction that did not bind to this second resin was collect and tested by ELISA for 
binding assessment (Figure III.6 C). 
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Figure III.6. Affinity purification chromatograms for purification of SA369 anti-HSA-HNE pAb using an 
HSA-HNE-coupled resin to recover the mixture of anti-HNE and anti-HSA-HNE antibodies (A) and an 
HSA-coupled resin for depletion of anti-HSA antibodies (B). The bound pooled fraction of the antibodies 
obtained in (A) was loaded into the second column, where the enriched pooled fraction of anti-HSA-HNE was 
collected from the unbound fraction. Binding assessment of the enriched pAbs to HSA, HSA-HNE, OVA and 
OVA-HNE was performed by direct ELISA (C) by immobilizing the antigens at 1.25 g/mL and testing with the 
antibody concentrations indicated on the graph. This assay was performed in duplicate (n=1), showing average 
of 3 technical replicates  SD. 
 
The enriched SA369 antibodies collected the flow through of the chromatographic run with 
the HSA-couple resin appeared to have stronger affinity to HNE-modified HSA and HNE-
modified OVA, as expected, but cross-reactivity to native HSA was observed. The fact that 
the pAbs recognized OVA-HNE and not non-modified OVA suggests that the fraction 
collected contains antibodies that recognize HNE modifications, regardless of the protein 
they are on. As cross-reactivity to unmodified HSA was observed and the yield and 
concentration of the enriched antibodies achieved was not high enough for further 
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3.4.4. Enrichment and Characterization of SA269 anti-HSA-HNE 
Antibodies using Protein G and KLH-HNE Conjugated Resins 
The second purification strategy applied for the enrichment of anti-HNE/HSA-HNE 
antibodies involved a first purification of all the IgG content from the sera, using a protein G 
resin, followed by a second purification with an NHS-activated sepharose column coupled 
to HNE-modified KLH for recovery of all the anti-HNE and, potentially anti-HSA-HNE 
antibodies, and depletion of the anti-HSA antibodies. KLH was chosen as carrier protein as 
it is a large protein (390 kDa) and has a high content of histidine and lysine residues (219 
and 151, respectively), and is therefore a good target for HNE modifications.  
The enrichment of IgGs using the Protein G resin (Figure III.7 A) yielded a very tall and 
sharp elution peak, which was collected and loaded on the KLH-HNE coupled resin (Figure 
III.7 B). A big fraction of the antibodies was depleted by this column (the unbound Ab 
fraction) and a small sharp elution peak corresponding to anti-HNE/HSA-HNE antibodies 
was collected (bound Ab fraction). The antibodies collected on both these fractions were 
tested by ELISA against HSA, HSA-HNE, KLH and KLH-HNE (Figure III.7 C and D). It was 
expected that this alternative enrichment strategy would select antibodies that recognized 
HNE with less cross-reactivity to HSA. Figure III.7 C shows that the unbound fraction 
(containing the antibodies that did not bind to the KLH-HNE modified resin) had a very high 
binding towards both HSA and HSA-HNE but showed little reactivity to KLH or HNE-treated 
KLH, indicating that substantial depletion of the anti-HSA antibodies was achieved with the 
second chromatography step. However, in Figure III.7 D it is seen that the bound fraction 
had similar binding to HSA, HSA-HNE, and HNE-modified KLH, but low affinity for native 
KLH. The cross-reactivity to native HSA suggests that some of the epitopes recognized by 
the SA369 enriched antibodies include not only the HNE moiety of the adducts on HSA or 
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Figure III.7. Purification of anti-HNE/HSA-HNE antibodies from SA369 crude serum. IgGs were first were 
enriched by affinity chromatography using a Protein G resin (A) and later a KLH-HNE-coupled resin was used 
for capture of anti-HNE pAbs (B). The IgG eluted fraction obtained in (A) was loaded into the second column, 
where the enriched pooled fraction of anti-HNE pAbs was collected (eluted peak) (B). Binding assessment of 
the both pAb populations (unbound (C) and bound (D) from KLH-HNE resin) were tested against HSA, HSA-
HNE, OVA and OVA-HNE by direct ELISA by immobilizing the antigens at 1.25 g/mL and testing with the 
antibody concentrations indicated on the graph. This assay was performed in duplicate (n=1), showing average 
of 3 technical replicates  SD. 
 
The purity of the enriched SA369 anti-HNE pAb fraction was assessed by SDS-PAGE 
electrophoresis (Figure III.8), under reduced and non-reduced conditions. As traces of 
serum albumin and immunoglobulins of higher molecular weight (possibly IgM) were 
observed in the lanes 2 and 5 of Figure III.8, so the SA369 anti-HNE antibody cannot be 
considered to be completely purified, but rather enriched. 
 
Figure III.8. SDS-PAGE gel analysis of the purified anti-HNE/HSA-
HNE SA369 pAbs using a KLH-HNE covalently bound a sepharose 
resin. The collected pooled fractions contain still a trace of serum 
albumin as observed by a band corresponding to the weight of 65 kDa 
and some other immunoglobulins of higher molecular weight, possibly 
IgM. Samples in lanes 1, 2 and 3 were run under non-reducing 
conditions, while samples in lanes 4, 5 and 6 were run under reducing 
conditions. In lanes 5 and 6 bands corresponding to the weight of the 
heavy (50 kDa) and light chains (25 kDa) of the pAbs are seen. 
Proteins were separated by SDS- PAGE and stained with Coomassie 
blue.  
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In order to investigate further the specificity of the SA369 enriched antibodies, HSA, OVA 
or alpha-1 anti-trypsin (A1AT) were incubated with HNE in three different molar ratios, and 
the binding of the pAb preparation to these different HNE-modified proteins was assessed 
by Western blotting (Figure III.9). A1AT was tested as an additional plasma protein of 
comparable size with clinical relevance. The same Western blot was also performed with a 
commercial anti-HNE pAb (Figure III.9 A), as a positive control, which demonstrated 
treatment concentration-dependent binding to all three HNE-modified proteins but not to the 
unmodified controls, reflecting the recognition of HNE adducts regardless of the protein 
carrier. The enriched SA369 anti-HNE pAb showed strong concentration-dependent 
binding to HSA-HNE, but also bound weakly to unmodified HSA (Figure III.9 B), confirming 
the results obtained by the ELISA assay. In contrast, the OVA-HNE and A1AT-HNE were 
weakly recognized, both in comparison to the HSA-HNE and the binding of the commercial 
antibody, and there was little detection of native OVA or A1AT. This suggests there is 
additional combined specificity to the carrier (HSA) in the purified SA369 pAb preparation. 
The decrease in signal at the MW corresponding to the native proteins with increasing 
HNE:protein molar ratio in both blots may be explained by the formation of higher molecular 
weight forms and aggregates seen in the gels. 
 
Figure III.9. Western blotting analysis of the SA369 anti-HNE enriched pAb. Human serum albumin (HSA), 
ovalbumin (OVA) and alpha 1-antitrypsin (A1AT) were treated with HNE at protein:HNE molar ratios of 1:1, 1:5 
and 1:10, and their detection by the SA369 anti-HNE enriched pAb (A) and by the Abcam anti-HNE (B) was 
determined by western blotting. Both membranes were visualized under identical conditions, so the binding 
strength would be comparable, and densitometry analysis of both the aggregates formed post-modification and 
the protein were generated for the blots detected with SA369 anti-HNE pAb (C) and Abcam anti-HNE pAb (D). 
The experiment was only performed once (n=1). 
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3.4.5. Epitope Mapping 
In view of the apparent recognition of both HNE and HSA epitopes from the SA369 pAb 
preparation, further epitope investigation using peptide arrays was performed. SPOT 
peptide array technology was used to identify and compare the binding sites of the 
commercial anti-HNE pAb (generated against HNE-modified KLH), and the in-house SA369 
enriched pAb (generated against HNE-modified HSA), using peptide arrays designed with 
15-mer peptides covering the whole sequence of HSA and OVA. One set of arrays was 
incubated with HNE prior to the incubation with each individual antibody, and the analysis 
was performed with control replicate membranes that were not treated with HNE. Figure 
III.10 shows that both antibodies are able to recognize many epitopes in the HNE-treated 
arrays, as indicated by the darker spots. For the commercial pAb, twelve main peptides on 
the array stand out in terms of the intensity of signal: A27–29, C1-3, C16, D2-4, E11-16, 
E21–24, F2–F7, F16-20, G12-17, G25-28, I1-4 and I26-29 (Figure III.10 A and Appendix 
5 for peptide sequences), but binding to HSA control membrane was very weak (Figure 
III.10 C). There was substantial overlap in the set of HNE-modified peptides recognized by 
the in-house SA369 pAb (Figure III.10 B), indicated by the red boxes, but there was also 
binding to a number of other peptides, and it can be seen that the background binding to 
the control HSA membrane (Figure III.10 D) was substantially stronger than that of the 
commercial pAb. Similarities between the SA369 pAb binding to the HSA-HNE and HSA 
control membranes are indicated by yellow boxes. The OVA-HNE arrays showed clear 
similarities between the binding of the commercial pAb (Figure III.10 E) and the SA369 pAb 
preparation (Figure III.10 F), although the non-specific background staining was higher for 
the latter. Five regions were recognized by both pAbs (A5-9, B5-9, B26–30, F8-16 and G3), 
while the peptides D8-11 were only recognized by SA369 pAb and only the commercial pAb 
bound to C1.  
One of the peptides to which both anti-HNE antibodies showed particular strong binding 
was the HNE-modified 365DPHECYAKVFDEFKPLV381 peptide sequence (located in the 
Figure III.10 A and B at positions G16 and G17). Although never seen reported in the 
literature as a potential target of HNE adduction on HSA, this peptide contains in its 
sequence one His, one Cys and two Lys residues, which when displayed in a linear probably 
suffer an HNE modification and yield a tetra-HNE peptide adduct. It is not clear, however, 
why adjacent peptides G18 and G19 are not recognized by the commercial anti-HNE pAb, 
or G14 and G15 by the SA369 anti-HNE pAb with similar intensities, nonetheless, both anti-
HNE antibodies have recognized this peptide very strongly in the membranes.  
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Figure III.10. Epitope mapping analysis for the SA369 enriched pAb using HNE-treated and untreated 
peptide arrays. A and B are arrays of HSA peptides (15-mer) treated with HNE; C and D are the equivalent 
arrays without HNE treatment; E and F are arrays of ovalbumin (OVA) peptides (15-mers) treated with HNE. 
Binding of the commercial Abcam anti-HNE pAb is shown in the left-hand column (panels A, C, E) and binding 
of the SA369 enriched pAb is shown in the righthand column (panels B, D, F). Peptides recognized by both 
polyclonal antibodies are boxed in red and cross-reactivity to HSA peptides recognized by the SA369 enriched 
pAb are boxed in yellow. The single purple peptide represents an OVA peptide recognized by the in-house pAb 
but not by the commercial pAb. All experiments were carried in duplicate and representative blots are shown. 
The list of all peptide sequences can be found in Appendix 5 and Appendix 6, respectively for the HSA and 




3.4.6. Synthesis of 365DPHECYACVFDEFKPLV381 Peptide 
As stated before, as the HNE-modified peptide 365DPHECYAKVFDEFKPLV381 was reported 
as one of the epitopes recognized by both anti-HNE antibodies with highest affinity, this 
peptide was thought be a good capture sequence to be used for selection of high affinity 
anti-HNE antibodies and exclusion of the anti-HSA cross-reactive antibodies.  
The peptide sequence 365DPHECYAKVFDEFKPLV381 was chemically synthesized by the 
Fmoc chemistry (Appendix 7 for reagents used), as previously for other HSA peptides, 
purified by reverse-phase chromatography (Figure III.11 A) and analysed by ESI-MS for 
mass confirmation (Figure III.11 B). 
 
122 of 260 
 
Figure III.11. HPLC chromatogram (A) and MS spectra (B) of the synthetic purified HSA peptide 
365DPHECYAKVFDEFKPLV381 (theoretical monoisotopic mass: 2034.99) identified by epitope mapping 
experiments as the strongest epitope for the enriched SA369 anti-HSA-HNE pAb. The crude peptide was 
initially dissolved in 5% v/v acetonitrile, 95% v/v water, plus 0.1% TFA, to a concentration of 1 mg/mL, all eluted 
peaks were collected for MS analysis and once the peak corresponding to the 365DPHECYAKVFDEFKPLV381 
peptide was identified further HPLC runs were set up for purification of that single product. In the end all the 
fractions were combined, the peptide was freeze dried, and analytical runs by HPLC (A) and ESI-MS (B) were 
performed for confirmation of purity. 
 
The peptide of average molecular weight 2036.34 and theoretical exact mass of 2034.99 
was confirmed by MS by the presence of the ion peaks at m/z 1018.3 and m/z 679.2, which 
correspond to the double protonated (M+22+) and triple protonated (M+33+) molecular ion 
species, respectively. 
Once purified, the peptide was reacted with HNE in vitro in a molar ratio peptide:HNE of 
1:10 for generation of HNE adducts. The formation of a single MA-HNE-peptide adduct was 
confirmed by the peak at m/z 1096.3, which corresponds to the protonated molecular ion 
[M+HNE+H]1+ (Figure III.12 A) and the formation of a double MA-HNE adduct was 
confirmed by the peak at m/z 1174.3, which corresponds to the protonated molecular ion 
[M+2HNE+H]1+(Figure III.12 B).  
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Figure III.12. Identification of HNE Michael adducts on peptide 365DPHECYAKVFDEFKPLV381 (m/z 
2034.99) by MS, following a 2 h reaction with HNE at a peptide-HNE molar ratio of 1:10. The formation of 
a single MA-HNE-peptide adduct was confirmed by the ion peak at m/z 1096.3, that corresponds to the double 
charged molecular ion [M+HNE+2H]2+ (A). The ions peak at m/z 1173.3 that corresponds to the protonated 
molecular ion [M+2HNE+H]+) confirms the formation of a double MA-HNE-peptide adduct (B). This MS analysis 
was performed in triplicate (n=3). 
 
3.4.7. Enrichment and Characterization of SA369 anti-HSA-HNE 
Antibodies using a 365DPHECYACVFDEFKPLV381 Conjugated 
Resin 
The HNE-modified 365DPHECYAKVFDEFKPLV381 peptide was immobilized on a 
carboxyLink resin, which is composed of crosslinked agarose beads pre-activated with 
diamino-dipropylamine for coupling of carboxyl-containing molecules, for purification of anti-
HSA-HNE antibodies from the SA369 anti-sera. 
The chromatogram in Figure III.13 A shows a very large depletion of proteins that did not 
bind to resin, followed by an unexpected large peak of proteins that were eluted with 1M 
NaCl, and therefore were only non-specifically bound to the resin, followed by a small 
elution peak of antibodies specifically bound to the modified resin. The unbound fraction 
collected from the flow through and both the bound fractions eluted with NaCl and glycine 
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were further analysed by ELISA and SDS-PAGE for binding and purification assessment, 
respectively. 
 
Figure III.13. Characterisation of SA369 anti-HNE/HSA-HNE antibodies after affinity purification using 
an agarose resin conjugated to the HNE-modified 365DPHECYAKVFDEFKPLV381 peptide. Proteins 
detected in the chromatogram (follow-through and both the eluted fractions after washes with 1M NaCl and 
0.1M Glycine-HCl) were collected and analysed by ELISA against HSA, KLH, HSA-HNE and KLH-HNE (B) and 
the purification pattern was assessed by SDS-Page gel (C). The experiment was done in duplicate (n=2), 
showing average of 3 technical replicates. 
 
When analysing the ELISA results depicted in Figure III.13 B, no significant enrichment 
toward HNE-modified proteins is observed, as all the three collected fractions show similar 
level of binding (relative to each other) towards HSA, HSA-HNE and KLH-HNE. The 
unbound antibodies from the flow through fraction showed a very high binding towards non-
modified HSA and both HSA-HNE and KLH-HNE, as the original loaded sera, which implies 
that the binding capacity of the column was surpassed, leading to the loss of anti-HSA-
HNE/anti-HNE antibodies on the flow-through fraction. 
Regarding the SDS-Page gel in Figure III.13 C, it is possible to see that the protein 
composition of the flow-through fraction (FT) is very similar to the original loaded bleed, 
being both characterized by two strong bands of molecular weight ~150 and 50 kDa 
(regarding non-reduced conditions) that correspond to the size of IgG and albumin, 
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respectively. Proteins eluted after the NaCl wash show a significant decrease in the binding 
towards the same antigens, with no difference being noted between HSA, HSA-HNE or 
KLH-HNE, which again confirms the loss of most of the target antibodies on the flow-through 
fraction. The separation of the proteins collected in this fraction by SDS-Page shows the 
presence of many bands of high molecular weight and a very low content of IgG, which 
supports the low binding observed by ELISA. Regarding the glycine-eluted fraction, the gel 
shows an almost pure IgG band (only with some traces of albumin), but the ELISA shows 
that once again the cross-reactivity to HSA was not eliminated. 
 
3.4.8. Anti-HNE Sandwich ELISA Assay 
Since both the commercial antibody anti-HNE and the SA369 enriched pAb anti-HSA-HNE 
are polyclonal, they are naturally a mixture of clones with individual characteristics and, 
therefore, recognise distinct epitopes. However, although there is a clear epitope diversity 
observed in the experiment with HSA peptide arrays, it is also clear that both these pAbs 
contain clones that are able to recognize HNE adducts in different proteins (HSA, OVA, 
KLH), and therefore, from the translational point of view, these could be valuable for 
immunoassay application (either a sandwich ELISA or a lateral flow assay) for analysis of 
biological, or even clinical samples. 
Therefore, a sandwich ELISA assay was developed by pairing both antibodies, using the 
enriched SA369 pAb as a capture Ab and the Abcam anti-HNE pAb as detection Ab 
(previously labelled to horseradish peroxidase (HRP)). The ELISA was tested for its ability 
to recognize HNE adducts on different HNE-treated proteins – KLH, HSA and OVA –, using 
as negative control the respective non-modified proteins (Figure III.14). The plot shows that 
the detection signal increases for HNE-modified proteins, with increasing concentrations of 
the capture pAb, reaching a plateau at approximately 2 μg/mL of HNE-modified protein, 
whereas the signal for non-modified proteins seems to be kept low. Statistical analysis 
(Appendix 9) confirm significative differences, with p-values below 0.05 for the all the 
proteins when using concentrations of capture antibody  2.5 μg/mL. 
For equivalent protein antigen concentrations, KLH-HNE showed by far the strongest 
intensity of signal, followed by OVA-HNE, and with HSA-HNE giving the weakest signal. In 
fact, the same ANOVA analysis show that for OVA and KLH, even when using capture 
antibody concentrations below 2.5 μg/mL there is statistical significative differences (p-
values below 0.01). The strong KLH response may be justified by the its higher number of 
nucleophilic amino acids (52 Cys, 219 His and 151 Lys), when compared with the number 
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of nucleophilic amino acids of HSA and OVA, which possibly yield a higher the number of 
potential adducts. Subsequently, the standard capture antibody concentration of 2 μg/mL 
was selected and the analysis of HSA-HNE adducts was investigated in more depth by 
testing a range of concentrations from 0 to 5 µg/mL. A strong specificity for HSA-HNE over 
unmodified HSA is seen in Figure III.14, with some negligible cross-reactivity to HSA. 
Statistical analysis based on the t-test formula (Appendix 10) confirms significative 




Figure III.14. Sandwich ELISA combining the enriched SA369 pAb as the capture Ab with HRP-linked 
Abcam anti-KLH-HNE at the detection Ab for analysis of HNE adducts. (A) Analysis of HNE-treated KLH, 
HSA and OVA by direct ELISA using the enriched SA369 pAb. Proteins were incubated individually with HNE 
at a 1:10 protein-HNE molar ratio, and non-HNE-treated protein tested as negative control. (B) Anti-HNE ELISA 
using a fixed concentration of the capture antibody (2 µg/mL) and a fixed concentration of the detection pAb 
(0.5 µg/mL). The antigen was added in a range of concentrations from 0 to 20 µg/mL. The assays were 
performed in triplicate (n=3) and data is presented as mean  SEM, * p<0.01. 
 
3.5.  Chapter III Discussion, Conclusions and Future Work 
The work presented in this chapter describes the generation of two different polyclonal 
antisera using as immunogens the neo-antigens of lipoxidised HSA. The antisera generated 
against HNE-modified HSA yielded some specific antibodies, but cross-reactivity to non-
modified HSA was always observed regardless of the enrichment method applied for the 
purification of the HNE-specific antibodies. The data suggest that the enriched antibody 
fraction obtained by purification with an HSA-HNE resin and depletion with an HSA resin 
contains a mixture of different antibody clones that recognise both the HNE molecule and 
HSA peptide backbone, which causes the cross-reactivity observed. 
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The use of human albumin rather than any other species of albumin, for the immunization 
process, relied on the fact that the final application of the antibodies is to be for human 
diagnostics, and therefore recognition of human serum albumin is required, but also 
because the immune response is typically better triggered when antigen molecules are 
different from host molecules (Harlow & Lane, 1988). Rabbit (UniProt ID: P49065) and 
sheep (UniProt ID: P14639) albumin proteins share, respectively, 75.33% and 75.66 % of 
their amino acid sequence with the human (UniProt ID: P02768) albumin, which shows 
small amino acid differences of 20-30% may in fact make a difference in the immune 
response. In addition, the great interest and, consequently, great challenge of this project 
was to find if, rather than just the HNE molecules itself, the immune system could induce 
the synthesis of antibodies specific to HSA-HNE adducts only, which selectivity is much 
needed in diagnostic assays. 
Immunisations with non-reduced and NaBH4-reduced HSA-HNE adducts were performed 
in order to evaluate potential effects of stability over the immune system action and, 
interestingly, only sheep SA369, immunised with non-reduced HSA-HNE adducts, 
responded to the antigen properly and produced antibodies able to recognise HNE-modified 
proteins. Moreover, the immunization of sheep and rabbits with HNE modified 
31LQQCPFE37-KLH-conjugated peptide, showed to not be successful either, as the ELISA 
assays performed with the collected sera did not show any recognition of HNE-treated 
proteins. The reversibility of the adduct, in this particular case, may have been critical for 
the immune response as, from the formation of the peptide adduct until the vaccination 
process, the peptide had to undergo several processing steps such as KLH conjugation, 
HPLC purification and freeze drying, that could have caused the disruption of the HNE from 
the target residues. Nevertheless, the work proceeded with the anti-sera generated from 
sheep SA369, which from the application point of view is in fact more appealing, as the 
reduction of adducts does not occur in vivo, and so the antibodies generated should 
recognize the structure of the HNE adducts that are likely to be formed. 
The population of anti-HSA-HNE and anti-HNE antibodies was purified/enriched from the 
SA369 antiserum by three different affinity purification strategies, and the eluted fractions 
showed binding to different HNE-modified proteins but also to unmodified HSA in direct 
ELISAs and western blotting. Direct ELISAs showed relatively poor ability of the SA369 
enriched pAb to discriminate between native and modified HSA, whereas western blotting 
indicated a substantially stronger binding to HSA-HNE. 
The inability to separate clones that recognise only HSA from the ones that recognize only 
HNE suggested that polyclonal mixture of antibodies generated includes a significant 
fraction of antibodies that recognize epitopes containing structural features of both HSA 
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and HNE. An alternative explanation could be that, as the commercial HSA used for the 
majority of this study was purified from plasma, it may already contain some oxidative 
modifications, as has been described previously (Aldini, Vistoli, et al., 2008). However, 
ELISA testing of the reactivity of the SA369 pAb against recombinant HSA expressed in 
Saccharomyces cerevisiae, showed the pAb binding to both plasma purified and 
recombinant HSA, whereas the commercial anti-HNE pAb from Abcam showed no binding 
(Appendix 8). This suggests there is recognition of both protein and modification in the 
epitope. It is also possible that reactivity of the SA369 pAb to HNE on other proteins such 
as A1AT might result from reversibility of HNE-adducts, especially Schiff's bases, leading 
to transfer of HNE to other proteins within the host. In two previous studies where anti-HNE 
antibodies were raised against HNE-treated HSA samples, antibodies were purified from 
the crude sera only with a protein A resin and the authors reported strong binding to the 
immunogen (i.e., HSA-HNE) and almost negligible reactivity to unmodified HSA, which is 
surprising in the absence of a relevant depletion step (Khan et al., 2016; Khatoon et al., 
2012). This discrepancy emphasizes the need to understand in more detail which peptide 
epitopes of HNE-modified HSA triggered B-cell clonal expansion during immunization and 
are recognized by the resulting immunoglobulins.  
The use of HNE-treated peptide arrays provided detailed information on the linear epitopes 
recognized by the in-house SA369 pAb raised against HSA-HNE, and supported the idea 
that the diversity of antibodies include clones that recognise specifically the HNE part of the 
adduct (e.g. on OVA-HNE), while others seem to recognise the HNE structure combined 
with residues from HSA. Examination of the peptides recognized strongly by both pAbs 
indicated that they contain at least two to three nucleophilic amino acids in the sequence 
that are susceptible to attack by HNE (Cys, His or Lys) (Domingues et al., 2013), although 
for HSA it is well established that only Cys34 is in the thiol form and susceptible to attack by 
HNE; all other cysteines are disulphides (Aldini et al., 2006; Aldini, Regazzoni, et al., 2008; 
Nagumo et al., 2014). It was clear that the profile of peptide recognition by the two pAbs 
was similar for OVA, with relatively few reactive peptides, but distinct for HSA. One limitation 
that is important to note is that peptide array screening is not a quantitative assay; rather, it 
is semi-quantitative as the amount of peptide in each spot on the array may vary due to 
differences in the synthetic yield and peptide purity (Hilpert, Winkler, & Hancock, 2007). 
However, arrays were prepared in duplicate and gave comparable results, suggesting that 
this was not a major issue.  
To understand the relationship between the HSA-HNE epitopes detected and the structure 
of the protein, peptides found to be HNE-modified by LC-MS/MS on chapter II were mapped 
onto the crystal structure of HSA and compared with those identified in the peptide arrays 
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(Figure III.15). As the epitope arrays only indicate which peptide sequences were 
recognized by the antibodies, the exact location of the HNE modification could not be 
pinpointed and therefore the possible modified residue was only labelled for the cases 
where the peptide detected matched the peptide identified by MS/MS. It can be seen that 
several peptides identified as HNE-modified by LC-MS/MS (Figure III.15 A) corresponded 
with epitopes detected in the arrays (Figure III.15 B). In particular, three HNE-modified 
peptides/residues detected by both pAbs (His105, His367 and His510), and two others 
detected only by the commercial pAb (His128 and His288), were found to be contain HNE 
adducts. It is notable that the majority of epitopes contained histidine residues, reflecting 
the higher stability of this adduct despite the greater reactivity of cysteine (Negre-Salvayre, 
Coatrieux, Ingueneau, & Salvayre, 2008; Uchida, 2003a).  
The peptide that showed the highest binding intensity for both pAbs had the sequence 
365DPHECYAKVFDEFKPLV381, and contained the potential target amino acids His367, 
Lys372 and Lys378. It is worth noting the residue numbering does not include the signal 
peptide (1–18) and pro-peptide (19–24) of HSA. These are part of an alpha helix and a loop 
located at the surface of the protein, which might play an important role in immunogenicity 
(Benjamin et al., 1984). The amino acid position within the peptide sequence seemed to be 
critical for the modification and/or the binding of the pAbs, as some peptides differing only 
by two neutral amino acids at one end of the peptide were consistently not recognized. 
Steric hindrance might explain this absence of binding, as adjacent bulky amino acids can 
hinder the access of HNE to the target amino acid, and thus slowing the chemical reaction. 
Alternatively, it is important to note that the isoelectric point, and consequently charge state 
of a peptide, as well as neighbouring-group participation effects, have a significant effect 
on the chemical reactivity of functional groups of individual amino acids. These are likely to 
be different even between adjacent, overlapping peptides on the array and may also 
account for the differences in modification observed for the same residue in different 
peptides. Another possible explanation is that synthetic linear peptides are not always 
authentic structural mimics of epitopes on globular proteins, where protein folding gives a 
distinct 3-dimensional structure (Forsström et al., 2014). This can lead to underestimation 
of affinity of the antibody binding. Detailed examination of the three-dimensional structure 
of HSA indicated that most of the epitopes recognized by the pAbs are alpha helix-
containing loops, which might suggest that certain secondary structures and loops, in 
particular, might be more immunogenic (Hermeling, Crommelin, Schellekens, & Jiskoot, 
2004).  
Regarding the development of a diagnostic assays for lipoxidation of HSA by HNE, using 
antibodies that cross-react to non-modified HSA would be a major drawback. However, the 
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sandwich ELISA assay herein developed, which pairs the in-house pAb as capture antibody 
and the commercial pAb as the detection antibody, was shown to be able to discriminate 
between HSA-HNE and native HSA, and presented sensitivity to concentrations as low as 
1 μg/mL of antigen. The availability of a supply of enriched SA369 pAb would make 
economically viable further development and testing of assays, including lateral flow 
assays, to analyse HSA-HNE and investigate its potential as an inflammatory marker. 
Alternatively, hybridoma technology or phage display for selection of single clones might 
offer a promising approach for the future to overcome cross-reactivity issues and improve 
specificity. 
 
Figure III.15. 3D structure of HSA (PDB:1AO6) depicting HNE-modified peptides identified using the 
Sequest database search (A), and HNE-modified peptides detected by the commercial anti-HNE pAb 
(blue) and the in-house SA369 enriched pAb (red) on the HNE-treated HSA peptide arrays (B). The 
peptides recognized are indicated by backbone structure unless the nucleophilic residue likely to be responsible 
within the peptide could be identified. The residue numbering does not include the signal peptide (1-18) and 
pro-peptide (19-24) of HSA, in contrast to the arrays which did include these peptides. 
 
Nevertheless, the enriched SA369 antibody and the commercial anti-HNE antibody were 
used as capture and detection antibodies, respectively, on a sandwich ELISA assay for the 
detection of HNE adducts on different proteins, and the assay succeeded in the distinction 
between HNE-modified and non-modified proteins with a sensitivity as low as 1 μg/mL of 
antigen. 
With regards to future work, it would have been interesting to follow the animal’s 
immunizations for a longer period. As the size of the aldehyde is very small and it is attached 
to large proteins like HSA and KLH, the host’s immune response might have needed extra 
immunizations and longer time for the B cells to develop memory and make their immune 
response stronger. 
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It would have been important to test, as well, how freshly prepared HNE adducts would 
affect the immune response, as opposed as preparing all immunogens at the same time 
and shipping them to the company responsible for the immunization protocol. It is possible 
that the aliquot administrated by the end of month 3 did not have the same number of HNE 
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CHAPTER IV 
DEVELOPMENT OF A DIAGNOSTIC LATERAL FLOW 
ASSAY FOR DETECTION OF LIPOXIDATION IN HUMAN 
MATRICES 
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4.1. Introduction 
4.1.1. The Importance of Lateral Flow Assays 
Lateral flow assays (LFA), also known as immunochromatographic assays or lateral flow 
strip tests, are immunoassays designed to operate along a single axis that can be used as 
diagnostic devices to confirm the presence or absence of a specific analyte. LFAs can be 
used to test a plethora of biological and physiological samples, such as urine, saliva, sweat, 
whole blood, serum, plasma and other body fluids, and are very well established in the 
fields of human diagnostics, veterinary medicine, environmental testing and pharmaceutical 
manufacturing (Wong & Tse, 2008). The most well-known type of LFA is the pregnancy 
test, developed to detect the pregnancy hormone, human chorionic gonadotrophin, in urine. 
LFA technology has gained great popularity in the diagnostics field mainly for overcoming 
the two biggest pitfalls of the ELISA assays: the long operational time and the high number 
of steps. Furthermore, these devices are considerably small and portable, have a long shelf 
life, are robust and are simple to use as, typically, little or no sample preparation is required. 
Also, because this technology employs inexpensive materials, the low development cost 
and ease of production of these tests is another advantage of this technology. If the target 
analyte and necessary antibodies are available, assay development costs can be between 
$30,000 and $100,000, and once full optimization is achieved, test kits can be manufactured 
for $0.10–$3.00 per test (Wong & Tse, 2008). Another useful property of LFAs relies on 
their easy integration with electronic devices, such as scanners or cameras, which permit 
data to be digitized and interpreted (Koczula & Gallotta, 2016). Potential disadvantages of 
these assays include lot-to-lot reproducibility, restriction to qualitative or semi-quantitative 
readout and unclear patent situation, in some instances (Koczula & Gallotta, 2016). 
Currently no LFA for (lipid) oxidation products exists, so there is potentially a commercial 
opportunity for deployment of anti-HNE antibodies, namely the enriched antiserum 
described in previous chapters, in rapid and simple diagnostic lateral flow assays for 
detection of HNE adducts in serum, and consequently assessment of oxidative-stress 
levels. 
 
4.1.2. Principles of Lateral Flow Assays 
In LFAs, a specified volume (10-100 µL) of aqueous sample is applied at one of the 
extremities of the test strip to a sample well and, due to capillary forces, it moves towards 
different components of the test, where antibody reagents are dried and immobilized. 
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Depending on the antibody reagents used, it is capable of reacting with specific analytes 
within the sample. The flow ceases when either there is no more sample left to flow into the 
strip or when the absorbent pad (also known as the sump) located at the other extremity of 
the assay becomes saturated (Berli & Kler, 2016).  
These assays are typically composed of four elements: a sample pad, a conjugate pad, a 
nitrocellulose lateral flow membrane, and an absorbent pad (Figure IV.1).  
 
Figure IV.1. Schematic representation of a lateral flow immunoassay test strip. LFA devices are usually 
composed of a sample pad, conjugate release pad, membrane with immobilized antibodies and an adsorbent 
pad. The components of the strip may be fixed to an inert backing material and encased in a thermoplastic case 
with inlet ports and a viewing window over the test and control lines. The sample is applied to the sample pad 
(A) and it migrates towards the conjugate release pad (B) where the conjugated antibodies bind the biomarker 
and migrate to the test line (C), where the bound biomarker is captured. 
 
The sample pad, as indicated by its name, is where the sample is applied, and its most 
important tasks are to promote the even distribution of the sample and control the rate at 
which the liquid enters the device. Then, as the sample penetrates the pad, it migrates to 
the conjugate release pad which is where specific labelled reagents (usually antibodies) are 
dried. 
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The most common label used for LFAs is in the form of gold nanoparticles (AuNP), to which 
the antibodies or other reagents can be adsorbed in such a way that a sufficient proportion 
of them can still retain their antigen binding properties. This pad is responsible not only for 
holding the dried detector molecules, but also to ensure their release occurs as soon as the 
liquid touches the pad. Once released, both the sample and the detection molecules flow 
together into the nitrocellulose test membrane, which is where specific capture reagents 
(again, typically antibodies) are pre-immobilized as invisible transverse line. In a 
conventional LFA, this membrane has two different immobilized antibodies in two different 
areas named as the test line and the control line. If the target analyte is present in the 
sample, the test line will become coloured, the intensity of colour being proportional to the 
concentration of the analyte, between predefined concentrations. In contrast, the control 
line is designed to develop a standard colour every time, simply indicating that the test 
sample had flowed properly through the strip. This membrane is usually made of 
nitrocellulose (NC), which has very high protein binding affinity and an ideal pore 
structure/size to support capillary flow. This combination enables the process of capillary 
flow to take place in a matrix in which localized antibody deposition provides a capture line 
for specific molecular detection. Lastly, once all the liquid has flowed through both reaction 
lines, it migrates into the absorbent pad, or sump. This pad is very important for the function 
and performance of the assay as it is for the means by which increased sample volumes 
can be applied and processed through the capture line. With larger volumes of sample, 
more analyte can be captured, thus increasing sensitivity. In addition, the capacity to cope 
with larger volumes of liquid allows for the use of “chase” or rinse fluids to wash away 
unbound detection antibodies, which can lower the background signal to enable greater 
sensitivity (improving the signal to noise ratio) (Koczula & Gallotta, 2016).  
 
4.1.3. Gold Nanoparticles (AuNP) as Detection Label in LFA 
The result of a lateral flow assay, in the end, depends entirely on the labelled reagent 
released from the conjugate pad, that upon deposition on test and/or control lines of the 
nitrocellulose membrane, exhibits a detectable signal. Ideally, a signalling label should be 
easy to conjugate to any target molecule without losing its biological integrity and activity 
and, of course, to be as sensitive as possible without compromising the results. Labels are 
expected to possess minimal specific binding characteristics and to be stable under various 
chemical conditions and temperatures (Sajid, Kawde, & Daud, 2015). 
The most commonly used visualisation labels include gold nanoparticles (AuNP) (Bailes, 
Mayoss, Teale, & Soloviev, 2012; Christopher, Robinson, & Shaw, 2007; Ngom, Guo, 
 
136 of 260 
Wang, & Bi, 2010), latex nanoparticles (5,266,497, 1993), magnetic particles (Huang, Wu, 
Hung, Wang, & Chang, 2018), carbon particles (van Amerongen et al., 1993), selenium 
particles (Wang et al., 2014), silver nanoparticles (Anfossi et al., 2019), quantum dots (Xie 
et al., 2019), up converting phosphors (Corstjens et al., 2001), enzymes and liposomes 
(Sajid et al., 2015). Latex nanoparticles were among the earliest used. They can be 
synthesized in different colours, which is ideal for multiplexing, are fairly inexpensive to 
synthesize, and easy to prepare and conjugate. However, they have a natural tendency to 
aggregate after conjugation to the ligands, which is not desired in rapid tests. Inert 
particulates such as gold, silver and carbon are much less prone to aggregation and 
therefore have been extensively used in many different applications (Christopher et al., 
2007).  
Colloidal gold nanoparticles (AuNP) are, perhaps, the most widely used label in LFA. These 
particles are synthesized by reduction of the chemical reduction of chloroauric anions (AuCl-
4) as the gold precursor. They can be synthesized in a variety of sizes from 5 to 100 nm, 
with the most appropriate diameters for LFA detection being between 40 and 80 nm. Below 
10 nm AuNPs start losing their bright and intense colour, and above 40 nm start to 
aggregate (López-Lorente, 2014). Although very easy to synthesize, the manufacture of 
high-quality AuNPs with consistent reproducibility is a hard task to achieve. Irregular 
morphologies in the particles make them prone to aggregate and compromise the 
distribution and availability of the conjugated ligand (Christopher et al., 2007). Nevertheless, 
their intense colour poses a great benefit, as direct visualization can be achieved without 
any requirement for further development steps. Another advantage of gold nanoparticles is 
their negatively charged surface, which makes them ionically attracted towards positively 
charged biomolecules, such as antibodies at high pH values, making them easy to be 
conjugated. Besides ionic attraction, the interaction between antibodies and gold 
nanoparticles can also be achieved via hydrophobic attraction between the antibody and 
the gold surface and/or dative binding between the gold conducting electrons and amino 
acid sulphur atoms of the antibody (Jazayeri, Amani, Pourfatollah, Pazoki-Toroudi, & 
Sedighimoghaddam, 2016). In all cases, antibody conjugation to AuNPs is a very sensitive 
procedure that requires a controlled pH buffer environment and a suitable concentration of 
both antibodies and particles (Cvak, Pum, Molinelli, & Krska, 2012). 
Regarding effective LFA detection limits, conventional AuNPs-based LFA have been 
constrained to limits of detection of ~1-10 ng/mL (Fernández-Sánchez et al., 2005; Lai, 
Fung, Yang, Renrong, & Xiong, 2009). The sensitivity obtained with carbon or silver 
nanoparticles that can reach sensitivities of low pg/mL. Nevertheless, sensitivity-
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enhancement methods have been developed such as silver deposition, NH2OH-HCl 
enlargement, and signal amplification of large AuNP (M. Chen et al., 2015). 
 
4.1.4. LFA Formats 
LFAs, like ELISAs, can be operated as direct (sandwich) assays or as competitive assays. 
In a sandwich LFA, the target analyte is captured between two complementary antibodies, 
the detection antibody, that is conjugated to detection reagent and is dried on the conjugate 
pad, and the capture antibody that is immobilized on the test line. The intensity of the colour 
developed by the deposition of detection reagent on the test line will be indicative of the 
amount of analyte present in the sample, making the LFA a quantitative assay (Wong & 
Tse, 2008). 
In competitive LFAs, labelled antigen is immobilized at the test line and if the same analyte 
is present in the sample it will bind to the detection antibody, dried in the conjugate pad, 
which will be unable to bind to the antigen on the test line. Therefore, the lower the signal, 
the higher the amount of analyte present in the tested sample. This format is usually applied 
to small analytes, that have a single epitope of interest, and therefore cannot bind to two 
antibodies simultaneously (Sajid et al., 2015).  
In order to improve efficiency and achieve high-throughput detection, LFAs can be designed 
to detect multiple analytes in a single sample simultaneously. These assays, known as 
multiplexed assays, are a derivatization of the aforementioned direct (sandwich) assays, 
with the difference of extra reaction lines on test strip. As a rule, LFAs include two reaction 
sites, the test and the control lines, which develop independently from each other, but the 
addition of further reaction sites along the test strip allows the assay to be multiplexed. 
However the spatial separation of multiple detection sites needs to be very well studied as 
reading the results is not as simple as with a conventional single parameter assay (Anfossi, 
Di Nardo, Cavalera, Giovannoli, & Baggiani, 2018). 
 
4.1.5. Chapter IV Aims  
The aim of the work described in this chapter was to assess the applicability of the in-house 
SA369 enriched anti-HNE pAb (generated by sheep immunization with HSA-HNE adducts) 
and the commercial anti-HNE pAb (generated by animal immunization KLH-HNE) in the 
development of a novel lateral flow immunoassay for detection of HNE adducts on proteins. 
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For the development of the LFA, several buffers were optimised, namely buffers used for 
conjugation of antibodies to gold nanoparticles, and buffers used for drying the conjugates 
to the conjugate release pad. Different HNE-modified proteins were tested, at different 
concentrations, and, for sensitivity, different HNE:protein molar ratios were investigated. 
 
4.2. Reagents 
Human serum albumin (A1653), bovine serum albumin (A7906) and albumin from chicken 
egg white (A5503) were obtained from Sigma-Aldrich (UK). 4-hydroxynonenal diethyl acetal 
(HNE-DEA) was generously supplied by Prof. Giancarlo Aldini from University of Milan. 
Tween 20, BES (N,N-bis(2-hydroxyethyl)-2-aminoethanesulfonic acid), MES (2-(N-
morpholino) ethane sulfonic acid), TES (2-[(2-hydroxy-1,1-
bis(hydroxymethyl)ethyl)amino]ethane sulfonic acid), TAPS (N-[tris(hydroxymethyl)methyl]-
3-aminopropanesulfonic acid), boric acid and sodium tetraborate decahydrate were 
acquired from Sigma Aldrich (UK). Sucrose and PBS tablets were purchased from Fisher 
scientific (UK), hydrochloric acid and sodium hydroxide from VWR (UK) and sodium 
chloride from Sigma-Aldrich (UK). Colloid gold nanoparticles 40 nm were purchased from 
BBI solutions (UK). Commercial goat polyclonal antibody anti-HNE (Ab46544) was 
purchased from Abcam (UK). All solvents were of LC-MS grade and all solutions were 
prepared using Milli-Q water. Backing card (60 mm) was purchased from Lohmann 
Technologies (UK), Nitrocellulose 140 (25 mm) from Sartorius Stedim Biotech GmbH 
(Germany), Sink pad (22 mm) and conjugate pad (17 mm) from Ahlstrom-Munksjö Germany 
GmbH Germany), sample pad FR1 from MDI Advanced Microdevices Pvt, Ltd (India), and 
universal LFA housing cassettes from Adreco Plastics (UK). 
 
4.3. Material and Methods 
4.3.1. Preparation of HNE-modified HSA, OVA and KLH Standards 
HNE adducts on HSA, OVA and KLH proteins were prepared as stated in 2.3.4. Generation 
of HNE Adducts on HSA, HSA Peptides. 
 
 
139 of 260 
4.3.2. Buffer Optimization for Antibody-gold Conjugation  
Abcam anti-HNE and SA369 enriched anti-HNE antibodies were diluted separately in 
different buffers (20 mM BES pH 6.3, 20 mM MES pH 6.7, 20 mM TES pH 7.1, 20 mM TES 
pH 7.5, 20 mM BES pH 7.8, 20 mM TAPS pH 8.5, 20 mM Borate pH 8.5, 25 mM Borate pH 
8.5, 20 mM Borate pH 9.3 and 25 mM Borate pH 9.3) to concentrations ranging from 0 to 5 
µL/mL.  
A 96-well plate was loaded with 20 µL of each solution, to which 200 µL of colloid gold 40 
nm OD1 was added and left to incubate for 10 min with shaking (150 rpm). To induce 
aggregation, 40 µL of 10% (w/v) NaCl were added to each antibody-gold solution and the 
absorbance was measured 10 min later at 550 nm and 600 nm. The aggregation ratio was 




      (Equation 1) 
 
4.3.3. Deposition of SA369 Enriched anti-HNE pAb onto Nitrocellulose 
An antibody solution at a concentration of 1 mg/mL in PBS with 1% (w/v) sucrose was 
prepared and dispensed across a 30 cm nitrocellulose (NC140) membrane, 7 mm away 
from the top edge, using the IsoFlowTM flatbed dispenser (Imagene Technology, USA) at a 
dispenser rate of 0.1 µL/mm. The band was then dried at 60 oC, at 10 mm/sec using the 
Drying Tunnel Type BT3 Conveyor Oven (Hedinair, UK). 
 
4.3.4. Atomization of Abcam anti-HNE pAb-gold Conjugate onto the 
Conjugate Pad 
The pAb-gold conjugates were prepared by incubating 5 µg/mL of Abcam anti-HNE pAb 
prepared in 25 mM sodium tetraborate pH 9.3 with 100 µL of gold nanoparticles 40 nm. The 
solution was incubated for 10 min before blocking with 1 µL of BSA (200 µg/mL) for 30 min 
at RT. For rapid optimization protocols, the assays were first tested under the “wet assay” 
format, i.e., by adding the pAb-gold conjugate solution in a microplate well and dipping the 
strip test on it. For the “dry form” of the LFA, the pAb-gold solution was atomized in a 30 cm 
non-woven glass fibre conjugate pad (17 mm), using the IsoFlowTM flatbed dispenser 
(Imagene Technology, USA) at a dispenser rate of 0.8 µL/mm. The band was dried at 60oC, 
at 5 mm/sec using the Drying Tunnel Type BT3 Conveyor Oven, (Hedinair, UK). 
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4.3.5. Device Assembly and Running 
The nitrocellulose membrane with immobilised capture Ab, the sink pad, the gold conjugate 
pad and the sample pad were mounted on a plastic backing card, in this specific order, at 
20 mm, 0 mm, 43 mm and 55 mm, respectively, counting from the top of the backing card, 
using a lateral flow strip laminator from Cambridge Systems Engineering, Ltd (Cambridge, 
UK).  
The mounted band was then cut in 5 mm strips using the Matrix 2360 Programmable Shear 
from Kinematic Automation, Inc (CA, USA) and each individual strip was then assembled 
within plastic cassettes that were closed using a cassette closure roller from Point A 
Technologies, Inc (CA, USA). The cassettes were packed in foil pouches with desiccant 
sachets and stored at room temperature. Schematic representations of the assembling of 
the different assay bands and of the final device is shown in Appendix 12. 
The lateral flow device was run by pipetting 80 µL of sample/standard to the sample pad of 
the device and the strength of the test line signal was read at 20 minutes using a lateral 
flow device reader, also known as Cube reader (opTricon GmbH, Germany). Further details 
on the use of the electronic reader are given in Appendix 13. 
 
4.4. Results 
4.4.1. Antibody Conjugation to Gold Nanoparticles (AuNP) 
In order to select the most suitable buffer for the conjugation of both anti-HNE antibodies to 
AuNPs, the aggregation of different of Ab-AuNPs conjugates, prepared using different 
amounts of antibody in different buffer compositions, was induced by adding NaCl solution, 
which is known to destabilize the gold and induce particle aggregation. When aggregated, 
conjugation to proteins is diminished, and this can be observed by a change in AuNP colour 
from bright red to purple, which shifts their maximum peak of absorption from ~550 nm to 
~600 nm. The aggregation ratio for each buffer and each antibody concentration was then 
calculated by dividing the Abs value measured at 600 nm by the Abs value measured at 
550 nm, and the results are depicted in Table IV.1 A and Table IV.1 B, respectively for the 
conjugation of the in-house SA369 pAb and the commercial anti-HNE pAb. The data shown 
in Table IV.1 A and B indicate that, regardless of the type of antibody, particle aggregation 
is inversely proportional to the concentration of antibody, i.e. higher the concentration of 
antibody conjugated, the lower the aggregation ratio. Therefore, the most suitable 
concentration of antibody for conjugation to AuNPs appeared to be 5 µg/mL. In terms of the 
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buffer composition, the results did not differ much between the two antibodies, although 
slightly lower aggregation values were achieved for the commercial anti-HNE pAb. 
Generally, the lower aggregation ratios were noticed when using 20 mM MES and TES at 
pH 6.7 and 7.1, respectively, and borate salts at the concentration of 20 and 25 mM and pH 
values of 8.5 and 9.3.  
 
Table IV.1. Aggregation ratios of AuNP-SA369 enriched pAb conjugates (A) and AuNP-Abcam anti-HNE 
pAb conjugates (B) using different conjugation buffers and antibody concentrations. Although not 
included in the tables, the aggregation ratio obtained for unconjugated colloid gold nanoparticles, in water, was 
0.24, and all the values are coloured in a gradient from red to green in comparison to that value, where the most 






4.4.2. Strip Performance using Commercial anti-HNE pAb-gold 
Conjugate in Solution (Wet testing) 
Before the development of the final lateral flow assay, where all the components previously 















































0 0.76 0.79 0.81 0.80 0.81 0.83 0.81 0.82 0.84 0.80 0.83 
1 0.75 0.93 0.89 0.90 0.89 0.90 0.89 0.91 0.90 0.92 0.91 
2 0.89 0.94 0.90 0.93 0.92 0.91 0.96 0.93 0.94 0.96 0.95 
2.5 0.97 0.98 0.96 0.97 0.95 0.95 0.95 0.94 0.96 0.93 0.95 
3 0.98 0.88 0.95 0.96 0.97 0.96 0.86 0.66 0.93 0.78 0.81 
3.5 0.92 0.81 0.70 0.75 0.67 0.83 0.70 0.62 0.72 0.60 0.57 
4 0.42 0.38 0.36 0.52 0.40 0.50 0.60 0.48 0.40 0.43 0.38 














































0 0.81 0.83 0.83 0.81 0.80 0.83 0.83 0.81 0.84 0.82 0.82 
1 0.90 0.88 0.90 0.89 0.90 0.90 0.93 0.94 0.92 0.95 1.02 
2 0.90 0.89 0.91 0.93 0.94 0.94 0.98 0.99 0.96 0.99 1.03 
2.5 0.98 0.94 0.97 0.95 0.97 1.00 1.01 1.03 1.00 1.05 0.60 
3 1.02 1.00 1.02 0.98 1.04 1.04 1.03 0.84 1.04 1.00 0.94 
3.5 1.05 1.05 1.06 1.02 1.04 1.05 0.93 0.39 0.93 0.47 0.61 
4 1.03 0.90 0.75 1.03 0.83 0.67 0.38 0.29 0.40 0.30 0.29 
5 0.45 0.36 0.31 0.69 0.37 0.33 0.30 0.29 0.29 0.28 0.27 
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Abcam anti-HNE pAb conjugate in solution, together with the antigen, and dipping the NC 
strip (with SA369 enriched anti-HNE previously adsorbed), into the solution. 
As the most promising conjugation buffers did not differ much in terms of salt concentration 
nor pH values, the first investigation of the assay was performed with AuNP-Abcam anti-
HNE pAb conjugates prepared in buffers of 20 mM borate pH 8.5 and 25 mM borate pH 
9.3, separately, and adding to them HNE modified HSA, KLH and OVA protein standards 
at a concentration of 50 µg/mL. The intensity of the test bands was measured using the 
cube reader after 20 min of sample application and the values were plotted together with 
their corresponding negative controls (Figure IV.2). The data show no substantial 
differences between the two tested conjugation buffers in terms of the detection of HNE 
adducts. It is worth noting, though, that without any previous optimization, the strip was able 
to differentiate between non-modified and modified proteins, indicating the two anti-HNE 
antibodies might form a good pair for LFA.  
 
Figure IV.2. AuNP-antibody buffer conjugation effect on strip performance. Anti-HNE pAb was conjugated 
to AuNPs under the same conditions with 20 mM Borate buffer pH 8.5 and 25 mM borate buffer pH 9.3, 
separately, and the detection of HNE adducts was assessed by dipping the strips on each Au-NP conjugate 
solution containing HNE-modified and non-modified HSA, OVA and KLH at 50 µg/mL. The intensity of the test 
lines was measured after 20 min after sample application and for each standard sample. The assays were 
performed in triplicate (n=3) and data is presented as mean  SEM. 
 
Of the three tested HNE modified proteins, KLH-HNE gave the stronger response as seen 
by the higher intensity of the test line, and regarding HSA and OVA they both seem to have 
the same level detection. Distinction between the negative controls and HSA-HNE and 
OVA-HNE was anyhow clear by eye (data not shown), which as a starting experiment was 
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The second optimization under solution conditions related to the antigen concentration used 
for testing. In the previous experiment the performance of the strip was tested by adding 
the antigens at a concentration of 50 µg/mL but in Figure IV.3 a range of concentrations 
between 1.56 and 100 µg/mL was tested.  
 
Figure IV.3. Antigen concentration effect on strip performance (wet testing). NC strips previously plotted 
with SA369 anti-HNE pAb were dipped in AuNP-Abcam anti-HNE pAb conjugate solution containing HNE-
modified HSA, OVA and KLH at 1.56, 6.25, 25 and 100 µg/mL and KLH-HNE tested strips were photographed 
20 min after sample application (B). The intensity of the test lines was measured with a cube reader after a 20 
min incubation (A). The assays were performed in duplicate (n=2) and data is presented as mean  SEM. 
 
Data shown in Figure IV.3 indicates that, surprisingly, the intensity of the test line is not 
directly proportional to the concentration of antigen added, within this range of tested 
concentrations. In fact, from 1.56 µg/mL to 6.25 µg/mL there is an increment of the test lines 
intensity, for all the three HNE-modified proteins, but from 6.25 µg/mL to 100 µg/mL the 
intensity of the signal starts to decrease, suggesting saturation of the antibodies. As the 
highest signals were achieved using antigen concentrations of 6.25 µg/mL, that value was 
fixed for further experiments. 
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4.4.3. Assay Performance (Dry testing)  
For dry testing LFA, strip tests composed of sample pad, conjugate pad, NC membrane 
and absorbent pad – the four elements of a conventional LFA – were assembled as depicted 
in Appendix 12. In the conjugate pad, AuNP-Abcam Anti-HNE pAb was dried at a 
concentration of 25 µg/mL and in the NC membrane the SA369 enriched pAb was plotted 
at a concentration of 1 mg/mL. 
The first tests performed in genuine assay conditions consisted in the assessment of the 
effect of the running and drying buffer compositions, which are, respectively, the buffers in 
which the antigen solutions, and AuNP-SA369 anti-HNE pAb conjugates were prepared 
Figure IV.4.  
Three different running buffers were tested against three different drying buffers, the 
compositions of which mainly varied in the concentration of Tween 20, BSA and sucrose – 
components that play an important role in assay sensitivity. In order to simplify the 
visualization and interpretation of the results, the intensity of the lines was analysed with 
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Figure IV.4. Effect of different running and drying buffers composition in assay performance. HNE-
modified and non-modified antigen solutions were prepared similarly in running buffers: 25 mM borate buffer 
pH 9.3 (A), 1% (w/v) BSA/PBST (0.1% (v/v) Tween 20) (B) and 25 mM borate buffer pH 9.3 containing 0.1% 
(v/v) Tween 20 and 3% (w/v) BSA (C). For each of these running buffers, the detection of HNE adducts was 
compared by preparing the AuNP-SA369 anti-HNE pAb conjugates in either (a) 25 mM Borate pH 9.3, 0.1% 
(v/v) Tween 20, 3% (w/v) BSA; 5% (w/v) Sucrose, (b) 25 mM Borate pH 9.3, 0.1% (v/v) Tween 20, 5% (v/v) 
BSA; 5% (v/v) Sucrose or (c) 25 mM Borate pH 9.3, 0.5% (v/v) Tween 20, 3% (w/v) BSA; 5% (w/v) Sucrose. An 
80-µL aliquot of each HNE-modified and non-modified standard solution (6.25 µg/mL) was added into the 
sample pad and the picture was taken after a 20 min incubation. The assays were performed in triplicate (n=3) 
and data is presented as mean  SEM. 
 
The results observed in Figure IV.4 reveal that the concentrations of detergents and 
blocking agents, in both running and drying buffers, play a critical role not only in the 
performance but also in the sensitivity of the assay. 
When preparing the protein standards in 25 mM borate buffer, pH 9.3 (Figure IV.4 A), one 
can see that Tween 20 and BSA are needed in the drying buffer at specific concentrations 
so the optimal flow of AuNP-pAb conjugate along NC membrane is achieved. For 
concentrations above 0.1% (v/v) and 3% (w/v), respectively for Tween 20 and BSA, as it is 
the case of drying buffers (b) and (c), irregular flow is observed preventing the sample from 
running properly and form of a thin test line. Therefore, when neither Tween 20 or BSA are 
present in the running buffer, 0.1% (v/v) Tween 20 and 3% (w/v) BSA seem to be the most 
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suitable for composition (drying buffer (a)). Nevertheless, the intensity of test lines regarding 
HSA-HNE and OVA-HNE are somehow very weak. 
Regarding Figure IV.4 B, when preparing the standards in 1% BSA/PBST, no obvious 
difference in between the three drying buffers was observed. For all the three, the liquid 
flow seemed to be constant and no dragged lines were observed. Again, test lines for HSA-
HNE and OVA-HNE were very weak and the AuNP-pAb conjugate seemed to deposit 
correctly on the test line. Drying buffer (c) showed the highest non-specific binding, as seen 
for the negative controls. 
Finally, when combining all the elements of the two previously tested running buffers to 
form running buffer 25 mM Borate, pH 9.3 containing 0.1% (v/v) Tween 20 and 3% (w/v) 
BSA (Figure IV.4 C), the sensitivity of the assays seemed to be considerably improved. For 
all of the tested drying buffers, a normal liquid flow was observed, and once again higher 
non-specific binding was noticed when using drying buffer (c) that contains 0.5% Tween 20. 
Although no replicas were performed in these experiments, according to Figure IV.4 D, 
drying buffer (b) seems to offer the best compromise between assay sensitivity and low 
non-specific binding. Thus, for further experiments 25 mM borate buffer, pH 9.3 containing 
0.1% of Tween 20 and 3% (w/v) BSA was used as running buffer and 25 mM Borate, pH 
9.3, containing 0.1% of Tween 20, 5% BSA and 5% of sucrose was used as drying buffer. 
 
4.4.4. Detection of HNE Adducts on KLH and HSA (Calibration Curves)  
Once the most important assay parameters were optimized, the linearity of the LFA in the 
detection of HNE adducts in HNE-modified KLH and HSA standard solutions was assessed 
through the performance of a calibration curve ranging from 0 to 20 g/mL (in triplicate) 
(Figure IV.5). Both HNE-modified and non-modified protein standard were prepared in 25 
mM borate buffer, pH 9.3 containing 0.1% of Tween 20, and 80-L aliquot of each standard 
were added to three devices.  
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Figure IV.5. Calibration curves represented in standard linear scale obtained from triplicate assays 
tested with HNE-modified and non-modified HSA and KLH standard solutions (A). As the signal is seen 
to saturate around the antigen concentration of 2 g/mL, the range 0-0.25 was investigated in more detail (B) 
so the differences within the range of 0-2.5 g/mL can be seen in greater detail. All the devices were 
photographed 20 min after sample running where the increment in intensity of the test lines can be observed 
for the increasing concentrations of HNE modified KLH and HSA (C). The assays were performed in triplicate 
(n=3) and data is presented as mean  SEM. 
 
The calibration curves depicted above (Figure IV.5 A) show that the developed LFA was 
able to detect HNE modifications in two different proteins (HSA and KLH), and was capable 
of distinguishing between HNE-modified proteins and non-modified proteins. Nevertheless, 
the dynamic range of the assay was relatively low, as the signal for both HNE-modified 
proteins appear to be saturated at around 1-2 g/mL. The devices showed a very high 
background signal as well when testing non-modified proteins (around 40 of absorbance), 
which might be related to the cross-reactivity of the SA369 pAb or the high optical density 
of the gold used in the assay. When curves were only plotted for the range of concentrations 
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between 0-2.5 g/mL (Figure IV.5 B), the increment in signal can be seen in greater detail. 
For the same concentrations, HSA was shown to be more HNE-modified than KLH. 
 
4.4.5. Detection of HNE Adducts on HSA Standards Treated with HNE 
Concentrations 
The developed LFA was tested extensively for the detection of HNE adducts on HSA protein 
standards treated with different concentrations of HNE. The devices in Figure IV.6 show 
calibration curves ranging from 0.625 to 10 g/mL obtained for HSA protein standards 
treated with HNE at molar ratios of 1:0, 1:10, 1:20, 1:40, 1:100 and 1:200.  
 
Figure IV.6. HSA-HNE detection on LFA devices. In each device concentrations from 0.625 (bottom assays) 
to 10 g/mL (top assays) of HSA proteins standard treated with HNE at molar ratios 1:0, 1:10, 1:20, 1:40, 1:100 
and 1:200 (left to right) were tested. The letter T on top of the window of each device stands for test line, which 
is where the capture antibody is immobilised and the gold-conjugated Ab binds if HNE is present in the sample. 
All the deviced were photographed 20 min after HSA-HNE samples were applied. These devices were only 
performed once (n=1).  
Although the intensity of the test lines of the assays in Figure IV.6 was not quantified with 
the cube reader, the calibration curves regarding the HSA-HNE samples treated with HNE 
at molar ratios of 1:100 and 1:200 show a considerably different intensity of colour from the 
HSA-HNE samples treated with HNE at molar ratios of 1:10,1:20 and 1:40. Again, although 
the distinction between modified and non-modified HSA is clear, the tested range of 
concentrations seems to be already in the saturation zone which does not allow inferring 
about the linearity of the signal. Nevertheless, the results suggest that, with further 
optimization, the LFA developed could be used for semi-quantitative purposes.  
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4.5. Chapter IV Discussion, Conclusions and Future Work 
The work in this chapter describes the deployment of the previously described sheep anti-
HNE antibody in a rapid diagnostic lateral flow test for the detection of HNE-protein adducts 
in clinical samples. 
The developed prototype was designed to detect general protein-HNE adducts, by using 
the Abcam commercial anti-HNE pAb conjugated to gold nanoparticles, as detection 
reagent, and the in-house SA369 enriched pAb as capture reagent, in the test line. Results 
showed the devices were able to distinguish between HNE-modified and non-modified 
protein standards, and sensitivities as low as 1.5 g/mL were achieved. The assay was 
shown to be capable of semi-quantifying HNE adducts in HSA as well, by display of different 
intensities of test lines colours for the same concentration of HSA standards modified at 
different HSA:HNE molar ratios, which as a proof-of concept is noteworthy. Unfortunately, 
due to time constraints, the assay was not tested with any biological samples. 
When developing an assay, the main aim is to achieve the highest intensity of signal with 
the lowest non-specific binding, which is directly related to the sensitivity and the specificity, 
respectively. The optimisation process generally includes testing different antibody pairs, 
conjugation conditions, sample pad and conjugate pad materials, types of nitrocellulose 
membranes, antibody concentrations, running buffers, and sample volume (Hsieh et al., 
2017); however, due to time constraints only a few of these metrics were tested. 
Regarding the antibody pair, the development of this assay was restricted to the use of the 
in-house anti-HSA-HNE enriched pAb and the commercially available anti-HNE pAb from 
Abcam. It is always best to start with the highest affinity antibody as the capture reagent, 
however, since deposition of antibody lines in the NC pad requires large quantities of 
reagent, because of cost and availability issues, the assay was had to use as detection 
antibody the commercial anti-HNE from Abcam, and the SA369 enriched pAb as capture 
antibody, conjugated to gold nanoparticles.  
The second critical aspect taken into consideration for the development of the assay was 
the interaction between the NC membrane and the detection particles, which is what defines 
the flow of the captured reagent and is, in part, related to the physical space of the 
nanoparticles in solution. If particles associate in larger aggregates, their flow along the strip 
will be largely impaired and consequently the detection of analyte will be disturbed (Wong 
& Tse, 2008). Thus, in order to evaluate the stability of both antibody-gold nanoparticles 
conjugates, their aggregation levels were determined by using different conjugation buffers 
and different antibody concentrations. Results showed that, for both the commercial and 
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the in-house antibody, the aggregation levels decrease with increasing concentrations of 
antibody and increasing pH values, which can be explained by the different charges present 
on the surface of both the particles and the antibodies. Typically, conjugation of antibodies 
occurs via non-covalent interactions such as dative bonding, hydrogen bonding, 
electrostatic forces, and hydrophobic adsorption (Cvak et al., 2012). Because the isoelectric 
point of an immunoglobulin is generally around 8, at pH values above 8, antibodies are 
positively charged and will naturally adsorb to AuNPs, that are negatively charged. 
However, if the concentration of antibody is not high enough to cover the whole surface of 
the particle, then antibodies can adsorb to multiple particles through different sites and 
induce aggregation; which is why for a range from 1-5 g/mL the lowest aggregation ratios 
were observed at 5 g/mL. Another reason for controlling the pH in antibody-AuNPs 
conjugation protocols is the fact antibodies orient themselves depending on the pH value 
of the solution where they are in, which affects the direction they bind to a certain particle 
(Cvak et al., 2012). At low pH values, antibodies were seen to face the surface of AuNPs 
with their Fab part, which is where the antigen binding regions are located, but at higher pH 
values, when both the colloid gold and the antibody are negatively charged, the adsorption 
occurs via hydrophobic interactions through the Fc part of the antibody, leaving the Fab part 
available for antigen binding (Ruiz, Tripathi, Okyem, & Driskell, 2019).  
Based on assays performed in wet conditions, ideal antigen concentrations were seen to 
be between 1.56 and 6.25 g/mL, as above 6.25 g/mL saturation of the signal was 
observed, generating false negative results. This phenomenon, seen to occur before in 
Chapter III when screening for sheep antibodies by ELISA, is known as the “hook effect”, 
and it occurs when the amount of antigen applied is so high that both the capture and 
detection antibodies become saturated, preventing the detection signal from increasing. In 
what regards buffer optimisation, the core of all the buffers used in this LFA was kept the 
same – 25 mM Borate pH 9.3 – as borate was seen in the literature to provide a good 
buffering capacity (EMD Merk Millipore, 2013) and to work well in different antibody 
conjugation protocols followed at Mologic. Moreover, because borate has a slight surfactant 
quality, this buffer seems to be particularly suitable for the re-solubilization of the AuNP. 
Apart from borate salts, in both running and drying buffers, Tween 20 and BSA were seen 
to be important, as extra components, in the reduction of non-specific binding of proteins 
(Wong & Tse, 2008). These are particularly crucial when the capture reagent is dispensed 
at concentrations lower that 100 g/mL and the surface of the NC membrane is unlikely to 
get saturated. The addition of Tween 20 was seen, as well, to promote the flow front 
stability, which is sometimes an issue due to the presence of surfactants in the capture 
reagent solution (EMD Merk Millipore, 2013). 
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Best results were observed when preparing the antigens in 25 mM borate solution, 0.1% 
(v/v) Tween 20 and 3% (w/v) BSA; however, the optimization of this buffer composition can 
be subjective, as devices would ideally be used for direct application of whole blood or 
serum samples, to which very few treatment can be done. Regarding optimisation of the 
buffer used for drying the Ab-AuNP conjugate, strongest test lines were observed when 
utilizing 25 mM borate buffer with the 0.5% (v/v) Tween 20, 3% (w/v) BSA and 5% (w/v) 
sucrose. Concentrations of Tween 20 higher than 0.1% (v/v) were seen to largely increase 
the background signal of the lines, and the concentration BSA was seen to be best between 
3 and 5% (w/v). Sucrose was also added to the drying buffer as it acts as a preservative 
and a re-solubilization agent. When the detecting particles are dried in the presence of 
sugar, the sugar molecules form a layer around the particles which helps them to stabilize 
their biological structures. Sucrose was also added in the detection reagent buffer (EMD 
Merk Millipore, 2013).  
As a proof of concept, calibration curves ranging from 0.15 and 20 g/mL were performed 
to assess the linearity of the adducts, and the assay was shown to give a clear distinction 
between modified and non-modified proteins, achieving sensitivities as low as 1.50 g/mL. 
As stated before in 1.3.1.14-Hydroxynonenal (HNE), the Most Toxic Lipid Peroxidation 
Product, levels of HNE in human plasma were reported to be between 0.1-1 M, i.e., 
0.0156-0.156 g/mL, which is unfortunately 100-10 times below the sensitivity achieved. 
Nevertheless, transient concentrations of HNE in severe conditions ranging 50-100 M 
were seen observed (Q. Liu et al., 2012), which could potentially be detected by this assay.  
However, it is worth remarking that the sensitivity of an assay is directly related to the affinity 
of the antibodies used, specially the on-rate affinity, which dictates how fast an antibody 
can bind to its target. In order to achieve great sensitivity assays, in the range of picomolar 
for instance, antibodies with KD values in the range of 10-10-10-12 are needed. In this case, 
from the sensitivity observed, there is evidence that the antibodies used are of low affinity, 
limiting, therefore, the sensitivity of this assay. 
Regarding non-specific binding, assays also showed quite high background values for non-
modified proteins, around ~40 AU cube reader Abs units, when typically, they should not 
be higher than 10 AU. Due to this high background level, the intensities of the test lines for 
the first concentrations tested were considerably high (around 90 AU for HSA-HNE and 55 
AU for KLH-HNE), impairing the determination of the assay sensitivity. This non-specific 
binding observed could potentially be related to the cross-reactivity of the SA369 antibody 
to HSA, as test lines are always stronger to HSA than KLH, and/or due to the gold optical 
density (OD) used for conjugation. Gold optical densities of 5 and 10, which are commonly 
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used, were compared (data not shown), being the intensity of the lines considerably higher 
when using OD 10. However, with the higher intensity of the gold colour comes a higher 
background signal, which sometimes can be attenuated by modifying other assay 
parameters. Another issue noticed with this assay was the dynamic range, which was very 
low. As signals started to become saturated around 1-2 g/mL, it would have been useful 
to start the calibration curves at a lower concentration. 
The assay also showed potential to be used as a semi quantitative tool as, when testing 
increasing concentrations of HNE used for generation of adducts, increasing intensities of 
the test line colours were observed for the different HNE:HSA molar ratios. Nevertheless, 
there seems to be a threshold in the number of HNE modifications (somewhere between 
the HSA:HNE molar ratio of 1:40 and 1:100), that is sensed by the antibodies and triggers 
the signal; however, these results were only assessed by eye which limits further the 
analysis of the data. 
Nevertheless, for a valid application of the assay, the optimization is far from being finished, 
as the assay presents several issues. The presence of a control line in the assay could 
have helped not only to confirm the correct functioning of the assay, as it could have helped 
to decrease the non-specific binding noticed for with negative controls, by promoting 
unspecific Ab-gold conjugates to flow to the control line. Possible future work could include 
testing different antibodies specific to serum proteins in the test line, and concerning the 
optimisation of Ab-AuNP conjugates, testing in situ, directly in NC membranes rather than 
in polystyrene plates, in order to get more accurate and reproducible results.  
Regarding the sensitivity and the dynamic range of the assay, these are slightly harder to 
adjust, as they depend mainly on the antibodies used. Sensitivity could potentially become 
higher if using a monoclonal Ab specific to HNE adducts in only HSA, rather than using a 
partially purified polyclonal antibody that cross-reacts with native HSA; however, assuming 
no changes were allowed in the antibody pair, testing other detection labels, such as latex 
or cellulose nanoparticles, could be a good follow-up experiment. 
In conclusion, the prototype LFA development describer for the detection of HNE adducts 
in proteins was shown to be successful when using HNE-treated protein standards. 
Calibration curves presented a clear distinction between HNE-modified and non-modified 
HSA and KLH proteins, and the use of the assay as a semi quantitative tool is not 
completely excluded. 
This is a promising test for detection of HNE protein adducts and presents the attractive 
opportunity of a point-of-care test for lipoxidation status, which would allow 
patients/clinicians to monitoring redox levels using simple, rapid and inexpensive LFA 
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devices. However, taking a lateral flow test strip from the design stage to final manufacture 
is very challenging and requires commitment of significant resources in order to achieve a 
product fit for the market. 
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CHAPTER V  
DEVELOPMENT OF SHEEP Fab AND scFv LIBRARIES 
for GENERATION OF ANTI-HSA-HNE ANTIBODY 
FRAGMENTS USING PHAGE DISPLAY TECHNOLOGY 
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5.1. Introduction 
Since polyclonal antibodies generated by immunization represent a mixture of molecules 
with different affinities and specificities, the development of techniques like hybridoma 
technology and phage display came to revolutionize completely the market of antibody 
molecules, by allowing the generation of antibodies from the same parent cell, containing 
uniform variable regions and thus presenting specificity to a single epitope. Therefore, since 
the cross-reactivity towards non-modified HSA was not eliminated by downstream 
processing techniques, phage display technology was applied to this work with the intention 
of surpassing the limitations of the anti HSA-HNE polyclonal antibodies generated. 
 
5.1.1. Generation of Antibody Phage Display Libraries 
The display of peptides and proteins on the surface of bacteriophages allows the 
construction of antibody libraries of enormous molecular diversity, making the phage display 
technology a great alternative to the hybridoma technology, regarding the production of 
mAbs. 
Due to limitations in the bacteria folding machinery, efficient expression of full-length 
antibody molecules is very difficult to achieve, and therefore, phage display of antibody 
fragments is the most common approach. Single-chain Fv (scFv), Fabs, single-domain 
antibodies (sdAb) and diabody fragments (Figure IV.1) are some examples of different 
antibody fragment formats that have been expressed successfully on the surface of M13 
phages with no apparent loss of the antibody’s affinity and specificity (Barbas, Kang, Lerner, 
& Benkovic, 1991; Davies & Riechmann, 1996; Holliger, Prospero, & Winter, 2006; 
McCafferty, Griffiths, Winter, & Chiswell, 1990). ScFv fragments consist of a variable 
domain of the antibody heavy chain (VH) and a variable domain of the antibody light chain 
(VL) connected by a flexible oligopeptide linker. Due to their small size (~25 kDa) are fairly 
easy to be cloned and be better tolerated by bacteria, however, they have propensity to 
undergo aggregation and form higher molecular weight species, which can complicate 
selection and characterization. Fabs, in turn, consist of the variable heavy chain along with 
its first constant domain (VHCH) associated with the whole light chain (VLCL). These 
fragments are bigger in size (~55 kDa), and therefore cause some toxicity for bacteria, but 
lack the tendency to multimerize. 
 





Figure V.1. Schematic illustration of an intact IgG molecule compared to Fab, scFv, sdAb and diabody 
fragments. For each fragment, their respective gene construct/ domain association for each arrangement of VH 
and VL is depicted. 
 
Nevertheless, notwithstanding the antibody fragment format desired, the achievement of 
highly specific antibody fragments relies on the construction of large functional antibody 
libraries with a high degree of genetic diversity (Teixeira & Gonzalez-Pajuelo, 2018). These 
can be constructed from natural repertoires obtained from immunized animals or naïve B 
cells, or even from synthetic or semi-synthetic libraries which diversity is introduced with 
designed synthetic DNA that targets precisely the regions encoding the CDR regions (G. 
Chen & Sidhu, 2014). In immune libraries, the antibody clones are generated from B cell 
mRNA, extracted from either the blood or spleen of animals on active immunization with the 
target immunogen. The mRNA is then reverse transcribed to cDNA, and from this cDNA 
the VH and VL-encoding genes can be amplified by PCR using sets of primers specific to 
the more conserved regions of the antibody genes. For the construction of naïve libraries, 
the same procedure is applied, but isolating B cells from diverse lymphoid sources of 
nonimmunized animals (i.e., healthy human) (Teixeira & Gonzalez-Pajuelo, 2018).  
Immune libraries have the advantage of being enriched in antigen-specific antibodies, as 
the immune system of the immunized animal has already gone through a process of 
antibody affinity maturation (Berry & Popkov, 2015). Generally, for libraries generated from 
immune repertoires, a diversity of 106-107 is sufficient to achieve a high-affinity clone, while 
when using naïve and synthetic libraries a diversity on the order of at least 1010 clones is 
required (Berry & Popkov, 2015). 
The size of a library is mainly limited by the transformation efficiency in bacteria, which 
depends on both the transformation method applied, usually electroporation, and on the 
strain of bacteria used. Strategies to achieve larger libraries usually include increasing the 
number of transformations and/or conjugating different libraries obtained from different 
donors (Teixeira & Gonzalez-Pajuelo, 2018). This last approach has the added advantage 
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of allowing recombination of VH genes from one animal with VL genes from another, thus 
increasing the pool of recombined antibodies not seen in the host animals. 
However, as the quality of the library functional diversity is achieved from the random 
combination of the pool of heavy and light chain variable genes, it depends on a larger 
number of factors. The origin of the V-gene repertoires (immune, naïve and synthetic 
libraries), the number of donors, the source of the B-cells and the molecular methods for 
amplifying and engineering the V-genes, which encompasses the primer sets used for 
synthesis of cDNA and the VH and VL genes, the used V-genes assembly procedure and 
phagemid vectors, are all important factors to consider (Tohidkia, Barar, Asadi, & Omidi, 
2012). 
Yet, standard transformation efficiencies obtained for bacterial cells are far away of 
reaching the natural human antibody diversity, that is at least 1011 clones (Murphy & 
Weaver, 2017). Typical transformation efficiencies for E. coli TG-1 cells when using a 
ligated vector with insert are 1-10×107 transformants per g of vector (du Plessis & Jordaan, 
1996). However, not all the antibody clones represented in a library will be displayed. Low 
expression of antibody fragments has been associated with toxicity effects, intracellular 
degradation, aggregation and inefficient translocation, which result in only a small 
percentage of phage particles displaying the antibody fragment (Kulmala, Huovinen, & 
Lamminmäki, 2017). 
To the date, construction of antibody libraries from a variety of species including mouse, 
human, chicken, rabbit, sheep, camel and shark have been reported (Brien et al., 2002; 
Leow et al., 2018; Palliyil, Downham, Broadbent, Charlton, & Porter, 2014); however, not 
much work in the field of lipid oxidation biomarkers has been done resorting phage display 
technology. Interestingly, in 2015 a group from Aarhus University applied this technique to 
identify antibody fragments specific to HNE adducts on the α7 subunit of the 20S 
proteasome using a naïve scFv phage library. Results were, unfortunately, very 
inconclusive due to the instability of the adduct, and not many data on the antibody were 
achieved (Just et al., 2015). 
 
5.1.2. Vectors used in Phage Display 
There is currently a wide selection of vectors available for expression of antibody fragments 
on the surface of bacteriophages. However, before constructing or selecting a vector, 
understanding the diversity and organization of the immunoglobulin genetics is very 
important. Regarding sheep, its VH loci includes a total of 9 genes whereas the VL loci 
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includes 100 V genes and 6 V genes (K. A. Charlton et al., 2018), which reveals that the 
large diversity of the sheep immunoglobulins arises mostly from the light chain genes. 
Moreover, sheep was seen to preferential express the λ light chains over the κ light chains, 
presenting a λ/κ ratio of 20:1 (Sajadi et al., 2016), which is the reason why the Ig  genes 
were not amplified or used in this work. Interestingly, studies have also shown that the 
diversity in both the VH and V genes in sheep does not a result from the classic V(D)J 
recombination mechanism mentioned before in 1.6.3 Antibody Variability, as occurs in 
humans, but from post-rearrangements diversification strategies of somatic hypermutation 
that occur in an organ known as the ileal Peyer’s patch (Jenne et al., 2006). Hypermutation 
mechanisms were seen to be particularly targeted on sequences encoding CDRs, and not 
so much on the frame work regions, which suggests this mechanism increases selectively 
the diversity in the antigen binding regions and preserves the structural properties of the 
antibody molecule (Jenne et al., 2006). 
The vector used in this work, currently used at Mologic and named pSFD (vector map 
showed in Figure V.2 A), is a 5547 bp bicistronic plasmid that allows the simultaneous 
expression of the heavy and light chain gene sequences protein using a single promotor. 
This co-expression is achieved by the presence of two ribosome binding site (RBS) 
sequences, each upstream each antibody chain genes, allowing each RNA transcript to be 
translated separately by multiple ribosomes. Besides this feature, this plasmid carries (1) a 
gene sequence that encodes for the pIII protein of the phage capsid, where the antibody 
fragment will be displayed, (2) an antibiotic resistance gene for ampicillin (ampR), that will 
be further used as selectable marker for cells containing the plasmid, (3) an origin of 
replication sequence for replication in bacteria and an (4) the origin of replication sequence 
for replication in bacteriophages, (5) a DNA sequence that encodes for the catabolite 
activator protein (CAP) binding site, responsible for the activation of the transcription of the 
operon when glucose levels are low, and (6) the sequences for the lac promoter and lac 
operator, required for the expression of Fabs in bacteria. Downstream these sequences, 
there is, as well, (7) a sequence for the binding of the reverse M13 primer, (8) sequences 
encoding the ribosome binding sites (for protein translation) and (9) DNA stuffer sequences 
encoding the variable and constant regions of the heavy and  light chains of a “control” 
Fab, that were removed and substituted by the sheep SA369 derived VH-CH and V-C 
encoding sequences, leading to the generation of the final a construct of a final construct 
of 5930 bp depicted in Figure V.2 B. Upstream the light  and the heavy chain sequences 
are the signal sequences of the proteins OmpA and PelB, respectively, that are responsible 
for leading the chains to the periplasmic space, during protein expression. Downstream the 
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heavy chain sequences, the vector carries, as well, the sequences encoding for a myc tag 
and a 6xHis tag, for enabling further analysis and purification of the Fab fragment. 
 
Figure V.2.  Illustration of phage display vector pSFD used in this work for the expression of anti-HSA-
HNE Fab fragments. The map had, originally, a stuffer fragment of a control Fab (A), that was removed and 
substituted by the VHCH-VLCL genes amplified from sheep SA369 B cells, yield a vector of 5930 pb (B). 
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5.1.3. Selection of Antibody Phage Display Libraries 
Once an antibody library is generated, the enrichment of a subpopulation of specific phage 
antibody fragments is performed by a process known as biopanning, which involves 
repetitive cycles of antigen binding, washing and elution. During the first round of 
biopanning, the whole library is exposed to the specific antigen, which might be immobilized 
by passive adsorption to a 96-well microplate or an immunotube. After a few hours of phage 
incubation, unbound background phage antibodies are washed away by using non-ionic 
detergents, and the specific bound antibody phages can afterwards be eluted by applying 
a pH-gradient. When antibodies specific to post-translational modifications are desired, 
which is the case of this work, competition strategies with the non-modified antigen are 
usually applied for depletion of antibodies specific to the native molecules. In the case of 
HNE-modified HSA, prior to the incubation with HSA-HNE, phages were pre-incubated with 
non-modified HSA, so phages displaying anti-HSA antibodies could be eliminated. The 
eluted antibody-phage are then recovered for subsequently amplification by infecting 
bacteria, and this whole process is repeated, usually 3 to 4 times, until sufficient enrichment 
is accomplished (Kretzschmar & Von Rüden, 2002; Pande, Szewczyk, & Grover, 2010).  
The success of each selection round can be assessed by determining the phage titers 
before and after elution and by testing the pool of eluted polyclonal antibody-phages by 
ELISA assay against the specific antigen. Even though it is believed the outcome of the 
selection process is largely dependent of the quality of the library, the biopanning strategy 
applied can affect the properties of the enriched antibody clones as well. For 
example, increasing the stringency of the selections by adjusting the antigen concentration, 
the time of phage incubation and the number of washing steps results in the selection of a 
narrow panel of antigen-specific phage binders, potentially with lower off-rates and/or higher 
on-rates. Moreover, the addition of subtraction/depletion steps before selections or the 
counterselection with a possible cross-reactive molecule during phage-antigen incubation 
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5.1.4. Chapter V Aims  
The aim of the work described in this chapter was to generate monoclonal antibody 
fragments specific to HNE adducts on HSA, in order to eliminate the cross-reactivity 
towards unmodified HSA observed in Chapter III in the sheep SA369 Anti-HNE polyclonal 
antibody. 
To accomplish this aim, Fab and ScFv antibody libraries were generated by means of the 
phage display technology and using as starting material RNA extracted from sheep SA369 
lymphocytes. 
The panning of the libraries was performed using different strategies, by immobilizing HSA-
HNE and OVA-HNE on immunotubes and by using biotinylated HSA-HNE and OVA-HNE 
whose capture was done via magnetic streptavidin microbeads. 
 
5.2. Reagents 
The following reagents were purchased by Acros Organics (UK): ethanol, sodium chloride 
(NaCl), isopropanol and glycerol 99%. 1,4-Dithiothreitol (DTT), hypodermic needles (20 
gauge/0.9 mm), magnesium chloride (MgCl2), ampicillin sodium salt, kanamycin, D-(+)-
Glucose 99.55% (GC), glycine, tween 20, Trizma® (TRIS base), PEG6000, isopropyl β-
D-1-thiogalactopyranoside (IPTG) and Corning® Costar® 96-well cell culture plates were 
purchased from Sigma-Aldrich, UK. 
Sheep Fab Primers, RNaseOUTTM recombinant ribonuclease inhibitor, RNase free water, 
SuperScript™ IV Reverse Transcriptase, phusion high fidelity DNA polymerase, DMSO, 
SOC media, culture plates, agarose I molecular biology grade, GeneJET gel extraction and 
DNA clean-up micro kits, 10x TAE buffer, plate spreaders, NuncTM bioassay plates, DNA 
gel loading dye 6X, GeneRuler 1 kb DNA ladder, EZ-Link NHS-PEG4 Biotinylation Kit, PBS, 
NuncTM Immunotubes Maxisorp 4 mL, NuncTM 96-well ELISA plates, TMB substrate 
solution, Dyna M-280 Streptavidin Magnetic beads were ordered from Thermo Fischer 
Scientific, UK. 
Deoxynucleotide (dNTP) Solution Mix (10 mM of dATP, dCTP, dGTP and dTTP), TG-1 
Turbo competent E. coli cells, restriction enzymes XbaI, SfiI, NotI-HF, NcoI-HF, EcoRI, 
MfeI, HaeIII, BstNI, MlluI and AscI, CutSmart® buffer, and T4 DNA ligase were purchased 
from New England Biolabs, UK.  
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The RNeasy minikit (50) was purchased from Qiagen (Germany), the PureLinkTM quick gel 
extraction kit and the 2-YT Broth from Invitrogen (UK), the ZippyTM Plasmid Miniprerp kit 
from ZymoResearch (UK), agar bacteriological from Oxoid (UK), GenePulser cuvettes (0.1 
cm) from BioRad (UK), the hydrochloric acid solution from Fluka (UK), Gelred® Nucleic 
Acid Gel Stain (10,000X in H2O) from Biotium/Cambridge Biosciences (UK) and Milk 
powder from Marvel (UK). Antibodies anti-mycTag antibody and ati-M13 were ordered from 
Abcam (UK) and Sino Biological (UK), respectively.  
 
5.3. Materials and Methods 
To facilitate the comprehension of the approaches followed, a visual representation of the 
methods followed for generation of both Fab and scFv libraries can be found in Figure V.3.  
 
Figure V.3. Flowchart depicting the main steps performed for the generation of antibody single-chain 
variable fragments (scFv) (left) and antibody Fab fragments (right) libraries. 
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5.3.1. Construction of Fab Antibody Libraries 
5.3.1.1. Preparation of Peripheral Blood Lymphocytes  
Peripheral blood lymphocytes (PBLs) from the sheep SA369 were prepared at Orygen 
Antibodies from approximately 100 mL of whole blood, collected into a blood collection bag 
containing an acid dextrose solution to prevent coagulation. The blood was diluted in PBS 
in a 1:1 ratio and loaded into Accuspin tubes with Histopaque 1077 for separation of the 
lymphocytes by centrifugation at 1000 × g for 10 min. If the PBLs did not form a clear band, 
or red blood cells remained above the frit, the sample was re-centrifuged at 1500 × g for 15 
min. The resulting PBL bands were removed from the tubes, pooled and washed in 10 mL 
PBS, followed by a centrifugation step at 1000 × g for 10 min. The resulting PBL pellet was 
re-suspended in 1 mL of RNA stabilization solution RNAlater and shipped to Mologic Ltd, 
where they were stored at -80oC until further use. 
 
5.3.1.2. RNA Extraction 
RNA was extracted from two-200 L PBL aliquots using the commercial RNeasy MiniKit 
(Qiagen, Germany), following the manufacturer’s instructions. Briefly, cells were pelleted by 
centrifugation at 300 × g and disrupted by adding buffer RLT. Homogenization was 
achieved by passing the lysate through a 20-gauge (0.9 mm) needle attached to a sterile 
plastic syringe at least 5–10 times or until a homogeneous lysate was achieved. One 
volume of 70% ethanol was added to the homogenized lysate and mixed well before adding 
the sample to a RNeasy spin column placed in a 2 ml collection tube (supplied). After a 15 
s centrifugation at ≥8000 × g, the flow through was removed and 700 L of buffer RW1 was 
added to the spin column and centrifuged again for 15 s at ≥8000 × g. Then, column was 
washed by adding 500 µl of buffer RPE to the RNeasy spin column, centrifuging under the 
same conditions, and repeating the same wash step with 500 µl Buffer RPE and centrifuging 
again for 2 min at ≥8000 × g. For elution of RNA, the RNeasy spin column was placed in a 
new 1.5 mL tube, 50 L of RNase free water were added directly to the spin column 
membrane and the column was centrifuged for 1 min at ≥8000 × g. The concentration of 
the eluted RNA was estimated using a nanodrop (Jenway Genova nano).  
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5.3.1.3. cDNA Generation 
The extracted RNA was used as template to synthesise the first strand of cDNA using 
primers specific for the ovine antibody heavy and light chain constant region of interest. 
Primers OvCH1 3’-Hinge- For and OvCL-3’For1 were used for the Fab library, respectively 
for the heavy and the lambda light chains. The kappa () light chain was not synthesised 
nor inserted into the vector, as the λ/κ ratio in a sheep IgG molecule is 20:1 and therefore 
the variability derived from the kappa light chain is not particularly relevant for the process 
(Sajadi et al., 2016). All the primer sequences used for the generation of the Fab libraries 
were kindly provided by Prof. Keith Charlon to Mologic Lltd under a non-disclosure 
agreement. 
For cDNA synthesis, per 1 g of RNA, 1 L of the primer mix (2 pmol/L of each primer), 
1L of dNTP mix (containing dATP, dCTP, dGTP and dTTP) and RNAse-free water to a 
final volume of 13 L were added and the mixture was incubated on a thermocycler at 65oC 
for 5 min. Afterwards, it was quenched for at least 1 min on ice, to allow the annealing of 
the primers to the RNA chain. Each cDNA mix (13 L) was further added to a reverse 
transcriptase mix (7 L) containing 1 l of SuperscriptTM IV reverse transcriptase enzyme, 
4 l of 5x SuperscriptTM IV buffer, 1 l of RnaseOUTTM recombinant ribonuclease inhibitor 
and 1 l of 0.1M DTT. The mixes (20 l) were incubated for 55°C for 15 min, followed by 
heat inactivation at 80°C for 10 min. The generated cDNA was stored in the freezer until 
further use. 
 
5.3.1.4. PCR Amplification of IgG Heavy and  Light Constant and Variable 
Gene Segments 
The amplification of the ovine heavy and light  chains was done by PCR using a unique 
set of forward and reverse specific primers designed by Keith Charlton, Scotia Biological 
(detailed sequences not shared).For the amplification of the heavy chain, PCR reactions 
were set up by using the following primer pairs: 
• H1 – OvCH1 hinge-Not-FOR and mixture of OvVH1-Ufab-Nco-REV, OvVH2-Ufab-
Nco-REV and OvVH3-Ufab-Nco-REV 
• H2 – OvCH1 hinge-Not-FOR and mixture of OvVH4-Ufab-Nco-REV, OvVH5-Ufab-
Nco-REV and OvVH6-Ufab-Nco-REV 
• H3 – OvCH1 hinge-Not-FOR and mixture of OvVH7-Ufab-Nco-REV, OvVH8-Ufab-
Nco-REV and OvVH9-Ufab-Nco-REV 
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For the amplification of the light  chain, PCR reactions were set up by using the following 
primer pairs: 
• L1 – OvCL-3-Xba-FOR and mixture of OvVL1 fab-SFi-REV, OvVL2 fab-SFi-REV, 
OvVL3 fab-SFi-REV, OvVL4 fab-SFi-REV and OvVL5 fab-SFi-REV 
• L2 – OvCL-3-Xba-FOR and mixture of and OvVL6 fab-SFi-REV, OvVL7 fab-SFi-
REV, OvVL8 fab-SFi-REV, OvVL9 fab-SFi-REV and OvVL12 fab-SFi-REV 
• L3 – OvCL-3-Xba-FOR and mixture of OvVL13 fab-SFi-REV, OvVL14 fab-SFi-REV, 
OvVL15 fab-SFi-REV, OvVL16 fab-SFi-REV and OvVL17 fab-SFi-REV 
• L4 – OvCL-3-Xba-FOR and mixture of OvVL18 fab-SFi-REV, OvVL19 fab-SFi-REV, 
OvVL20 fab-SFi-REV, OvVL21 fab-SFi-REV and OvVL22 fab-SFi-REV 
PCR reactions for each chain were set up individually by mixing 5 L of cDNA with 45 L 
of a Master mix containing 10 L of 5x Phusion buffer (GC), 1 L of Phusion polymerase, 
1.25 L forward primer (20 pmol/L), 1.25 L of reverse primer set (20 pmol/L), 2 L 
dNTPs, 1.5 L of DMSO and RNase-free water up to 45 L. The PCR mixes were incubated 
for 2 min at 98°C, then subjected to 35 cycles of 98°C for 10 seconds, 58°C for 30 seconds 
and 72°C for 40 seconds, and finally incubated at 72°C for 10 min. Tubes were incubated 
at 4°C until further use. 
 
5.3.1.5. Agarose Gel Electrophoresis and DNA Extraction  
The heavy and light chain DNA PCR products were loaded, separately, into a 1% (w/v) 
agarose gel for purification. Agarose was melted in 1x TAE buffer (40 mM Tris, 20 mM 
acetic acid and 1 mM EDTA) for a few minutes in a microwave, allowed to cool down for 15 
min and before pouring the gel into the cast, 1x gel red Stock was added for DNA staining. 
Samples were mixed with 1x DNA gel loading buffer before being loaded. The gel was run 
at 150 V in 1x TAE buffer until the sample reached the bottom of the gel, to ensure a good 
separation between the desired PCR products and the background PCR sub-products. 
The bands corresponding to the heavy and light chains (~400 bp) were excised from the 
gel using a scalpel, and the DNA was extracted from the gel bands using the PureLink™ 
quick gel extraction kit and following the manufacturer’s instructions. Briefly, to each gel 
slice containing the DNA fragment, gel solubilization buffer L3 was added in a gel weight: 
buffer volume proportion of 1:3, and the mixture was placed in a 50°C water bath for a 10-
minute incubation, for gel dissolution. Once dissolved, 1 gel volume of isopropanol was 
added to the solution and the DNA was purified by attaching the quick gel extraction 
columns to a vacuum manifold. The dissolved gel mixture was pipetted onto the centre of 
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the column and vacuum was applied until all the liquid passed through the column. For 
washing the column, 700 L of buffer W1 were added to the column and, again, vacuum 
was applied until all the liquid passed through the column. To remove any traces of ethanol, 
the column was centrifuged at maximum speed for 5 minutes, and the flow-through was 
discarded. Elution was achieved by adding 50 L of elution buffer (E5), leaving the buffer 
to incubate for 5 min at room temperature and centrifuging the tube at >12,000 × g for 1 
minute. The concentration of both heavy and light chains was estimated using a nanodrop 
(Jenway Genova Nano). 
 
5.3.1.6. Generation of Stock pSFD Phagemid Vector 
The template vector used for the development of both Fab scFv antibody libraries was the 
pSFD, kindly provided by Professor Keith Charlton’s group from Aberdeen University. The 
pSFD phagemid plasmid (AmpRES) was transformed into turbo competent E. coli cells by 
heat shock transformation. Cells (50 L aliquots) were thaw on ice for 10 min, before 1 L 
of phagemid DNA was added. The mixture was placed on ice for 30 min, then incubated at 
42°C for 30 s and placed back on ice for 5 min. For cell recovery, 950 L of SOC media 
(super optimal broth with catabolite repression: 2% Tryptone, 0.5% Yeast Extract, 10 mM 
NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4 and 20 mM glucose) was added to each 
transformation and the cells were incubated at 37°C for 1 h with shaking (250 rpm). Cell 
were mixed, 10-fold serial dilutions were performed in SOC media, and 100 L of each 
dilution was spread onto 2-YT plates with 1% glucose/100 µg/mL ampicillin (2-YT/glu/amp). 
Plates were incubated overnight at 37°C. Single pSFD-Turbo cell colonies were picked 
using a pipette tip and added to lysogeny broth media supplemented with 100 µg/mL 
ampicillin (LB/Amp) for growth overnight at 37°C with shaking (250 rpm). The phagemid 
was purified using ZippyTM plasmid midiprep kit by initially centrifuging the cell culture for 3 
min at max speed (>10,000 rpm), removing the supernatant, and resuspending the cell 
pellet in 600 µL of RNAse free water. For cell lysis, 100 µL of 7x Lysis Buffer were added 
to the culture and mixed by inverting the tubes 4-6 times. Once the colour of the solution 
has changed from opaque to clear blue, 350 µL of cold neutralization buffer were added to 
the tube and mixed thoroughly. Tubes were centrifuged for 4 minutes at 11,000 × g, 
supernatant was transferred into a Zymo-Spin µL IIN column, and placed for centrifugation 
for 15 seconds at 11,000 × g. The flow-through was discarded, the column was placed in 
the same collection tube, and 200 µL of Endo-Wash buffer were added to the column. The 
columns were centrifuged for 30 seconds at 11,000 × g. For the washing step, 400 µL of 
the ZyppyTM Wash buffer were added to the column and centrifuged for 1 minute at 11,000 
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× g. The column was then transferred into a clean 1.5 mL tube, 30 µL of the ZyppyTM Elution 
buffer were applied directly into the centre of the column matrix and left to incubate for 5 
minutes at room temperature. The column was then centrifuged for 30 seconds at 11,000 
× g to elute the plasmid DNA. The concentration of the eluted DNA was estimated using a 
nanodrop (Jenway Genova Nano). 
 
5.3.1.7. Restriction Enzyme Digestion of the pSFD Phagemid and of the 
Heavy and  Light Chain Fragments 
The insertion of the heavy and light lambda chain fragments into the pSFD phagemid was 
performed sequentially by two restriction cuts and respective ligations. The restriction sites 
of the enzymes used are located strategically in the vector to, as well, remove the already 
existing stuffer heavy and light chain fragments. The cloning strategy applied is described 
below in Figure V.4. 
 
Figure V.4. Cloning strategy for the insertion of the heavy and light  chain gene fragments into the 
pSFD phagemid. The insertion of the  chain into the vector was performed first by digesting both the vector 
and the  chain genes, separately, with SfiI and XbaI restriction enzymes. After purification, both the vector and 
the  chain fragments were ligated via the action of ligase, and the resulting ligation mix was transformed into 
E. coli. Cells were grown and plated, single colonies were picked for extraction and purification of the  chain 
containing phagemid (pSFD-L), and subsequently the insertion of the heavy chain into the pSFD-L vector 
was performed. Both the pSFD-L and variable heavy chain fragment were digested, separately, with NotI and 
NocI restriction enzymes, and again, after purification, the ligation of the fragments was performed using the 
enzyme ligase. The vector was further transformed, cells were grown and plated, and the library containing the 
final vector (pSFD-L-H) was generated. 
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For the first digestion, a reaction mix was prepared by mixing the phagemid (~50 g) with 
the SfiI enzyme (50 L, i.e.20 units per 1 g of phagemid DNA),10x CutSmart® buffer and 
nuclease free water. The whole mix was split in 40 PCR tubes (49 L each) and incubated 
at 50°C for 20h in the thermocycler. Once the digestion with SfiI was finished, 1 L of Xbal 
enzyme was added to each PCR tube and left to incubate for further 20h at 37°C. 
After the digestion with XbaI was completed, the digested pSFD phagemid was loaded onto 
a 1% agarose gel for purification, from which a band corresponding to the digested 
phagemid (~5000 bp) was excised and purified using the PureLinkTM quick gel extraction 
kit. 
The  light chain fragment was also digested with the enzymes XbaI and SfiI following the 
same protocol, but the digested fragments were purified using the PureLinkTM quick PCR 
purification kit. 
The digestion of the heavy chain fragments with NocI-HF and NotI-HF enzymes was 
performed at the same time by mixing 1 L of each enzyme. The tubes were incubated at 
37°C for 20 h and further inactivation was done at 65°C for 20 min. Digested heavy chains 
were purified using Invitrogen PureLinkTM quick PCR purification kit and stored at 4°C until 
further use. 
 
5.3.1.8. Ligation of the  Light Chain to the pSFD vector 
The  light chain was inserted onto the digested plasmid by setting up a 400 L ligation mix 
containing the 2 g of XbaI-SfiI digested pSFD vector, 2 g of XbaI-SfiI digested light chain 
insert (equal amounts of L1, L2, L3 and L4), 40 L of T4 DNA ligase buffer, 20 L of T4 
DNA ligase enzyme and nuclease free water. The mix was split in 8 PCR tubes, which were 
incubated in a thermocycler at 16°C for 16 h and then heat inactivated at 65°C for 10 min. 
The ligation products were further cleaned up using the GeneJET gel extraction and DNA 
clean-up micro kit (following the manufacturer’s instructions) before transformation by 
electroporation into TG-1 cells. 
 
5.3.1.9. Electroporation into TG-1 Cells 
The total volume of ligation mix was split into 1 µL aliquots and multiples electroporations 
were performed by adding 1 µL of ligation mix into a 30 µL-aliquot of Lucigen TG-1 
electrocompetent cells. Before initiating the transformation, the DNA/cell mix was allowed 
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to chill on ice for further 15-20 min together with the required number of electroporation 
cuvettes and microcentrifuge tubes. The electropulser was set up to deliver an electrical 
pulse of 1.8 kV, the DNA/cell mixture was pipetted into the electroporation cuvette and once 
the pulse is released, 1 ml of recovery SOC medium at room temperature is added to the 
cuvette. Transformed cultures were grown at 37°C for 1 h with shaking (225 RPM), from 
which 20 µL of cells were collected and serially diluted tenfold in 2-YT medium to be plated 
onto 2-YT plates containing 1% (w/v) glucose and 100 µg/mL Ampicillin (2-YT/Glu/Amp). 
The plates were incubated at 37°C overnight and the size of the library is calculated from 
the titer obtained from serial dilution plates according Equation 2. The remaining culture is 
plated onto large 2-YT/Glu/Amp bioassay plates and incubated overnight at 30°C. 
 




No colonies ×  Serial dilution (1 × 10x)
Volume inoculated (mL)
 × Volume of transformations (mL) 
 
Where x stands for the dilution applied.  (Equation 2) 
 
5.3.1.10. Preparation of the pSFD-L vector 
The pSFD-L library was recovered from the bioassay plate by pipetting ~2 mL of 15% (v/v) 
glycerol in 2-YT media and using a cell spreader to gently loosen the cells. A 500 µL-aliquot 
of the resuspended  chain-PSFD library was used to purify the phagemid, while the 
remaining of the library was aliquoted and stored at -80°C.  
The genetic material was extracted by using the ZippyTM Plasmid Miniprep kit, following the 
instructions of the kit.  
 
5.3.1.11. Colony PCR 
Single colonies were picked from the serial dilution plates and used as source of template 
DNA in colony PCR to confirm the library has the correct insert. A PCR reaction mix was 
set up by mixing 12.5 L of DreamTaq Green Master Mix, 1 L of forward primer (OvCH1 
hinge Not For), 1 L of reverse primer (M13 Rev) and 10.5 L of nuclease free water, to 
which a single colony was added. The PCR mixes were incubated at 95oC for 5 min, 
followed by 35 cycles of incubation at 95°C for 30 seconds, 58°C for 30 seconds and 72°C 
for 60 seconds, and a last step at 72°C for 10 min. The PCR products (5 L) were run on 
1% (w/v) agarose gel in 1x TAE buffer, as previously described, to analyse the presence of 
the insert (~650 bp). 
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5.3.1.12. Restriction Digest for Cloning the Heavy Chain  
For the insertion of the variable heavy chain fragment, the pSFD-L was digested using the 
restriction enzymes NotI-HF and NcoI-HF. Several digestion mixes were prepared by 
mixing 1 µg of pSFD-L with 1 µL NotI-HF, 1 µL of NcoI-HF, 5 µL of 10x CutSmart® buffer 
and nuclease free water up to 50 µL. The tubes were incubated at 37°C for 20h and at 65°C 
for 20 min for inactivation of the enzymes. The digested vector was run on 1% (w/v) Agarose 
gel in 1x TAE for purification and the DNA was extracted from the gel bands using the 
PurelinkTM quick gel extraction kit., as described before. DNA concentration was estimated 
using a nanodrop by measurement of the absorbance at 260 nm. 
 
5.3.1.13. Ligation of the Heavy Chain to the pSFD-L and Transformation 
The insertion of the heavy chain fragment into the pSFD-L was performed by preparing 
ligation mixes using a molar ratio of 1:3 of vector to insert. For a ligation mix of 400 µL, 2 
µg of digested vector were mixed with 0.84 ug of digested heavy chain (equal amounts of 
H1, H2 and H3), 40 µL ligase buffer, 20 µL of ligase and nuclease free water. The mix was 
divided into 8 PCR tubes of 50 µL, which were incubated in a thermocycler at 16°C for 16 
h and then heat inactivated at 65°C for 10 min. The ligation products were further cleaned 
up using the GeneJET gel extraction and DNA clean-up micro kit (following the 
manufacturer’s instructions) and transformed by electroporation into TG1 cells. The 
transformation of the cleaned ligation mix into TG-1 cells was performed by electroporation, 
as described before, and the library was generated following the same protocol. A colony 
PCR was as well performed to assess the presence of the correct insert into the vector (~ 
1500 bp). 
 
5.3.1.14. Restriction Digestion for Assessment of Clone Diversity 
For positive clones, the remaining colony PCR mix was cleaned up using the PurelinkTM 
PCR purification kit for purification of the vector. To assess the diversity of the genetic 
material, the vector was individually digested with restriction enzymes HaeIII and BstNI, by 
setting up 40 µL digestion reaction containing, 1 µg of DNA, 10 U of the enzyme, 4 µL of 
10x CutSmart® buffer and nuclease free water. Reaction mixes for HaeIII digestion were 
incubated at 37°C for 90 min and heat inactivate at 80°C for 20 minutes, and reaction mixes 
for BstNI were incubated at 60°C for 90 min. The DNA products were loaded into 3% 
agarose gel, and the digestion pattern was assessed.  
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5.3.2. Construction of scFv Antibody Libraries 
5.3.2.1. cDNA Generation 
cDNA was synthesised using primers OvCHFOR and OvCLFOR specific for the ovine 
antibody heavy and light chain, respectively. The kappa light chain, once again for the same 
reasons stated below, was not synthesised or inserted in the vector. All the primers used 
for the development of the scFv library are shown in Appendix 14. 
For cDNA synthesis, per 1 g of RNA, 1 L of the primer mix (2 pmol/L of each primer), 
1L of dNTP mix (containing dATP, dCTP, dGTP and dTTP) and RNAse-free water to a 
final volume of 13 L were added and the mix was incubated on a thermocycler at 65oC for 
5 min and quenched for at least 1 min on ice, to allow the annealing of the primers to the 
RNA chain. Each cDNA mix (13 L) was further added to a reverse transcriptase mix (7 L) 
containing 1 l of SuperscriptTM IV reverse transcriptase enzyme, 4 l of 5x SuperscriptTM 
IV buffer, 1 l of RnaseOUTTM recombinant ribonuclease inhibitor and 1 l of 0.1M DTT. 
The mixes (total volume of 20 l) were incubated for 55°C for 15 min, followed by heat 
inactivation at 80°C for 10 min. The generated cDNA was stored in the freezer until further 
use. 
 
5.3.2.2. PCR Amplification of IgG Heavy and  Light variable Gene Segments 
The amplification of the ovine heavy and  chains was done by PCR using a unique set of 
forward and reverse specific primers.  
For the amplification of the heavy chain, PCR reactions were set up by using the following 
primer pairs: 
• H1 – Mixture of OvJH1LINKFOR, OvJH2LINKFOR, OvJH3LINKFOR and 
OvJH4LINKFOR, and OvVH1BACK 
• H2 – Mixture of OvJH1LINKFOR, OvJH2LINKFOR, OvJH3LINKFOR and 
OvJH4LINKFOR, and OvVH2BACK 
• H3 – Mixture of OvJH1LINKFOR, OvJH2LINKFOR, OvJH3LINKFOR and 
OvJH4LINKFOR, and MuVH1BACK 
• H4 – Mixture of OvJH1LINKFOR, OvJH2LINKFOR, OvJH3LINKFOR and 
OvJH4LINKFOR, and Hu4aBACK 
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For the amplification of the  chain, PCR reactions were set up by using the following primer 
pairs: 
• 1 – Mixture of OvJL1FOR and OvJL2FOR and OvVL1LINKBACK 
• 2 – Mixture of OvJL1FOR and OvJL2FOR and OvVL2LINKBACK 
• 3 – Mixture of OvJL1FOR and OvJL2FOR and OvVL3LINKBACK 
• 4 – Mixture of OvJL1FOR and OvJL2FOR and OvVL4LINKBACK 
• 5 – Mixture of OvJL1FOR and OvJL2FOR and OvVL5LINKBACK 
 
PCR reactions for each chain were set up individually by mixing 5 L of cDNA with 45 L 
of a Master mix containing 10 L of 5x Phusion buffer (GC), 1 L of Phusion polymerase, 
1.25 L forward primer (20 pmol/L), 1.25 L of reverse primer set (20 pmol/L), 2 L 
dNTPs, 1.5 L of DMSO and RNase-free water up to 45 L. The reaction mixes were heated 
up to 98°C for 30 s, subjected to a 30 cycle temperature gradient program of denaturation 
at 98°C for 10 seconds, annealing at gradient temperature of 52-72°C for 30 seconds and 
polymerization at 72°C for 40 seconds, followed by a final extension at 72°C for 10 min. 
Tubes were incubated at 4°C until further use. 
 
5.3.2.3. Agarose Gel Electrophoresis and DNA Extraction  
The heavy and light DNA PCR products were purified by agarose gel electrophoresis, using 
a 1% (w/v) agarose gel. Bands corresponding to the heavy and light chains (~350 bp) were 
excised from the gel using a scalpel, and the DNA was extracted from the gel bands using 
the PurelinkTM quick gel extraction kit, following the manufacturer’s instructions. The 
concentration of both heavy and light chains was estimated using a nanodrop (Jenway 
Genova Nano). 
 
5.3.2.4. Restriction Enzyme Digestion of the Heavy and  Light Chain 
Fragments with MluI and AscI Restriction Enzymes 
The primers used for the amplification of the variable heavy (VH) and lambda light chain 
(V) from cDNA were designed to incorporate the restriction sites of the enzyme AscI for 
the heavy chain and restriction sites of the enzyme MluI for the light chain at the linker 
region, for enabling further cloning processes. 
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Equal amounts of VH1, VH2, VH3, VH4 were individually digested by setting up reaction mixes 
containing 1 g of DNA, 1 L of AscI enzyme (10 U), 5 L of 10x CutSmart® buffer and 
nuclease free water up to a final volume of 50 L, and the same mixes were prepared for 
the digestion of the V1, V2, V3, V4 and V5 using MluI enzyme instead. The PCR 
tubes were incubated at 37°C for 3 h. After the digestions are complete, the DNA is purified 
by agarose gel electrophoresis and extracted from the gel bands using the PureLinkTM quick 
gel extraction kit. 
 
5.3.2.5. Ligation of the Variable Heavy Chain (VH) and the  Light Chain (V) 
A total amount of 1 g of digested heavy chain (0.25 g of VH1, VH2, VH3, VH4) was ligated to 
a total amount of 1 g of digested  chain (0.2 g of V1, V2, V3, V4 and V5 by adding 20 
L of T4 DNA ligase and 40 L of ligase buffer and water to a final volume of 40 L. The 
enzymes MluI and AscI (2 L, i.e. 20 U of each) were as well added to the mix to prevent 
the formation of VH-VH and V- V products, as successful ligation of VH-V removes AscI 
and MluI sites from the linker region. Ligation was performed for 4 h at 37°C, and the ligation 
products were purified by gel electrophoresis by cutting of a band of ~750 bp, and extracting 
its DNA using the PureLinkTM quick gel extraction kit. 
 
5.3.2.6. Incorporation of SfiI and NotI Cloning sites into VH-V DNA 
Fragments 
A PCR reaction was performed to include the cloning sites of the restriction enzymes SfiI 
and NotI into the ligated VH-V, for its later insertion into the phagemid vector. The 
amplification was performed by adding to a 1 L of purified VH-V fragment, 25 pmol of a 
forward primer mix containing primers OvJL1FOR-Not and OvJL2FOR-Not, 25 pmol of a 
reverse primer mix containing primers OvVH1BACK-Sfi, OvVH2BACK-Sfi, MuVH1BACK-
Sfi and Hu4aBACK-Sfi, 1 L of Phusion DNA Polymerase, 10 L of a 5x Phusion buffer 
GC, 2 L of a dNTP mix, 1.5 L of DMSO and nuclease free water to a final volume of 50 
L. The PCR mixes were incubated at 98°C for 30 s and subjected to 2 cycles of 
denaturation at 98°C for 10 seconds, annealing at 65°C for 30 seconds and polymerization 
at 72°C for 30 seconds, followed by an extension step at 72°C for 10 min. After 2 cycles of 
initial amplification, mixes were subjected to further 25 cycles of PCR reactions with 72°C 
as the annealing temperature. Products were purified by gel electrophoresis and extracted 
from the gel using the PureLink™ quick gel extraction kit. 
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5.3.2.7. Restriction Digestion of VH-V Fragment and Phagemid Vector 
For construction of the scFv library both the VH-V fragments and the vector were digested, 
individually, with SfiI and NotI-HF. Both DNA products were firstly digested with SfiI by 
adding to each g of DNA 2L of SfiI enzyme (20 U), 5 L of 5x CutSmart® Buffer and 
nuclease free water up to 50 L. The mixes were incubated for 4h at 50°C, and afterwards, 
2 L of NotI-HF were added to each mix. Tubes were again incubated for another 4 h-period 
at 37°C and 20 min at 65°C for heat inactivation of the enzyme. The digested phagemid 
was later purified by agarose gel electrophoresis, by excising a band corresponding to 
~5000 bp and extracting the DNA using the PureLink™ quick gel extraction kit, while the 
digested VH-V fragments were purified using the PureLink™ quick PCR purification kit. 
DNA product were stored at 4°C until further use. 
 
5.3.2.8. Ligation of the VH-V Fragment to the Phagemid Vector and 
Transformation of the Ligation Product 
The VH-V fragment was ligated into the phagemid vector following a 1:3 molar ratio of 
vector:insert. A ligation mix of 400 L was prepared by mixing 2 g of vector with 0.9 g of 
insert, 20 L of T4 ligase, 40 L ligase buffer and nuclease free water. The mix was split 
into 8-50L tubes and the reaction was performed for 16 h at 16°C. The ligated DNA was 
purified and cleaned up using the GeneJET gel extraction and DNA clean-up micro kit 
before being transformed into TG-1 cells. 
 
5.3.3. Rescue and Panning of Recombinant Antibody Phage Display 
Library 
5.3.3.1. Rescue of the Phagemid Libraries  
Since the infection of bacterial cells by phages is dependent of the interaction between the 
pIII of the phage particle and the tip of the F conjugative pilus of the bacteria, an aliquot of 
the bacterial library is grown to mid log phase, so cells start expressing the f-pilus. In order 
to ensure a good representation of the library, at least a ~10x fold excess of cells to clones 
in the library was used by inoculating 50 mL 2-YT media supplemented with 100 g/mL of 
ampicillin and 2% of glucose (2-YT/glu/amp) to an OD600 of 0.1 (or 4x109 cells total)*. Cells 
were incubated at 37°C with shaking for 1-2 h and allowed to grow until OD600 of 0.5 was 
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reached (mid log phage). For infection with helper phage, 10 mL of the culture were 
inoculated into a 15 mL falcon tube and infected with helper phage (M13K07), in a 1:20 
ratio of helper phage:bacteria, for 30 min in a 37°C water bath. Infected cells were 
centrifuged at 3300 × g for 10 min, part of the supernatant was discarded, and the pellet 
was gently resuspended in 2-3 mL of the remaining supernatant. The culture was 
transferred into 100 mL of 2-YT media containing 100 g/mL of ampicillin and 50 g/mL of 
kanamycin and incubated overnight at 30°C with 220 rpm shaking.  
On the next day, phage-antibody particles were harvested by centrifugation and PEG 
precipitation. The overnight cultures were decanted into two 50-mL tubes, centrifuged for 
30 min at 4500 × g and 4°C, and the pellet was discarded. The supernatant was divided 
into three 50-mL tubes (~35 mL each), and to each 1/5th volume of 20% PEG6000 in 2.5 M 
NaCl was added. Tubes were incubated for 1 h at 4°C, before centrifuging again for 30 min 
at 4500× g and 4°C. The supernatants were discarded, and the pellets resuspended in ~3 
mL of cold deionized water. The three fractions were combined and 1/5th volume of 20% 
PEG 6000 in 2.5 M NaCl was once again added and leave to incubate for 20 min at 4°C. 
After another centrifugation step (same conditions), the supernatant was discarded and the 
pellet was resuspended in 1.5 mL of PBS, followed by a centrifugation at 3300 × g for 10 
min to remove any residual bacterial debris. 
 
5.3.3.2. Selection of Phage-antibody Libraries by Panning in Immunotubes 
Immunotubes were coated with (freshly prepared) HSA-HNE and OVA-HNE antigens 
overnight 10, 5 and 1 g/mL, in PBS, respectively for the first, second and third rounds of 
panning. On the next day, the immunotubes were washed three times with PBS and blocked 
with 2% of MPBS (skimmed milk powder in PBS) for 2 h at room temperature. After blocked, 
the immunotube was washed three times with PBS and filled with 1 mL of rescued phage 
(between 1012 to 1013 transducing units), 2 mL of 2% MPBS and 1 mL of 4% MPBS. The 
tube was incubated for 30 min at room temperature rotating continuously on an under-over 
turntable and for further 90 minutes in a fixed position. 
After the incubation step, the non-specific phages were removed by washing the tube 20 
times with PBST and 20 times with PBS. The elution of the bound phages was done by 
adding 1 mL of 100 mM Glycine, pH 3.0 and let the tube incubate for 10 min while rotating. 
The phages were neutralized by addition of 500 L of 1 M Tris-HCl pH 7.4. To allow the 
infection, 1 mL of eluted phage was incubated with 9 mL of exponentially growing culture 
of TG-1 cells (OD600 0.5), for 30 min in a water bath at 37°C, with no shaking. A 20 L 
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aliquot of the infected culture is serially diluted tenfold in 2-YT medium and plated onto 2-
YT/Glu/Amp plates and incubated overnight at 37°C. The rest of the culture was centrifuged 
for 10 min at 3300 rpm for pelleting the cells, which were later resuspended in 1 mL of 2-
YT medium and plated onto a large bioassay plate. The plate was incubated overnight at 
30°C. The library size was estimated by counting the number of bacterial colonies on the 
serial dilution plates using Equation 2. 
The library was recovered from the bioassay plate by loosen the cells, with a spreader, in 
~2 mL of filtered 2-YT medium containing 15% glycerol. The bacterial suspension was 
aliquoted and stored at -80°C as a bacterial stock containing the selected phage from the 
first round of selection. This panning process was further repeated 2-3 more times, always 
using the bacterial stock generated from the previous selection as the starting material for 
the next round of panning. 
 
5.3.3.3. Selection of Phage-Antibody Libraries by Panning with Biotinylated 
Antigens 
Two 100 L aliquots of Dynabeads™ M-280 Streptavidin were washed three times with 
PBS and blocked with 2% MPBS for 1h at room temperature with end-over-end mixing. 
Phages were blocked as well with 2% MPBS for 30 min at 4°C, and if competition is needed 
for the selections, a 10-fold molar excess of the non-biotinylated competitor molecule was 
added as well. After 30 min, to the blocked solution of phages 50 nM of biotinylated antigen 
were added, and left incubating with end-over-end mixing overnight at 4°C. 
The phage solution (containing the antigen) was mixed with 100 L of blocked beads and 
left incubating for 10 min with end-over-end mixing. For removal of non-specific phages, 
beads are washed 6 times with MTPBS (PBS containing 2% milk powder and 2% Tween 
20), transferred to a new 1.5 mL tube where were washed again 6 times with MTPBS, and 
transferred one more time to a new 1.5 mL tube, where they were washed twice with PBS. 
To elute the antigen bound antibody-phages, beads were resuspended in 1 mL of glycine 
pH 3 and incubated for 10 min at room temperature with end-over-end mixing. The eluted 
phages were neutralized by adding 0.5 mL of 0.1 M of Tris-HCl pH 7.4. The total volume of 
eluted phage was incubated with 10 mL of exponentially growing culture of TG-1 cells 
(OD600 0.5), for 30 min in a water bath at 37°C, with no shaking. The infected culture was 
later plated as described before in section 5.3.3.2. 
 
 
177 of 260 
5.3.4. Screening and Expression of Selected Clones 
5.3.4.1. Polyclonal Phage ELISA 
After each round of panning, an ELISA assay was performed for screening the binding of 
the eluted antibody phages to assess library enrichment.  
A 96-well ELISA plate was coated overnight at 4°C with 100 L of the antigen (HNE-
modified and non-modified antigen) at different concentrations, ranging from 0.001 to 1 
g/mL. The wells were washed three times with PBS and further blocked with 200 L of 1% 
BSA in PBS for 2 h at room temperature. Plates were washed again three times with PBS 
and incubated for 90 min with 100 L of the harvested phages (diluted 10x in 1% BSA/PBS) 
from the different generated libraries. Plates were further washed three times with PBST 
and three times with PBS and incubated for 1 h with 100 L of 0.1 g/mL HRP-labelled anti-
M13 bacteriophage antibody. TMB substrate solution (100 μL) was used for detection and 
its reaction was stopped after 15–30 min by addition of 50 μL of stopping solution (1 M HCl). 
Absorbance was read at 450 nm. 
 
5.3.4.2. Removal of Gene III from Final pSFD-L-H Vector 
The genetic material of each final library was extracted using the ZyppyTM mini-prep kit, by 
following the manufacturer’s protocol, and the DNA concentration was measured with the 
nanodrop. 
For each library, 1 g of DNA was digested with restriction enzymes EcoRI and MfeI by 
preparing a 50 L master mix containing 5 L of 10X CutSmart® Buffer, 1 L of each 
enzyme and nuclease free water. Tubes were incubated at 37°C for 1h in a thermocycler, 
and once finished the reaction, the digested products were run on a 1% agarose gel for 
purification. A band corresponding to the vector without the gene III was excised (~5000 
bp), and the DNA was purified from the gel band using the PureLink™ Quick Gel Extraction 
Kit. 
The vector was later re-ligated by setting up a 400 L ligation mix, for each vector, 
containing 2 g of digested vector, 20 L of T4 DNA ligase, 40 L of ligase buffer and 
nuclease free water, that was split up in 50 L aliquots over 8 PCR tubes. The ligation 
reaction was performed at 16°C overnight, and after a heat inactivation step of 15 minutes 
at 65°C, 0.5 L aliquots of each ligated vector were electroporated into 30 L of TG-1 cells, 
following the same conditions aforementioned. Transformed cultures were grown at 37°C 
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for 1 h with shaking (225 RPM), a fraction of the cells was collected for serial dilution and 
plating onto 2-YT/Glu/Amp plates. The plates were incubated at 37°C overnight 
 
5.3.4.3. Fab Expression and Screening 
Induction of Colony Cultures 
From the dilution plates generated in the previous step, 96 individual colonies were picked 
and grown individually into 100 L of 2-YT/Glu/Amp in a 96-well culture plate (plate 1). The 
plate was left incubating overnight at 30°C with 230 rpm shaking, and on the next day, 2 L 
of each well were transferred into a second 96-well plate (plate 2) containing 200 L of 2-
YT/Glu/Amp. Plate 2 was incubated at 37º, with 230 rpm shaking until the OD reaches 0.9 
(2-3 h). To generate glycerol stocks of all the clones, 100 L 2-YT/Glu/Amp + 50% glycerol 
were added to each well of the plate 1 and the plate was stored at - 80°C. 
To induce protein expression, IPTG was added to each well of the plate 2 to a final 
concentration of 1 mM and left incubating overnight with at 30°C with shaking. On the next 
day, the plate was centrifuged down at 1800 G for 10 min and the supernatant was 
discarded. For periplasmic expression of the antibody clones, the pellets were resuspended 
in 100 L of ice-cold lysis buffer (20% sucrose, 200 mM Tris-HCl pH 7.5, 1 mM EDTA, 500 
g/mL of lysozyme) and left shaking for 10 min at 4°C with shaking (200 rpm). Magnesium 
sulfate was added to each well to a final concentration of 5 mM and the incubation with 
shaking was continued for further 10 minutes. The plate was centrifuged at 1800 × g for 10 
min and the periplasmic supernatant was used for assessment by an ELISA assay. 
 
Monoclonal Expression ELISA 
ELISA plates were coated overnight with 100 L of antigen (HSA, HSA-HNE, or other) at 1 
g/mL and blocked with 2% MPBS for 2 h at room temperature. After three washes with 
PBS, the plates were incubated with 100 L of the periplasmic fraction (10x diluted) to each 
corresponding well, for 90 min. After another set of washes, 1 µg/ml of mouse anti-Myc 
antibody was added to the plates and incubated for more 90 min. Plates were again washed 
and a secondary anti-mouse-HRP labelled antibody was used for detection. TMB substrate 
solution (100 μL) was used for detection and its reaction was stopped after 15–30 min by 
addition of 50 μL of stopping solution (1 M HCl). Absorbance was read at 450 nm. 
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5.3.4.4. Small Scale Fab Antibody Expression 
The best responding clones observed on the monoclonal ELISA were selected for small 
scale expression. For each clone, a 5 µL aliquot of the monoclonal glycerol stock was 
inoculated into 10 mL of 2-YT/Glu/Amp and culture were grown overnight with 230 RPM 
shaking at 30°C. On the next day, an aliquot of the overnight culture was inoculated into 
100 mL 2xTY/Amp/0.1%Glu, so initial OD600=0.1, and cultures were grown during the day 
until OD600 reached 1. For induction, IPTG was added to a final concentration of 0.5 mM, 
and cultures were incubated overnight at 23°C with shaking (230 rpm). On the next day, 
expression cultures were centrifuged for 10 min at 5000 rpm and 4°C, supernatant was 
discarded, and the pellet was resuspended in 25 mL of periplasmic lysis buffer. Cultures 
were incubated in ice for 20 min with shaking until MgSO4 was added to a final concentration 
of 5 mM, and left incubating in ice for another 20 min period. Cultures centrifuged for 30 
min at 5000 rpm, and the supernatant (containing the Fab) was kept for further analysis. 
 
5.3.4.5. Fab Antibody Purification 
Expressed Fabs were purified by affinity chromatography using 1 mL of Ni-NTA agarose 
resin to each Fab. The resin was washed three times with PBS before being incubated with 
5 mL of periplasmic fraction for 1h with end-over-end mixing. The unbound fraction was 
kept for further analysis and the resin was washed three times in washing buffer (50 mM 
NaH2PO4, 300 mM NaCl, 20 mM imidazole pH 8.0). Bound fabs were eluted from the resin 
by adding 0.5 mL of elution buffer (50 mM NaH2PO4, 300 mM NaCl, 250 mM imidazole pH 
8.0), and buffer exchanged to PBS overnight by dialysis. The periplasmic, unbound and 
eluted fractions were analysed by ELISA and SDS PAGE electrophoresis. 
 
5.4. Results 
5.4.1. Construction of Sheep Fab Antibodies Libraries 
Once the RNA was extracted from the PBL and the cDNA was synthesised by reverse 
transcriptional PCR, the variable and constant lambda light (L) and heavy (H) chains were 
amplified by using the specific primers sets. An agarose gel analysis showed that the size 
of the L (Figure V.5 A) and H (Figure V.5 B) chains was ~650 bp, as expected, indicating 
that the quality of the cDNA was adequate for the following library construction. The L 
amplified fragments and the template vector were further digested with restriction enzymes 
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SfiI and XbaI, so the chain could be inserted in the pSFD vector. Figure V.5 C confirms that 
the vector was effectively digested, as seen by the presence of a band with the size of 
~5000 bp, that corresponds to the size of the digested pSFD vector and a band of ~500 bp, 
that corresponds to the size of excised stuffer fragment. 
 
Figure V.5. Agarose gel analysis of the DNA products resulting from the PCR amplification of the lambda 
chains (L1, L2, L3 and L4) (A) and the heavy chains (H1, H2, and H3) (B), and of the digested pSFD 
phagemid (C). The DNA bands corresponding to the size of 500 bp in gels depicted in A and B were excised 
and purified from the gels, and further cloned into the XbaI /SfiI digested phagemid which band (~5000 bp) was 
as well excised and purified from gel C. DNA bands corresponding to lower sizes in gels A and B, namely ~300 
bp and 50-100 bp represent mis-priming PCR products and primers, respectively. Since samples did not fit in a 
single gel lane, two or more lanes were loaded in order to purify as much DNA as possible. Red oblongs indicate 
expected band size for an antibody variable and constant chain genes. 
 
The digested vector and digested L fragments were ligated together with T4 DNA ligase 
and after purification, the ligation mix was subjected to electro-transformation with TG1 
cells, so bacteria could incorporate the vector containing the L chain (pSFD-L). The 
generated library yielded ~1.3x107 clones, from which 19 randomly picked clones were 
selected for assessment of the insertion rate of the target fragment. By using primers that 
amplify the DNA sequence between the SfiI and XbaI specific DNA sequences (i.e. the light 
chain region), the amplification of a DNA fragment of around 650 bp confirms the correction 
insertion of the light chain sequence into the vector. From the gel depicted in Figure V.6, 4 
out of 19 selected single colonies did not have the correct insert, as seen by the presence 
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Figure V.6. Agarose gel analysis of colony PCR of 19 randomly selected clones from the pSFD-L library. 
PCR reactions were performed using primers specific to the light chain region, that should amplify a fragment 
of around 650 bp if the insertion of the light chain was achieved. Colonies number 1, 7, 11 and 19 do not show 
the correct size of insert, which by extrapolation suggests that 21% of the library clones does not contain the 
light chain inserted. 
 
The pSFD-L vector was then extracted from the cells and subjected to a digestion step 
with the restriction enzymes NocI and NotI, for removal of the heavy stuffer fragment 
present in the vector and further insertion of the SA369 heavy chain sequence previously 
PCR amplified. Figure V.7 confirms again the digestion of the vector was successful, as 
seen by the presence of a band with the size of ~500 bp that corresponds to the removal 
of the H stuffer fragment. The H chain amplified fragments were as well digested with the 
same enzymes, before both digested vector and chain were ligated together with T4 DNA 
ligase.  
 
Figure V.7. Agarose gel analysis of the NotI and NocI digested pSFD vector. The bands of around 5000 
bp correspond to the digested vector, while the bands of around 500 bp correspond to the removed heavy 
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New TG1 bacterial cells were electroporated with the ligation mix for generation of the final 
Fab library, and again, randomly picked clones were selected for assessment of the 
insertion rate of the whole Fab gene segment (Figure V.8 A) and the library diversity 
(Figure V.8 B). The antibody diversity was assessed by HaeIII and BstNI fingerprinting of 
those same individual clones, as these restriction enzymes are seen to cleave in different 
sites in the antibody’s variable regions. Although DNA sequencing is always more advisable 
for confirming the diversity, DNA fingerprinting with these two restriction enzymes is very 
often a reliable method. 
For the assessment of the insertion rate of the whole Fab gene segment (~1300 bp), 
primers that bind between the SfiI and NotI and should amplify both the light and heavy 
chain sequences inserted were used. From 18 single selected clones, only 9 had the correct 
size of insert (~1300 bp) (Figure V.8 A), which suggests a 50% success rate of insertion; 
however, each of these 9 clones seemed to have a unique sequence, as the digestion 
pattern observed with both restriction enzymes was different for all of them (Figure V.8 B). 
According to the serial dilution plates generated, the final library had a total size of ~2.4x108 
clones, from which ~1.2x108 clones that have the correct Fab insert. 
 
Figure V.8. Agarose gel analysis of colony PCR of 18 randomly selected clones from the pSFD-L library 
(A) and gel analysis of the diversity of the positive clones (1, 4, 5, 7, 12, 13, 15, 16 and 17), by digestion 
with restriction enzymes HaeIII and BstNI. PCR reactions run in gel A were performed using primers specific 
to amplify the light and heavy chain fragments (~1300 bp) allowing the presence of the Fab fragment into the 
vector to be assessed. Only clones 1, 4, 5, 7, 12, 13, 15, 16 and 17 show the correct size of insert. Each of 
these positive clones was further digested separately with restriction enzyme HaeIII and BstNI, for assessment 
of DNA variability. As the digested fragments generated from these enzymatic reactions is different for all the 9 
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5.4.1.1. Selection of anti-HSA-HNE Fab Fragments 
For the selection of specific Fabs against HNE-modified HSA, there rounds of 
selection/panning (PAN) were performed and adducts were freshly generated on the day 
before each panning process. For PAN1, 2 and 3 the HNE modified HSA was adsorbed 
into immunotubes at 10, 5 and 1 g/mL, respectively. In order to deplete anti-HSA 
antibodies, after a positive selection in PAN 1 (where no competition with non-modified HSA 
was performed), PAN 2 and 3 were done alongside with HSA competition. For PAN 2, the 
competition was carried by incubating the harvested phages with the competitor 1 h after 
the phages had been incubating with HSA-HNE, i.e., competition in the end (Comp E), but 
for PAN 3, two different HSA competitions were tested: in the end (Comp E), as performed 
for PAN 2, and in the beginning (Comp B), by adding HSA at the same time as the phage 
were incubated with the HSA-HNE. Note that for both PAN 2 and 3, selection with no 
competition (N comp) was performed as well, for control. 
After three rounds of panning, an ELISA assay was performed with the pool of phages 
harvested before starting any selection (Pre-Pan phages) and after each round of panning 
(Pan1, Pan 2 N Comp, Pan 2 Comp E, Pan 3 N Comp, Pan 3 Comp B, and Pan 3 Comp 
E) for assessment of the enrichment of the library towards HSA-HNE (Figure V.9 A). 
Positive enriching against HSA-HNE can be observed in Figure V.9 A, by the increasing 
signal observed along pannings 1, 2 and 3. Before any selection, due to the high amount 
of unspecific clones, no specific binding to HSA-HNE is observed, and even after a first 
positive selection against HSA-HNE, the signal is very low. However, after PANs 2 and 3 
the binding increases suggesting a good enrichment of the library to the target antigen. 
Nevertheless, when comparing the three different eluted pools of phages from the last 
panning (PAN 3 with no competition, PAN 3 with HSA competition in the beginning and 
PAN 3 with HSA competition in the end), against different antigens, enrichment for HSA 
was also seen, which indicates the competition strategies applied were not sufficient to 
deplete all the anti-HSA clones. Phages eluted from PAN 3 Comp B and PAN 3 Comp E 
show, on average, a better specificity to HSA-HNE than HSA, than phages eluted from the 
panning without competition, which might suggest these libraries contain clones with higher 
specificity to HNE modified HSA. Furthermore, no significant binding to KLH or KLH-HNE 
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Figure V.9. Polyclonal phage ELISA binding affinity (A) and specificity (B) of the enriched libraries 
generated after three rounds of panning. In (A) pooled phages harvested before starting any selection (Pre-
Pan phages) and after each round of panning (Pan1, Pan 2 N Comp, Pan 2 Comp E, Pan 3 N Comp, Pan 3 
Comp B, and Pan 3 Comp E) were added to wells previously coated with 1 µg/mL of HSA-HNE, while in (B), 
only phages harvested after the three PAN 3 strategies were tested against three different concentrations (1, 
0.1 and 0 µg/mL) of HSA-HNE, HSA, KLH-HNE and KLH.  
 
Once the enrichment of the library was confirmed, all the three generated PAN 3 libraries 
were grown for purification of the genetic material for removal of the gene III sequence of 
the vector (Figure V.10). Since this DNA sequence is responsible for the display of Fab 
fragments on the protein pIII of the bacteriophage capsid, in order to achieve a successful 
expression of the Fab clones in bacteria, this gene had to be excised from the expression 
vector. For ease of reading, libraries generated without HSA competition, with HSA 
competition in the beginning and with HSA competition in the end were named libraries 3.1, 
3.2 and 3.3, respectively. The success of the gene III removal from the vector was evaluated 
by agarose gel analysis (Figure V.10)., from which the digested vector (band of around 
5000 bp) was purified before being ligated and transformed back again into TG1 cells. From 
each transformation performed, 96 randomly picked clones were selected for small scale 
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Figure V.10. Agarose gel analysis of the EcoRI and MfeI digestion of the pSFD vector extracted from the 
three 3rd PAN libraries. The removal of gene III can be observed by the presence of a band corresponding to 
~1500 bp that corresponds to the gene III sequence. For ease of reading, libraries generated without HSA 
competition, with HSA competition in the beginning and with HSA competition in the end were named 3.1, 3.2 
and 3.3, respectively. Red oblongs indicate the expected band size for the digested vector. 
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Table V.1. Monoclonal phage ELISA of 96 random clones selected from PAN 3 library without HSA competition (3.1), with HSA competition in the beginning (3.2) and with 
HSA competition in the end (3.3), against HSA-HNE (left side tables) and HSA (right side tables) coated plates. Numbers depicted are the absorbance values obtained at 450 
nm. The binding intensity was coloured from green to red, where green stands for low binding and red for high binding. 
 HSA-HNE   HSA 
3.1              3.1             
 1 2 3 4 5 6 7 8 9 10 11 12   1 2 3 4 5 6 7 8 9 10 11 12 
A 0.63 1.32 6.21 0.43 0.68 5.68 0.48 0.4 0.73 0.5 3.23 0.37  A 0.33 0.56 4.6 0.33 0.38 3.81 0.59 0.37 0.37 0.38 2.24 0.78 
B 0.58 0.34 0.83 0.37 0.32 0.33 1.04 0.45 0.65 0.41 2.82 0.5  B 0.29 0.39 0.5 0.34 0.31 0.41 0.7 0.41 0.38 0.42 1.67 0.55 
C 0.68 0.31 1.47 0.38 0.37 0.89 1.43 0.45 0.76 0.57 0.41 0.53  C 0.44 0.31 0.93 0.39 0.32 0.64 0.78 0.3 0.45 0.41 0.3 0.94 
D 1.33 0.94 0.92 0.35 0.39 1.76 0.64 0.77 1.05 0.68 1 0.66  D 0.69 0.6 0.89 0.29 0.31 1.06 0.71 0.4 0.48 0.33 0.76 0.84 
E 0.43 0.8 0.74 0.73 1.14 0.86 0.5 0.39 1.07 1.25 0.72 0.47  E 0.42 0.55 0.6 0.4 0.54 0.71 0.58 0.35 0.54 0.57 0.57 0.53 
F 0.39 0.67 0.62 0.75 0.33 0.53 0.59 0.46 0.38 0.38 0.6 0.38  F 0.41 0.37 0.4 0.4 0.36 0.37 0.4 0.34 0.39 0.36 0.42 0.35 
G 0.98 0.39 0.47 0.3 0.34 0.54 0.89 0.82 0.49 4.58 0.61 0.44  G 0.43 0.47 0.76 0.42 0.4 0.39 0.64 0.58 0.44 1.68 0.41 0.39 
H 0.51 0.5 0.45 0.71 0.46 0.45 0.54 0.45 0.56 0.49 0.57 1.37  H 0.31 0.47 0.98 0.55 0.43 0.37 0.36 0.33 0.41 0.36 0.44 0.6 
                           
3.2              3.2             
 1 2 3 4 5 6 7 8 9 10 11 12   1 2 3 4 5 6 7 8 9 10 11 12 
A 0.61 0.6 0.39 0.58 0.67 0.7 0.34 0.4 0.36 0.37 0.58 0.43  A 0.52 0.5 0.47 0.64 0.86 0.49 0.57 0.37 0.38 0.42 0.4 0.51 
B 0.4 0.57 0.55 0.59 1.21 0.94 0.74 0.99 0.46 0.68 0.5 0.45  B 0.43 0.53 0.51 0.58 1.32 0.71 0.71 0.61 0.43 0.54 0.43 0.47 
C 0.4 0.48 0.47 0.72 0.61 0.62 0.59 2.52 0.47 0.38 2.21 0.32  C 0.41 0.46 0.64 0.55 0.63 0.46 0.57 1.4 0.51 0.54 1.41 0.4 
D 0.76 0.47 0.67 2.61 0.59 0.63 0.64 0.93 1.02 3.88 3.54 0.6  D 0.56 0.63 0.86 1.55 0.75 0.49 0.77 0.85 0.73 3.1 2.27 0.55 
E 0.38 0.48 0.55 0.72 0.99 0.57 0.43 0.64 0.42 0.47 0.34 0.51  E 0.4 0.53 0.81 0.67 0.9 0.46 0.61 1.22 0.47 0.5 0.54 0.52 
F 0.4 0.62 0.39 0.46 0.41 0.86 0.48 0.53 0.46 0.48 0.34 0.44  F 0.42 0.48 0.48 0.47 0.43 0.6 0.52 0.43 0.4 0.54 0.4 0.45 
G 0.43 0.5 0.76 0.6 0.71 0.62 0.52 0.47 0.55 0.39 0.48 0.39  G 0.38 0.51 0.67 0.47 0.57 0.6 0.54 0.68 0.42 0.5 0.55 0.51 
H 0.41 0.51 0.6 0.43 0.46 0.35 0.37 0.6 0.58 0.34 0.42 3.23  H 0.42 0.56 0.5 0.36 0.4 0.39 0.42 0.63 0.37 0.41 0.45 0.52 
                           
3.3              3.3             
 1 2 3 4 5 6 7 8 9 10 11 12   1 2 3 4 5 6 7 8 9 10 11 12 
A 0.38 0.3 0.41 0.31 0.51 0.3 0.35 0.45 0.31 0.51 0.37 0.3  A 0.38 0.33 0.44 0.36 0.49 0.44 0.36 1.15 0.43 0.4 0.41 0.36 
B 0.39 0.3 0.3 0.36 0.3 3.17 0.49 0.44 0.33 0.4 0.33 0.35  B 0.38 0.36 0.36 0.36 0.43 1.37 0.53 0.37 0.36 0.38 0.32 0.36 
C 0.88 0.46 0.54 0.59 0.42 1 0.36 0.38 0.53 0.37 0.4 0.84  C 0.7 0.38 0.43 0.48 0.45 0.59 0.31 0.38 0.51 0.53 0.43 0.86 
D 0.3 0.41 0.56 0.55 1.09 0.37 0.91 0.29 0.29 0.44 0.31 0.34  D 0.39 0.36 0.48 0.41 1.16 0.34 0.58 0.34 0.56 0.35 0.31 0.42 
E 0.47 0.82 0.28 0.38 0.34 0.45 0.3 0.53 0.25 0.36 0.41 0.36  E 0.47 0.57 0.3 0.31 0.3 0.33 0.32 0.42 0.38 0.34 0.4 0.37 
F 0.5 0.46 0.28 0.3 0.43 0.42 0.28 1.39 0.28 0.37 0.81 0.32  F 0.43 0.37 0.33 0.32 0.36 0.68 0.29 0.92 0.3 0.3 0.64 0.41 
G 0.3 0.31 0.49 0.44 0.29 0.36 0.38 1.33 0.3 0.37 0.63 0.59  G 0.35 0.38 0.59 0.41 0.38 0.88 0.35 0.73 0.33 0.32 1.08 0.7 
H 0.41 0.31 0.35 0.44 0.31 0.29 0.32 0.36 0.37 0.35 0.47 0.57  H 0.37 0.36 0.34 0.37 0.4 0.33 0.3 0.31 0.37 0.32 0.41 0.71 
187 of 260 
The data in Table V.1 indicates the affinity of 96 individual clones randomly selected from 
libraries 3.1, 3.2 and 3.3 (a total of 288 different clones) towards HNE modified HSA and 
native HSA. The presence of clones with higher binding to HSA-HNE than to HSA, such as 
clones A3, A5 and A11 from library 3.1 might indicate Fab antibody fragments with higher 
affinity towards the HNE adducts. Therefore, potentially anti-HNE-specific clones (i.e. abs 
values higher than 2) were selected for further expression, but some clones that showed 
high binding to non-modified HSA were selected as well, as negative controls. 
The selected clones for expression and assessment of diversity were the following: clones 
A3, A5, A11, B11, C3, C12, D1, D6, G1, G10 and H12 from library 3.1, clones B5, B6, C1, 
C8, C11, D4, D10, D11, E8, F6 and H11 from library 3.2 and clones A8, B6, C1, C6, C12, 
D5, D7, F8, G8 and G11 from library 3.3. 
All the clones mentioned above were individually subjected to a colony PCR using primers 
specific to amplify the whole Fab sequence (~1300 bp), for size assessment of the inserted 
Fab fragment (Figure V.11 A) and to a digestion step with BstNI and HaeIII restriction 
enzymes for diversity evaluation (Figure V.11 B and C). 
 
Figure V.11. Gel analysis of colony PCR of 32 clones presenting higher affinities to HNE-modified HSA 
and native HSA (A) and their respective diversity analysis by digestion with HaeIII (B) and BstNI (C) 
restriction enzymes. PCR reactions run in gel A were performed using primers specific to amplify the light and 
heavy chain fragments (~1300 bp) allowing the presence of the Fab fragment into the vector to be assessed. 
Red arrows indicate clones with different digestion patterns, suggesting, therefore, different nucleotide 
sequence.  
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As seen in Figure V.11 A all the selected clones contain the correct size of vector (~1300 
bp), but from Figure V.11 B and C only clone D4 from library 3.2 and clone C12 from library 
3.3 seem to present a different DNA digestion pattern from all the other 30 clones, which 
suggests that from a pool of 30 clones, there are only 3 different Fab clones. 
To double check the results of the monoclonal phage ELISA, clones G10, A3, A6, D11, H12 
and B6 were chosen for large scale expression and purification (Figure V.12), but the gel 
only shows the presence of a single band around ~25 kDa, rather than a double band, which 
suggests that only the heavy chain was successfully expressed and purified.  
 
Figure V.12. SDS-PAGE analysis of the periplasmic, unbound and eluted collected fractions during the 
purification of clones G10, A3, A6, D11, H12 and B6, numbered 1 to 6, respectively. Samples were run on 
a NuPAGE 12% Bis-Tris protein gel. 
 
Nevertheless, the binding of clone G10 towards HSA, HSA-HNE, OVA and OVA-HNE was 
assessed by ELISA, using the commercial anti-HNE pAb as a positive control (Figure V.13). 
The results show the absence of binding of clone G10 to any of the proteins, while the 
commercial pAb binds to HNE-modified HSA and OVA. 
 
Figure V.13. Binding analysis of Fab G10 clone to HSA and HSA-HNE (A), and OVA and OVA-HNE (B) by 
direct ELISA. The Abcam anti-HNE pAb was used as positive control. This experiment was done once (n=1) 
with technical triplicates. 
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5.4.1.2. Selection of Fab fragments against biotinylated HSA-HNE 
As no Fab antibody fragments specific to HSA-HNE adducts were obtained by panning the 
Fab generated library with HSA-HNE coated immunotubes, a different strategy involving 
magnetic streptavidin beads and biotinylated HSA-HNE was tested. 
HSA was firstly biotinylated using a commercial kit and then aliquots of 1 mg/ mL were 
freshly modified by HNE before each round of panning. Figure V.14 shows the commercial 
anti-HNE pAb recognition of HNE adducts equally on both non-biotinylated and biotinylated 
HSA-HNE, confirming the present of biotin did not affect the formation of HNE adducts. 
 
 
Figure V.14. Direct ELISA assay using the commercial anti-HNE pAb for confirmation of HNE adducts 
on biotinylated HSA-HNE samples. Biotinylated and non-biotinylated HSA and HSA-HNE were immobilised 
on a 96-well plate at a concentration range of 0-5 µg/mL and the detection was performed with the Abcam 
commercial anti-HNE pAb at 1 µg/mL. This experiment was done once (n=1) with technical triplicates. 
 
 
After a positive selection in PAN 1, with no competition, PAN 2 and 3 were carried out with 
HSA competition by adding HSA at the same time as the phages were incubated with 
biotinylated HSA-HNE. After three rounds of panning, the enrichment of libraries was 
evaluated by a polyclonal phage ELISA (Figure V.15), where a positive enrichment against 
both HSA-HNE and HSA can be observed. The binding of the polyclonal phages to HNE 
modified HSA seems to be stronger than to HSA. 
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Figure V.15. Polyclonal phage ELISA analysis of the library enrichment after three rounds of panning 
against biotinylated-HSA-HNE. The plate was coated with HSA-HNE and HSA ate concentrations ranging 
from 0-10 g/mL). This experiment was done once (n=1) with technical duplicates. 
 
The library generated from the 3rd PAN was grown overnight for purification of its genetic 
material; gene III was removed from the vector and, after its ligation, the vector was 
transformed into grown TG1 cells. A monoclonal phage ELISA was then conducted by 
selecting 96 random clones to assess their binding to HSA (Table V.2 A) and HSA-HNE 
(Table V.2 B). 
 
Table V.2. Binding assessment of 96 random clones picked from the 3rd PAN by monoclonal phage 
ELISA against HSA (A) and HSA-HNE (B). Numbers depicted are the absorbance values obtained at 450 nm. 




1 2 3 4 5 6 7 8 9 10 11 12 
A 2.257 1.148 0.547 0.533 0.549 0.39 0.369 0.357 0.382 0.199 0.337 0.429 
B 0.847 1.333 0.49 0.624 0.403 0.326 0.455 0.343 0.408 0.28 0.36 0.341 
C 0.875 0.485 0.437 0.439 0.418 0.378 0.55 0.363 0.507 0.295 0.349 0.583 
D 1.095 1.137 0.497 0.432 0.439 0.369 0.395 0.354 0.602 0.37 0.521 0.226 
E 5.067 0.781 0.466 0.412 0.496 0.4 0.492 0.36 0.41 0.384 0.375 0.376 
F 1.079 0.829 0.491 0.474 0.415 0.422 0.418 0.364 0.441 0.411 0.362 0.94 
G 1.16 1.044 0.735 0.527 0.439 0.421 0.371 0.494 0.47 0.499 0.44 0.417 
H 1.187 1.575 0.599 0.236 0.644 0.381 0.572 0.461 0.458 0.51 0.467 0.432 
             
B 
HSA-HNE 
1 2 3 4 5 6 7 8 9 10 11 12 
A 2.929 1.32 1.298 1.09 1.135 1.011 0.614 0.729 0.79 0.218 0.642 0.717 
B 1.266 1.506 1.216 1.228 0.984 0.808 0.884 0.74 0.764 0.69 0.864 0.547 
C 1.261 0.654 1.015 0.846 0.841 0.812 1.295 0.785 1.022 0.725 0.702 1.302 
D 1.515 1.384 0.994 1.016 1.077 0.856 0.868 0.75 1.012 0.703 0.692 0.235 
E 4.12 0.982 1.172 0.953 1.055 0.735 1.242 0.608 0.669 0.748 0.591 0.554 
F 1.152 1.067 1.026 1.189 0.86 0.76 0.919 0.806 0.832 0.759 0.625 1.922 
G 1.062 1.052 1.017 0.294 0.428 0.877 0.384 1.117 0.742 0.731 0.662 0.628 
H 1.62 1.922 1.01 0.224 1.194 0.334 1.053 0.933 0.75 0.779 0.801 0.625 
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Given the obtained results clones E1, A1, H2, H1, B2, F12, C12, E7, C7, A3, B3 and F4 
were selected for colony PCR (Figure V.16 A). and diversity assessment (Figure V.16 B 
and C).  Once again, all the selected clones present the correct size of vector (~1500 kb), 
but they all seem to be the same clone as their digestion pattern obtained with HaeIII and 
BstNI is the same. 
 
Figure V.16. Agarose gel analysis of colony PCR of the 12 best responding clones (A) and their 
respective digestion with restriction enzymes HaeIII (B) and BstNI (C). PCR reactions run in gel A were 
performed using primers specific to amplify the whole light and heavy chain DNA fragment (~1300 bp) allowing 
the presence of the Fab fragment into the vector to be assessed.  
 
Clone E1 and A1 were selected for large scale production and purification by affinity 
chromatography using a nickel resin (Figure V.17). Purification of Fab E1 did not work as 
expected, as no band is seen in the elution fraction, but the presence of a double band in 
the eluted fraction of Fab A1 (Figure V.17 B) suggests the clone was expressed and 
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Figure V.17. SDS-PAGE analysis of the periplasmic, flow through and eluted fractions of clones E1 and 
A1 from their affinity purification. The samples were run under non-reducing (A) and reducing conditions (B). 
 
Clone A1 was then analysed by ELISA for binding assessment towards HSA, HSA-HNE, 
OVA and OVA-HNE, however the clone did not show binding to any of the antigens (Figure 
V.18). 
 
 A            B 
 
 
Figure V.18. ELISA analysis comparing the binding of Fab A1 and commercial anti-HNE antibody to 
HSA, HSA-HNE, OVA and OVA-HNE. In graph A the antigen was coated in a range of concentrations from 0-
5 g/mL and both the Fab A1 and the anti-HNE pAb were incubated at a concentration of 1 g/mL. In graph B, 
the concentration of the antigens was fixed at 1 g/mL while the Fab A1 and the commercial anti-HNE pAb were 
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4.4.2. Construction of Sheep scFv Antibody Libraries 
Given the fact that any of the Fab clones expressed previously showed any binding to HSA 
or HSA-HNE, a new library was generated for production of a different format of antibody 
fragment, single chain Fv (scFv) fragments. ScFv fragments, as seen in Figure V.1, are 
actually fusion proteins of the variable regions of the heavy and light chains of 
immunoglobulins, connected with a short linker peptide, and therefore, the cloning process 
only requires one insertion step, rather that the two used before for Fabs. 
All the primers used for synthesis of the first-strand cDNA, amplification of heavy and light-
chain variable-regions and cloning primers with SfiI and NotI restriction sites are given in 
Appendix 14. 
Again, once the first strand of cDNA was synthesized, the variable regions of the heavy (H) 
and lambda light (L) chains were amplified by using the specific primer sets. This time, 
because only the variable region is being amplified, PCR products or ~350 bb are expected. 
As shown in  
Figure V.19, the chains have a size of ~350 kb, as expected, confirming the quality of the 
cDNA was suitable for further construction of the library. 
 
 
Figure V.19. Agarose gel analysis of the PCR amplified heavy (H1, H2, H3 and H4) chains (A) and lambda 
light (L1, L2, L3 and L4) chains (B). An extra lambda light chain using primer set L5 was as well PCR amplified 
and gel purified, however the gel is not included in this figure. DNA bands of ~ 350 bp correspond to the amplified 
heavy (A) and light (B) chain variable regions, while DNA bands corresponding to lower sizes represent mis-
priming PCR products or primers. Since samples did not fit in a single gel lane, two lanes were loaded with each 
PCR product in order to purify as much DNA as possible. Red oblongs indicate the expected band size for the 
antibody variable heavy and light chain genes. 
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After purifying both variable heavy (VH) and lambda light (V) chains from the agarose gel, 
both VH and VL chains were digested separately with AscI and MluI restriction enzymes, so 
they could be further ligated to each other with T4 DNA ligase to generate the VH-V 
segment. The successful ligation of both chains was confirmed by running the ligation 
products on a agarose gel (Figure V.20), where a fragment of ~700 kb can be observed. 
 
Figure V.20. Agarose gel analysis of the ligated VH-V fragment (band of ~700 kb) (A) and of its PCR 
amplification product (B).  
 
The VH-V ligated fragment and the pSFD vector were further subjected to a digestion with 
NcoI and NotI restriction enzyme before being ligated with T4 DNA ligase. After purification 
of the ligation product, the vector was transformed into TG-1 cells and the final scFv library 
was generated.  
To assess the insertion rate of the VH-V fragment into the vector, 10 randomly picked 
clones were subjected to a colony PCR using primers specific to the scFV fragment, and 
the genomic content was analysed on a agarose gel (Figure V.21). All the 17 clones 
contained the correct size of fragment (~700 bp), i.e., a 100% rate of insertion was achieved. 
The size of the scFv library obtained was >108 clones. 
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Figure V.21. Agarose gel analysis of colony PCR of 17 randomly selected clones from the scFv library. 
 
4.4.2.1. Selection of anti-HSA-HNE and anti-OVA-HNE scFv Antibody 
Fragments 
The selection of scFv antibody fragments against HNE adducts was done against HNE-
modified HSA and HNE-modified OVA, separately, through the use of immunotubes. As for 
previous panning methods, HNE adducts were prepared freshly on the day the 
immunotubes were coated and for PAN1, 2 and 3 the immunotubes were coated with 10, 5 
and 1 g/mL of each HNE-modified antigen. Regarding the panning process with HSA-
HNE, the first round of panning was done with no competition, for positive selection, and 
two remaining Pans were done by adding HSA in 5-molar excess. The three OVA-HNE 
pannings were done with no competition.  
The enrichment of the libraries against HSA-HNE and OVA-HNE was again assessed by 
ELISA, by testing the different eluted pooled antibody-phage fractions against HSA, HSA-
HNE, OVA and OVA-HNE. Regarding the selection against HSA-HNE (Figure V.22 A), the 
antibody-phages eluted after PAN 1 seem to show higher specificity to HSA, however, when 
started to compete with non-modified HSA on the second PAN, that specificity is lost after 
PAN 2 (green bar). After PAN 3, where a more stringent competition was performed, 
specificity to HSA but as well to HSA-HNE and OVA-HNE is observed, which may suggest 
an enrichment of antibody-phages specific to HNE-modified molecules was achieved. 
Regarding the selection against OVA-HNE, enrichment towards OVA-HNE and HSA-HNE 
is only noticed after the third round of panning (Figure V.22 B), with a quite a big difference 
in the signal between the two modified standards. However, as seen in Figure V.22 C, also 
for the control antibody a considerable difference is observed between HSA-HNE and OVA-
HNE, which indicates the ovalbumin standard used for the assay contains more HNE 
modifications than HSA. Hence, the pooled fraction of antibody-phages collected after PAN 
3 may contain promising clones specific to HNE. 
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Figure V.22. Polyclonal ELISA assay depicting the enrichment of the scFv library performed against 
HSA-HNE (A) and OVA-HNE (B) after three rounds of selective biopanning. All the pooled phages collected 
before (Pre-PAN) and after panning (PAN 1, PAN 2 and PAN 3) were tested on 96-well plates coated with HSA, 
HSA-HNE, OVA and OVA-HNE at 1 µg/mL. As a control, the assay was as well performed with Abcam anti-
HNE pAb at 0.5 µg/mL (C). The assay was performed once (n=1) with technical triplicates. 
 
5.5. Chapter V Discussion, Conclusions and Future Work 
In the work described in this chapter, two different antibody fragment libraries were 
generated for the first time against HNE lipoxidation adducts, by using RNA extracted from 
B cells of a sheep immunized with HNE-treated HSA. For the construction of both Fab and 
scFV libraries, the VH and VL genes were amplified using sheep specific primers previously 
designed by Professor Keith Charlton’s group, and both the genes were cloned, according 
to the specific antibody format, into a bicistronic phagemid vector pSFD, as well designed 
by the same group. One of the most important features of this vector is the presence of the 
replication origins for both bacteria and bacteriophages, that allows the vector to be 
replicated in both bacteria and phage particles. Furthermore, this vector does also contain 
a DNA sequence encoding for the protein pIII, which is one of the five capsid proteins of a 
phage particle, to which an antibody can be expressed. 
For the construction of the Fab vector, the insertion of heavy and light genes was done 
separately, in two steps, by generating first a large library with the vector containing just the 
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CLVL gene sequences, and later by inserting the heavy chain genes and generating the 
complete and final CLVL - CHVH library. The light chain gene was inserted first into the vector, 
in order to obtain the greatest diversity possible, as sheep IgG possess higher diversity in 
VL loci (Berry & Popkov, 2015). The light chain insertion rate obtained was 79%, which is 
reasonable high; however, when inserting the heavy chain genes for generating the full Fab 
library, only 50% of the selected the clones appeared to have both the VLCL and VHCH genes 
in their genomic DNA. Therefore, from the final library of 2.4x108 clones, only 1.2 x108 
clones contained the complete Fab sequence, while the other 1.2 x108 clones were just 
background clones containing only the light chain fragment. This low insertion rate might 
be explained by the low efficiency of the restrictions enzymes used for the insertion of the 
genes, as in presence of salts and organic solvents, these enzymes might not reach their 
maximum activity or be led to cleave in non-specific sites. The DNA purification/washing 
protocols preformed before each restriction reaction were optimised to remove as much as 
possible of all the impurities from the PCR reactions; however, it is never easy to guarantee 
100% removal. This limitation of the protocol could, however, be overcome in the future by 
the application of more modern cloning strategies, such as the so-called “seamless” cloning 
procedures. Both Gibson (Gibson et al., 2009) and Golden Gate (Engler, Kandzia, & 
Marillonnet, 2008) assembly methods, came to revolutionise the old school molecular 
engineering methods by allowing sequence-independent and scarless insertion of more 
than one fragment of DNA into a plasmid vector, at once. Therefore, the heavy and light 
gene sequences of an antibody could be inserted in a single step without the use of the 
traditional restriction enzymes, which would not only improve the insertion rate but also 
diminish the work load, time and resources spent in the generation of both light and 
light+heavy chain libraries. These seamless strategies were, not applied in this work mainly 
due to the non-compatibility of the available primers and also the lack of time for optimizing 
a new cloning system. However, companies like Antibody Design LaboratoriesTM are 
already employing these methods.  
Although there is no work published regarding the generation of sheep Fab libraries to which 
we could compare our work with, methodologies for displaying Fab antibody fragments on 
the surface of phages using human, rabbit and mouse libraries have already been reported 
(Andris-Widhopf et al., 2011; Nelson & Valadon, 2017; Shen et al., 2007; Thu, Nguyen, Lee, 
& Shim, 2018). The use of sheep for development of mAbs is not so common within the 
academic community, as treatment and lodgement of these animals is considerably more 
complex and expensive than when using smaller animals, like mice. Consequently, a 
significantly larger amount of research has been done for the development and optimization 
of cloning and expression methods to be used in small/domestic animals rather than in 
sheep or goat. On the other hand, companies usually resort to bigger animals from which a 
larger serum volume can be collected, because they rely on polyclonal sera for the 
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development of their products; moreover, companies often patent their investigative work 
than publish it. A good example of a successful Fab library is the one used to select anti-
HIV-1 mAbs from human, that had a diversity of 1x107 clones, from which one of the most 
potent HIV-1 neutralising mAbs, the b12, was achieved (Zwick et al., 2003). In this work, 
unfortunately, the selection of specific anti-HSA-HNE Fabs was not as successful. In the 
first antibody panning strategy, where HSA-HNE was used as target, and competition with 
HSA was performed, phage enrichment after three rounds of panning was observed but the 
different clones selected for small-scale expression ended up by not presenting much DNA 
diversity nor specificity towards HSA or HSA-HNE. In fact, clone G10 was later fully 
expressed and by SDS-PAGE was found to be a single chain molecule, revealing that the 
formation of the disulphide bridges between the heavy and light chains was not 
accomplished. It is not clear why the expression of the Fab was not successfully 
accomplished, but folding problems in E. coli have been reported before (Levy, Weiss, 
Chen, Iverson, & Georgiou, 2001). The second selection approach performed for 
biopanning the library was based on the use of biotinylated HSA-HNE and magnetic 
streptavidin beads, which is a strategy typically applied to maximize the number of epitopes 
in the target antigen, as the antigens are freely in solution and do not suffer type of 
conformational changes (Teixeira & Gonzalez-Pajuelo, 2018). However, after three rounds 
of panning, the diversity gel from different colonies showed no sequence diversity and the 
expressed clones showed no specific binding towards HNE-modified proteins. The fact that 
both selection approaches failed to provide clones specific even to the carrier protein (HSA) 
suggests that the vast presence of background phages carrying the wrong size of insert did 
affect the selection of an anti-HNE specific clone. 
Regarding the scFv library, its construction followed the protocol described by Palliyil et al 
(Palliyil, 2018), which relies on the cloning of the VH and V domains, linked together with a 
15 amino acid peptide linker, into a slightly different version of the pSFD vector used 
previously for the generation of the Fab library (the vector map is depicted in Appendix 15). 
To the date, only Whitelam et al (1999) and Charlton et al (2001) reported the generation 
of sheep scFv libraries, with sizes of 4.23 x106 and 2.8 x 107 clones, respectively (K. 
Charlton, Harris, & Porter, 2001; Y. Li, Kilpatrick, & Whitelam, 2000), but the construction 
of scFv antibody libraries from other animals had been described before by the pioneers 
McCafferty et al. (1990), Barbas et al., (1991) and Clackson et al. (1991) (Barbas et al., 
1991; Clackson, Hoogenboom, Griffiths, & WInter, 1991; McCafferty et al., 1990). However, 
no one has ever attempted the construction of antibody libraries for lipoxidised proteins, 
which makes this work a novelty. The herein described anti HSA-HNE scFv library 
presented a considerable large size (>108 clones) with all the clones, from a sample of 18 
clones, expressing the expected size of insert, which was a great success. 
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The biopanning with immobilized HSA-HNE yielded a significant enrichment towards HSA, 
HSA-HNE and slightly to OVA-HNE after three rounds panning, but the biopanning with 
immobilized OVA-HNE seemed very promising, as the pooled phages only bound to HNE-
modified proteins. When comparing the signals obtained for both HSA-HNE and OVA-HNE, 
there seems to be a greater affinity towards OVA-HNE; however, the number of HNE 
modifications on OVA was seen to be considerably higher than in HSA, which might justify 
the large difference. Due to time constrains, no further work was done with the enriched 
scFv library, but the positive enrichment achieved indicates promising clones could be 
present in the library.  
One of the main bottlenecks of this work was, without any doubt, the extremely time-
consuming biopanning protocol. When using immunotubes, for a full 3-round panning 
protocol, a minimum of 3-4 weeks is necessary to confirm the enrichment of the libraries, 
which limited the number of different panning strategies applied. In order to circumvent this 
issue, it would be interesting for the future to scale down the protocol and try panning the 
libraries on 96-microwell plates, where different concentration of antigens and different 
types of washes can be tested at the same time.  
Despite the fact that no specific anti-HNE clones were found, the construction of Fab and 
scFv libraries is a novelty in the lipid oxidation field, opening the doors for the possibility of 
developing monoclonal antibody fragments specific to such lipid-protein adducts by phage 
display. However, the small molecular weight of the lipid oxidation products together with 
the instability of the adducts makes this work extremely challenging, as biopanning involves 
the selection of single clones out of millions of phage-displaying antibodies, by 
immobilisation of the adducts to a surface for several hours. Furthermore, depletion of 
antibodies specific to the native protein requires pre-incubation of the phages with 
competing antigens, which is very time consuming. Nonetheless, exploitation of new 
biopanning strategies could be valuable for the implementation of phage display technology 
in the development of high affinity antibodies to lipoxidation adducts.  
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6.1. Discussion  
The consequence of the reactivity of certain lipid peroxidation products towards specific 
groups of proteins has received particular attention in 1976, when Esterbauer reports lipid 
peroxidation products such as 4-hydroxynonenal, acrolein and crotonaldehyde to bind to 
thiol groups of cysteine residues (H. Esterbauer, Ertl, & Scholz, 1976). At the time, it was 
known that lipid peroxidation yielded a variety of reactive carbonyl species, but the 
terminology of “lipoxidation products” only emerged years later, in 1996, when Requena et 
al suggested clustering this name for this type of protein-lipid adducts (Requena et al., 
1996). Since then, several homologous families of reactive lipid peroxidation products have 
been identified and their mechanisms of reaction with proteins studied (Kumano-Kuramochi 
et al., 2012; Requena et al., 1996; Uchida, 2015; Vistoli et al., 2013), but their relationship 
with the development of chronic pathologies still remains a subject of considerable interest. 
Lipoxidation adducts have been found in neurodegenerative and inflammatory diseases, 
such as Alzheimer’s disease, Parkinson’s disease, atherosclerosis, ischemia reperfusion 
injury (Domingues et al., 2013; Jung, Kang, Lee, & Kim, 2018; McLeod & Sevanian, 1997; 
Sakamoto, Tsuyoshi Ohnishi, Ohnishi, & Ogawa, 1991), type 2 diabetes mellitus (Inouye, 
Mio, & Sumino, 1999; Jakus et al., 2000; Lyons & Jenkins, 1997), cancer (Guéraud, 2017; 
Martín-Sierra et al., 2019; Zhong & Yin, 2015) and cardiovascular diseases (Chavez, Wu, 
Bisson, & Maier, 2011; Gianazza, Brioschi, Fernandez, & Banfi, 2019; Wu & Stevens, Jan 
F.; Maier, 2011), which makes these products highly relevant as biomarkers for the 
diagnosis of oxidative stress related pathologies. HSA-HNE adducts, in particular, are of 
very great interest as a blood biomarker of oxidative stress, due to the abundance of HSA 
in blood. Therefore, the work described in this thesis was focussed on the generation of 
novel anti-HSA-HNE specific antibodies and characterisation of their epitopes. The aim was 
to build an in-depth understanding of the neo-antigens that result from HSA lipoxidation by 
HNE, and to reveal the way that the antibodies recognise these epitopes as the foundation 
on which to translate this important biomarker into the centre-piece of a rapid lipoxidation-
based oxidative stress diagnostic test. 
By high-resolution tandem MS, eleven HNE modifications were identified in vitro on HNE 
treated HSA standards, suggesting these adducts could, in fact, be used for immunising 
animals and generating specific polyclonal sera. Moreover, the chemical synthesis of HSA 
peptide sequences containing key nucleophilic amino acid residues and their treatment with 
HNE confirmed the reactivity of this aldehyde towards multiple amino acids. This also 
opened the possibility of generating polyclonal antibodies towards specific HNE adducts by 
using these synthetic HNE-modified sequences as synthetic immunogens. Analysis by 
MALDI-TOF MS, direct infusion ESI-MS and immunoassays performed with a commercial 
anti-HNE pAb also reinforced the results by confirming the formation of HNE adducts on 
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intact HNE-modified HSA. The data seem to also be in agreement with previous studies in 
which tandem MS approaches were applied to probe the location of HNE adducts on HSA 
(Aldini et al., 2006; Q. Liu et al., 2012). 
The immunogenicity of different HNE-adducted structures was evaluated by immunisation 
of different animals, and the resulting antisera were characterised by ELISA. KLH 
conjugated HSA peptide 31LQQC(HNE)PFE37, containing the only free cysteine of HSA, did 
not yield any specific antibodies to the HNE structure, either in rabbits or sheep; however, 
from the immunisation of four sheep with intact HNE-modified HSA, antibodies capable of 
recognising HNE adducts on different molecules were found. Polyclonal antibodies of 
interest were partially purified and enriched from remaining antibodies of sheep sera using 
different affinity chromatography strategies and, after characterisation, were further tested 
for ELISA applications. However, in order to develop a rapid diagnostic assay with sufficient 
sensitivity and specificity for application to complex samples, extensive work is required not 
only in the development of antibodies, but also in the selection of a good antibody pair. 
Although several anti-HNE antibodies already exist commercially, both polyclonal and 
monoclonal, most of them were raised against HNE treated proteins and purified by affinity 
chromatography using different HNE modified proteins, which yields antibodies specific to 
general HNE adducts rather than specific to a single type of adduct or even a specific type 
of peptide/protein adduct. Moreover, the development and optimisation of a novel 
immunoassay requires large amounts of antibody, and therefore it is not practically or 
economically feasible to rely solely on commercial antibodies. 
Since both Michael and Schiff’s base adducts are reversible, reduced and non-reduced 
HSA-HNE adducts were used to immunise in four different sheep to assess the effect of 
their stability in the triggering of adaptive immune system. Curiously, the only sheep whose 
immune system responded to HSA-HNE adducts was sheep SA369 which was immunised 
with non-reduced adducts. No direct correlation could be made between the 
reduction/stabilisation of adducts and the recognition by B cells, yet the results obtained 
regarding sheep SA369 showed that non-reduced adducts appeared to be sufficiently 
stable to stimulate the production of antibodies capable of recognising the HNE moiety of 
the adducts. These antibodies, however, were shown to be cross-reactive to non-modified 
HSA, as the larger protein molecular weight also provides numerous molecular structures 
which can act as immunogenic epitopes for triggering a wide range of antibodies. To 
circumvent the cross-reactivity and in order to achieve a higher specific pool of polyclonal 
antibodies, immunisations with KLH conjugated 31LQQC(HNE)PFE37 peptide were tested 
as well, but without any success. Since KLH is not found in mammals and is extremely large 
it is commonly used as an immune stimulant; however, due to the short length of the peptide 
and even smaller size of the HNE aldehyde on it, the response to KLH possibly ended up 
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by diverting the immune response toward its own more immunodominant epitopes, rather 
than the relatively non provocative adducts. However, over the course of the three 
immunisations, a small increment in the immune response to HNE modifications was 
observed, which could suggest more immunisations and time were needed to obtain a 
sufficient response. However, studies in the literature where synthetic peptides were used 
in the immunisation of rabbits have shown that 2 to 3 boosts are usually enough to get a 
substantial production of specific antibodies (Christodoulides, McGuinness, & Heckels, 
1993; Ideno et al., 2013). A third immunisation strategy with HNE-treated KLH was tried 
(data not shown) but again the immune response towards HNE was very low, whereas very 
high to KLH, supporting the theory that steric hindrance effects might have occurred due to 
the small molecular weight of HNE compared to the size of KLH protein. 
Different affinity chromatography strategies were applied in order to deplete anti-HSA 
clones from the SA369 pool of antibodies, but cross-reactivity persisted. Epitope 
characterisation studies with HSA peptide arrays showed that the enriched SA369 anti-HNE 
pAbs, were still recognising backbone sequences of the native protein, while also binding 
to the HNE moiety of the adducts, which suggested that the cross-reactivity towards non-
modified HSA was inherent to the antibodies and could not be eliminated by downstream 
processing techniques. It is probable that the epitopes consisted of the adduct as well as 
some of the neighbouring polypeptide backbone. 
Hence, in attempt to eliminate the cross-reactivity observed with the pAbs and work with 
antibodies that are unique to HSA-HNE and/or HNE, monoclonal antibody fragments were 
generated, through the construction of Fab and scFV libraries, using RNA extracted from B 
cells from sheep SA369. Although the Fab library contained a large number of clones (107), 
it was found that only 50% of the clones were carrying the correct size of the insert, which 
made further enrichment of the library towards HNE-modified antigens very difficult. None 
of the expressed Fabs was shown to be specific to HNE or HSA, which implied that the 
library carried too many background clones preventing the selection of the (relatively rare) 
correct ones. The scFv library constructed, on the other hand, was shown to be of a very 
large size (108), as all the clones in it (from a random selection of 17 clones) were found to 
be carrying the correct size of fragment. However, there was not enough time to proceed 
with the expression of scFV clones. Even so, the panning strategies looked promising, 
suggesting that phage display technology could be successfully applied for the 
development of lipoxidation-specific antibodies, something that has not previously been 
attempted. For commercial application, phage display is possibly one of the major 
approaches employed in the discovery of specific antibodies, stated to be used for 
enrichment and identification of antibodies with high affinity and specificity from immunised 
libraries (Bruin, Spelt, Mol, Koes, & Quattrocchio, 1999).  
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Notwithstanding that limitation, the in-house enriched SA369 pAb was deployed in a lateral 
flow assay, together with a commercial anti-HNE pAb – as an LFA always requires one 
antibody for capture and another one for detection – for the detection of HNE adducts on 
different proteins. Although not tested with biological samples, the assay was capable of 
detecting HNE adducts on in vitro HNE treated solutions of HSA, KLH and OVA, with a 
sensitivity as low as 1.50 g/mL, and shown to be capable of displaying different test line 
intensities for different HNE:protein molar ratios. 
For many years, scientists have used the “gold standard methods” of HPLC and GC-MS for 
studying lipid peroxidation products, but one of the biggest challenges in oxidative research 
has always been the development of accurate and non-invasive methods for the in vivo 
evaluation of redox status. A rapid multiplex test in which several different lipoxidation 
biomarkers are detected within a few minutes, by simple application of a single drop of 
blood, would not only be valuable to guide clinical therapeutics but also in the monitoring of 
the effectiveness of therapies. In patients with obstructive sleep apnoea, for instance, 
where hypoxic events were seen to initiate oxidative stress and the formation of lipid 
peroxidation products has been confirmed, the monitoring of the formation of different 
lipoxidation products might be extremely valuable to prevent exacerbated cell damage, and 
consequently, diminish the rate of cardiovascular diseases events and hypertension (Lavie, 
2003).  
The small size of lipid oxidation products is what makes their detection so challenging, 
especially when regarding the generation of antibodies. Haptens (molecular weight below 
1000 Da) are considered to be invisible to the host immune system unless presented 
conjugated to carrier proteins, which made the generation of antibodies specific to HNE 
adducts on HSA (without cross-reacting to the native protein) very challenging. Khan et al 
reported the development of anti-HSA-HNE antibodies by HSA-HNE immunising rabbits, 
yet, the group states the antibodies were simply purified from the animal sera by using a 
protein A agarose column, which is just specific to the whole IgG fraction of antibodies 
(Khan et al., 2016) and not specifically to the anti-immunogen injected. 
Immunisation of less frequently used animals such as camelids (llamas, alpacas, 
dromedaries) or shark, in which immune system only produces heavy-chain antibodies 
present a possible alternative approach for development of high quality antibodies, as the 
VH domains from these animals can (depending on the antigen) present higher affinity and, 
as a general rule these structures have a good thermostability, good solubility and ease of 
being genetically engineered (Arbabi-Ghahroudi, 2017). Genetic studies on camelid heavy 
chain antibodies reported that antibody diversification in these animals relies on gene 
recombination mechanisms that involve a larger number of unique VH gene segments 
recombining with DH and JH genes and possibly with additional non-templated nucleotide 
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insertions leading to longer CDR3 loops (Deschacht et al., 2010). Moreover, involvement of 
FR2 residues in the antigen binding and in structuring the CD3 loop were reported 
(Klarenbeek et al., 2015), suggesting the VH paratopes in these animals acquire more 
structural complexity, possibly to compensate the lack of VL domains. 
Regarding the prototype LFA, per se, in the future it should be refined and tested with 
biological matrices, such as whole blood or sera, in order to evaluate the behaviour of the 
assay the presence of such complex biological matrices. The enhancement of the 
colorimetric response of the strips would probably be required for quantification purposes, 
which could be achieved by exploring new strategies, such as the inclusion of other 
materials in the nitrocellulose membrane. A recent study reported the use of nanofibers in 
the test line can boost the sensitivity of the assay by 40% (Quesada-González et al., 2019).  
In conclusion, the studies described in this thesis have helped understanding how 
lipoxidation adducts act as oxidation-specific epitopes to trigger the immune system to 
generate antibodies, as exemplified by the generation and characterization of the novel anti-
HSA-HNE polyclonal antibodies. The work has also helped in opening the doors to the 
point-of-care diagnostic market to the oxidative stress/lipoxidation field of research, by 
demonstrating that antibodies specific to lipid oxidation products, or even to lipoxidation 
adducts, (as is the case of the SA369 in-house antibody), can be functional in lateral flow 
assays. Further research on the nature of the neo-antigen epitopes is likely to reveal 
complex and informative epitopes that provide information not only about the fact that 
lipoxidation occurred, but also about which proteins or regions of proteins were subject to 
lipoxidation. A better understanding of how lipoxidation epitopes influence the anti-
inflammatory responses and act in the maintenance of redox homeostasis is still very much 
needed.  
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Appendix 1. Nomenclature of reactive species (Halliwell & Gutteridge, 2015). 
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Appendix 3. Usage report for synthesis of peptide MOL 664 141EIARRHPYFYAPEL154 generated by 
Liberty Pepdriver Software.  
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Appendix 4. Usage report for synthesis of peptide MOL 665 198LKCASLQK205generated by Liberty 
Pepdriver Software. 
 
229 of 260 
Appendix 5. List of the human serum albumin (UniProt ID: P02768) peptides synthesized on the arrays. 














































A1 Blank B26 G-E-M-A-D-C-C-A-K-Q-E-P-E-R-N 
A2 M-K-W-V-T-F-I-S-L-L-F-L-F-S-S B27 M-A-D-C-C-A-K-Q-E-P-E-R-N-E-C 
A3 W-V-T-F-I-S-L-L-F-L-F-S-S-A-Y B28 D-C-C-A-K-Q-E-P-E-R-N-E-C-F-L 
A4 T-F-I-S-L-L-F-L-F-S-S-A-Y-S-R B29 C-A-K-Q-E-P-E-R-N-E-C-F-L-Q-H 
A5 I-S-L-L-F-L-F-S-S-A-Y-S-R-G-V B30 K-Q-E-P-E-R-N-E-C-F-L-Q-H-K-D 
A6 L-L-F-L-F-S-S-A-Y-S-R-G-V-F-R C1 E-P-E-R-N-E-C-F-L-Q-H-K-D-D-N 
A7 F-L-F-S-S-A-Y-S-R-G-V-F-R-R-D C2 E-R-N-E-C-F-L-Q-H-K-D-D-N-P-N 
A8 F-S-S-A-Y-S-R-G-V-F-R-R-D-A-H C3 N-E-C-F-L-Q-H-K-D-D-N-P-N-L-P 
A9 S-A-Y-S-R-G-V-F-R-R-D-A-H-K-S C4 C-F-L-Q-H-K-D-D-N-P-N-L-P-R-L 
A10 Y-S-R-G-V-F-R-R-D-A-H-K-S-E-V C5 L-Q-H-K-D-D-N-P-N-L-P-R-L-V-R 
A11 R-G-V-F-R-R-D-A-H-K-S-E-V-A-H C6 H-K-D-D-N-P-N-L-P-R-L-V-R-P-E 
A12 V-F-R-R-D-A-H-K-S-E-V-A-H-R-F C7 D-D-N-P-N-L-P-R-L-V-R-P-E-V-D 
A13 R-R-D-A-H-K-S-E-V-A-H-R-F-K-D C8 N-P-N-L-P-R-L-V-R-P-E-V-D-V-M 
A14 D-A-H-K-S-E-V-A-H-R-F-K-D-L-G C9 N-L-P-R-L-V-R-P-E-V-D-V-M-C-T 
A15 H-K-S-E-V-A-H-R-F-K-D-L-G-E-E C10 P-R-L-V-R-P-E-V-D-V-M-C-T-A-F 
A16 S-E-V-A-H-R-F-K-D-L-G-E-E-N-F C11 L-V-R-P-E-V-D-V-M-C-T-A-F-H-D 
A17 V-A-H-R-F-K-D-L-G-E-E-N-F-K-A C12 R-P-E-V-D-V-M-C-T-A-F-H-D-N-E 
A18 H-R-F-K-D-L-G-E-E-N-F-K-A-L-V C13 E-V-D-V-M-C-T-A-F-H-D-N-E-E-T 
A19 F-K-D-L-G-E-E-N-F-K-A-L-V-L-I C14 D-V-M-C-T-A-F-H-D-N-E-E-T-F-L 
A20 D-L-G-E-E-N-F-K-A-L-V-L-I-A-F C15 M-C-T-A-F-H-D-N-E-E-T-F-L-K-K 
A21 G-E-E-N-F-K-A-L-V-L-I-A-F-A-Q C16 T-A-F-H-D-N-E-E-T-F-L-K-K-Y-L 
A22 E-N-F-K-A-L-V-L-I-A-F-A-Q-Y-L C17 F-H-D-N-E-E-T-F-L-K-K-Y-L-Y-E 
A23 F-K-A-L-V-L-I-A-F-A-Q-Y-L-Q-Q C18 D-N-E-E-T-F-L-K-K-Y-L-Y-E-I-A 
A24 A-L-V-L-I-A-F-A-Q-Y-L-Q-Q-C-P C19 E-E-T-F-L-K-K-Y-L-Y-E-I-A-R-R 
A25 V-L-I-A-F-A-Q-Y-L-Q-Q-C-P-F-E C20 T-F-L-K-K-Y-L-Y-E-I-A-R-R-H-P 
A26 I-A-F-A-Q-Y-L-Q-Q-C-P-F-E-D-H C21 L-K-K-Y-L-Y-E-I-A-R-R-H-P-Y-F 
A27 F-A-Q-Y-L-Q-Q-C-P-F-E-D-H-V-K C22 K-Y-L-Y-E-I-A-R-R-H-P-Y-F-Y-A 
A28 Q-Y-L-Q-Q-C-P-F-E-D-H-V-K-L-V C23 L-Y-E-I-A-R-R-H-P-Y-F-Y-A-P-E 
A29 L-Q-Q-C-P-F-E-D-H-V-K-L-V-N-E C24 E-I-A-R-R-H-P-Y-F-Y-A-P-E-L-L 
A30 Q-C-P-F-E-D-H-V-K-L-V-N-E-V-T C25 A-R-R-H-P-Y-F-Y-A-P-E-L-L-F-F 
B1 P-F-E-D-H-V-K-L-V-N-E-V-T-E-F C26 R-H-P-Y-F-Y-A-P-E-L-L-F-F-A-K 
B2 E-D-H-V-K-L-V-N-E-V-T-E-F-A-K C27 P-Y-F-Y-A-P-E-L-L-F-F-A-K-R-Y 
B3 H-V-K-L-V-N-E-V-T-E-F-A-K-T-C C28 F-Y-A-P-E-L-L-F-F-A-K-R-Y-K-A 
B4 K-L-V-N-E-V-T-E-F-A-K-T-C-V-A C29 A-P-E-L-L-F-F-A-K-R-Y-K-A-A-F 
B5 V-N-E-V-T-E-F-A-K-T-C-V-A-D-E C30 E-L-L-F-F-A-K-R-Y-K-A-A-F-T-E 
B6 E-V-T-E-F-A-K-T-C-V-A-D-E-S-A D1 L-F-F-A-K-R-Y-K-A-A-F-T-E-C-C 
B7 T-E-F-A-K-T-C-V-A-D-E-S-A-E-N D2 F-A-K-R-Y-K-A-A-F-T-E-C-C-Q-A 
B8 F-A-K-T-C-V-A-D-E-S-A-E-N-C-D D3 K-R-Y-K-A-A-F-T-E-C-C-Q-A-A-D 
B9 K-T-C-V-A-D-E-S-A-E-N-C-D-K-S D4 Y-K-A-A-F-T-E-C-C-Q-A-A-D-K-A 
B10 C-V-A-D-E-S-A-E-N-C-D-K-S-L-H D5 A-A-F-T-E-C-C-Q-A-A-D-K-A-A-C 
B11 A-D-E-S-A-E-N-C-D-K-S-L-H-T-L D6 F-T-E-C-C-Q-A-A-D-K-A-A-C-L-L 
B12 E-S-A-E-N-C-D-K-S-L-H-T-L-F-G D7 E-C-C-Q-A-A-D-K-A-A-C-L-L-P-K 
B13 A-E-N-C-D-K-S-L-H-T-L-F-G-D-K D8 C-Q-A-A-D-K-A-A-C-L-L-P-K-L-D 
B14 N-C-D-K-S-L-H-T-L-F-G-D-K-L-C D9 A-A-D-K-A-A-C-L-L-P-K-L-D-E-L 
B15 D-K-S-L-H-T-L-F-G-D-K-L-C-T-V D10 D-K-A-A-C-L-L-P-K-L-D-E-L-R-D 
B16 S-L-H-T-L-F-G-D-K-L-C-T-V-A-T D11 A-A-C-L-L-P-K-L-D-E-L-R-D-E-G 
B17 H-T-L-F-G-D-K-L-C-T-V-A-T-L-R D12 C-L-L-P-K-L-D-E-L-R-D-E-G-K-A 
B18 L-F-G-D-K-L-C-T-V-A-T-L-R-E-T D13 L-P-K-L-D-E-L-R-D-E-G-K-A-S-S 
B19 G-D-K-L-C-T-V-A-T-L-R-E-T-Y-G D14 K-L-D-E-L-R-D-E-G-K-A-S-S-A-K 
B20 K-L-C-T-V-A-T-L-R-E-T-Y-G-E-M D15 D-E-L-R-D-E-G-K-A-S-S-A-K-Q-R 
B21 C-T-V-A-T-L-R-E-T-Y-G-E-M-A-D D16 L-R-D-E-G-K-A-S-S-A-K-Q-R-L-K 
B22 V-A-T-L-R-E-T-Y-G-E-M-A-D-C-C D17 D-E-G-K-A-S-S-A-K-Q-R-L-K-C-A 
B23 T-L-R-E-T-Y-G-E-M-A-D-C-C-A-K D18 G-K-A-S-S-A-K-Q-R-L-K-C-A-S-L 
B24 R-E-T-Y-G-E-M-A-D-C-C-A-K-Q-E D19 A-S-S-A-K-Q-R-L-K-C-A-S-L-Q-K 
B25 T-Y-G-E-M-A-D-C-C-A-K-Q-E-P-E D20 S-A-K-Q-R-L-K-C-A-S-L-Q-K-F-G 














































D21 K-Q-R-L-K-C-A-S-L-Q-K-F-G-E-R F16 L-A-A-D-F-V-E-S-K-D-V-C-K-N-Y 
D22 R-L-K-C-A-S-L-Q-K-F-G-E-R-A-F F17 A-D-F-V-E-S-K-D-V-C-K-N-Y-A-E 
D23 K-C-A-S-L-Q-K-F-G-E-R-A-F-K-A F18 F-V-E-S-K-D-V-C-K-N-Y-A-E-A-K 
D24 A-S-L-Q-K-F-G-E-R-A-F-K-A-W-A F19 E-S-K-D-V-C-K-N-Y-A-E-A-K-D-V 
D25 L-Q-K-F-G-E-R-A-F-K-A-W-A-V-A F20 K-D-V-C-K-N-Y-A-E-A-K-D-V-F-L 
D26 K-F-G-E-R-A-F-K-A-W-A-V-A-R-L F21 V-C-K-N-Y-A-E-A-K-D-V-F-L-G-M 
D27 G-E-R-A-F-K-A-W-A-V-A-R-L-S-Q F22 K-N-Y-A-E-A-K-D-V-F-L-G-M-F-L 
D28 R-A-F-K-A-W-A-V-A-R-L-S-Q-R-F F23 Y-A-E-A-K-D-V-F-L-G-M-F-L-Y-E 
D29 F-K-A-W-A-V-A-R-L-S-Q-R-F-P-K F24 E-A-K-D-V-F-L-G-M-F-L-Y-E-Y-A 
D30 A-W-A-V-A-R-L-S-Q-R-F-P-K-A-E F25 K-D-V-F-L-G-M-F-L-Y-E-Y-A-R-R 
E1 A-V-A-R-L-S-Q-R-F-P-K-A-E-F-A F26 V-F-L-G-M-F-L-Y-E-Y-A-R-R-H-P 
E2 A-R-L-S-Q-R-F-P-K-A-E-F-A-E-V F27 L-G-M-F-L-Y-E-Y-A-R-R-H-P-D-Y 
E3 L-S-Q-R-F-P-K-A-E-F-A-E-V-S-K F28 M-F-L-Y-E-Y-A-R-R-H-P-D-Y-S-V 
E4 Q-R-F-P-K-A-E-F-A-E-V-S-K-L-V F29 L-Y-E-Y-A-R-R-H-P-D-Y-S-V-V-L 
E5 F-P-K-A-E-F-A-E-V-S-K-L-V-T-D F30 E-Y-A-R-R-H-P-D-Y-S-V-V-L-L-L 
E6 K-A-E-F-A-E-V-S-K-L-V-T-D-L-T G1 A-R-R-H-P-D-Y-S-V-V-L-L-L-R-L 
E7 E-F-A-E-V-S-K-L-V-T-D-L-T-K-V G2 R-H-P-D-Y-S-V-V-L-L-L-R-L-A-K 
E8 A-E-V-S-K-L-V-T-D-L-T-K-V-H-T G3 P-D-Y-S-V-V-L-L-L-R-L-A-K-T-Y 
E9 V-S-K-L-V-T-D-L-T-K-V-H-T-E-C G4 Y-S-V-V-L-L-L-R-L-A-K-T-Y-E-T 
E10 K-L-V-T-D-L-T-K-V-H-T-E-C-C-H G5 V-V-L-L-L-R-L-A-K-T-Y-E-T-T-L 
E11 V-T-D-L-T-K-V-H-T-E-C-C-H-G-D G6 L-L-L-R-L-A-K-T-Y-E-T-T-L-E-K 
E12 D-L-T-K-V-H-T-E-C-C-H-G-D-L-L G7 L-R-L-A-K-T-Y-E-T-T-L-E-K-C-C 
E13 T-K-V-H-T-E-C-C-H-G-D-L-L-E-C G8 L-A-K-T-Y-E-T-T-L-E-K-C-C-A-A 
E14 V-H-T-E-C-C-H-G-D-L-L-E-C-A-D G9 K-T-Y-E-T-T-L-E-K-C-C-A-A-A-D 
E15 T-E-C-C-H-G-D-L-L-E-C-A-D-D-R G10 Y-E-T-T-L-E-K-C-C-A-A-A-D-P-H 
E16 C-C-H-G-D-L-L-E-C-A-D-D-R-A-D G11 T-T-L-E-K-C-C-A-A-A-D-P-H-E-C 
E17 H-G-D-L-L-E-C-A-D-D-R-A-D-L-A G12 L-E-K-C-C-A-A-A-D-P-H-E-C-Y-A 
E18 D-L-L-E-C-A-D-D-R-A-D-L-A-K-Y G13 K-C-C-A-A-A-D-P-H-E-C-Y-A-K-V 
E19 L-E-C-A-D-D-R-A-D-L-A-K-Y-I-C G14 C-A-A-A-D-P-H-E-C-Y-A-K-V-F-D 
E20 C-A-D-D-R-A-D-L-A-K-Y-I-C-E-N G15 A-A-D-P-H-E-C-Y-A-K-V-F-D-E-F 
E21 D-D-R-A-D-L-A-K-Y-I-C-E-N-Q-D G16 D-P-H-E-C-Y-A-K-V-F-D-E-F-K-P 
E22 R-A-D-L-A-K-Y-I-C-E-N-Q-D-S-I G17 H-E-C-Y-A-K-V-F-D-E-F-K-P-L-V 
E23 D-L-A-K-Y-I-C-E-N-Q-D-S-I-S-S G18 C-Y-A-K-V-F-D-E-F-K-P-L-V-E-E 
E24 A-K-Y-I-C-E-N-Q-D-S-I-S-S-K-L G19 A-K-V-F-D-E-F-K-P-L-V-E-E-P-Q 
E25 Y-I-C-E-N-Q-D-S-I-S-S-K-L-K-E G20 V-F-D-E-F-K-P-L-V-E-E-P-Q-N-L 
E26 C-E-N-Q-D-S-I-S-S-K-L-K-E-C-C G21 D-E-F-K-P-L-V-E-E-P-Q-N-L-I-K 
E27 N-Q-D-S-I-S-S-K-L-K-E-C-C-E-K G22 F-K-P-L-V-E-E-P-Q-N-L-I-K-Q-N 
E28 D-S-I-S-S-K-L-K-E-C-C-E-K-P-L G23 P-L-V-E-E-P-Q-N-L-I-K-Q-N-C-E 
E29 I-S-S-K-L-K-E-C-C-E-K-P-L-L-E G24 V-E-E-P-Q-N-L-I-K-Q-N-C-E-L-F 
E30 S-K-L-K-E-C-C-E-K-P-L-L-E-K-S G25 E-P-Q-N-L-I-K-Q-N-C-E-L-F-E-Q 
F1 L-K-E-C-C-E-K-P-L-L-E-K-S-H-C G26 Q-N-L-I-K-Q-N-C-E-L-F-E-Q-L-G 
F2 E-C-C-E-K-P-L-L-E-K-S-H-C-I-A G27 L-I-K-Q-N-C-E-L-F-E-Q-L-G-E-Y 
F3 C-E-K-P-L-L-E-K-S-H-C-I-A-E-V G28 K-Q-N-C-E-L-F-E-Q-L-G-E-Y-K-F 
F4 K-P-L-L-E-K-S-H-C-I-A-E-V-E-N G29 N-C-E-L-F-E-Q-L-G-E-Y-K-F-Q-N 
F5 L-L-E-K-S-H-C-I-A-E-V-E-N-D-E G30 E-L-F-E-Q-L-G-E-Y-K-F-Q-N-A-L 
F6 E-K-S-H-C-I-A-E-V-E-N-D-E-M-P H1 F-E-Q-L-G-E-Y-K-F-Q-N-A-L-L-V 
F7 S-H-C-I-A-E-V-E-N-D-E-M-P-A-D H2 Q-L-G-E-Y-K-F-Q-N-A-L-L-V-R-Y 
F8 C-I-A-E-V-E-N-D-E-M-P-A-D-L-P H3 G-E-Y-K-F-Q-N-A-L-L-V-R-Y-T-K 
F9 A-E-V-E-N-D-E-M-P-A-D-L-P-S-L H4 Y-K-F-Q-N-A-L-L-V-R-Y-T-K-K-V 
F10 V-E-N-D-E-M-P-A-D-L-P-S-L-A-A H5 F-Q-N-A-L-L-V-R-Y-T-K-K-V-P-Q 
F11 N-D-E-M-P-A-D-L-P-S-L-A-A-D-F H6 N-A-L-L-V-R-Y-T-K-K-V-P-Q-V-S 
F12 E-M-P-A-D-L-P-S-L-A-A-D-F-V-E H7 L-L-V-R-Y-T-K-K-V-P-Q-V-S-T-P 
F13 P-A-D-L-P-S-L-A-A-D-F-V-E-S-K H8 V-R-Y-T-K-K-V-P-Q-V-S-T-P-T-L 
F14 D-L-P-S-L-A-A-D-F-V-E-S-K-D-V H9 Y-T-K-K-V-P-Q-V-S-T-P-T-L-V-E 







H11 V-P-Q-V-S-T-P-T-L-V-E-V-S-R-N J6 K-Q-T-A-L-V-E-L-V-K-H-K-P-K-A 
H12 Q-V-S-T-P-T-L-V-E-V-S-R-N-L-G J7 T-A-L-V-E-L-V-K-H-K-P-K-A-T-K 
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H13 S-T-P-T-L-V-E-V-S-R-N-L-G-K-V J8 L-V-E-L-V-K-H-K-P-K-A-T-K-E-Q 
H14 P-T-L-V-E-V-S-R-N-L-G-K-V-G-S J9 E-L-V-K-H-K-P-K-A-T-K-E-Q-L-K 
H15 L-V-E-V-S-R-N-L-G-K-V-G-S-K-C J10 V-K-H-K-P-K-A-T-K-E-Q-L-K-A-V 
H16 E-V-S-R-N-L-G-K-V-G-S-K-C-C-K J11 H-K-P-K-A-T-K-E-Q-L-K-A-V-M-D 
H17 S-R-N-L-G-K-V-G-S-K-C-C-K-H-P J12 P-K-A-T-K-E-Q-L-K-A-V-M-D-D-F 
H18 N-L-G-K-V-G-S-K-C-C-K-H-P-E-A J13 A-T-K-E-Q-L-K-A-V-M-D-D-F-A-A 
H19 G-K-V-G-S-K-C-C-K-H-P-E-A-K-R J14 K-E-Q-L-K-A-V-M-D-D-F-A-A-F-V 
H20 V-G-S-K-C-C-K-H-P-E-A-K-R-M-P J15 Q-L-K-A-V-M-D-D-F-A-A-F-V-E-K 
H21 S-K-C-C-K-H-P-E-A-K-R-M-P-C-A J16 K-A-V-M-D-D-F-A-A-F-V-E-K-C-C 
H22 C-C-K-H-P-E-A-K-R-M-P-C-A-E-D J17 V-M-D-D-F-A-A-F-V-E-K-C-C-K-A 
H23 K-H-P-E-A-K-R-M-P-C-A-E-D-Y-L J18 D-D-F-A-A-F-V-E-K-C-C-K-A-D-D 
H24 P-E-A-K-R-M-P-C-A-E-D-Y-L-S-V J19 F-A-A-F-V-E-K-C-C-K-A-D-D-K-E 
H25 A-K-R-M-P-C-A-E-D-Y-L-S-V-V-L J20 A-F-V-E-K-C-C-K-A-D-D-K-E-T-C 
H26 R-M-P-C-A-E-D-Y-L-S-V-V-L-N-Q J21 V-E-K-C-C-K-A-D-D-K-E-T-C-F-A 
H27 P-C-A-E-D-Y-L-S-V-V-L-N-Q-L-C J22 K-C-C-K-A-D-D-K-E-T-C-F-A-E-E 
H28 A-E-D-Y-L-S-V-V-L-N-Q-L-C-V-L J23 C-K-A-D-D-K-E-T-C-F-A-E-E-G-K 
H29 D-Y-L-S-V-V-L-N-Q-L-C-V-L-H-E J24 A-D-D-K-E-T-C-F-A-E-E-G-K-K-L 
H30 L-S-V-V-L-N-Q-L-C-V-L-H-E-K-T J25 D-K-E-T-C-F-A-E-E-G-K-K-L-V-A 
I1 V-V-L-N-Q-L-C-V-L-H-E-K-T-P-V J26 E-T-C-F-A-E-E-G-K-K-L-V-A-A-S 
I2 L-N-Q-L-C-V-L-H-E-K-T-P-V-S-D J27 C-F-A-E-E-G-K-K-L-V-A-A-S-Q-A 
I3 Q-L-C-V-L-H-E-K-T-P-V-S-D-R-V J28 A-E-E-G-K-K-L-V-A-A-S-Q-A-A-L 
I4 C-V-L-H-E-K-T-P-V-S-D-R-V-T-K J29 E-G-K-K-L-V-A-A-S-Q-A-A-L-G-L 
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A1 Blank B26 E-E-R-Y-P-I-L-P-E-Y-L-Q-C-V-K 
A2 M-G-S-I-G-A-A-S-M-E-F-C-F-D-V B27 R-Y-P-I-L-P-E-Y-L-Q-C-V-K-E-L 
A3 S-I-G-A-A-S-M-E-F-C-F-D-V-F-K B28 P-I-L-P-E-Y-L-Q-C-V-K-E-L-Y-R 
A4 G-A-A-S-M-E-F-C-F-D-V-F-K-E-L B29 L-P-E-Y-L-Q-C-V-K-E-L-Y-R-G-G 
A5 A-S-M-E-F-C-F-D-V-F-K-E-L-K-V B30 E-Y-L-Q-C-V-K-E-L-Y-R-G-G-L-E 
A6 M-E-F-C-F-D-V-F-K-E-L-K-V-H-H C1 L-Q-C-V-K-E-L-Y-R-G-G-L-E-P-I 
A7 F-C-F-D-V-F-K-E-L-K-V-H-H-A-N C2 C-V-K-E-L-Y-R-G-G-L-E-P-I-N-F 
A8 F-D-V-F-K-E-L-K-V-H-H-A-N-E-N C3 K-E-L-Y-R-G-G-L-E-P-I-N-F-Q-T 
A9 V-F-K-E-L-K-V-H-H-A-N-E-N-I-F C4 L-Y-R-G-G-L-E-P-I-N-F-Q-T-A-A 
A10 K-E-L-K-V-H-H-A-N-E-N-I-F-Y-C C5 R-G-G-L-E-P-I-N-F-Q-T-A-A-D-Q 
A11 L-K-V-H-H-A-N-E-N-I-F-Y-C-P-I C6 G-L-E-P-I-N-F-Q-T-A-A-D-Q-A-R 
A12 V-H-H-A-N-E-N-I-F-Y-C-P-I-A-I C7 E-P-I-N-F-Q-T-A-A-D-Q-A-R-E-L 
A13 H-A-N-E-N-I-F-Y-C-P-I-A-I-M-S C8 I-N-F-Q-T-A-A-D-Q-A-R-E-L-I-N 
A14 N-E-N-I-F-Y-C-P-I-A-I-M-S-A-L C9 F-Q-T-A-A-D-Q-A-R-E-L-I-N-S-W 
A15 N-I-F-Y-C-P-I-A-I-M-S-A-L-A-M C10 T-A-A-D-Q-A-R-E-L-I-N-S-W-V-E 
A16 F-Y-C-P-I-A-I-M-S-A-L-A-M-V-Y C11 A-D-Q-A-R-E-L-I-N-S-W-V-E-S-Q 
A17 C-P-I-A-I-M-S-A-L-A-M-V-Y-L-G C12 Q-A-R-E-L-I-N-S-W-V-E-S-Q-T-N 
A18 I-A-I-M-S-A-L-A-M-V-Y-L-G-A-K C13 R-E-L-I-N-S-W-V-E-S-Q-T-N-G-I 
A19 I-M-S-A-L-A-M-V-Y-L-G-A-K-D-S C14 L-I-N-S-W-V-E-S-Q-T-N-G-I-I-R 
A20 S-A-L-A-M-V-Y-L-G-A-K-D-S-T-R C15 N-S-W-V-E-S-Q-T-N-G-I-I-R-N-V 
A21 L-A-M-V-Y-L-G-A-K-D-S-T-R-T-Q C16 W-V-E-S-Q-T-N-G-I-I-R-N-V-L-Q 
A22 M-V-Y-L-G-A-K-D-S-T-R-T-Q-I-N C17 E-S-Q-T-N-G-I-I-R-N-V-L-Q-P-S 
A23 Y-L-G-A-K-D-S-T-R-T-Q-I-N-K-V C18 Q-T-N-G-I-I-R-N-V-L-Q-P-S-S-V 
A24 G-A-K-D-S-T-R-T-Q-I-N-K-V-V-R C19 N-G-I-I-R-N-V-L-Q-P-S-S-V-D-S 
A25 K-D-S-T-R-T-Q-I-N-K-V-V-R-F-D C20 I-I-R-N-V-L-Q-P-S-S-V-D-S-Q-T 
A26 S-T-R-T-Q-I-N-K-V-V-R-F-D-K-L C21 R-N-V-L-Q-P-S-S-V-D-S-Q-T-A-M 
A27 R-T-Q-I-N-K-V-V-R-F-D-K-L-P-G C22 V-L-Q-P-S-S-V-D-S-Q-T-A-M-V-L 
A28 Q-I-N-K-V-V-R-F-D-K-L-P-G-F-G C23 Q-P-S-S-V-D-S-Q-T-A-M-V-L-V-N 
A29 N-K-V-V-R-F-D-K-L-P-G-F-G-D-S C24 S-S-V-D-S-Q-T-A-M-V-L-V-N-A-I 
A30 V-V-R-F-D-K-L-P-G-F-G-D-S-I-E C25 V-D-S-Q-T-A-M-V-L-V-N-A-I-V-F 
B1 R-F-D-K-L-P-G-F-G-D-S-I-E-A-Q C26 S-Q-T-A-M-V-L-V-N-A-I-V-F-K-G 
B2 D-K-L-P-G-F-G-D-S-I-E-A-Q-C-G C27 T-A-M-V-L-V-N-A-I-V-F-K-G-L-W 
B3 L-P-G-F-G-D-S-I-E-A-Q-C-G-T-S C28 M-V-L-V-N-A-I-V-F-K-G-L-W-E-K 
B4 G-F-G-D-S-I-E-A-Q-C-G-T-S-V-N C29 L-V-N-A-I-V-F-K-G-L-W-E-K-A-F 
B5 G-D-S-I-E-A-Q-C-G-T-S-V-N-V-H C30 N-A-I-V-F-K-G-L-W-E-K-A-F-K-D 
B6 S-I-E-A-Q-C-G-T-S-V-N-V-H-S-S D1 I-V-F-K-G-L-W-E-K-A-F-K-D-E-D 
B7 E-A-Q-C-G-T-S-V-N-V-H-S-S-L-R D2 F-K-G-L-W-E-K-A-F-K-D-E-D-T-Q 
B8 Q-C-G-T-S-V-N-V-H-S-S-L-R-D-I D3 G-L-W-E-K-A-F-K-D-E-D-T-Q-A-M 
B9 G-T-S-V-N-V-H-S-S-L-R-D-I-L-N D4 W-E-K-A-F-K-D-E-D-T-Q-A-M-P-F 
B10 S-V-N-V-H-S-S-L-R-D-I-L-N-Q-I D5 K-A-F-K-D-E-D-T-Q-A-M-P-F-R-V 
B11 N-V-H-S-S-L-R-D-I-L-N-Q-I-T-K D6 F-K-D-E-D-T-Q-A-M-P-F-R-V-T-E 
B12 H-S-S-L-R-D-I-L-N-Q-I-T-K-P-N D7 D-E-D-T-Q-A-M-P-F-R-V-T-E-Q-E 
B13 S-L-R-D-I-L-N-Q-I-T-K-P-N-D-V D8 D-T-Q-A-M-P-F-R-V-T-E-Q-E-S-K 
B14 R-D-I-L-N-Q-I-T-K-P-N-D-V-Y-S D9 Q-A-M-P-F-R-V-T-E-Q-E-S-K-P-V 
B15 I-L-N-Q-I-T-K-P-N-D-V-Y-S-F-S D10 M-P-F-R-V-T-E-Q-E-S-K-P-V-Q-M 
B16 N-Q-I-T-K-P-N-D-V-Y-S-F-S-L-A D11 F-R-V-T-E-Q-E-S-K-P-V-Q-M-M-Y 
B17 I-T-K-P-N-D-V-Y-S-F-S-L-A-S-R D12 V-T-E-Q-E-S-K-P-V-Q-M-M-Y-Q-I 
B18 K-P-N-D-V-Y-S-F-S-L-A-S-R-L-Y D13 E-Q-E-S-K-P-V-Q-M-M-Y-Q-I-G-L 
B19 N-D-V-Y-S-F-S-L-A-S-R-L-Y-A-E D14 E-S-K-P-V-Q-M-M-Y-Q-I-G-L-F-R 
B20 V-Y-S-F-S-L-A-S-R-L-Y-A-E-E-R D15 K-P-V-Q-M-M-Y-Q-I-G-L-F-R-V-A 
B21 S-F-S-L-A-S-R-L-Y-A-E-E-R-Y-P D16 V-Q-M-M-Y-Q-I-G-L-F-R-V-A-S-M 
B22 S-L-A-S-R-L-Y-A-E-E-R-Y-P-I-L D17 M-M-Y-Q-I-G-L-F-R-V-A-S-M-A-S 
B23 A-S-R-L-Y-A-E-E-R-Y-P-I-L-P-E D18 Y-Q-I-G-L-F-R-V-A-S-M-A-S-E-K 
B24 R-L-Y-A-E-E-R-Y-P-I-L-P-E-Y-L D19 I-G-L-F-R-V-A-S-M-A-S-E-K-M-K 
B25 Y-A-E-E-R-Y-P-I-L-P-E-Y-L-Q-C D20 L-F-R-V-A-S-M-A-S-E-K-M-K-I-L 







D21 R-V-A-S-M-A-S-E-K-M-K-I-L-E-L F16 H-A-A-H-A-E-I-N-E-A-G-R-E-V-V 
D22 A-S-M-A-S-E-K-M-K-I-L-E-L-P-F F17 A-H-A-E-I-N-E-A-G-R-E-V-V-G-S 
D23 M-A-S-E-K-M-K-I-L-E-L-P-F-A-S F18 A-E-I-N-E-A-G-R-E-V-V-G-S-A-E 
D24 S-E-K-M-K-I-L-E-L-P-F-A-S-G-T F19 I-N-E-A-G-R-E-V-V-G-S-A-E-A-G 
D25 K-M-K-I-L-E-L-P-F-A-S-G-T-M-S F20 E-A-G-R-E-V-V-G-S-A-E-A-G-V-D 
D26 K-I-L-E-L-P-F-A-S-G-T-M-S-M-L F21 G-R-E-V-V-G-S-A-E-A-G-V-D-A-A 
D27 L-E-L-P-F-A-S-G-T-M-S-M-L-V-L F22 E-V-V-G-S-A-E-A-G-V-D-A-A-S-V 
D28 L-P-F-A-S-G-T-M-S-M-L-V-L-L-P F23 V-G-S-A-E-A-G-V-D-A-A-S-V-S-E 
D29 F-A-S-G-T-M-S-M-L-V-L-L-P-D-E F24 S-A-E-A-G-V-D-A-A-S-V-S-E-E-F 
D30 S-G-T-M-S-M-L-V-L-L-P-D-E-V-S F25 E-A-G-V-D-A-A-S-V-S-E-E-F-R-A 
E1 T-M-S-M-L-V-L-L-P-D-E-V-S-G-L F26 G-V-D-A-A-S-V-S-E-E-F-R-A-D-H 
E2 S-M-L-V-L-L-P-D-E-V-S-G-L-E-Q F27 D-A-A-S-V-S-E-E-F-R-A-D-H-P-F 
E3 L-V-L-L-P-D-E-V-S-G-L-E-Q-L-E F28 A-S-V-S-E-E-F-R-A-D-H-P-F-L-F 
E4 L-L-P-D-E-V-S-G-L-E-Q-L-E-S-I F29 V-S-E-E-F-R-A-D-H-P-F-L-F-C-I 
E5 P-D-E-V-S-G-L-E-Q-L-E-S-I-I-N F30 E-E-F-R-A-D-H-P-F-L-F-C-I-K-H 
E6 E-V-S-G-L-E-Q-L-E-S-I-I-N-F-E G1 F-R-A-D-H-P-F-L-F-C-I-K-H-I-A 
E7 S-G-L-E-Q-L-E-S-I-I-N-F-E-K-L G2 A-D-H-P-F-L-F-C-I-K-H-I-A-T-N 
E8 L-E-Q-L-E-S-I-I-N-F-E-K-L-T-E G3 H-P-F-L-F-C-I-K-H-I-A-T-N-A-V 
E9 Q-L-E-S-I-I-N-F-E-K-L-T-E-W-T G4 F-L-F-C-I-K-H-I-A-T-N-A-V-L-F 
E10 E-S-I-I-N-F-E-K-L-T-E-W-T-S-S G5 F-C-I-K-H-I-A-T-N-A-V-L-F-F-G 
E11 I-I-N-F-E-K-L-T-E-W-T-S-S-N-V G6 I-K-H-I-A-T-N-A-V-L-F-F-G-R-C 
E12 N-F-E-K-L-T-E-W-T-S-S-N-V-M-E G7 H-I-A-T-N-A-V-L-F-F-G-R-C-V-S 
E13 E-K-L-T-E-W-T-S-S-N-V-M-E-E-R G8 A-T-N-A-V-L-F-F-G-R-C-V-S-P 
E14 L-T-E-W-T-S-S-N-V-M-E-E-R-K-I   
E15 E-W-T-S-S-N-V-M-E-E-R-K-I-K-V   
E16 T-S-S-N-V-M-E-E-R-K-I-K-V-Y-L   
E17 S-N-V-M-E-E-R-K-I-K-V-Y-L-P-R   
E18 V-M-E-E-R-K-I-K-V-Y-L-P-R-M-K   
E19 E-E-R-K-I-K-V-Y-L-P-R-M-K-M-E   
E20 R-K-I-K-V-Y-L-P-R-M-K-M-E-E-K   
E21 I-K-V-Y-L-P-R-M-K-M-E-E-K-Y-N   
E22 V-Y-L-P-R-M-K-M-E-E-K-Y-N-L-T   
E23 L-P-R-M-K-M-E-E-K-Y-N-L-T-S-V   
E24 R-M-K-M-E-E-K-Y-N-L-T-S-V-L-M   
E25 K-M-E-E-K-Y-N-L-T-S-V-L-M-A-M   
E26 E-E-K-Y-N-L-T-S-V-L-M-A-M-G-I   
E27 K-Y-N-L-T-S-V-L-M-A-M-G-I-T-D   
E28 N-L-T-S-V-L-M-A-M-G-I-T-D-V-F   
E29 T-S-V-L-M-A-M-G-I-T-D-V-F-S-S   
E30 V-L-M-A-M-G-I-T-D-V-F-S-S-S-A   
F1 M-A-M-G-I-T-D-V-F-S-S-S-A-N-L   
F2 M-G-I-T-D-V-F-S-S-S-A-N-L-S-G   
F3 I-T-D-V-F-S-S-S-A-N-L-S-G-I-S   
F4 D-V-F-S-S-S-A-N-L-S-G-I-S-S-A   
F5 F-S-S-S-A-N-L-S-G-I-S-S-A-E-S   
F6 S-S-A-N-L-S-G-I-S-S-A-E-S-L-K   
F7 A-N-L-S-G-I-S-S-A-E-S-L-K-I-S   
F8 L-S-G-I-S-S-A-E-S-L-K-I-S-Q-A   
F9 G-I-S-S-A-E-S-L-K-I-S-Q-A-V-H   
F10 S-S-A-E-S-L-K-I-S-Q-A-V-H-A-A   
F11 A-E-S-L-K-I-S-Q-A-V-H-A-A-H-A   
F12 S-L-K-I-S-Q-A-V-H-A-A-H-A-E-I   
F13 K-I-S-Q-A-V-H-A-A-H-A-E-I-N-E   
F14 S-Q-A-V-H-A-A-H-A-E-I-N-E-A-G   
F15 A-V-H-A-A-H-A-E-I-N-E-A-G-R-E   
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Reagent Volume (mL) Mass (g)













Main Wash (DMF) 824.39877
Deprotection (Piperidine) 189
Activator (HOBt monohydrate) 36
Activator Base (DIC) 18
Total waste volume: 1171 mL
Worst-Case (UV) Reagent Amounts
Reagent Volume (mL) Mass (g)
Main Wash (DMF) 1161.841236
Deprotection (Piperidine) 284
Total waste volume (worst-case): 1625 mL
Usage Report
Reported: Page 1 of 17/10/2019 9:43:31 AM
235 of 260 
Appendix 8. Statistical analysis obtained for data depicted in Figure II.14. The two data sets were also 
represented individually, and their respective ANOVA statistical analysis was performed (A). Statistical 
analysis for the combined data represented in Figure II.14 was also performed using the Kruskal-Wallis 
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B 
Protein p value from Kruskal-Wallis test 
A1AT vs 1:1 vs 1:5 vs 1:10 0.01535 
HSA vs 1:1 vs 1:5 vs 1:10 0.1051 
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Appendix 9. Statistical analysis obtained for data depicted in Figure III.14 A using a Student’s t-Test. 
 
t-Test: Paired Two Sample for Means  
 KLH (5 ug/mL) KLH-HNE (5 ug/mL) 
Mean 0.36 5.586 
Variance 0.005299 0.117883 
Observations 3 3 
Pearson Correlation 0.892221277  
Hypothesized Mean Difference 0  
df 2  
t Stat -32.28982791  
P(T<=t) one-tail 0.000478866  
t Critical one-tail 2.91998558  
P(T<=t) two-tail 0.000957733  
t Critical two-tail 4.30265273  
   
   
t-Test: Paired Two Sample for Means  
 KLH (2.5 ug/mL) KLH-HNE (2.5 ug/mL) 
Mean 0.243833333 5.283333333 
Variance 0.001978083 0.052295583 
Observations 3 3 
Pearson Correlation 0.824218788  
Hypothesized Mean Difference 0  
df 2  
t Stat -45.0700013  
P(T<=t) one-tail 0.000245966  
t Critical one-tail 2.91998558  
P(T<=t) two-tail 0.000491931  
t Critical two-tail 4.30265273  
   
   
t-Test: Paired Two Sample for Means  
 KLH (1.25 ug/mL) KLH-HNE (1.25 ug/mL) 
Mean 0.162133333 4.120166667 
Variance 0.000927203 0.045735083 
Observations 3 3 
Pearson Correlation 0.526414118  
Hypothesized Mean Difference 0  
df 2  
t Stat -34.36086994  
P(T<=t) one-tail 0.000422951  
t Critical one-tail 2.91998558  
P(T<=t) two-tail 0.000845903  
t Critical two-tail 4.30265273  
   
   
t-Test: Paired Two Sample for Means  
 KLH (0.625 ug/mL) KLH-HNE (0.625 ug/mL) 
Mean 0.104666667 2.062833333 
Variance 0.000196333 0.009654083 
Observations 3 3 
Pearson Correlation 0.966169934  
Hypothesized Mean Difference 0  
df 2  
t Stat -39.99846444  
P(T<=t) one-tail 0.000312231  
t Critical one-tail 2.91998558  
P(T<=t) two-tail 0.000624463  
t Critical two-tail 4.30265273  
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t-Test: Paired Two Sample for Means  
 KLH (0.3125 
ug/mL) 
KLH-HNE (0.3125 ug/mL) 
Mean 0.080033333 0.763 
Variance 6.40033E-05 0.017932 
Observations 3 3 
Pearson Correlation 0.99401552  
Hypothesized Mean Difference 0  
df 2  
t Stat -9.391254874  
P(T<=t) one-tail 0.005574579  
t Critical one-tail 2.91998558  
P(T<=t) two-tail 0.011149159  
t Critical two-tail 4.30265273  
 
t-Test: Paired Two Sample for Means   
  HSA (5 ug/mL) HSA-HNE (5 ug/mL) 
Mean 0.367166667 1.016833333 
Variance 0.002002583 0.026261083 
Observations 3 3 
Pearson Correlation 0.989350348  
Hypothesized Mean Difference 0  
df 2  
t Stat -9.539376946  
P(T<=t) one-tail 0.005405581  
t Critical one-tail 2.91998558  
P(T<=t) two-tail 0.010811162  
t Critical two-tail 4.30265273   
   
   
t-Test: Paired Two Sample for Means   
  HSA (2.5 ug/mL) HSA-HNE (2.5 ug/mL) 
Mean 0.1963 0.6575 
Variance 0.02217712 0.02604225 
Observations 3 3 
Pearson Correlation 0.479096595  
Hypothesized Mean Difference 0  
df 2  
t Stat -5.032906483  
P(T<=t) one-tail 0.018642352  
t Critical one-tail 2.91998558  
P(T<=t) two-tail 0.037284705  
t Critical two-tail 4.30265273   
   
   
t-Test: Paired Two Sample for Means   
  HSA (1.25 ug/mL) HSA-HNE (1.25 ug/mL) 
Mean 0.178833333 0.373333333 
Variance 0.000496083 0.005792333 
Observations 3 3 
Pearson Correlation 0.99996998  
Hypothesized Mean Difference 0  
df 2  
t Stat -6.257665014  
P(T<=t) one-tail 0.012299474  
t Critical one-tail 2.91998558  
P(T<=t) two-tail 0.024598948  
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t Critical two-tail 4.30265273   
   
   
t-Test: Paired Two Sample for Means   
  HSA (0.625 ug/mL) HSA-HNE (0.625 ug/mL) 
Mean 0.137833333 0.198066667 
Variance 0.001396583 0.000992263 
Observations 3 3 
Pearson Correlation 0.982713729  
Hypothesized Mean Difference 0  
df 2  
t Stat -12.03357057  
P(T<=t) one-tail 0.003417516  
t Critical one-tail 2.91998558  
P(T<=t) two-tail 0.006835031  
t Critical two-tail 4.30265273   
   
   






Mean 0.104 0.138333333 
Variance 0.000361 0.000906333 
Observations 3 3 
Pearson Correlation 0.999122311  
Hypothesized Mean Difference 0  
df 2  
t Stat -5.333137843  
P(T<=t) one-tail 0.016703489  
t Critical one-tail 2.91998558  
P(T<=t) two-tail 0.033406978  
t Critical two-tail 4.30265273   
 
t-Test: Paired Two Sample for Means   
  OVA (5 ug/mL) OVA-HNE (5 ug/mL) 
Mean 0.340666667 3.027833333 
Variance 1.63333E-05 0.002331583 
Observations 3 3 
Pearson Correlation -0.648654812  
Hypothesized Mean Difference 0  
df 2  
t Stat -91.25950269  
P(T<=t) one-tail 6.00255E-05  
t Critical one-tail 2.91998558  
P(T<=t) two-tail 0.000120051  
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t-Test: Paired Two Sample for Means   
  OVA (2.5 ug/mL) OVA-HNE (2.5 ug/mL) 
Mean 0.232 2.27735 
Variance 0.001227 0.007356468 
Observations 3 3 
Pearson Correlation 0.353756819  
Hypothesized Mean Difference 0  
df 2  
t Stat -44.08444511  
P(T<=t) one-tail 0.000257078  
t Critical one-tail 2.91998558  
P(T<=t) two-tail 0.000514155  
t Critical two-tail 4.30265273   
   
   
t-Test: Paired Two Sample for Means   
  OVA (1.25 ug/mL) OVA-HNE (1.25 ug/mL) 
Mean 0.140166667 1.371 
Variance 0.000282583 0.004791 
Observations 3 3 
Pearson Correlation -0.444543375  
Hypothesized Mean Difference 0  
df 2  
t Stat -27.27767809  
P(T<=t) one-tail 0.000670627  
t Critical one-tail 2.91998558  
P(T<=t) two-tail 0.001341253  
t Critical two-tail 4.30265273   
   
   
t-Test: Paired Two Sample for Means   
  OVA (0.625 ug/mL) OVA-HNE (0.625 ug/mL) 
Mean 0.115833333 0.6255 
Variance 5.30833E-05 0.00468525 
Observations 3 3 
Pearson Correlation 0.820120807  
Hypothesized Mean Difference 0  
df 2  
t Stat -14.09890423  
P(T<=t) one-tail 0.002496532  
t Critical one-tail 2.91998558  
P(T<=t) two-tail 0.004993063  
t Critical two-tail 4.30265273   
   
   






Mean 0.083 0.3725 
Variance 0.000028 0.00428025 
Observations 3 3 
Pearson Correlation -0.966234496  
Hypothesized Mean Difference 0  
df 2  
t Stat -7.107460713  
P(T<=t) one-tail 0.009613324  
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t Critical one-tail 2.91998558  
P(T<=t) two-tail 0.019226649  
t Critical two-tail 4.30265273   
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Appendix 10. Statistical analysis obtained Figure III.14 B. 
 
Anova: Single Factor       
       
SUMMARY       
Groups Count Sum Average Variance   
HSA 8 0.540167 0.067521 1.89E-05   
HSA-HNE 8 5.401167 0.675146 0.101018   
       
       
ANOVA       
Source of Variation SS df MS F P-value F crit 
Between Groups 1.476833 1 1.476833 29.23358 9.25E-05 4.60011 
Within Groups 0.707257 14 0.050518    
       
Total 2.18409 15         
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Appendix 11. ELISA assay comparing the binding of the anti-HNE Abcam and the Anti-HSA-HNE SA369 
antibodies to recombinant HSA expressed in Saccharomyces cerevisiae and standard HSA (the same HSA 
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Appendix 12. Schematic representation of the lamination process of the different components of the anti-
HNE lateral flow assay. On top of a 30 cm long backing card the nitrocellulose membrane with immobilised capture 
Ab, the sink pad, the gold conjugate pad and the sample pad were mounted on a plastic backing card, in this 
specific order, at 20 mm, 0 mm, 43 mm and 55 mm, respectively, counting from the top of the backing card (A). 
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Appendix 13. Flowchart depicting the main followed steps for running and reading a lateral flow assay 
(LFA). Once all the components of the assay are assembled, each individual strip is encased in a in plastic cassette 
(A), and only then the sample is applied to the sample pad (B). The liquid will then flow through the conjugate pad, 
dragging with itself the conjugated reagent to the nitrocellulose membrane (C). For this assay, the device was left 
for 20 min until all the liquid had been absorbed by the sink pad and the signal of the test line was stable (D). The 
intensity of the test line was measured using a cube reader which was mounted on top of the cassette (E). This 
camera reader emits a LED green light within the window area where the test and control lines are shown, which 
will be reflected back by the gold surface, and measures the absorbance of light (1-transmission). Depending on 
type of the assay and how many lines exist, the cube can be programmed to integrate the various differences in 
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Appendix 14. Sheep Phage Display primers used for construction of the scFv library. 
 
1. Ovine heavy chain constant region 3’ primer. 
(a) OvCHFOR: 5’-GAC TTT CGG GGC TGT GGT GGA GGC-3’. 
2. Ovine kappa chain constant region 3’ primer. 
(a) OvCKFOR: 5’-GA TGG TTT GAA GAG GGA GAC GGATGG CTG AGC-3’. 
3. Ovine lambda chain constant region 3’ primer. 
(a) OvCLFOR: 5’-A CAG GGT GAC CGAGGG TGC GGA CTT GG-3’. 
4. Ovine heavy chain variable region 5’ primers. 
(a) OvVH1BACK: 5’-CAG GTK CRR CTG CAG GRG TCG GG-3’. 
(b) OvVH2BACK: 5’-CAG GTKCAG YTKCAGGAGTCG GG-3’. 
(c) MuVH1BACK: 5’-SAG GTSMARCTGCAGSAGTCW GG-3’. 
(d) Hu4aBACK: 5’-CAG GTG CAG CTG CAG GAG TCG GG-3. 
5. Ovine heavy chain variable region 3’ primers. 
(a) OvJH1LINKFOR: 5’-CTC AGA AGG CGC GCC AGA AGA TTT ACC TTC TGA 
GGA GAC GGT GAC CAG GAG TCC-3’. 
(b) OvJH2LINKFOR: 5’-CTC AGA AGG CGC GCC AGA AGA TTT ACC TTC TGA 
GGA GRC GGW GAY YAG KAG TCC-3’. 
(c) OvJH3LINKFOR: 5’-CTC AGA AGG CGC GCC AGA AGA TTT ACC TTC TGA 
GGA GAY RGT RAS CAG GAS TCC-3’. 
(d) OvJH4LINKFOR: 5’-CTC AGA AGG CGC GCC AGA AGA TTT ACC TTC TGA 
AAG AAC GCT GAT CAG GAG-3’. 
6. Ovine lambda chain variable region 5’ primers. 
(a) OvVL1LINKBACK: 5’-AG TCA AAC GCG TCT GGC GAG TCT AAA GTG GAT 
GAC CAG GCT GTG CTG ACT CAG CCG-3’. 
(b) OvVL2LINKBACK: 5’-AG TCA AAC GCG TCT GGC GAG TCT AAA GTG GAT 
GAC CAR GCT GTG CTG ACY CAR CYG-3’. 
(c) OvVL3LINKBACK: 5’-AG TCA AAC GCG TCT GGC GAG TCT AAA GTG GAT 
GAC CAG GCY STG STG ACT CAG CCR-3’. 
(d) OvVL4LINKBACK: 5’-AG TCA AAC GCG TCT GGC GAG TCT AAA GTG GAT 
GAC MRG GTC RTG CKG ACT CAR CCG-3’. 
(e) OvVL5LINKBACK: 5’-AG TCA AAC GCG TCT GGC GAG TCT AAA GTG GAT 
GAC CAG KCT GYS CTG ACT CAG CCK-3’. 
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7. Ovine lambda chain variable region 3’ primers. 
(a) OvJL1FOR: 5’-ACC CAG GAC GGT CAG CCT GGT CC-3’. 
(b) OvJL2FOR: 5’-ACC CAG GAC GGT CAG YCK RGW CC-3’. 
8. Cloning primers (restriction sites underlined). 
(a) OvVH1BACK-Sfi:5’-GTC CTC GCA ACT GCG GCC CAG CCG GCC ATG GCC 
CAG GTKCRRCTG CAG GRG TCG GG-3’. 
(b) OvVH2BACK-Sfi:5’-GTC CTC GCA ACT GCG GCC CAG CCG GCC ATG GCC 
CAG GTKCAG YTKCAG GAG TCG GG-3’. 
(c) MuVH1BACK-Sfi:5’-CAT GCC ATG ACT GCG GCC CAG CCG GCC ATG GCC 
SAG GTS MARCTG CAG SAG TCW GG-3‘. 
(d) Hu4aBACK-Sfi:5’-GTC CTC GCA ACT GCG GCC CAG CCG GCC ATG GCC CAG 
GTG CAG CTG CAG GAG TCG GG-3’. 
(e) OvJL1FOR-Not:5’-GAG TCA TTC TCG ACT TGC GGC CGC ACC CAG GAC GGT 
CAG CCT GGT CC-3’. 
(f) OvJL2FOR-Not:5’-GAG TCA TTC TCG ACT TGC GGC CGC ACC CAG GAC GGT 
CAG YCK RGW CC-3’. 
(g) OvJK1FOR-Not:5’-GAG TCA TTC TCG ACT TGC GGC CGC CCG TTT GAT TTC 
CAC GTT GGT CCC-3’. 
(h) OvJK2FOR-Not:5’-GAG TCA TTC TCG ACT TGC GGC CGC CCT TTT GAT CTC 
TAG TTT GGT TCC-3’. 
(i) OvJK3FOR-Not:5’-GAG TCA TTC TCG ACT TGC GGC CGC CCT TTT GAT CTC 
TAC CTT GGT TCC-3’. 
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Appendix 15. pSFD vector used for the construction of the SA369 scFV fragment. The fragments in between 
the restriction sites for enzymes NcoI and NotI were removes and substituted by the VH-V fragment. 
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